

## **Preliminary Programme**

36th Congress of the European  
Society of Clinical Microbiology  
and Infectious Diseases

**Munich, Germany**

17–21 April 2026

**20  
26**

EW006	08:30 – 10:30	Hall A1-4
2-hour Educational Session		

AMR IPC PHEI

### Outbreak investigation: through the eyes of a field epidemiologist and public health microbiologist

*Chairs* Angela Novais (Porto, Portugal)  
Yassen Tcholakov (Montréal, Canada)

W0081	08:30	Field epidemiology: principles and the 10 steps of outbreak investigation Ricardo Mexia (Lisbon, Portugal)
W0082	08:50	Public health microbiology: practical applications of epidemiological markers and key tools for outbreak response João Pires (Oslo, Norway)
W0083	09:10	Real case study of healthcare-associated infection outbreak, Vera Manageiro (Lisbon, Portugal), Alma Tostmann (Nijmegen, The Netherlands)

Co-organised with: EPIET alumni network (EAN), ESCMID Study Group for Epidemiological Markers (ESGEM)

EW004	08:30 – 10:30	Hall B0-1
2-hour Educational Session		

AMR CLN DX

### The antibiogram: from theory to clinical practice

*Chairs* Giulia De Angelis (Rome, Italy)  
Holger Rohde (Hamburg, Germany)

W0073	08:30	The antibiogram demystified: principles, methods, and clinical significance Paul Christoffer Lindemann (Bergen, Norway)
W0074	08:50	Interpreting Gram-negative antibiograms Katy Jeannot (Besançon, France)
W0075	09:10	Interpreting Gram-positive antibiograms Stefania Stefani (Catania, Italy)
W0076	09:30	From the antibiogram to antibiotic choice: clinical reasoning in action Robin Howe (Cardiff, United Kingdom)

Co-organised with: ESCMID AMR Action Subcommittee

EW005	08:30 – 10:30	Hall B0-2
2-hour Educational Session		

CLN IPC

### Prevention and treatment for specific intra-abdominal infections

*Chairs* Alida C.M. Veloo (Groningen, The Netherlands)  
Birgit Willinger (Vienna, Austria)

W0077	08:30	Prevention of postoperative infection in bowel surgery: mechanical and/or oral antibiotics: what and when? Christian Eckmann (Hannover, Germany)
W0078	08:50	Selective decontamination: benefits and resistance development Nick Daneman (Ontario, Canada)
W0079	09:10	Necrotising pancreatitis and antibiotics: prophylaxis or early therapy? Hjalmar Van Santvoort (Utrecht, The Netherlands)
W0080	09:30	Diverticulitis: exact diagnosis and indications for antibiotic therapy Massimo Sartelli (Macerata, Italy)

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), ESCMID Study Group for Anaerobic Infections (ESGAI)

EW001	08:30 – 10:30	Hall ICM 13a
2-hour Educational Session		

TRN

### Strategies to tackle biofilm-associated infections

*Chairs* Arnaldo Lopes Colombo (São Paulo, Brazil)  
Luís Melo (Coimbra, Portugal)

W0061	08:30	Pathogenesis of biofilm-associated infections Kimberly
-------	-------	--

Kline (Geneva, Switzerland)

W0062	08:50	Viral therapies to tackle biofilm-associated infections Joana Azeredo (Braga, Portugal)
W0063	09:10	Molecular basis of tolerance and resistance in biofilms Tom Coenye (Ghent, Belgium)
W0064	09:30	Assessing <i>In vivo</i> anti-biofilm activity Valerie Waters (Toronto, Canada)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

EW002	08:30 – 10:30	Hall ICM 13b
2-hour Educational Session		

PRO

### Overcoming ongoing challenges in CM/ID publishing

*Chairs* Kirsten Bibbins-Domingo (Chicago, United States)  
Leonard Leibovici (Yahud, Israel)

W0065	08:30	Peer-review: the future? Amelia Joseph (Nottingham, United Kingdom)
W0066	08:50	Preparing the next generation of peer reviewers Preeti Malani (Ann Arbor, United States)
W0067	09:10	Efforts to make the literature unbiased Ursula Hofer (London, United Kingdom)
W0068	09:30	From authors to peer reviewers to editors: how should we handle the use of AI in publishing? Robert C. Read (Southampton, United Kingdom)

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors

EW003	08:30 – 10:30	Hall ICM 5
2-hour Educational Session		

IPC PHEI TRN

### A gentle introduction to bioinformatics for microbial genomics

*Chairs* Natacha Couto (Cardiff, United Kingdom)  
John W. A. Rossen (Groningen, The Netherlands)

W0069	08:30	Quality control of whole genome sequencing data Tarah Lynch (Calgary, Canada)
W0070	08:50	Genome assembly, read mapping and variant calling Torsten Seemann (Melbourne, Australia)
W0071	09:10	Species determination, genotyping and AMR prediction Andreas Stroehlein (Berlin, Germany)
W0072	09:30	Understating trees: phylogenomics for infection control Zoe Anne Dyson (London, United Kingdom)

TEST2	10:00 – 11:00
1-hour Case Session	

### TEST2FB

TESTPC01	Test intervention 01 Pauline Cazanova (Nice, France)
TESTPC02	Test PC02 Florence Boinnot (Nice, France)
TESTPC03	Test PC02 assigned to Flo 2 Florence Boinnot Test (France)

ME013	11:00 – 12:00	Hall A1-4
Meet-the-Expert		

IPC PHEI

### Legionnaires' disease: insights from recent large outbreaks

M0001	11:00	Maria Scaturro (Rome, Italy)
M0002	11:12	Florian Heger (Vienna, Austria)

Co-organised with: ESCMID Study Group for Legionella Infections (ESGLI)

ME010	11:00 – 12:00	Hall B0-1
Meet-the-Expert		

CLN PRO

### Useful endpoints for antimicrobial therapy and stewardship: what if not only mortality mattered?

M0025 11:00 *Esther Calbo (Terrassa, Spain)*  
M0026 11:12 *Antonios Katsounas (Bochum, Germany)*

ME012 11:00 – 12:00 Hall B0-2

Meet-the-Expert

AMR DX IPC

How best to detect ESBL and carbapenemase producers

M0029 11:00 *Orjan Samuelsen (Tromsø, Norway)*

M0030 11:12 *Shiri Navon-Venezia (Ariel, Israel)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), EUCAST Steering Committee

ME007 11:00 – 12:00 Hall ICM 13a

Meet-the-Expert

CLN IPC

Nosocomial infections in ECMO: clinical challenges and case-based discussion

M0019 11:00 *Konstanty Szuldrzynski (Mazowieckie, Poland)*

M0020 11:12 *Marta Hernández-Meneses (Barcelona, Spain)*

Co-organised with: European Extracorporeal Life Support Organization

ME008 11:00 – 12:00 Hall ICM 13b

Meet-the-Expert

PED PRO

Designing and conducting clinical trials in paediatric infectious diseases: barriers and challenges

M0021 11:00 *Emmanuel Roilides (Thessaloniki, Greece)*

M0022 11:12 *Irja Lutsar (Tartu, Estonia)*

ME009 11:00 – 12:00 Hall ICM 5

Meet-the-Expert

CLN DX

Travel, migration and immunosuppression: a two-way challenge

M0023 11:00 *Martin Peter Grobusch (Amsterdam, The Netherlands)*

M0024 11:12 *María Velasco (Madrid, Spain)*

Co-organised with: Federation of European Societies for tropical medicine and international health (FESTMIH)

EW018 13:30 – 15:30 Hall A1-4

2-hour Educational Session

PRO

Method morsels: breaking trial methodology down into digestible components

Chairs *Amelia Joseph (Nottingham, United Kingdom)*  
*Navaneeth Narayanan (New Brunswick, United States)*

W0015 13:30 **How much is enough? Old and new methods for calculating sample size** *Yin Mo (Singapore, Singapore)*

W0016 13:50 **Bayesian versus frequentist statistics: differences and advantages** *Tom Snelling (Sydney, Australia)*

W0017 14:10 **Immortal time bias: avoiding, recognising, and addressing it** *Emily McDonald (Montreal, Canada)*

W0018 14:30 **Open the DOOR and win? How to understand and interpret novel outcome measures** *Sean Wei Xiang Ong (Toronto, Singapore)*

Co-organised with: CMI Communications Board of Editors

EW017

13:30 – 15:30

Hall B0-1

2-hour Educational Session

CLN DX PED

Advancing paediatric infectious disease management: from stewardship to precision therapeutics

Chairs *Luise Martin (Berlin, Germany)*  
*João Paulo Telles (São Paulo, Brazil)*

W0011 13:30 **Paediatric antimicrobial stewardship: evidence-based interventions and practical barriers** *Johannes Hübner (Munich, Germany)*

W0012 13:50 **Optimising treatment in infants with access to newer antimicrobials** *Aspasia Katragkou (Morristown, United States)*

W0013 14:10 **Modelling and simulation for optimising initial paediatric and neonatal dosing** *Agathe Béanger (Paris, France)*

W0014 14:30 **Rapid identification and resistance profiling in neonates** *Surbhi Malhotra-Kumar (Antwerp, Belgium)*

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW016 13:30 – 15:30 Hall ICM 5

2-hour Educational Session

CLN DX

Clinical challenges in tropical medicine: lessons for global health

Chairs *Hilmir Asgeirsson (Stockholm, Sweden)*  
*Maria Cristina Loader (London, United Kingdom)*

W0007 13:30 **Clinical impact of hybrid *Leishmania* strains** *Özgür Kurt (Istanbul, Türkiye)*

W0008 13:50 **Hybrid *Schistosoma*: what's the real picture?** *Bonnie Webster (London, United Kingdom)*

W0009 14:10 **Therapeutic challenges for nematode and trematode infections** *Carlos Seas (Lima, Peru)*

W0010 14:30 **Imported tropical diseases: what clinicians need to know** *Camilla Rothe (Munich, Germany)*

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V., ESCMID Study Group for Clinical Parasitology (ESGCP)

ME015 13:30 – 14:30 Hall B0-2

Meet-the-Expert

DX IPC

Genomics in clinical microbiology and virology across settings: hype, hope, or a game-changer?

M0005 13:30 *Abhilasha Karkey (Kathmandu, Nepal)*

M0006 13:42 *Judith Breuer (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), European Society of Clinical Virology

ME011 13:30 – 14:30 Hall ICM 13a

Meet-the-Expert

ANT CLN

Different sets of diagnostic tools for endocarditis: how to resolve discrepancies and make them work?

M0027 13:30 *Thomas Wouter Van Der Vaart (Amsterdam, The Netherlands)*

M0028 13:42 *Marta Hernández-Meneses (Barcelona, Spain)*

ME014 13:30 – 14:30 Hall ICM 13b

Meet-the-Expert

CLN DX

How to approach pneumonia in patients with neutropenia

M0003 13:30 *Mark Reinwald (Brandenburg, Germany)*

M0004 13:42 Johan Maertens (Leuven, Belgium)

ME021 14:45 – 15:45 Hall B0-2

Meet-the-Expert

AMR CLN

Optimising treatment of severe infections due to DTR organisms

M0035 14:45 Jean-Francois Timsit (Paris, France)

M0036 14:57 Lowell Ling (Hong Kong, Hong Kong)

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIPI), European Society of Intensive Care Medicine

ME019 14:45 – 15:45 Hall ICM 13a

Meet-the-Expert

CLN IPC PRO

Ethical discourse on isolation precautions: to isolate or not to isolate that is the question!

M0031 14:45 Babette Rump (Middelburg, The Netherlands)

M0032 14:57 Angelo Pan (Cremona, Italy)

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

ME020 14:45 – 15:45 Hall ICM 13b

Meet-the-Expert

CLN DX

Hepatitis in the immunocompromised host: is it infection?

M0033 14:45 Susanne Gjeruldsen Dudman (Oslo, Norway)

M0034 14:57 Oana Sandulescu (Bucharest, Romania)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Viral Hepatitis (ESGVH), Viral Hepatitis Society of Türkiye (VHSD)

EW027 16:15 – 18:15 Hall B0-1

2-hour Educational Session

AMR DX

Overcoming resistant *Candida* infections

*Chairs* Alexandre Alanio (Paris, France)  
Nelesh Govender (Johannesburg, South Africa)

W0051 16:15 Global epidemiology of antifungal resistance in *Candida*: trends and hotspots Arnaldo Lopes Colombo (São Paulo, Brazil)

W0052 16:35 Next-generation diagnostics: rapid tests and molecular methods Cornelia Lass-Flörl (Innsbruck, Austria)

W0053 16:55 *Candida auris* and *Candida parapsilosis* resistance and transmission Anuradha Chowdhary (Delhi, India)

W0054 17:15 Adopting guidelines and resources for *Candida* diseases in LMICs Methae Chayakulkeeree (Bangkok, Thailand)

Co-organised with: German-Speaking Mycological Society, ÖGACH, EFISG, Portuguese Society of Infectious Diseases and Clinical Microbiology, Hellenic Society of Medical Mycology, Turkish Society of Paediatric Infectious Diseases

EW025 16:15 – 18:15 Hall ICM 13a

2-hour Educational Session

IPC PRO

Enhancing infection prevention and control through implementation science: the REVERSE experience

*Chairs* Tatjana Lejko Zupanc (Ljubljana, Slovenia)  
Walter Zingg (Zurich, Switzerland)

W0043 16:15 Embedding implementation science in infection prevention and control Kathrin Blum (Zurich, Switzerland)

W0044 16:35 Culture as a determinant of IPC implementation Diana

Gabriela Iacob (Bucharest, Romania)

W0045 16:55 Boundary spanning as a prerequisite to IPC implementation María Teresa Pérez-Rodríguez (Vigo, Spain)

W0046 17:15 When implementation leadership facilitates IPC implementation Davide Mangioni (Milan, Italy)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP), Swiss Society for Infectious Diseases (SSID), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

EW026 16:15 – 18:15 Hall ICM 5

2-hour Educational Session

PED VAX

Vaccines for children: innovations, impact, and future directions

*Chairs* Ilias P. Iosifidis (Thessaloniki, Greece)  
Hanna M. Nohynek (Helsinki, Finland)

W0047 16:15 New and emerging frontiers in paediatric vaccinology Paolo Palma (Antwerp, Italy)

W0048 16:35 Beyond the needle: innovative delivery systems for paediatric vaccines Ulrich Heininger (Basel, Switzerland)

W0049 16:55 Direct and indirect roles for vaccines against antimicrobial resistance Vana Spoulou (Athens, Greece)

W0050 17:15 Vaccines and innate immunity: harnessing trained immunity in early life Elisabeth Duffer (Nijmegen, The Netherlands)

ME024 16:15 – 17:15 Hall A1-4

Meet-the-Expert

AMR DX

Quality controlled AST: use your cell phone and your data

M0041 16:15 Onur Karatuna (Växjö, Sweden)

M0042 16:27 Iva Butic (Zagreb, Croatia)

Co-organised with: Médecins Sans Frontières (MSF), CAESAR Network, ESCMID Education Subcommittee

ME023 16:15 – 17:15 Hall B0-2

Meet-the-Expert

ANT CLN

PK/PD-based dose optimisation in challenging patient groups

M0039 16:15 Birgit Koch (Rotterdam, The Netherlands)

M0040 16:27 Christina König (Hamburg, Germany)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

ME022 16:15 – 17:15 Hall ICM 13b

Meet-the-Expert

TRN

Multi-omics dissection of bacterial pathogenesis and host-microbiome interactions

M0037 16:15 Virginie Stévenin (Toulouse, France)

M0038 16:27 Romain Guérillot (Melbourne, Australia)

ME030 17:30 – 18:30 Hall A1-4

Meet-the-Expert

DX PHEI

How to prepare for pathogen X emergence: a practical approach

M0059 17:30 David Chien Lye (Singapore, Singapore)

M0060 17:42 David Hayman (Palmerston North, New Zealand)

ME029 17:30 – 18:30 Hall B0-2  
Meet-the-Expert

ANT CLN

Overcoming challenges to implementing system-wide antimicrobial stewardship

M0057 17:30 Sara Cosgrove (Baltimore, United States)

M0058 17:42 Paul Turner (Oxford, United Kingdom)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

ME028 17:30 – 18:30 Hall ICM 13b  
Meet-the-Expert

CLN DX

De-escalation or escalation: using rapid diagnostics in patients with sepsis

M0055 17:30 Pierluigi Viale (Bologna, Italy)

M0056 17:42 Ana Gales (São Paulo, Brazil)

Saturday, 18 April 2026

EW040 08:30 – 10:30 Hall A2-1  
2-hour Educational Session

ANT TRN

Next-generation therapies against infectious diseases

Chair Nicolas Mueller (Zurich, Switzerland)  
TBA

W0204 08:30 Cellular therapies targeting infectious diseases Lukas Jeker (Basel, Switzerland)

W0205 08:50 Discovery of new antibody-based anti-infectives Jan Rybniker (Köln, Germany)

W0206 09:10 Proteasome-derived defence peptides Yifat Merbl (Rehovot, Israel)

W0207 09:30 Neutralising antibodies for treatment of vector borne pathogens Davide Robbiani (Bellinzona, Switzerland)

Co-organised with: Swiss Society for Infectious Diseases (SSID), ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group of Forensic and Post-Mortem Microbiology (ESGFOR)

EW039 08:30 – 10:30 Hall ICM 13a  
2-hour Educational Session

PHEI TRN

Milk matters: risks and safe practices in a changing global landscape

Chairs Sally Jane Cutler (London, United Kingdom)  
Ana Raquel Freitas (Porto, Portugal)

W0200 08:30 Raw milk misconceptions: health benefits vs risks Enda Cummins (Dublin, Ireland)

W0201 08:50 Brucellosis and bovine tuberculosis in LMICs Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)

W0202 09:10 *Coxiella burnetii* in milk and cheese Loïc Epelboin (Cayenne, French Guiana)

W0203 09:30 Unexpected surprises in milk: avian influenza to *Listeria monocytogenes* Nicole Martin (Ithaca, United States)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM)

OS001 08:30 – 10:30 Hall A1-2  
2-hour Oral Session

AMR DX IPC

Novel insights and tools to tackle hospital outbreaks

Chairs Fusun Can (Istanbul, Türkiye)  
Rekha Pai Mangalore (Melbourne, Australia)

O0001 08:30 A pathogen-agnostic machine learning framework for precision outbreak detection in hospital and

community settings K. Ko\* (Singapore, Singapore), C. Suphavitai, P. Boonsimma, H. Yingtaeweestittikul, K.M. Lim, U. Shanmugam, W.E. Ong, J.H. Yeo, T.H.N. Wong

O0002 08:42 Towards data-driven refinement of an automated hospital outbreak detection system: validation of expert classification through genotypic evidence in neonatology wards F.D. Ruether\* (Berlin, Germany), B. Piening, F. Maechler, A. Weber, C. Geffers, S.J.S. Aghdassi

O0003 08:54 Designing and evaluating an infection prevention and control (IPC) dashboard to track and interrupt spread of healthcare-associated infections A. Luk\* (Oxford, United Kingdom), D. Adlard, H. Thai, G. Durant, S.A. Walker, D. Eyre

O0004 09:06 Ceftazidime/avibactam-resistant *Klebsiella pneumoniae* driven by multiple  $\beta$ -lactamase mutation: a hospital outbreak report W. Yang\* (Shanghai, China), C. Tang, Q. Shi, H. Ou, D. Yin, R. Han, J. Chen, Y. Guo, F. Hu

O0005 09:18 Comparative evaluation of the IR Blotyper and whole genome sequencing for detecting bacterial outbreak C. Sakr\* (Creteil, France), C. Subramanian, F. Cizeau, D. Ducellier, M. Danjean, J.W. Decousser

O0006 09:30 Nosocomial outbreak by NDM- and OXA-48-producing hypermucoviscous high-risk ST383 *Klebsiella pneumoniae* clone J.M. Sánchez-Calvo\* (Jerez De La Frontera, Spain), S. López-Cárdenas, J.A. Córdoba Doña, M. Murillo-Pineda, R. Lobato-Cano, I.M. Santiago Soler, I. Pozo Jiménez, M. Coppi, I. Baccani, A. Antonelli, G.M. Rossolini, N. Zuabi, J. Rodríguez-Baño, P. Retamar

O0007 09:42 Chasing accuracy: does 1% really change the story in an ExPEC outbreak? T. Severs\* (Zwolle, The Netherlands), A.J. Gebbink, A.K.P.K. Bari, H. Gremmels, S. Debast, J.H.E. De Lange, B. Sinha, J.W.A. Rossen, B.B. Xavier

O0008 09:54 Whole genome sequencing (WGS) and improved diagnostics uncover a multispecies plasmid-borne GES-5/OXA-917 carbapenemase outbreak driven by the *Citrobacter freundii* complex A. Rath\* (Regensburg, Germany), N. Förster, N. Pfennigwerth, C. Keller, B. Neumann, A. Caplunik-Pratsch, B. Lenker, A. Eichner, J. Fritsch, W. Schneider-Brachert, B. Kieninger

O0009 10:06 Development of outbreak-specific TaqMan PCR assays for tracking vancomycin-resistant *Enterococcus faecium* in Dutch hospitals A.J. Sabat\* (Groningen, The Netherlands), J. Flipse, C.J.H. Von Wintersdorff, A. Pettersson, V. Akkerboom, W.C. Van Der Zwet, P.H.M. Savelkoul, A. Voss, E. Bathoorn

O0010 10:18 Beyond species: integrated bacterial and OXA-48 plasmid clustering with EPISEQ® reveals a polyclonal, multi-species hospital outbreak L. Aguilera Muros\* (Granada, Spain), M.A. Roldán Ruiz, A. Badillo Carrasco, C. Roldán Fontana, F. García García, N. Chueca Porcuna

OS002 08:30 – 10:30 Hall A1-3  
2-hour Oral Session

ANT CLN TRN

Three viruses, one winter: what we miss, what we treat, what comes next

Chairs Christopher Chiu (London, United Kingdom)  
Neven Papic (Zagreb, Croatia)

O0011 08:30 Pathogen-specific viral infections among adults hospitalised with severe acute respiratory infection: European multi-centre surveillance study, 2024–2025 (Id.DRIVE) K. Newell\* (Rotterdam, The Netherlands), N. Vroom, C. Marques, E. Maslova, F. Khan, K.Y. Ngew, H.R. Volkman, C. Wang, J.V. Hernandez-Villena, N. Aliabadi, E. Begier, J. Nguyen, H. Dunford, S. Basu, A. Antón, I. Casas, B. Grüner, G. Icardi, F.M. Torres, A. Mira-Iglesias, C.M. Oñoro López, A. Orrico-Sánchez, O. Parés-Badell, W. Gleiber, A. Torres, K. Bollaerts

O0012 08:42 Predictors of severe outcomes in hospitalised patients with viral respiratory tract infections: a prospective cohort study O. Usta\* (Istanbul, Türkiye), Ö. Aktaş, B. Çakan, A. Ardalı, Y. Beşli, Ö. Ergönül, Ş. Keske

O0013 08:54 Zelicapavir decreases symptom duration, hospitalisation and viral load in a global,

		randomised, double-blinded, placebo-controlled phase II trial of high-risk adults with RSV. <i>Rottinghaus* (Watertown, Massachusetts, United States), C. Harris, J. Devincenzo, S. Chen, T. Ngo, A. Ahmad, M. Turnak</i>	00025	09:18	Costs of hospital admissions linked with Gram-negative bloodstream infections among adults in England: an analysis using health resource groups. <i>K. Hayes* (London, United Kingdom), L. Miller, E. Van Leeuwen, J. Robotham, L. Uwais, E. Agnew, S. Evans</i>
00014	09:06	Postmortem study: analysis of mortality associated with respiratory viruses in four seasons of influenza. <i>Lucía Argente Colás (Pamplona, Spain)</i>	00026	09:30	Beyond the tip of the iceberg: quantifying the effect of MDRO-carriage on postacute inpatient rehabilitation. <i>H. Kaba* (Goettingen, Germany), P. Wenzlaff-Lodge, S. Scheithauer</i>
00015	09:18	Antiviral efficacy of baloxavir marboxil, favipiravir, and oseltamivir in adults with acute non-severe influenza virus infection: an open-label, phase II, randomised, controlled, adaptive platform trial. <i>S.J. Leopold* (Bangkok, Thailand), P. Jittamala, K. Kotchum, P. Wongnak, T. Asawasriworanan, T. Seers, S. Boyd, E. Beer, S. Singh, E. Batty, K. Chotivanich, S. Pukrittayakamee, A.M. Dondorp, N.P. Day, A. Karkey, M.M. Teixeira, E.A. Ashley, M. Imwong, W. Phumratanaprapin, J.A. Watson, W.H. Schilling, N.J. White</i>	00027	09:42	Mind the governance gap: a One Health systematic review of national AMR performance indicators. <i>E. O'Neill* (London, United Kingdom), U. Shafaque, V. Karadimitris, B. Hill, S. Ranganathan, E. Mossialos, M. Anderson</i>
00016	09:30	A sequence-based update on mutations in influenza polymerase acidic protein in Europe conferring resistance to baloxavir from 2009 to 2025: the old, the new, and the emerging mutations. <i>A. Martín-Toribio* (Valladolid, Spain), M. Toquero-Asensio, S. García-Díaz, J. Sánchez-Martínez, C. Rodríguez-Crespo, I. Inchausti-Moya, S. Rojo-Rello, M. Domínguez-Gil, E. Nistal-Villán, M. Hernández-Pérez, J.M. Eiros, I. Sanz-Muñoz</i>	00028	09:54	Benchmarking AWARe: estimating expected need of AWARe antibiotic use in 186 countries based on infection and resistance burden. <i>A. Cook* (London, United Kingdom), K. Pouwels, M. Sharland, B. Cooper</i>
00017	09:42	Effectiveness of nirmatrelvir/ritonavir in preventing severe COVID-19 outcomes: national multi-year real-world data from Greece. <i>E.G. Kostaki* (Athens, Greece), M. Gkova, K. Mathioudakis, D. Menegas, V. Grammelis, V. Kossyvak, I. Antoniou, P. Nikolopoulou, L. Puzniak, T. Bergroth, D. Paraskevis</i>	00029	10:06	Interactive causal inference framework for assessing policy and consumption effects on antimicrobial resistance. <i>A. Gupta* (Natick, United States), C. Vania</i>
00018	09:54	Phase II study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19. <i>S. Kezbor* (Florham Park, United States), E. Mitchell, Y. Iwasaki, G. Ichihashi, T. Baba, S. Lacey, H. Nobori, A.C. Hurt, A. Fukushi, Y. Takeda</i>	00030	10:18	UKHSA's contribution to the UK Antimicrobial Resistance National Action Plan 2024–2029 (year one). <i>C. Brown* (London, United Kingdom), R. Hope, V. Finistrella, J. Conneely, G. Eldridge, J. Charlesworth, S. De Cordova, E. Ombakho, F. Ambreen, J. Gritton</i>

00019	10:06	Macrophage and platelet activation drive inflammation in people living with Long COVID, irrespective of symptom cluster. <i>E. Wall* (London, United Kingdom), D. Greenwood, G. Ahimbisibwe, C. Dubois, I. Aniq, O. Haguge, A. Parabita, G. Prescott, M. Skehl, M. Scully, T. Hillman, A. Banerjee, E. Carr</i>	LB001	08:30 – 10:30	Hall A3-1
00020	10:18	MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates broad-spectrum activity against influenza viruses, respiratory syncytial virus, and SARS-CoV-2 with oral proof-of-concept in mice. <i>D. Haders* (La Jolla, United States), V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, B. McGovern, M. Rodriguez, A. García-Sastre, K. White, W. Brubaker, P. Gallay, D. Smith</i>			

OS003	08:30 – 10:30	Hall A1-4
	2-hour Oral Session	

Driving global AMR action through data, economics, and policy	
Chairs	<i>Diane Ashiru-Oredope (London, United Kingdom), Chantal Morel (Bonn, Germany)</i>

00021	08:30	Past, present and future of bacterial antimicrobial resistance (AMR) in the WHO Eastern Mediterranean Region: comprehensive AMR burden modelling from 1990 to 2021 with forecasts to 2050. <i>T. Mestrovic* (Varaždin, Croatia), T. Meštrović, M. Naghavi, G. Robles Aguilar, N.D. Weaver, L.R. Swetschinski, D.T. Araki, E.E. Wool, A. Gray, A. Gershberg Hayoon, C. Han, K.S. Ikuta, E. Rosenblad, R.L. Hsu, B.S. Cooper, C. Dolecek, B. Sartorius, S. Hay, C.J.L. Murray</i>	L0001	08:30	Impact of colonisation acquisition and PCV15 on symptoms following serotype 3 experimental human pneumococcal challenge (EHPC): results from a phase IV double-blind randomised clinical trial. <i>J.L. Martinelli* (Oxford, United Kingdom), Y. Ni, K. Tanha, R. Huq, B. Rocha De Macedo, C. Solórzano, A. Hyder-Wright, R. Mahmud, H. Gill, R. White, A. Singha, F. Elterish, T. Condreanu, B. Urban, E. Mitsi, X. Liu, A.M. Collins, D.M. Ferreira, S.B. Drysdale</i>
00022	08:42	Novel metrics for antimicrobial resistance surveillance: velocity, acceleration, and indicator antibiotic analysis using 191,810 global records. <i>P. Kilgore* (Detroit, United States)</i>	L0002	08:42	Updated safety and immunogenicity results from a UK-based phase I clinical trial of the Nipah virus candidate vaccine ChAdOx1 NipahB. <i>D. Jenkin* (Oxford, United Kingdom), R. Kenneil, N. Marchevsky, I. Haeusler, L. Saldana Ortega, R. White, Y. Zhang, E. Morey, T. Madupuri, N. Panchal, E. Sheehan, J. Wright, E. Vannaxay, H. Zhang, S. Kelly, L. Hahn, D. Pulido-Gomez, G. Morshead, A. Boyd, A. Pollard, T. Lambe, S. Gilbert, B. Angus</i>
00023	08:54	Mapping and synthesising global antibiotic use datasets to improve evidence for surveillance, modelling, and policy. <i>K. Zay Ya* (London, United Kingdom), D. R M Smith, A. Cook, K. B Pouwels, M. Sharland</i>	L0003	08:54	High-dose influenza vaccine effectiveness in immunosuppressed older adults: an individual-level pooled analysis (FLUNITY-HD). <i>A.M. Reimer Jensen* (Copenhagen, Denmark), N.D. Johansen, J. Pardo-Seco, C. Rodríguez-Tenreiro-Sánchez, M.M. Loiacono, R.C. Harris, K. Sharff, J.A. Hill, Y. Huang, R. Van Aalst, A. Chit, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, C. Duran-Parrondo, M. Piñeiro-Sotelo, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S.D. Solomon, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, F. Martínón-Torres, T. Biering-Sørensen</i>
00024	09:06	The cost-effectiveness of a personalised <i>in vitro</i> antibiotic combination testing (IACT) service for treatment of carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CRPA) infections. <i>Y. Cai* (Singapore, Singapore), T.P. Lim, W. Lee, J.Q. Teo, A.L. Kwa, N. Graves</i>	L0004	09:06	Safety, tolerability and immunogenicity of SPVX02, a fridge-free thermostable tetanus-diphtheria vaccine compared to Tetadif and diTeBooster: a multi-centre, phase I, blinded, randomised clinical trial. <i>S.N. Faust* (Southampton, United Kingdom), T.A.N. Reed, P. Clarke, M. Razaque, J. De La Torre Arrieta, A. Garcia De Castro, R. Alexiev, C. Panainte, N. Khan, L. Grey, M. Matheson, H. Cuthbertson, O. Tuncer, S. Chatfield, B. Roser, A. Boyd, J.S. Nguyen-Van Tam, K. O'hanlon, A.P. Dale</i>
			L0005	09:18	Safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine: first results of the <i>TherVacB</i> phase Ia trial. <i>M. Addo* (Hamburg, Germany), M. Schunk, S.D. Jeske, N. Körber, S. Hardtke, H.M. Weichel, T. Bauer, F. Thiele, M. Wiegand, M. Hoelscher, U. Protzer</i>
			L0006	09:30	Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary

00025	09:18	Costs of hospital admissions linked with Gram-negative bloodstream infections among adults in England: an analysis using health resource groups. <i>K. Hayes* (London, United Kingdom), L. Miller, E. Van Leeuwen, J. Robotham, L. Uwais, E. Agnew, S. Evans</i>
00026	09:30	Beyond the tip of the iceberg: quantifying the effect of MDRO-carriage on postacute inpatient rehabilitation. <i>H. Kaba* (Goettingen, Germany), P. Wenzlaff-Lodge, S. Scheithauer</i>
00027	09:42	Mind the governance gap: a One Health systematic review of national AMR performance indicators. <i>E. O'Neill* (London, United Kingdom), U. Shafaque, V. Karadimitris, B. Hill, S. Ranganathan, E. Mossialos, M. Anderson</i>
00028	09:54	Benchmarking AWARe: estimating expected need of AWARe antibiotic use in 186 countries based on infection and resistance burden. <i>A. Cook* (London, United Kingdom), K. Pouwels, M. Sharland, B. Cooper</i>
00029	10:06	Interactive causal inference framework for assessing policy and consumption effects on antimicrobial resistance. <i>A. Gupta* (Natick, United States), C. Vania</i>
00030	10:18	UKHSA's contribution to the UK Antimicrobial Resistance National Action Plan 2024–2029 (year one). <i>C. Brown* (London, United Kingdom), R. Hope, V. Finistrella, J. Conneely, G. Eldridge, J. Charlesworth, S. De Cordova, E. Ombakho, F. Ambreen, J. Gritton</i>

LB001	08:30 – 10:30	Hall A3-1
	2-hour Oral Session	

Late-breaking vaccine trials	
Chairs	<i>Zitta Barrella Harboe (Hillerød, Denmark), Maheshi Ramasamy (Oxford, United Kingdom)</i>

L0001	08:30	Impact of colonisation acquisition and PCV15 on symptoms following serotype 3 experimental human pneumococcal challenge (EHPC): results from a phase IV double-blind randomised clinical trial. <i>J.L. Martinelli* (Oxford, United Kingdom), Y. Ni, K. Tanha, R. Huq, B. Rocha De Macedo, C. Solórzano, A. Hyder-Wright, R. Mahmud, H. Gill, R. White, A. Singha, F. Elterish, T. Condreanu, B. Urban, E. Mitsi, X. Liu, A.M. Collins, D.M. Ferreira, S.B. Drysdale</i>
L0002	08:42	Updated safety and immunogenicity results from a UK-based phase I clinical trial of the Nipah virus candidate vaccine ChAdOx1 NipahB. <i>D. Jenkin* (Oxford, United Kingdom), R. Kenneil, N. Marchevsky, I. Haeusler, L. Saldana Ortega, R. White, Y. Zhang, E. Morey, T. Madupuri, N. Panchal, E. Sheehan, J. Wright, E. Vannaxay, H. Zhang, S. Kelly, L. Hahn, D. Pulido-Gomez, G. Morshead, A. Boyd, A. Pollard, T. Lambe, S. Gilbert, B. Angus</i>
L0003	08:54	High-dose influenza vaccine effectiveness in immunosuppressed older adults: an individual-level pooled analysis (FLUNITY-HD). <i>A.M. Reimer Jensen* (Copenhagen, Denmark), N.D. Johansen, J. Pardo-Seco, C. Rodríguez-Tenreiro-Sánchez, M.M. Loiacono, R.C. Harris, K. Sharff, J.A. Hill, Y. Huang, R. Van Aalst, A. Chit, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, C. Duran-Parrondo, M. Piñeiro-Sotelo, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S.D. Solomon, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, F. Martínón-Torres, T. Biering-Sørensen</i>
L0004	09:06	Safety, tolerability and immunogenicity of SPVX02, a fridge-free thermostable tetanus-diphtheria vaccine compared to Tetadif and diTeBooster: a multi-centre, phase I, blinded, randomised clinical trial. <i>S.N. Faust* (Southampton, United Kingdom), T.A.N. Reed, P. Clarke, M. Razaque, J. De La Torre Arrieta, A. Garcia De Castro, R. Alexiev, C. Panainte, N. Khan, L. Grey, M. Matheson, H. Cuthbertson, O. Tuncer, S. Chatfield, B. Roser, A. Boyd, J.S. Nguyen-Van Tam, K. O'hanlon, A.P. Dale</i>
L0005	09:18	Safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine: first results of the <i>TherVacB</i> phase Ia trial. <i>M. Addo* (Hamburg, Germany), M. Schunk, S.D. Jeske, N. Körber, S. Hardtke, H.M. Weichel, T. Bauer, F. Thiele, M. Wiegand, M. Hoelscher, U. Protzer</i>
L0006	09:30	Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary

		vaccination with protein-based vaccine <i>M. Desaj*</i> (Cambridge, United States), <i>J. Cardona, S. Khetan, S. Mehta, A. Kapoor, A. Okparavero, Z. Lin, F. Priddy</i>
L0007	09:42	<b>A double-blind randomised controlled trial on baloxavir marboxil and flufenamic acid combination for severe hospitalised influenza infection</b> <i>W. Chu*</i> (Hong Kong, Hong Kong), <i>I.F. Hung, J. Choi, T. Anthony</i>
L0008	09:54	<b>First-in-human study of EVT894, a monoclonal antibody against chikungunya virus</b> <i>H. Watson*</i> (Lyon, France), <i>K. Miller, A. Safder, S. Raja, L. Jordan, M. Mack, X. Boulenc, M. Mandron, M. Gordon, M. Jahromi, S. Woodson</i>
L0009	10:06	<b>Sequential administration of an mRNA-based seasonal influenza vaccine in older adults</b> <i>E. Malkin*</i> (Cambridge, United States), <i>A. Kohli, R. Chen, E. Du, A. Pucci, R. Das, E. Wilson</i>
L0010	10:18	<b>Longitudinal B cell immunity after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients</b> <i>M. Kern-Smith*</i> (Toronto, Canada), <i>P.M. Lavoie, A. Humar, D. Kumar, J. Mattsson, V.G. Hall, V.H. Ferreira</i>

SY035	08:30 - 10:30	Hall A1-1
	2-hour Symposium	

#### Microbial interactions and bacterial adaptation in the microbiome

<i>Chairs</i>	<i>Zuzanna Drulis-Kawa (Wroclaw, Poland)</i> <i>Mauricio Farfan (Santiago, Chile)</i>	
S0183	08:30	<b>The interplay of genetic drift and bacterial adaptation in skin microbiomes</b> <i>Julia Oh (Durham, United States)</i>
S0184	09:00	<b>Pathways of adaptive evolution in chronic lung infections</b> <i>Helle Krogh Johansen (Copenhagen, Denmark)</i>
S0185	09:30	<b>Bacteriophages and their interaction with the gut microbiome</b> <i>Naama Geva-Zatorsky (Israel)</i>
S0186	10:00	<b>Quantifying microbiome-host interactions in the human gut</b> <i>Markus Arnoldini (Zurich, Switzerland)</i>

SY036	08:30 - 10:30	Hall A1-5
	2-hour Symposium	

#### Recent advances in malaria molecular surveillance: experiences from malaria endemic countries

<i>Chairs</i>	<i>Abdoulaye Djimde (Bamako, Mali)</i> <i>Martin Peter Grobusch (Amsterdam, The Netherlands)</i>	
S0187	08:30	<b>Malaria molecular surveillance in the Horn of Africa using the MAD4HatTeR amplicon sequencing panel</b> <i>Fitsum Tadesse (Addis Ababa, Ethiopia)</i>
S0188	09:00	<b>A field-based nanopore amplicon sequencing (NOMADS) assay for malaria parasites and vectors</b> <i>Mulenga Chilumba Mwenda (Lusaka, Zambia)</i>
S0189	09:30	<b>Molecular surveillance in Africa using the Pf-SMARRT assay</b> <i>Ronald Futila Kyong-Shin (Chapel Hill, United States)</i>
S0190	10:00	<b>Genetic surveillance of <i>P. vivax</i> in the Greater Mekong Subregion using the Pv microhaplotype AmpSeq assay</b> <i>Thanh Thuy Nhien Nguyen (Ho Chi Minh City, Vietnam)</i>

SY037	08:30 - 10:30	Hall A3-2
	2-hour Symposium	

#### Unmet SDGs: Europe's struggle with HIV, TB, hepatitis and STIs

<i>Chairs</i>	<i>Tomislav Mestrovic (Varazdin, Croatia)</i> <i>Senia Rosales-Klantz (Solna, Sweden)</i>	
S0191	08:30	<b>Current epidemiological concerns and key gaps in progress towards the SDGs: where should Europe focus efforts to achieve maximum impact?</b> <i>Anastasia Pharris (Stockholm, Sweden)</i>
S0192	09:00	<b>Prevention of STIs across Europe: what is working and how to stem the tide?</b> <i>Nicola Low (Bern, Switzerland)</i>

S0193	09:30	<b>Equity in treatment: why is Europe lagging behind in terms of optimal TB care and access to all necessary medical products?</b> <i>Christophe Perrin (Paris, France)</i>
S0194	10:00	<b>Migration and the importance of an international approach to tackling the SDGs for TB, HIV and hepatitis</b> <i>Dominik Zenner (London, United Kingdom)</i>
Co-organised with: European Centre for Disease Prevention and Control (ECDC)		

SY033	08:30 - 10:30	Hall B0-1
	2-hour Symposium	

#### AI-enhanced sepsis care: from early detection to long-term follow-up

<i>Chairs</i>	<i>Michele Bartoletti (Milan, Italy)</i> <i>Damien Ming (London, United Kingdom)</i>	
S0175	08:30	<b>Early recognition and decision-making in sepsis: the role of AI-enhanced clinical pathways</b> <i>Sylvain Meylan (Lausanne, Switzerland)</i>
S0176	09:00	<b>Initial and adaptive antimicrobial therapy in sepsis: personalisation and stewardship in the age of AI</b> <i>Shruti Gohil (Irvine, United States)</i>
S0177	09:30	<b>From stabilisation to supportive care: integrating the ICU-level multimodal strategy</b> <i>Eric Kipnis (Lille, France)</i>
S0178	10:00	<b>Beyond survival: post-sepsis care, risk stratification, and AI-driven follow-up models</b> <i>Hannah Wozniak (Geneva, Switzerland)</i>
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)		

SY034	08:30 - 10:30	Hall B0-2
	2-hour Symposium	

#### Rapid pathogen sequencing for patient management: advancing diagnostic implementation

<i>Chairs</i>	<i>Claudio Neidhöfer (Basel, Switzerland)</i> <i>Torsten Seemann (Melbourne, Australia)</i>	
S0179	08:30	<b>State-of-the-art methodologies for clinical pathogen sequencing: bridging technology and application</b> <i>Oon Tek Ng (Singapore, Singapore)</i>
S0180	09:00	<b>Ensuring reliability: validation, regulation, and quality control in pathogen sequencing</b> <i>Paula Mölling (Örebro, Sweden)</i>
S0181	09:30	<b>From data to decision: clinical interpretation and integration of pathogen sequencing in patient pathways</b> <i>Luke Blagdon Snell (London, United Kingdom)</i>
S0182	10:00	<b>Genotypic predictions of antimicrobial resistance: unlocking the power of sequencing for treatment decisions</b> <i>Lorena Diaz (Santiago, Chile)</i>
Co-organised with: UK National Health Service Genomic Network of Excellence; Consortium for Clinical Metagenomics in Infectious Diseases (CCMID), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee		

SY031	08:30 - 10:30	Hall ICM 13b
	2-hour Symposium	

#### Biofilms, the hidden threat in healthcare environment: unveiling detection, control and prevention strategies

<i>Chairs</i>	<i>Joana Azeredo (Braga, Portugal)</i> <i>Claus Moser (Copenhagen, Denmark)</i>	
S0167	08:30	<b>Tackling dry surface biofilms</b> <i>Jean-Yves Maillard (Cardiff, United Kingdom)</i>
S0168	09:00	<b>That slimy stuff in water pipes!</b> <i>Michael Weinbren (London, United Kingdom)</i>
S0169	09:30	<b>Skin and soft tissue microbiomes and biofilms</b> <i>Blaine Fritz (Copenhagen, Denmark)</i>
S0170	10:00	<b>Biofilm coats catheters</b> <i>Gordon Ramage (Glasgow, United Kingdom)</i>
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)		

SY032	08:30 – 10:30	Hall ICM 5
	2-hour Symposium	
	<b>CLN</b> <b>DX</b> <b>VAX</b>	
<b>Beyond recovery: post-acute syndromes after respiratory viral infections</b>		
<i>Chairs</i>	<i>Raquel Duarte (Porto, Portugal)</i> <i>Paraskevi C. Fragkou (Markopoulo Mesogeion, Greece)</i>	
S0171	08:30	<b>Post-COVID-19 syndrome: respiratory and multisystem sequelae</b> <i>Ziyad Al-Aly (Saint Louis, United States)</i>
S0172	09:00	<b>Post-influenza syndromes: a hidden burden in clinical practice</b> <i>Sotirios Tsiodras (Athens, Greece)</i>
S0173	09:30	<b>RSV and other endemic respiratory viruses: what comes after acute infection?</b> <i>Chrysanthi Skevaki (Marburg, Germany)</i>
S0174	10:00	<b>Genetic basis of post-acute viral syndromes</b> <i>Hanna Ollila (Helsinki, Finland)</i>
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), European Respiratory Society (ERS)		

EW038	08:30 – 11:30	Hall ICM 1
	3-hour Educational Session	
	<b>AMR</b> <b>DX</b>	
<b>EUCAST user workshop</b>		
<i>Chairs</i>	<i>Alasdair Peter Macgowan (Bristol, United Kingdom)</i> <i>Amara Marlene (Paris, France)</i>	
W0195	08:30	<b>EUCAST Update</b> <i>Sören Gatermann (Bochum, Germany)</i>
W0196	09:00	<b>Challenges of testing beta-lactam/beta-lactamase inhibitors</b> <i>Mandy Wootton (Cardiff, United Kingdom)</i>
W0197	09:30	<b>When do you need an MIC</b> <i>Barbara Juliane Holzknacht (Copenhagen, Denmark)</i>
W0198	10:00	<b>Challenges of setting up a NAC in a large country</b> <i>Qiwen Yang (Beijing, China)</i>
W0199	10:30	<b>The role of clinical data in setting breakpoints</b> <i>Jesús Rodríguez-Baño (Seville, Spain)</i>
Co-organised with: EUCAST Steering Committee		

EF004	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	<b>ANT</b>	
<b>Beyond guidelines: how behaviour and social context shape antimicrobial prescribing</b>		
<i>Chair</i>	<i>Jaap Ten Oever (Nijmegen, The Netherlands)</i>	
E0031	08:30	<b>Prescribing inequities: evaluating under- and over-treatment across patient and neighborhood factors</b> <i>C. Evans* (Chicago, United States), S. Reddy, M. Dhanani, A. Rivera, D. Glover, G. Wilson, S. Balbale, M. Keintz, K. Suda, J. Marcelin</i>
E0032	08:36	<b>Understanding what matters to patients in antimicrobial stewardship in hospitals: a mixed-method study</b> <i>B. Jacob* (Dublin, Ireland), A. Kurian, E. De Barra</i>
E0033	08:42	<b>Impact in capacity building of an online training program and evaluation of factors related to behavioural change in infection prevention and control and antimicrobial stewardship practices</b> <i>O. Neth* (Seville, Spain), W. Goycochea-Valdivia, A. Gâchet, M. Amores, I. Kopsidas, G. Brigadoi, E. Barbieri, M. Bason, D. Kousi, M. Aboza, V. Serena, D. Daniele, T. Grammatiki-Christina, A. Arias, L. Cantarutti, C. Gianquinto, I. Gastesi, P. Rojo, C. Epalza</i>
E0034	08:48	<b>Reframing antimicrobial stewardship by empowering stakeholders through the One Health lens</b> <i>C. Mulrooney* (Waterford, Ireland), Z. Ramsamaroo, J. Britton, H. Awad, G. Rothwell-Kelly, M. Doyle, G. Chan</i>
E0035	08:54	<b>Evaluating primary care antimicrobial stewardship through simulated patient visits: a scoping review and application of patient management indicators in an intervention evaluation in two LMIC</b> <i>B. Ingelbeen* (Antwerpen, Belgium), D. Valia, V. Bertels, B. Mbangi, E. Tiendrebeogo, S. Declercq, D. Phanuz, H. Tinto</i>

E0036	09:00	<b>Beyond the algorithm: human factors driving AI-adoption in antimicrobial stewardship (AMS)</b> <i>D. Yij* (Singapore, Singapore), S. Tang, L. Loo, J. Chung, W. Lee, A. Kwa, E. Lum</i>
E0037	09:06	<b>Knowledge and attitudes of allied healthcare professionals towards antibiotic use and antimicrobial resistance: questionnaire-development and a quantitative, cross-sectional study</b> <i>M. Gajdács* (Szeged, Hungary), Z.L. Szabó, E.R. Major, R. Finta, E. Paulik</i>
E0038	09:12	<b>Patients' and the public's knowledge and understanding of antimicrobial resistance and antimicrobial stewardship: a systematic review and meta-analysis</b> <i>B. Jacob* (Dublin, Ireland), A. Kurian, E. De Barra</i>
E0039	09:18	<b>Behavioural determinants of hospital antimicrobial prescribing in Italy: a multi-centre COM-B and TDF-informed study</b> <i>M. Torre* (Rome, Italy), A. Bandera, S. Leone, A. Tedesco, A. Capone, S. Tedeschi, A. Mularoni, A. Cona, R. Murri, C. Torti, S. Cicalini</i>

EF005	08:30 – 09:30	Arena 2
	ePoster Flash Session	
	<b>ANT</b> <b>TRN</b>	
<b>Old viruses, new weapons: emerging antiviral therapies from bench to bedside</b>		
<i>Chair</i>	<i>Heli Harvala (Turku, Finland)</i>	
E0040	08:30	<b>MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates single-agent efficacy against HCV/HBV co-infection <i>in vitro</i>, and achieves HCV and HBV preclinical proof-of-concept</b> <i>D. Haders* (San Diego, United States), V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, W. Brubaker, P. Gally, D. Smith</i>
E0041	08:36	<b>Real-world effectiveness of extended use of letermovir among adult allogeneic haematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies</b> <i>R. Chemaly* (Houston, United States), A. Vyas, H. Appaneal, A. Beyer</i>
E0042	08:42	<b>Antiviral efficacy of a single dose of EV25, a novel antibody recruiting molecule, in a human influenza A/H3N2 challenge trial</b> <i>A. Cohen* (The Sea Ranch, United States), A. Wozniak, M. Niedrauer, S. Low, A. Blouin, C.L. Campbell, I. Shahriar, J. Nielsen, P.S. Low</i>
E0043	08:48	<b>Zelicapavir demonstrates high clinical and functional barrier against antiviral resistance: results from a randomised double-blind placebo-controlled paediatric RSV antiviral clinical trial</b> <i>J. Devincenzo* (Watertown, Ma, United States), M. Rhodin, T. Ngo, A. Ahmad, C. Harris, R. Levene, S. Rottinghaus</i>
E0044	08:54	<b>Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam</b> <i>H. Koshimichi* (Osaka, Japan), T. Sonoyama, R. Yonemoto, R. Kubota</i>
E0045	09:00	<b>Identification and structural characterisation of CID-375076 as a promising small molecule inhibitor of HCV NS3 protease</b> <i>D. Diksha* (Rishikesh, India), S.K. Gupta, Y.P. Mathuria</i>
E0046	09:06	<b>Next-generation alkaloid entry inhibitors against emerging flaviviruses and coronaviruses: a step toward broad-spectrum antivirals</b> <i>S. Sadhu* (Faridabad, India), A. Awasthi</i>
E0047	09:12	<b>DEN-HOST: a randomised, adaptive phase III trial evaluating host-directed therapeutics for moderate and severe dengue</b> <i>A. McBride* (Oxford, United Kingdom), L. Peto, H.Q. Chanh, P.K. Lam, J. Cattrall, N.L. Vuong, P.Y. Chia, A. Rojek, J. Whitehorn, L. Villar, P. Horby, T.W. Yeo, J. Watson, E. Kestelyn, S. Yacoub</i>
E0048	09:18	<b>Factors influencing ganciclovir trough concentrations during prophylaxis or therapy of CMV infections</b> <i>O. Epaulard* (Grenoble, France), C. Masseur, L. Liaigre, C. Chapuis, R. Le Cras, R. Germi, E. Gautier-Veyret</i>
EF006	08:30 – 09:30	Arena 4
	ePoster Flash Session	
	<b>CLN</b> <b>DX</b> <b>PHEI</b>	
<b>Trending topics in TB and other mycobacterial infections</b>		
<i>Chair</i>	<i>Hanif Esmail (London, United Kingdom)</i>	

E0049	08:30	<b>CRISPR and phage footprints reveal an aquatic ancestry for the tuberculosis pathogen <i>A. Ghodousi*</i> (Milan, Italy), M. Omrani, C. Gaudin, M. Marceau, P. Supply, D.M. Cirillo</b>
E0050	08:36	<b>Developing a 2-gene host-response lateral flow test for TB <i>R. Reid*</i> (London, United Kingdom), C. Patwardhan, R. Armiger, J. Sturgeon, J. Herberg</b>
E0051	08:42	<b>Asymptomatic is not less infectious: school-based study using targeted maximum likelihood estimation method highlights critical role of asymptomatic TB in transmission <i>Q. Ruan*</i> (Shanghai, China), S. Ge, Y. Ren</b>
E0052	08:48	<b>Seeing what symptoms can't: community-based PDX screening as a game-changer for asymptomatic TB diagnosis in Nigeria <i>S. Batur*</i> (Abuja, Nigeria), A. Okoh, M. Sheshi</b>
E0053	08:54	<b>Asymptomatic mediastinal tuberculosis (TB) emerging in non-TB clinical pathways: findings from a multi-centre UK EBUS cohort <i>F. Fama*</i> (London, United Kingdom), A. Read, J. Murray, D. Creer, M. Belton, M. Brown, A. Garcia Mingo, J. Goldring, P. Gothard, H. Ip, H. Jarvis, S. Lee, Z. Mangera, R. Moores, N. Navani, A. Patel, R. Thakrar, C. Tweed, C. Valerio, S. Bamanugama, H. Sansum, R. Bhatia, P. Papineni, A. Whittington, M. Burman, S. Moody, N. Kakkar, A. Houston, M. Ye, O. Kon, A. Alexiadis, R. Merriman, F. Perrin, H. Burgess, G. Santis, H. Kunst, J. Brown, R. Gupta, S. Joseph, A. Daunt, J. Potter, S. Capocci, M. Lipman</b>
E0054	09:00	<b>Comparative transmissibility of bacteriologically confirmed vs clinically diagnosed pulmonary TB in school settings: implications for contact screening strategies <i>C. Chu*</i> (Shanghai, China), Y. Ren</b>
E0055	09:06	<b>Interim findings from community-wide screening to treat TB disease and infection in a high prevalence MDR-TB setting in Papua New Guinea <i>S. Majumdar*</i> (Melbourne, Australia), T. Marukutira, N. Pank, A. Aung, G. Kama, I. Krangaie, M. Boga, S. Islam, S. Maguri, J. Greig, A. Maha, G. Chan, G.K.L. Huang, W. Pomat, M. Kal, S. Graham</b>
E0056	09:12	<b>Pre-existing isoniazid resistance and acquired rifampicin-resistant tuberculosis <i>R. Spies*</i> (Ho Chi Minh City, Vietnam), N.H. Hanh, P.T. Phu, N.L. Quang, D.D.A. Thu, T.T.B. Tram, V.T.N. Ha, G. Thwaites, M. Choisy, N.T.T. Thuong, J. Watson, T. Walker</b>
E0057	09:18	<b>Longitudinal imaging reveals severe lung pathology in preclinical <i>M. avium</i> BALB/c mouse model using hypervirulent clinical isolates <i>T. Van Win*</i> (Leuven, Belgium), W. Brangers, G.J. Wijnant, A. Reséndiz Sharpe, G. Vande Velde, E. André</b>
OS007	09:30 - 10:30	Hall A2-2 1-hour Case Session <b>CLN DX</b>
<b>Bad to the bone</b>		
Chairs	<i>Gina Suh</i> (Rochester, Minnesota, United States) <i>Erlangga Yusuf</i> (Rotterdam, The Netherlands)	
O0058	09:30	<b>Disseminated MDR tuberculosis manifesting as Pott's disease with tuberculous septic ankle arthritis: an uncommon sequential dual-site involvement <i>J. Muqtadir*</i> (Rochester, United States), I. Batool</b>
O0059	09:41	<b><i>Bacteroids fragilis</i> an unusual cause of bone and joint infection in children, a case report <i>H. Al Dhanhani*</i> (Abu Dhabi, United Arab Emirates), N. Elsayed, E. Shebany</b>
O0060	09:52	<b>A rare aetiology of periprosthetic joint infection in a patient from a rural area <i>C. Gay González*</i> (Logroño, Spain), I. Arregui García, J.A. Madrigal Cruz, J.R. Blanco Ramos</b>
O0061	10:03	<b>Extensive tibial and calcaneal osteomyelitis with bilateral knee septic arthritis caused by <i>Burkholderia thailandensis</i> <i>K.V. Abalajon*</i> (Pasig City, Philippines), K.E. Henson</b>
O0062	10:14	<b>Conventional and unconventional use of a commercial panel in paediatric patients with severe infections: the experience of the paediatric hospital of Padua, Italy <i>D. Doni*</i> (Padua, Italy), B. Veronica, M. Sciro, C. Mariachiara, M. De Pieri, G. Brigadoi, D. Donà</b>

SY041	09:30 - 10:30	Hall ICM 14 1-hour Symposium <b>IPC</b>
<b>Year in infection control</b>		
Chairs	<i>Ermira Tartari</i> (Msida, Malta) <i>Walter Zingg</i> (Zurich, Switzerland)	
S0208	09:30	- <i>Nico Tom Mutters</i> (Bonn, Germany)
S0209	10:00	- <i>Maaïke Van Mourik</i> (Utrecht, The Netherlands)
EF008	09:30 - 10:30	Arena 3 ePoster Flash Session <b>AMR</b>
<b>Genomic and epidemiological patterns of antimicrobial resistance</b>		
Chair	<i>Filip Bielec</i> (Łódź, Poland)	
E0063	09:30	<b>Epidemiologic shift in MRSA bacteraemia in Chile: clinical impact of emerging community strains <i>L. Rojas*</i> (Puerto Montt, Chile), A. Peters, B. Conrads, J. Martínez, A. Aguayo, J.M. Munita, L. Diaz, L. Rivas, P. García, M.L. Rioseco, J. Moreno</b>
E0064	09:36	<b>High-risk clones and resistance gene convergence among community uropathogens in India: genomic evidence from a nationwide study <i>S. Pundir*</i> (New Delhi, India)</b>
E0065	09:42	<b>The coverage paradox in global AMR surveillance: low-coverage countries report 3.4-fold higher resistance rates <i>P. Kilgore*</i> (Detroit, United States), P. E. Kilgore</b>
E0066	09:48	<b>Is the high prevalence of antibiotic resistance in LMICs the result of local or global emergence? <i>S. Benvari*</i> (St Andrews, United Kingdom), M. Holden, K. Keenan, A. Sandeman</b>
E0067	09:54	<b>The effects of broad-spectrum antibiotics vs placebo on antimicrobial resistance of faecal <i>Escherichia coli</i> <i>A. Hakanen*</i> (Turku, Finland), P. Salminen, A. Pajander, T. Kallonen, S. Vanhatalo, S. Hurme, M. Gunell, R. Penttinen, E. Munukka, J. Haijanen, S. Sippola</b>
E0068	10:00	<b>Sentinel surveillance of macrolide resistance in <i>Salmonella</i>: genomic prevalence and phenotypic expression <i>A. Robinson*</i> (London, United Kingdom), S. Nair, C. Maguire, A. Levy, D. Powell, A. Ismailahmed, M.A. Chattaway</b>
E0069	10:06	<b>Epidemiological evolution of shigellosis after COVID-19: data from a tertiary hospital in Spain <i>L. Argente Colás*</i> (Pamplona, Spain), L. Argente, G. Martínez, I. Beguiristain, C. Martin, M. Elia, M.E. Portillo</b>
E0070	10:12	<b>Genomic epidemiology and plasmid architecture of NDM carbapenemase-producing Enterobacterales in Germany (2015–2021) <i>M. Elbediwi*</i> (Oldenburg, Germany), J. Sattler, A.F. Wendel, B. Bader, J. Müller, S. Peter, A. Hamprecht</b>
OS013	11:00 - 12:00	Hall A1-4 1-hour Case Session <b>CLN DX</b>
<b>Life-threatening fungal infections</b>		
Chairs	<i>Daniel Aguilar-Zapata</i> (Mexico City, Mexico) <i>Armelle Villalobos</i> (Winnipeg, Canada)	
O0072	11:00	<b>Importance of source control in prosthetic fungal endocarditis: multiple antifungal therapy failures, including breakthrough infection under long-term suppressive rezafungin therapy <i>C. Colarossi*</i> (Piacenza, Italy), G. Priante, V. Lepera, L. Gerra, D. Aschieri, S. El Qarra, F. Nicolini, G. Lo Cascio, F. Trapani</b>
O0073	11:11	<b>Recurrent prosthetic valve endocarditis by <i>Candida parapsilosis</i> with <i>de novo</i> azole resistance: a five-thousand-day clinical evolution confirmed by genomic sequencing <i>J. Marroyo Laso*</i> (Madrid, Spain), P. Merino Amador, F. Gonzalez Romo, I. Vilacosta, C. Olmo, O. Zaragoza</b>
O0074	11:22	<b>Disseminated mucormycosis in an apparently immunocompetent adult: case report and systematic review <i>S. Rao Kordcal*</i> (New Delhi, India), A.</b>

*Sengupta, R. Sarda, G. Singh, M. Soneja*

00075	11:33	<b>Cerebral histoplasmosis in a patient under ibuprofen therapy: diagnostic challenges and paradoxical radiological progression after treatment initiation</b> <i>G. Thizy* (Paris, France), M. Schmitt, S. Hamane, A. Alanio, B. Denis</i>
00076	11:44	<b>Disseminated aspergillosis and cryptococcal meningitis in patients treated for immunotherapy-related myocarditis and myocarditis-myositis-myasthenia gravis (Triple M) overlap syndrome: an unmet need for antifungal prophylaxis?</b> <i>J. Cruise* (Liverpool, United Kingdom), L. Cossar, T. Guinan, A. Johnson, A. Howard, L. Turtle, N. Garbutt, A. Olsson-Brown</i>

OS010	11:00 - 12:00	Hall A1-1
	1-hour Oral Session	

**Exploiting biology for therapy: novel approaches against antimicrobial-resistant pathogens**

*Chairs Katy Jeannot (Besançon, France) Robert C. Read (Southampton, United Kingdom)*

00077	11:00	<b>Calcium phosphate nanostructures: alternative approach against antibiotic-resistant <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i></b> <i>M. Mariotti* (Rome, Italy), D. Squitieri, L. Degli Esposti, C. Fusacchia, R. Torelli, M. Sanguinetti, M. Iafisco, F. Bugli</i>
-------	-------	---

00078	11:12	<b>AMR-endemic flies represent an underexplored reservoir of lytic bacteriophages</b> <i>W. Martins* (Oxford, United Kingdom), C. Rubio, K. Cook, T. Iannetelli, S. Premchand-Branker, E. Portal, G. Jordao, T. Beard, A. Lankapalli, K. Iregbu, S. Afegbua, A. Aliyu, Y. Mohammed, I. Nwafia, O. Oduyebo, A. Ibrahim, Z. Tanko, T. Walsh, C. Achi, K. Sands</i>
-------	-------	--

00079	11:24	<b>Neutrophil peptidyl-arginine deiminase as dual anti-bacterial and anti-biofilm agents</b> <i>R. Baird* (Dublin, Ireland), D. Gogoi, L. Forde, M. Niu, S.W. Ahmed, F. Fitzpatrick, E.P. Reeves</i>
-------	-------	--

00080	11:36	<b>Af-DAPI0-CD3z-CAR-NK92 cells exert enhanced antifungal activity against <i>A. fumigatus</i></b> <i>M. Mauget* (Rennes, France), A.L. Schmitt, H. Einsele, M. Hudecek, J. Löffler, M. Seif</i>
-------	-------	--

00081	11:48	<b>Characterisation of novel vibrio phages as biocontrol agents against <i>Vibrio alginolyticus</i> and insights into its phage-resistant mutant</b> <i>R. Nepal* (Battery Point, Australia), T. Charles, R. Taylor, J. Wynne</i>
-------	-------	---

OS011	11:00 - 12:00	Hall A1-2
	1-hour Oral Session	

**Mechanisms of hypervirulence and resistance in *Klebsiella pneumoniae***

*Chairs Alessandra Carattoli (Rome, Italy) Yunn-Hwen Gan (Singapore, Singapore)*

00082	11:00	<b>Immunotherapeutic monoclonal antibodies against antibiotic-resistant <i>Klebsiella pneumoniae</i> derived from glycoconjugate-based immunisation</b> <i>B. Fries* (Yes, United States), K. Mihooliya, C. Boniche-Alfaro, T. Imeraj</i>
-------	-------	---

00083	11:12	<b>The plasmid-borne lytic transglycosylase PLT-1 augments virulence in ST11 carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> by exacerbating immune responses and macrophage death</b> <i>P. Jia* (Beijing, China), W. Yu, Q. Yang</i>
-------	-------	--

00084	11:24	<b>Differences in basal adaptation of core proteome expression between hypervirulent and multidrug-resistant <i>Klebsiella pneumoniae</i> lineages</b> <i>P. Miguela-Villoldo* (Madrid, Spain), D. Fousteris, I. Alonso-González, L. Vaughan, A. Tajuelo, B. Cano-Castaño, S. Prieto Martín-Gil, E. Gato, A. Peláez-García, V. Martín, A. Pérez, A.J. Martín-Galiano</i>
-------	-------	--

00085	11:36	<b>The virulence related response of Hypervirulent <i>Klebsiella pneumoniae</i> to phagocytosis by murine macrophage</b> <i>S. Belge* (Istanbul, Türkiye), C. Vatanserver, Ö. Albayrak, S. Yalçın, A. Akpınar, F. Can</i>
-------	-------	---

00086	11:48	<b>Genetically-defined hypervirulent carbapenem-resistant <i>Klebsiella pneumoniae</i> (Hv-CRKP) exhibited diverse biological phenotypes: evidence from</b>
-------	-------	---

**different clades of ST11-KL64, the most prevalent hv-CRKP strains in China** *X. Chu\* (Beijing, China), Q. Zhang, W. Yu, Y. Zhu, X. Jia, Q. Yang*

OS012	11:00 - 12:00	Hall A1-3
	1-hour Oral Session	

**Sexually transmitted infections: typing to therapy**

*Chairs Nicola Low (Bern, Switzerland) Aaron Schembri (Attard, Malta)*

00087	11:00	<b>Optimising multi-modal surveillance of drug-resistant <i>Neisseria gonorrhoeae</i></b> <i>N. Sherry* (Melbourne, Australia), C. Glover, P. Roydhouse, H. Shrestha, M. Wilmot, N. Higgins, M. Chen, M. Ivan, B. Howden</i>
-------	-------	--

00088	11:12	<b>Towards global harmonisation of the mgpB typing scheme for <i>Mycoplasma genitalium</i>: updating the PubMLST platform to enable effective surveillance</b> <i>S. Manoharan-Basil* (Antwerp, Belgium), I. De Baetselier, S. Pereyre, J. Guiraud, L. Piñeiro, J. Danielewski, M.J. Borrego, N. Adriaens, J.S. Jensen, N. Nordal-Budinsky, K. Imai, R. Dumke, O. Harrison</i>
-------	-------	--

00089	11:24	<b>Benzathine penicillin G plus doxycycline vs benzathine penicillin G alone for early syphilis in people with HIV: interim analysis</b> <i>K.Y. Lin* (Taipei, Taiwan), C.P. Chen, C.S. Tsai, M.S. Tsai, P.L. Lu, K.H. Chen, P.L. Chen, Y.W. Weng, H.J. Tang, C.C. Hung</i>
-------	-------	---

00090	11:36	<b>Advancing STI care in low- and middle-income countries: development of a multiplex lateral flow assay for gonorrhoea and chlamydia</b> <i>B. Blumel* (Geneva, Switzerland), H. Ramachandriaiah, B. Gleeson, V. Chuchu, S. Mchugh, M. Lear, E. Cruz-Andres, K. Keith, J. D. Klausner</i>
-------	-------	--

00091	11:48	<b>Syphilis in bone and joint: what the skeletons tell us and why it matters today</b> <i>F. Spada* (Naples, Italy), N. Schiano Moriello, J. Kowalska, G. Monsel, K. Roberts, M. Augello, F.B. Farkas, M. Farajova, A. Harxhi, A. Fidji Glaria Campo, I. Gentile</i>
-------	-------	--

OS014	11:00 - 12:00	Hall A1-5
	1-hour Oral Session	

**Turning AMS evidence to action**

*Chairs Sara Cosgrove (Baltimore, United States) Flaminia Olearo (Berlin, Germany)*

00092	11:00	<b>Bridging surveillance and stewardship: using the ECRAID Emerging Resistance Index to prioritise reserve antibiotics when guidelines offer equivalent options</b> <i>M.D. Pezzani* (Verona, Italy), D. Ortiz, J. Garlasco, K. Odoj, F. Arieti, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Prestrel, G. Kahlmeter, A. Savoldi, E. Tacconelli</i>
-------	-------	--

00093	11:12	<b>A cluster-randomised controlled pragmatic trial to evaluate antibiotic stewardship strategies for short-course and oral-switch antibiotic therapy for Enterobacteriales bloodstream infections</b> <i>C.Y.G. Lui* (Hong Kong, Hong Kong), C.M.T. Li, M. Mung, C. Cheung, C.T. Au-Yeung, H.Y. Ho, W.L.F. Luk, C.M. Leung, C. Lai, V. Chow</i>
-------	-------	---

00094	11:24	<b>Active auditing in antimicrobial stewardship programs improves appropriateness of prescribing: an observational cohort study</b> <i>C. Chen* (Melbourne, Australia), L. Hall, K. Thursky, N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson</i>
-------	-------	---

00095	11:36	<b>Multidrug-resistant Gram-negative bacteria screening to guide perioperative prophylaxis in colorectal surgery: a multi-centre quasi-experimental study</b> <i>D. Fasan* (Verona, Italy), M. Morra, M. Da Meda, M.D. Pezzani, M. Tebon, V. Mengardo, A. Di Gioia, M. Genna, S. Zerva, A.R. Andritsos, I.M. Fieraru, D. Costin, I. Salcedo-Leal, C. Diaz-López, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi-García, A. Hristea, C.M. Nicolae, W. Zingg, E. Tacconelli, E. Carrara</i>
-------	-------	--

00096	11:48	<b>An electronic medical record-based 'persuasive' antimicrobial stewardship intervention to align bloodstream infection treatment duration with evidence from the BALANCE trial</b> <i>J. Bramwell* (Melbourne, Australia), J. Hinh, S. Koning, K. Horne, L. Upjohn, J. Hughes, R. Junckerstorff, B. Rogers</i>
-------	-------	--

OS015 11:00 - 12:00 Hall A2-2

1-hour Oral Session

CLN TRN VAX

**Burden, immunity and management of viral infections in immunocompromised hosts**

*Chairs* Jon Salmanton-García (Cologne, Germany)  
Carla Walti (Basel, Switzerland)

00097 11:00 **Durability of immunity six months after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients** V. Hall\* (Melbourne, Australia), A. Alexander, F. Mavandadnejad, M. Kern-Smith, R. Kang, X. Dang, P. Lavoie, S. Humar, P. Winichakoon, R. Johnstone, M. Aversa, I. Novitzky-Basso, D. Kumar, J. Mattsson, V.H. Ferreira

00098 11:12 **Adoptive transfer of polyomavirus-specific T cells in progressive multifocal leukoencephalopathy: a multi-centre retrospective real-world analysis** G. Martin-Blondel\* (Toulouse, France), A. Chevalier, B. Bonneau, I. Cortese, D. Bensoussan, L. Grote-Levi, N. Möhn, P. Cinque, J. Rubinstein, R. Wicklein, T. Pfeiffer, B. Omer, M. Steinhardt, J.J. Tudesq, N. Testard, P. Chevallier, R. Bernard-Valnet, M. Le Maréchal, G. Catalano, B. Pignolet, A. Sommet, B. Eiz-Vesper, P. Comoli, T. Skripuletz

00099 11:24 **Cytomegalovirus infections after bispecific antibodies for relapsed/refractory multiple myeloma** J.S. Little\* (Boston, United States), I.A. Perez Villa, E. Arbona Haddad, E.B. Kim, A.J. Yee, O. Nadeem, S. Midha, A.S. Sperling, N. Munshi, N.S. Raju, D.D. Cirstea, S.P. Hammond

00100 11:36 **Therapeutic drug monitoring of letermovir in allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients: a prospective, two-centre observational study** J.S. Tang\* (Taipei, Taiwan), T.Y. Pai, Y.W. Wang, C.Y. Chen, H.A. Hou, B.S. Ko, P.Y. Chen, Y.J. Liu, H.Y. Lin, Y.H. Wu, Y.J. Chen, S.W. Lin

00101 11:48 **Target trial emulation of viral infection vs no infection and risk of invasive fungal disease after haematopoietic stem cell transplantation** L. Bussini\* (Pieve Emanuele, Milan, Italy), D.F. Bavaro, D. Sacchet, F. Mediolli, F. Berardi, M. Ronconi, P. Crombie, F.M.P. Tordato, B. Varisco, L. Diella, D. Mannina, J. Mariotti, C. Scuderi, M. Calabrò, R. Renzulli, V. Cento, S. Bramanti, M. Bartoletti

OS016 11:00 - 12:00 Hall A3-2

1-hour Oral Session

AMR

**Resistance trends in *Candida* species**

*Chairs* Maïken Cavling Arendrup (Copenhagen, Denmark)  
Jean-Pierre Gangneux (Rennes, France)

00102 11:00 **Activity of comparator antifungal agents against drug-resistant *Candida glabrata*** M. Winkler\* (North Liberty, United States), A. Klauer, S. Edeker, H. Kimbrough, P. Rhomberg, M. Castanheira

00103 11:12 **Clinical emergence and spread of *Candidozyma auris* outbreak-adapted lineages harboring mutations in RBA1** L. Doorley\* (Memphis, United States), A. La Bella, S. Jones, G. Zhao, M. Asadzadeh, Q. Choudhury, S. Ahmad, E. Mokaddas, I. Al-Obaid, W. Alfouzan, K. Al-Banwan, T. O'meara, F. Santiago-Tirado, A. Flores-Mireles, J. Rybak

00104 11:24 **Genomic analysis of *Candida parapsilosis* over a decade across multiple hospitals highlights clonal persistence and increasing fluconazole resistance** S. Srivastava\* (Delhi, India), N. Shukla, P. Kagra, K. Jain, A. Chowdhary

00105 11:36 **Calcineurin mediates caspofungin heteroresistance, a precursor to stable resistance in *Nakaseomyces glabratus*** Y. Su\* (Beijing, China), Y. Li, Y. Xu

00106 11:48 **Comparison of manogepix activity against 8,722 community-acquired and nosocomial yeast isolates from the SENTRY Antimicrobial Surveillance Program (2017-2024)** M. Winkler\* (North Liberty, United States), P. Rhomberg, S. Edeker, A. Klauer, M. Castanheira, M. Huband

OS009 11:00 - 12:00 Hall ICM 13b

1-hour Oral Session

ANT

**Tomorrow's antibiotics today: from first-in-human to phase III**

*Chairs* Daniele Roberto Giacobbe (Genoa, Italy)  
Erin McCreary (Pittsburgh, United States)

00107 11:00 **Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HAPB/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial** R. Takaya\* (Tokyo, Japan), K. Yanagihara, K. Tateda, H. Huang, H. Mukae, H. Ohge, Y. Doi, S. Takahashi, M. Yasuda, K. Matsumoto, M. Sumiya, K. Suwada, S. Kamiyabu, Y. Sasagawa, T. Minamida, S. Kato, K. Kondo, T. Naruse, H. Mikamo

00108 11:12 **Subgroup analysis of tebipenem pivoxil efficacy in patients with complicated urinary tract infection or acute pyelonephritis: results from the phase III PIVOT-PO study** S. Ascigli\* (London, United Kingdom), D. Hong, T. Otiker, Y. Sánchez-Pearson, A.J. Sheets, M. Sprys, N.E. Scangarella-Oman, N. Bhatt, I.A. Critchley, L.B. Gasink, K.A. Hamed, D. Sotolongo, K. Wrzosek, A. Peppercorn

00109 11:24 **Characterisation of *Pseudomonas aeruginosa* isolates from bronchiectasis patients in a phase II trial of a bispecific monoclonal antibody: GREAT-2** R.C. Hull\* (Dundee, United Kingdom), M.B. Long, A. Gilmour, I. Petrou, R. Galloway, K. Vilgorska, H. Richardson, J.M. New, C. Hennayake, E. Johnson, E. McIntosh, Z. Eke, H. Lind, M. Band, H. Bandara, G. Martin, S. Aliberti, M. Vendrell, E. Polverino, G. Suarez-Cuartin, M.R. Loebinger, M. Tunney, K. Cartwright, R. Hughes, A. Digliandomenico, M.G. Belvisi, W. Brailsford, C. Haworth, O. Sibila, J. Stobo, J.D. Chalmers

00110 11:36 **Overall response and microbiological eradication of cefepime/enmetazobactam vs piperacillin/tazobactam in patients with acute pyelonephritis: a post-hoc subgroup analysis from the ALLIUM phase III trial** J. Quevedo Marin\* (Cartagena, United Kingdom), J. Quevedo, S. Cure, N. Dunkel, N. Jemmely

00111 11:48 **Evaluating the efficiency of platform trial designs relative to stand-alone trials: a simulation study for the evaluation of new antibacterials** M. Hardy\* (Herston, Australia), P. Harris, Y. Mo, D. Paterson

SY046 11:00 - 12:00 Hall A2-1

1-hour Symposium

PHEI

**Engaging citizens in infectious disease surveillance, prevention, and research**

*Chairs* Tyra Grove Krause (Copenhagen, Denmark)  
Joel Mossong (Luxembourg, Luxembourg)

S0105 11:00 **Digital countermeasures for epidemic control** Emmanuel André (Leuven, Belgium)

S0106 11:30 **Virus monitoring at workplaces** Tine Graakjær Larsen (Værløse, Denmark)

SY047 11:00 - 12:00 Hall A3-1

1-hour Symposium

CLN DX

**Diagnostic stewardship: asking the right questions to measure clinical impact - a pro/con debate**

*Chairs* Adarsh Bhimraj (Houston, Texas, United States)  
Bhanu Sinha (Groningen, The Netherlands)

S0107 11:00 **Diagnostic stewardship is an important part of quality of care and has clinical impact** Heiman Wertheim (Nijmegen, The Netherlands)

S0108 11:30 **Diagnostic stewardship is an auxiliary to antimicrobial stewardship, but has no impact on quality of care** Evelina Tacconelli (Verona, Italy)

SY044 11:00 - 12:00 Hall BO-1

1-hour Symposium

AMR IPC

**The hospital bathroom as a hotspot for AMR**

<i>Chairs</i>	<i>Fidelma Fitzpatrick (Dublin, Ireland)</i> <i>Juliette Severin (Rotterdam, The Netherlands)</i>
S0101	11:00 <b>The sink: design and behavioural aspects to mitigate risks: towards a "sink bundle"</b> <i>Hillary Craddock (Dublin, Ireland)</i>
S0102	11:30 <b>Toilets: flushing and spread of pathogens</b> <i>Kalisvar Marimuthu (Singapore, Singapore)</i>

SY045 11:00 – 12:00 Hall B0-2

CLN

1-hour Symposium

**Updates on severe pneumonia**

<i>Chairs</i>	<i>Antonios Katsounas (Bochum, Germany)</i> <i>Preeti Malani (Ann Arbor, United States)</i>
S0103	11:00 <b>Severe community-acquired pneumonia</b> <i>Pedro Povoia (Lisbon, Portugal)</i>
S0104	11:30 <b>Severe hospital-acquired pneumonia</b> <i>Jordi Rello (Barcelona, Spain)</i>

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIPI), ESCMID Study Group for Infections in the Elderly (ESGIE), European Extracorporeal Life Support Organization, European Society of Intensive Care Medicine

SY043 11:00 – 12:00 Hall ICM 13a

CLN DX

1-hour Symposium

**Top papers in imported tropical diseases and diagnosis of parasitic infections**

<i>Chairs</i>	<i>Miriam José Alvarez Martinez (Barcelona, Spain)</i> <i>Ferenc Balázs Farkas (Budapest, Hungary)</i>
S0099	11:00 <b>Top papers in tropical diseases</b> <i>Pedro Legua (Lima, Peru)</i>
S0100	11:30 <b>Top papers in diagnosis of imported parasitic diseases</b> <i>Charlotte Sriruttan-Nel (Johannesburg, South Africa)</i>

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EF017 11:00 – 12:00 Arena 2

PHEI VAX

ePoster Flash Session

**Update in mosquito-borne infections and vector control**

<i>Chair</i>	<i>Gathsaurie Neelika Malavige (Nugegoda, Sri Lanka)</i>
E0112	11:00 <b>A one health regional framework for predictive dengue surveillance and early warning in Southeast Asia</b> <i>S. Sidhik* (Phnom Penh, Cambodia), S. Boyer</i>
E0113	11:06 <b>Blood-stage controlled human malaria infection in Tanzanian adults to assess the protective effect of the malaria vaccine candidates R78C and/or RH5.1 in a matrix adjuvant</b> <i>J. Van Heerden* (Oxford, United Kingdom), A.E. Kahatano, S. Silk, C. Rigby, S. Pollock, N. Lilolime, L. Batao, J. Salkeld, N. Kamau, R. Roberts, H. Msami, N. Urusa, E. Kenya, M. Mohamed, I. Mtaka, C. Carnrot, C. Nielsen, M. Mpina, S. Draper, A. Minassian, A. Olotu</i>
E0114	11:12 <b>Humoral and cellular immune responses to an intradermal live attenuated tetravalent dengue vaccine: a pilot study among healthy adults</b> <i>T. Khaimook* (Hat Yai, Thailand), S. Chusri, N. Pinpathomrat, P. Siripaitoon, N. Kositpantawong, S. Kanchanasuwan, S. Chittrakarn, S. Uppanisakorn</i>
E0115	11:18 <b>Immune response to TAK-003: updated results from the DENG-VAC Study</b> <i>A. D'abramo* (Rome, Italy), L. Ponzetta, F. Colavita, S. Vita, E. Cimini, P. De Marco, L. Rosa, M. Tiberi, F. Maggi, D. Goletti, E. Nicastrì</i>
E0116	11:24 <b>Wolbachia-mediated incompatible-insect technique robust to future climate change scenarios</b> <i>L. Geng* (Singapore, Singapore), P. Ross, A. Hoffmann, J.T. Lim</i>
E0117	11:30 <b>Projected chikungunya transmission in Australia is virus genotype dependent</b> <i>F. Frentiu* (Herston,</i>

Australia)

E0118	11:36 <b>Modelling the efficacy of vaccine and vector control tools of chikungunya in Asia Pacific</b> <i>E. Choo* (Singapore, Singapore), J.T. Lim</i>
E0119	11:42 <b>Rollout of seasonal R21 malaria vaccination and chemoprevention for children in Kule Refugee Camp in Gambela, Ethiopia during the 2024 malaria season</b> <i>Y. Atnafu* (Yeka Sub City, Ethiopia), Y. Girma, K. Siferaw, K. Lavilla, A. Tawassar, D. Koang, D. Tugizimana, A. Dirks, M. Ayalew, J. Loonen, C. Ariti, G. Mapiye, W. Mulanda, A.D.L. Pereira, A. Bestman, K. Velivela, B. Rao, B. Stringer, R. Wilson, A. Abbara, P. Keating</i>

EF018 11:00 – 12:00 Arena 4

AMR PHEI

ePoster Flash Session

**Socioeconomic and structural drivers of AMR**

<i>Chair</i>	<i>Sara Tomczyk (Berlin, Germany)</i>
E0121	11:00 <b>National priority assessment of multidrug-resistant microorganisms based on the multicriteria decision analysis</b> <i>Y.K. Yoon* (Seoul, Korea, Republic of), S.Y. Yu, E.Y. Bae, H. Seok, Y.J. Choe, S.J. Choi, H.S. Oh, J.W. Suh, J.Y. Kim</i>
E0122	11:06 <b>Socioeconomic inequality and corruption as determinants of antibiotic access and AMR burden</b> <i>S. Saeedi Moghaddam* (Kiel, Germany), M. Stolpe</i>
E0123	11:12 <b>Everyday realities of antibacterial drug resistance in Uganda: an ethnographic study of social and economic impacts</b> <i>S. Nayiga* (London, United Kingdom), A. Namajja, C. Chandler</i>
E0124	11:18 <b>"Bacteria and the Resistance": a microbial comic book</b> <i>G. Greub* (Lausanne, Switzerland), C. Aubry</i>
E0125	11:24 <b>Critical levels of multidrug resistance in pathogens circulating in the Niger river: implications for public health surveillance</b> <i>C. Touré* (Bamako, Mali), T. Cheick</i>
E0126	11:30 <b>A case study on effective student engagement in antimicrobial resistance: the Makerere University AMR club model</b> <i>V. Nabisere* (Kampala, Uganda), C. Akello</i>
E0127	11:36 <b>Sex, gender, and antimicrobial resistance: evidence and gaps across infection, selection and transmission</b> <i>G. Knight* (London, United Kingdom), O. Edun, A. Kjaersgaard, K. Horton, K. Keenan, J. Robotham, C. Wenham, C. Chandler</i>
E0128	11:42 <b>Caste-based disparities and AMR risks</b> <i>S. Goel* (Bengaluru, India), R. Bhagawati, A. Banerji, D. Batheja</i>
E0129	11:48 <b>Integrating antibiotic stewardship within a One Health framework: a pilot study on knowledge, attitude and practice questionnaire in companion animal veterinary medicine of Northern Italy</b> <i>F. Compostella* (Verona, Italy), M. Domaschio, D. Fasan, F. Sbardellati, E. Tacconelli, E. Carrara</i>

KNO42 11:00 – 12:00 Hall ICM 14

AMR IPC

Keynote lecture

**Containment of MRSA in hospitals: past, present, future**

<i>Chairs</i>	<i>Robert Leo Skov (Copenhagen, Denmark)</i> <i>Margreet C. Vos (Rotterdam, The Netherlands)</i>
K0098	11:00 <i>Susan Huang (Irvine, United States)</i>

ME048 11:00 – 12:00 Hall ICM 5

IPC PHEI

Meet-the-Expert

**Viral threats and antibiotic resistance in wastewater in the postpandemic era**

M0109	11:00 <i>Steen Ethelberg (Copenhagen, Denmark)</i>
M0110	11:12 <i>Henry-Michel Cauchie (Belvaux, Luxembourg)</i>

FO049 11:00 - 12:00 Arena 1  
Open Forum

PRO

**Sharing made simple: how standardised data exchange improves infectious diseases research and care**

Chair *Marc J.M. Bonten (Utrecht, The Netherlands)*

- FO111 11:00 **Sharing clinical laboratory and infectious disease data in the European Health Data Space for primary and secondary use** *Hynek Kruzik (Prague, Czechia)*
- FO112 11:10 **Using standards to bridge the divide between clinical trials and cohort studies: the ECRAID Base experience** *Ankur Krishnan (Heidelberg, Germany)*
- FO113 11:20 **Standardised sharing of national AMR surveillance data: showcase Netherlands** *Bram Lestrade (Roermond, The Netherlands)*
- FO114 11:30 **Standardised exchange of microbiological data for patient care, research and surveillance** *Alexandra Hoffmann (Berlin, Germany)*

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), European Clinical Research Alliance on Infectious Diseases (ECRAID), EU Lab Semantic WG HL7

FO050 11:00 - 12:00 Arena 3  
Open Forum

PRO

**Sharpening communication and leadership skills in CM/ID**

Chair *Mary Horgan (Dublin, Ireland)*

- FO115 11:00 **Communication skills for culturally competent infectious disease care** *Muge Cevik (Edinburgh, United Kingdom)*
- FO116 11:10 **Becoming doctor-influencers for better redefining CM/ID professionalism** *Akshatha Ravindra (Karnataka, India)*
- FO117 11:20 **Dealing with the Imposter syndrome** *Maeve Doyle (Waterford, Ireland)*

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee, ESCMID Education Subcommittee, TAE Steering Committee

OS021 13:30 - 14:30 Hall A3-1  
1-hour Oral Session

AMR CLN

**Clinical impact of drug resistance in Gram-negative infections**

Chairs *Lorena Diaz (Santiago, Chile)*  
*Helena Zemlickova (Prague, Czechia)*

- OO130 13:30 **Clinical Impact of Delayed Appropriate Antibiotic Therapy in Bloodstream Infections Caused by WHO Critical Priority Gram-Negative Pathogens: A Target Trial Emulation** *L. Mezzadri\* (Singapore, Singapore), W.C. Tan, X. Hao, J. Quah, A. Manesh, Y.T. Chang, A.T.K. Nguyen, Y. Ding, Y. Cao, Y. Cai, S. Kitsaran, H.H. Chua, S. Bory, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S. Faisal Mahmood, A.D. Roman, L. Thwaites, P.V. Tho, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O. Rehman Khalid, G.M. Salahuddin Mamun, G.S. Rajahram, H. Guterres, H.N. Hon, T. Van Giang, N.T. Pham, A. Karkey, S. Gunasekara, R. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, N.L. Priya, Y. Doi, H. Hitoshi, B. Baljin, U. Gurjav, R. Asli, L. Ling, A. Dhungana, L.Y. Hsu, D. Paterson, Y. Mo*
- OO131 13:42 **Impact of third-generation cephalosporin resistance on mortality in Enterobacteriales bloodstream infections: an individual participant data meta-analysis** *M. Guedes\* (Seville, Spain), M.E.A. De Kraker, N. Hassoun-Kheir, E. Salamanca, E. Rubio, A.D.L.S. Bazan, L.B. Pulido, A. Dambrauskienė, J. Rodríguez-Baño*
- OO132 13:54 **Antibiotic prescribing for presumed *Stenotrophomonas maltophilia* infections in the United States using Epic Cosmos** *S. Boettcher\* (Detroit, United States), R. Kenney, R. Tibbetts, A. Shallal, G. Suleyman, S. Davis, M. Veve*
- OO133 14:06 **Colonisation with multidrug-resistant Gram-negative**

**bacteria in a low endemic country is associated with substantial morbidity: a population-based observational study** *V. Andrews\* (Lund, Sweden), M. Inghammar, E. Senneby, O. Ljungquist*

- OO134 14:18 **Comparison of mortality after bloodstream infection with piperacillin/tazobactam-resistant vs -susceptible *Escherichia coli* and *Klebsiella pneumoniae*: a nationwide cohort study in Denmark, 2018-2024** *E. Tusch\* (Copenhagen, Denmark), B. Holzknacht, M. Lindegaard, R. Thoft Nielsen, U. S. Justesen, K. Kobberø Søgaard, T.S. Kostyanov, F. Boetius Hertz, M. Pedersen, R. B. Dessau, S. Skovgaard, J. Gitz Holler, L. Lützen, S. Ellermann-Eriksen, B. Kristensen, R. Skov, L. Engbo Christensen, A. Rhod Larsen, A. Hviid, A. Hammerum, P. Bager*

OS022 13:30 - 14:30 Hall A3-2  
1-hour Oral Session

PRO

**Game on: leveling up education through simulation and serious play**

Chairs *Anette Friedrichs (Kiel, Germany)*  
*Daniel Grupel (Jerusalem, Israel)*

- OO135 13:30 **Enhancing infectious diseases clinical practice through in situ simulation: a feedback-based evaluation** *R. Francis\* (Nottingham, United Kingdom), Y. Milnes, P. Bailey*
- OO137 13:54 **Design and Development of an Educational Card Game on Infectious Diseases for Anaesthesiology Residents: An Innovative Approach to Medical Education** *P. Lunenburg\* (Groningen, The Netherlands), W. Bult, H. Aardema, G. Wietasch, C. Van Den Berg*
- OO138 14:06 **Septis 2.0: A Mixed-Methods Multinational Evaluation of a Gamified Digital Tool for Sepsis Education and Quality Improvement** *S. Meylan\* (Lausanne, Switzerland), L. Shieh, S. Gupta, I. Pottmeyer, N. Mischler, E. Moulin, R. Williams*
- OO139 14:18 **First implementation of an educational escape room for the key symptom "diarrhea" within the course "key symptoms of internal medicine" of the medical curriculum at Christian-Albrechts-University Kiel to strengthen diagnostic and therapeutic reasoning and teamwork skills** *C. Kujat\* (Kiel, Germany), N. Mirwald, U. Macioszek, A. Friedrichs*

OS020 13:30 - 14:30 Hall BO-1  
1-hour Oral Session

CLN IPC

**From risk to resilience: advances in catheter-related infections across care settings**

Chairs *Shruti Gohil (Irvine, United States)*  
*Pilar Retamar Gentil (Seville, Spain)*

- OO140 13:30 **Risk of catheter-related infections with peripherally vs centrally inserted central catheters in critically ill patients: a propensity score-matched emulated target trial** *N. Boulet\* (Nimes, France), A. Friggeri, A. Gavaille, M. Gautier, B. Louart, A. Machut, A. Lepape, C. Roger*
- OO141 13:42 **Incidence, risk factors and mortality of catheter-related bloodstream infections: retrospective single centre study in non-ICU wards** *L. Gazzola\* (Milano, Italy), V. Vitaletti, E. Pezzoli, A. Tavelli, G.C. Marchetti*
- OO142 13:54 **Impact of a National Quality-Improvement Programme on CLABSI Reduction in Ten Greek Hospitals: Results from the GRIPP-SNF Consortium** *I. Kopsidas\* (Athens, Greece), G.C. Tsopela, A. Moutou, P. Varda, P. Pantelidou, D. Kousi, E. Kourkouni, A. Karaiskou, E. Thireos, D. Kaitelidou, A. Koutsoukou, T. Zaoutis*
- OO143 14:06 **Epidemiology and Outcomes of Nosocomial Infections in Patients Undergoing ECMO Support: An Eight-Year Retrospective Cohort Study** *M. Oliveira\* (Sao Paulo, Brazil), R. Lobo, F. Galas, C. Sambo, L. Pastore, N. Matos, E. Costa, H. Fernandes, D. Araujo, L. Cardoso, A.R. Guedes*
- OO144 14:18 **Genomic characterisation and molecular epidemiology of *Ralstonia thomasii* catheter-related bloodstream infections: report of an outbreak after disruption of the standardised process for venous**

**catheter care** *M. Delays Martínez\** (Mexico City, Mexico), *M.A. Delays-Martínez*, *P. Volkow-Fernández*, *E. López-Jácome*, *J. Ortiz-Álvarez*, *C. Velazquez-Acosta*, *M.D.L. García-Hernández*, *M. Hernández-Durán*, *C.F. Hernández-Pérez*, *M.D.R. Vázquez-Olivares*, *C.U. Franco-Frias*, *P. Cornejo-Juárez*, *F.M. Medina-Aguilar*, *D. Vilar-Compte*

OS019 13:30 – 14:30 Hall ICM 13a

1-hour Oral Session

AMR PED PHEI

**AMR in paediatric populations: from dynamic acquisition to predictive models**

*Chairs* Johannes Hübner (Munich, Germany)  
Theresa J. Ochoa (Lima, Peru)

00145 13:30 **Modelling the acquisition of extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacteriaceae* in neonates in Madagascar households** *M. Alexa\** (Paris, France), *B.T. Huynh*, *L. Opatowski*, *A.L. Beaumont*, *A. Harimanana*, *A. Rakotondraso*, *L. Odile Rivoarilala*, *A. Criscuolo*, *E. Fara Nandrasana Rakotomanana*, *P. Herindrany*, *J.M. Collard*, *T. Crucitti*

00146 13:42 **Intestinal acquisition and clearance dynamics of extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriales* in hospitalised Kenyan children: a longitudinal, multi-site follow-up study** *R. Aizouk\** (Oxford, United Kingdom), *C. Tigoi*, *S. Yan*, *M. Timbwa*, *M. Shalton*, *M. Ngari*, *R. Musyimi*, *H. Browne*, *J. Walson*, *T. Lawley*, *N. Stoesser*, *E. Van Kleef*, *J. Berkley*

00147 13:54 **Global surveillance gaps in maternal antimicrobial resistance: insights from isolate-level data on Gram-negative bacteria in LMICs** *L. Hookham\** (Falmer, United Kingdom), *J.R. Price*, *M. Sekikubo*, *J. Alger*, *F.A. Dávila Ramírez*, *O. Dissanayake*, *J.A. Frem*, *O. Herrera*, *O. Makanjuola*, *I. Martín-Jorge*, *J. Leach*, *J.H. Cross*

00148 14:06 **Multidrug-resistant bacterial and fungal colonisation and transmission dynamics in hospitalised neonates** *R. Kelleghan\** (Sydney, Australia), *M. Aberoumand*, *J. Beardsley*, *L.T. Cao*, *C. Duc Pham*, *T.M. Duong Nu*, *P.T. Hang*, *M. Harrison*, *L. Howie*, *M.H. Le*, *K. Luu Boi*, *N. Ngo*, *T. Ngo*, *T.M.A. Nguyen*, *T.A. Nguyen*, *P.A. Pham Dinh*, *A.T. Pham*, *V.A. Nguyen*, *T.D. Thi Hoang*, *P. Williams*

00149 14:18 **Artificial intelligence to predict antimicrobial resistance in Gram-negative bloodstream infections among paediatric onco-haematology patients** *I. Sartini\** (Bologna, Italy), *E. Rocchi*, *C. Campoli*, *C. Bonazzetti*, *D. Leardini*, *F. Baccelli*, *L. Chiularoli*, *D. Zama*, *M. Spadea*, *G. Tridello*, *P. Viale*, *S. Cesaro*, *M. Giannella*

SY052 13:30 – 14:30 Hall A2-2

1-hour Symposium

CLN PED

**Mycobacterial infections in childhood**

*Chairs* Elisabeth Schölvinck (Groningen, The Netherlands)  
Delane Shingadia (London, United Kingdom)

S0087 13:30 **New treatments and management of Tuberculous meningitis in children** *Diana Gibb* (London, United Kingdom)

S0088 14:00 **Optimising the diagnosis of NTM infections in childhood** *Jakko Van Ingen* (Nijmegen, The Netherlands)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

YIA 13:30 – 14:30 Hall ICM 1

Awards

**Young Investigator Award lecture**

*Chairs* Jon S. Friedland (London, United Kingdom)  
Jan A.J.W. Kluytmans (Utrecht, The Netherlands)

A001 13:30 **Re-thinking diagnostics to improve care in resource-limited settings** *Grace Androga* (Blantyre, Malawi)

A002 13:42 **Antibiotics on Target: Predicting Efficacious Dosing in Challenging Patient Populations** *Iris K. Minichmayr* (Vienna, Austria)

A003 13:54 **Can we develop better tests to measure individual infectiousness in respiratory virus infections?** *Daniel Pan* (Leicester, United Kingdom)

A004 14:06 **Beyond the Mold: Shifting Diagnosis and Therapy Through Host Immunity** *Sarah Delliere* (Paris, France)

A005 14:18 **Host-directed therapies and patient stratification for common bacterial diseases** *Clark Russell* (Edinburgh, United Kingdom)

EF023 13:30 – 14:30 Arena 1

ePoster Flash Session

CLN IPC TRN

**Gut microbiota-based interventions against gastrointestinal pathogens and antibiotic resistance**

*Chair* Marcela Krutova (Prague, Czechia)

E0150 13:30 **VE303 strains disrupt *Clostridioides difficile* growth and induce transition metal starvation responses** *L.P. Cornacchione\** (Cambridge, United States), *J.N. Brehm*, *Z. Anderson*, *G.L. Medlock*, *J.A. Sorg*

E0151 13:36 **Tolerance and efficacy of the *Faecalibacterium prausnitzii*/EXL01 strain for preventing recurrence of *Clostridioides difficile* infection: results from a multi-centre phase I study** *N. Benech\** (Lyon, France), *P. Guarino-Vignon*, *P. McLellan*, *S. Truong*, *A. Delmeule*, *C. Landman*, *A. Bourrier*, *L. Alric*, *J. Scanzir*, *N. Cassir*, *A. Dureault*, *E. Piet*, *S. Gallet*, *E. Botelho-Nevers*, *M. Guillet*, *F. Ader*, *H. Sokol*

E0152 13:42 **Impact of a defined bacterial consortium on host immune response and gut function in patients with *Clostridioides difficile* infection (CDI)** *J. Norman\** (Cambridge, United States), *R. Menon*, *S. Bhattacharai*, *A. Prince*, *Y. Huang*, *M. Giddins*, *V. Bucci*, *B. Olle*, *J.L. Silber*, *J. Faith*

E0153 13:48 **A global evaluation of the use of faecal microbiota transplant** *B. Merrick\** (Harrow, United Kingdom), *B.H. Mullish*, *S.D. Goldenberg*, *S. Khanna*, *V. Ahuja*, *C.L. Hvas*, *G.K. Makharia*, *H.R.T. Williams*

E0154 13:54 **Investigation of enterococcus colonisation impact on *Clostridioides difficile* disease severity** *T. Eubank\** (Houston, United States), *A. Mai*, *A. Horvath*, *K. Begum*, *T. Horvath*, *K. Garey*

E0155 14:00 **Faecal microbiota transplantation in paediatric patients: the first national experience** *B. Szabo\** (Budapest, Hungary), *B.G. Szabó*, *D. Korózs*, *J. Czelecz*, *L. Takács*, *Á. Visnyovszki*, *K. Csordás*, *C. Kassa*, *G. Kriván*

E0156 14:06 **Faecal microbiota transplantation in patients with irritable bowel syndrome profoundly reshapes the gut microbiome, but does not have any detectable clinical effects** *O. Cinek\** (Prague, Czechia), *J. Vejmelka*, *K. Hubáčková*, *K. Litosova*, *L. Hlinakova*, *M. Kulich*, *P. Kohout*, *J. Hurych*

E0157 14:12 **Improved clinical outcomes and shifts in intestinal microbiome and metabolites following intestinal microbiota transplantation in patients colonised with multidrug-resistant organisms** *R. Ghani\** (London, United Kingdom), *J. Bilinski*, *L. Martinez-Gili*, *P. Takis*, *J. Miguens Blanco*, *N. Geva-Zatorsky*, *H. Bar-Yoseph*, *M.R. Thurst*, *F. Davies*, *B.H. Mullish*, *J.R. Marchesi*

EF024 13:30 – 14:30 Arena 3

ePoster Flash Session

CLN DX TRN

**Molecular insights and surveillance of parasitic diseases**

*Chair* Özgür Kurt (Istanbul, Türkiye)

E0159 13:30 **Differential expression of carboxypeptidase (metallopeptidase M32) protein contributes to miltefosine drug resistance in *Leishmania donovani*** *K. Kumar\** (Hyderabad, India), *R. Maurya*

E0160 13:36 **Integrating PCR on Giemsa-Stained Smears for accurate diagnosis of cutaneous leishmaniasis** *F. Maatallah\** (Tunis, Tunisia), *W. Aissi*, *N. Boulehmi*, *O. Souissi*, *A. Bouratbine*, *K. Aoun*

E0161	13:42	<b>Protein-protein network is responsible for artemisinin induced cyto-toxic effects in liver cells</b> <i>E. Dodwani*</i> (Guwahati, India), <i>V. Trivedi</i>
E0162	13:48	<b>Temporal and geo-ecological patterns of malaria transmission and <i>Plasmodium falciparum</i> antimalarial drug resistance in Cameroon, 2019–2021 and 2025</b> <i>V.N.N. Ntui*</i> (Banjul, Gambia), <i>O.C. Eniyu, M.A. Demba, T.O. Apinjoh, A. Amambua-Ngwa</i>
E0163	13:54	<b>Dengue mortality rates in the elderly population of Brazil and Colombia, 2019 and 2020</b> <i>A. Rodriguez-Morales*</i> (Pereira, Colombia), <i>J.A. Cardona-Ospina, C.E. Perez, T.D.S.S. Chaves, P. Quispe, R.N. Angerami</i>
E0164	14:00	<b>Proteomic profiling of eluted Schistosoma antigens for enhanced diagnostic sensitivity</b> <i>B. Babalola*</i> (Ondo, Nigeria), <i>K. Sulaiman, T. Oriade, O. Oyeyemi</i>
E0165	14:06	<b>Molecular characterisation of <i>Cryptosporidium</i> infections in a tertiary hospital in Barcelona during three years of post-COVID19 pandemic period</b> <i>M. Alguacil Guillén*</i> (Barcelona, Spain), <i>D. Carmena, M.J. Alvarez-Martínez, M. Alguacil-Guillén, P. Köster, S. Sánchez-Prieto, P. Juan-Pardo, C. Aylagas, M.R. Ferré, J. Barrachina, P. Rodríguez, L. Horvath, J. Iglesias, M. Espasa, M.E. Valls</i>
E0166	14:12	<b>Ten-year retrospective surveillance of <i>Cryptosporidium</i> spp., Giardia lamblia and Entamoeba histolytica in the Netherlands</b> <i>E.M.J. Groenen*</i> (Bilthoven, The Netherlands), <i>T.J. Roodsant, A. Al-Dawaf, A. Bart, G.J.H. Bastiaens, M. Berends, D.A.T. Hanssen, J.J. Van Hellemond, S.D. Kuij, S. Lekkerkerk, J.D. Machiels, B. Mulder, M.R. Ramos Diaz, E. Ruizendaal, J.M. Da Silva, S. Slavenburg, D. Souverein, E. Schaftenaar, K. Tassche-Borggreve, E. Vermeer, J.J. Verweij, A.L.M. Vlek, L.J. Wammes, R. Zonneveld, J.J. Hofstra, L. Mughini-Gras, I.H.M. Friesema</i>

EF025 13:30 – 14:30 Arena 4

ePoster Flash Session

AMR DX PHEI

#### Molecular diagnostic innovations across specimens

Chair *Mario Ramirez (Lisbon, Portugal)*

E0168	13:30	<b>PCNE: a tool for plasmid copy number estimation</b> <i>R. Bollini*</i> (Pavia, Italy), <i>V. Cento</i>
E0169	13:36	<b>Cerebrospinal fluid lipidome in central nervous system infections: A study of diagnostic accuracy</b> <i>S. Staal*</i> (Amsterdam, The Netherlands), <i>S. Olie, J.B. Van Klinken, M. Van Weeghel, F. Vaz, J. Bodilsen, H. Nielsen, D. Van De Beek, M. Brouwer</i>
E0170	13:42	<b>Use of a multiplex joint infection PCR panel on non-synovial fluids: comparing PCR vs culture</b> <i>G.M. Chuang*</i> (Singapore, Singapore), <i>S.Y.L. Tan, Y.E. Tan, K.S. Chan, L.L.E. Oon</i>
E0171	13:48	<b>Clinical evaluation of the OCEAN Dx culture-free assay for early detection of bacteraemia in critically ill patients</b> <i>A. Dewitte*</i> (Bordeaux, France), <i>J. Thierry, S. Cronier, O. Peuchany, V. Dubois, M. Mamani</i>
E0172	13:54	<b>Performance assessment of a real-time test for intrapartum detection of group B <i>Streptococcus</i> vaginal colonisation</b> <i>A. Tazi*</i> (Paris, France), <i>M. Selmi, S. Snoussi, C. Poyart, C. Plainvert</i>
E0173	14:00	<b>Breath aerosol PCR for detection of lower respiratory tract infections: evaluation of a non-invasive face mask collector in pneumonia patients</b> <i>M. Osthoff*</i> (Basel, Switzerland), <i>S. Dräger, K. Tiseo, H. Santhosh Kumar, M. Alkhatzavili, A. Hammann, P. Risch, R. Willi, T. Mkhathvari, C. Fialová, C. Adlhart, D. Szabó, M. Suknidze, I. Pachkoria, T. Broger, E. Ivanova Reipold, K. Varshaniidze</i>
E0174	14:06	<b>Enhancing molecular and genomic approaches for <i>Bordetella pertussis</i> investigation and public health surveillance in Victoria, Australia</b> <i>L. Sadeesh Kumar*</i> (Melbourne, Australia), <i>M. Sait, J. Merrett, J. Lacey, S. Baines, J. Strachan, N. Sherry, B. Howden</i>
E0175	14:12	<b>Viral dominance in CNS infections: five-year epidemiological surveillance using multiplex PCR panel</b> <i>Z. Tsinaris*</i> (Thessaloniki, Greece), <i>A. Tychala, G. Kagkalou, K. Kouirouxis, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou</i>

E0176	14:18	<b>Impact of rapid multiplex PCR testing on the clinical and therapeutic management of pneumonia: a prospective randomised study</b> <i>A. Galar*</i> (Madrid, Spain), <i>E. Bouza, A. Álvarez-Uría, P. Martín-Rabadán, E. Cercenado, M. Ferris-Villanueva, L. Martín-Aguilera, J. Serrano, L. Alcalá, M.L. Sánchez-Alegre, J. De La Torre Fernández, J.J. García-López, L. Puente, P. Muñoz</i>
-------	-------	--

JS001 13:30 – 14:30 Hall A2-1

Journal Session

CLN IPC

#### Late-breaking research from JAMA: novel insights on treating and preventing infections around the world

Chairs *Kirsten Bibbins-Domingo (Chicago, United States)*  
*Preeti Malani (Ann Arbor, United States)*

J0001	13:30	<b>Amoxicillin-clavulanate vs amoxicillin for acute sinusitis in adults</b> <i>Timothy Savage (Boston, United States)</i>
J0002	13:45	<b>Long-term cognitive ability and academic achievement after childhood severe malaria</b> <i>Chandy John (Indianapolis, United States)</i>
J0003	14:00	<b>Dalbavancin pharmacokinetics in complicated <i>Staphylococcus aureus</i> bacteraemia. A secondary analysis of the DOTS randomised clinical trial</b> <i>Thomas Holland (Durham, United States)</i>
J0004	14:15	<b>Fast antimicrobial susceptibility testing for Gram-negative bacteraemia: the FAST randomised clinical trial</b> <i>R. Banerjee*</i> (Nashville, United States), <i>L. Komarow, Y. Li, D. Mau, A. Dodd, H. Geres, K. Greenwood-Quaintance, A. Adler, S. Baliga, M. Chowders, G. Chrysos, M. Paul, S. Pournaras, D. Sousa Regueiro, S. Evans, H. Chambers, V. Fowler, Jr, R. Patel</i>

KN051 13:30 – 14:30 Hall ICM 14

Keynote lecture

PED PHEI

#### Rheumatic heart disease: a global problem

Chairs *Fidelma Fitzpatrick (Dublin, Ireland)*  
*Annelies Zinkernagel (Zurich, Switzerland)*

K0086 13:30 *Liesl Zuhlke (Cape Town, South Africa)*

ME055 13:30 – 14:30 Hall B0-2

Meet-the-Expert

CLN DX

#### Changing landscape of fungal infections in the solid organ transplant recipient

M0093 13:30 *Alessandra Mularoni (Palermo, Italy)*

M0094 13:42 *John Baddley (Baltimore, United States)*

ME053 13:30 – 14:30 Hall ICM 13b

Meet-the-Expert

AMR IPC PHEI

#### *Candida auris* surveillance: when, how and why

M0089 13:30 *Joseph Meletiadis (Athens, Greece)*

M0090 13:42 *Giulia De Angelis (Rome, Italy)*

Co-organised with: Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie (SIMPIOS), International Society of Human and Animal Mycology (ISHAM), EUCIC Steering Committee

ME054 13:30 – 14:30 Hall ICM 5

Meet-the-Expert

CLN IPC

#### LVAD infections: practical approaches to a complex challenge

M0091 13:30 *Saima Aslam (San Diego, United States)*  
M0092 13:42 *Margaret Hannan (Dublin, Ireland)*  
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Implant-associated Infections (ESGIAI)

FO056 13:30 - 14:30 Arena 2  
Open Forum

AMR

**Moving ahead with the AMR agenda in a changing environment**

Chair *Benedikt Huttner (Geneva, Switzerland)*

FO095 13:30 From 'making the economic case' for AMR to securing financing for core interventions *Chantal Morel (Bonn, Germany)*  
FO096 13:40 Reaching out to those who need to act: education and pre-service training of health workforce *Li Yang Hsu (Singapore, Singapore)*  
FO097 13:50 Progress in measuring prevalence and impact on human health *Olga Tosas Auguet (Geneva, Switzerland)*

Co-organised with: World Health Organisation (WHO)

WT002 13:30 - 14:30 Poster area  
Poster Walkthrough

DX

**Innovations in infectious disease diagnostics and surveillance**

Chair *Fusun Can (Istanbul, Türkiye)*

R0011 P0192 - Targeted metagenomic sequencing of respiratory infections from UK healthcare workers in the SIREN study, winter 2023 - 2024 *Marissa Knoll (Hinxtun, United Kingdom)*  
R0012 P2505 - Deep learning model for rapid outbreak detection in a rapid phenotypic AST system *Christer Malmberg (Uppsala, Sweden)*  
R0013 P2439 - Evolution of respiratory virome profile in children under five years with persistent low respiratory symptoms *Niloofer Hejazifar (Milan, Italy)*  
R0014 P4371 - Climate-driven expansion and clinical risk of *Vibrio vulnificus*: integrating global genomics, environmental reservoirs, and adaptive transcriptomics *Yaovi M. Gildas Hounmanou (Frederiksberg, Denmark)*  
R0015 P2489 - Enhancing urine culture diagnostics with image analysis powered by AI: a novel approach *Yasmeen Vincent Marbaniang (Etobicoke, Canada)*  
R0016 P4355 - Uptake of antibacterial vaccines and the effects on antimicrobial resistance associated mortality in children under five in Sub-Saharan Africa *Oyedele Oyedele (Abuja, Nigeria)*  
R0017 P2399 - Global population structure and convergent MDR-hypervirulence in high-risk *Pseudomonas aeruginosa* lineages *Riccardo Bollini (Pieve Emanuele, Italy)*  
R0018 P2111 - Optimising the blood culture pathway (BCP) through multidisciplinary team collaboration: a two-year quality improvement initiative *Suryabrata Banerjee (Newcastle Upon Tyne, United Kingdom)*  
R0019 P0459 - VEGF-A-induced tissue factor vesicle release as a hallmark of vascular dysregulation in long COVID *Samuel Benarroch (Ile-De-France, France)*  
R0020 P2299 - Real-world diagnostic performance and antimicrobial stewardship impact of the fsyndromic multiplex PCR panel for meningitis/encephalitis in adult patient *Marisa Del Lujan Sanchez (Buenos Aires, Argentina)*

WT001 13:30 - 14:30 Poster area  
Poster Walkthrough

DX

**Emerging vector-borne and zoonotic diseases: surveillance, diagnostics, and clinical management in a changing world**

Chair *Luisa Barzon (Padua, Italy)*

R0001 P0322 - Identifying emerging vector-borne pathogens in a time of climate change, the ARBO-WATCH network *Silvia Bianchi (Milano, Italy)*  
R0002 P0261 - Wolbachia deployment in *Aedes aegypti*: a meta-analysis of dengue reduction in endemic regions *Abdullah Al Owesie (Martin, Slovakia)*  
R0003 P0275 - Antibodies to non-structural protein 1 in tick-borne encephalitis: long-term kinetics in serum and cerebrospinal fluid *Sara Morgardt (Trollhättan, Sweden)*  
R0004 P0276 - Clinical course and outcome of tick-borne encephalitis in immunocompromised patients *Daša Stupica (Ljubljana, Slovenia)*  
R0005 P0320 - Factors associated with death or neurological sequelae in a cohort of patients hospitalised for West Nile virus infection in a non-endemic area in Southern Italy *Pierantonio Grimaldi (Naples, Italy)*  
R0006 P0317 - Rapid diagnosis by metagenomics analysis of zoonotic orf virus in human cases using a nanopore sequencing workflow *Elif Neyligül Arslan (Istanbul, Türkiye)*  
R0007 P0280 - Development and external validation of the early mortality score (EMS) for Crimean-Congo haemorrhagic fever, with comparative evaluation against the severity scoring index (SSI) *Deniz Güllü (Istanbul, Türkiye)*  
R0008 P0283 - Western equine encephalitis outbreak in Argentina 2023-2024: multi-centre clinical and epidemiological analysis of human cases *Sofía Elena Echazarreta (CABA (CABA), Argentina)*  
R0009 P0297 - Rodent reservoirs and high human exposure to hantaviruses in a rural agricultural area of Sri Lanka: a One Health perspective *Rydhniya Vijeyakumaran (Peradeniya, Sri Lanka)*  
R0010 P0306 - Epidemiological overview of local transmission of chikungunya in mainland France in 2025 *Clémentine Calba (Marseille, France)*

WT003 13:30 - 14:30 Poster area  
Poster Walkthrough

PHEI

**Of lice and laundry: data-driven public health around the globe**

Chair *Joel Mossong (Luxembourg, Luxembourg)*

R0021 P4435 - Strengthening scientific advice for pandemic decision-making: insights from interdisciplinary tabletop simulation exercises *Femke Overbosch (Rotterdam, The Netherlands)*  
R0022 P4387 - Genomic investigation of crocodile-to-human occupational transmission of *Vibrio cholerae* *Isca Hershkowitz (Jerusalem, Israel)*  
R0023 P4356 - Learning from the past: historical lessons on non-pharmaceutical interventions in the United Kingdom and Hong Kong *Mi Joo Choi (Leicester, United Kingdom)*  
R0024 P4308 - Parental views towards childhood vaccination in the United States before and after the COVID-19 pandemic *Amanda Eiden (Glenside, United States)*  
R0025 P4298 - Estimating measles containing vaccine-induced immunity waning and future prediction in South Korea: a mathematical modeling study *Sol Kim (Seoul, Korea, Republic of)*  
R0026 P4373 - Pathogen-specific effects of PM2.5 on pneumococcal pneumonia in a low-pollution microstate: a population-based time-series analysis *Cristina Royo-Cebrecos (Escaldes-Engordany, Andorra)*  
R0027 P4324 - Early implementation outcomes of a nurse-led antenatal immunisation service: Improving access, experience, and vaccine uptake in a metropolitan health service *Dorothy Ling (Victoria, Australia)*  
R0028 P4486 - Identifying active paragonimiasis in rural Nagaland in North Eastern India: results from a community-based cross-sectional study *Rohan Michael Ramesh (Vellore, India)*  
R0029 P4384 - Genomic diversity of *Campylobacter jejuni* and *Campylobacter coli* from human clinical isolates and swine/poultry industry associated sources in Latvia, 2022 - 2025 *Inara Kampenusa (Riga, Latvia)*

WT004 13:30 - 14:30 Poster area  
Poster Walkthrough

PHEI

Changing landscape of parasitic diseases: genes, screens, and scenes

Chair Carlos Seas (Lima, Peru)

- R0031 P3442 - Visceral leishmaniasis in Northern Brazil (2000–2023): an ageing epidemic with rising case-fatality *Lorenzo Brando Lundgren (Varese, Italy)*
- R0032 P3431 - HLA-linked genetic susceptibility in alveolar echinococcosis *Lynn Peters (Ulm, Germany)*
- R0033 P3457 - Systematic investigation of suspected angiostrongyliasis cases in Réunion Island *Wacil Patel (France, France)*
- R0034 P3453 - Clinical profile and epidemiology of granulomatous *Acanthamoeba encephalitis*: a systematic review *Nitin Gupta (Manipal, India)*
- R0035 P3447 - CE acquired in England: signs of emergence? *Stephanie Harris (London, United Kingdom)*
- R0036 P3535 - Review of malaria diagnosis, severity, and management, 2019–2023, University Hospital Galway *Ellen Sugrue (Kerry, Ireland)*
- R0037 P3531 - Risk behaviours and health problems in international travellers: prospective questionnaire study *Milan Trojanek (Prague, Czechia)*
- R0038 P3528 - Implementation of a screening programme among migrants to Italy: key challenges and prevalence results *Stefania Caronni (Milan, Italy)*
- R0039 P3484 - Correlation between PCR CT values, microscopy parasitaemia and RDT results in imported malaria *Harold Alfredo Bermúdez Marval (Alcalá De Henares, Spain)*
- R0040 P3443 - Scabies is strongly associated with rheumatic heart disease: evidence from cross-sectional studies of school children in Tonga *Saptorshi Gupta (Auckland, New Zealand)*

OS030 14:45 - 15:45 Hall A2-1  
1-hour Case Session

DX

Unmasking infectious diseases through genomic approaches

Chair Natacha Couto (Cardiff, United Kingdom)  
TBA

- O0177 14:45 Shotgun metagenomics for CSF diagnostics guides targeted therapy in culture-negative bacterial meningitis caused by *Capnocytophaga canimorsus* G. Lorenzin\* (Trento, Italy), M. Bertoldi, F. Bonaffini, M. Carlin, C. Scarparo
- O0178 14:56 Genomic characterisation of an extensively drug-resistant *Shigella sonnei* carrying bla<sub>CTX-M-15</sub> in a sexually transmitted infection in an MSM patient in Spain *N. Valcárcel Fraile\* (Santander, Spain), N. Fraile-Valcárcel, B.M. Armas-Luján, D. Fernández-Vecilla, M.J. Urrutikoetxea-Gutiérrez, J. Rodríguez Grande, C. Ruiz De Alegría Puig, S. Labrador Descalzo, E. Mesa Santana, S. Riesco Alonso, A. Ocampo-Sosa, M.P. Roiz Mesones*
- O0179 15:07 Dual enterococcal bacteraemia with central nervous system infection by *Enterococcus faecium* ST117: a whole genome analysis *M. Roch\* (Geneva, Switzerland), R. Sierra, P. Vetter, D. Neofytos, C. Van Delden, K.A. Kline, D.O. Andrey*
- O0180 15:18 Unmasking the pathogen: how metagenomics enables the diagnosis of hard-to-detect infections *A. Belati\* (Bergamo, Italy), L.B. Giva, R. Bruschi, T. Perrone, M. Bartoli, M. Mazzoni, G. Albano, P.G.G. Panisi, M. Sampaolo, N. Clementi, V. Cento, M. Bartoletti, C. Filippi*
- O0181 15:29 Chronic *Mycobacterium kansasii* pleural infection mimicking metastatic breast cancer: a seven-year diagnostic odyssey and the critical role of metagenomic sequencing *Q. Miao\* (Shanghai, China), T. Fang, P. Hu, Y. Zhang, B. Hu*

OS027 14:45 - 15:45 Hall ICM 13b

CLN

1-hour Case Session

Unusual causes of broken heart: cardiac infections

Chairs Diane Ashiru-Oredope (London, United Kingdom)  
Margaret Hannan (Dublin, Ireland)

- O0182 14:45 Outbreak investigation of non-tuberculous mycobacteria (NTM) sepsis following cardiac surgery in an LMIC tertiary care centre: implication of contaminated heater-cooler units *M. Khan\* (Peshawar, Pakistan)*
- O0183 14:56 Beyond the usual suspects: three cases of infective endocarditis by rare pathogens *N. Pansari\* (Ahmedabad, India), S. Madan, B. Thacker, M. Chag, D. Shah, K. Gupta*
- O0184 15:07 Disseminated BCG infection with cardiac device involvement and immune thrombocytopenia *A. Bergas Farrés\* (Barcelona, Spain), A. Bergas, R. Vila-Olives, S. Molinos, M.D. Quesada, A. Sarrias, R. Villuendas, A. Peris, A. Antuori, E. Berastegui, N. Fernández-Hidalgo, M.T. Tórtola, J.J. López-González, M.L. Pedro-Botet, R. Paredes, L. Mateu*
- O0185 15:18 *Bartonella henselae* a great mimicker: endocarditis, bone marrow infiltration and glomerulonephritis mimicking vasculitis ANCA-positive *J. Alza Arcila\* (Medellín, Colombia), J. Alza-Arcila, S. Coboleda-Cano, C. Rincón-Márquez, J.M. Bacca-Gonzalez*
- O0186 15:29 Intracardiac cysticercosis: a case report and diagnostic challenge *R. Manchon\* (Paris, France), N. Argy, A. Sivapathasundaram, D. Lussato, J. Feignoux, D. Attias, P. Le Besnerais, J. Rousseau, S. Lariven, N. Peiffer-Smadja*

LB002 14:45 - 15:45 Hall A1-4  
1-hour Oral Session

PHEI

Late-breaking public health challenges

Chairs David Fisman (Toronto, Canada)  
Ricardo Mexia (Lisbon, Portugal)

- L0011 14:45 Stress testing acute care chains for high-volume war-related trauma and MDROs *A. Tostmann\* (Nijmegen, The Netherlands), B. Beishuizen, V. Stürler, E. Ruizendaal, D. De Jong, E. Tan, C. Rovers*
- L0012 14:57 Imported MERS-CoV cases in France, November 2025: diagnosis, management and public health response *A. Bal\* (Lyon, France), L. Van-Den-Bogaart, A. Maisa, S. Dan, M. Bouscambert-Duchamp, S. Burrel, A. Avondo, A. Cossard, E. Fougere, Z. Boudalaa, C. Castor, E. Hope-Rapp, C. Durand, J.S. Casalegno, L. Josset, A. De-Clercq, H. Regue, D. Nguyen, C. Vignals, L. Rojas-Lopez, A. Oblotte, A. Brinza, A. Massardier-Pilonchery, C. Dananche, P. Fascia, J. Godon, M. Simon, M.A. Rameix Welti, J.M. Turmel, N. Leveque, D. Perez-Bercoff, B. Lina, A. Lapendry, X. Lescure, M. Mailhe, F. Ader, B. Coignard, A. Gaymard, T. Perpoint*
- L0013 15:09 Measles hospitalisations during an outbreak in Jerusalem, 2025 *O. Gordon\* (Jerusalem, Israel), G. Oren, O. Itamar, S. Dorozhko, S. Zahran, E. Roda, N. Peled, A. Bracha Moshe, N. Juven Wetzler, D. Averbuch, S. Hashavya, U. Pollak, D. Wolf, J. Strahilevitz, Y. Oster, N. Abramson, Z. Mor, N. Bar Zeev, O. Megged, R. Brooks, A. Tenenbaum*
- L0014 15:21 Epidemic of *Chlamydia pneumoniae* infections in France in 2024 *S. Trombert Paolantoni\* (Frepillon, France), S. Trombert-Paolantoni, L. Baussant, K. Sood, E. Hedbaut, A. Bergeron, Y. Tandjaoui-Lambiotte, B. Visseaux*
- L0015 15:33 Scrub typhus in children: an emerging under-recognised threat: seroprevalence, demographic trends, co-infections and cross-reactions in a tertiary care paediatric institute in North India *S. Nandwani\* (Noida, India), J. Sachdev, A. Puri, R. Edoliya, N. Perween, D.K. Singh, D.K. Sahu*

OS029 14:45 - 15:45 Hall B0-2  
1-hour Oral Session

VAX

Respiratory viral infection prevention across age groups

Chairs Christopher Chiu (London, United Kingdom)



00187	14:45	<b>Maternal RSV vaccination and reduced risk of hospitalisation for babies in England, 2024/25</b> <i>Matt Wilson (London, United Kingdom)</i>
00188	14:57	<b>Impact of universal infant immunisation with nirsevimab on RSV-related hospitalisation beyond the first season: the NIRSE-GAL study</b> <i>F. Martínón-Torres* (Santiago De Compostela, Spain), J.L. Razzini, I. Giné-Vázquez, J. Jin, N. Mallah, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieto, C. Álvarez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo</i>
00189	15:09	<b>Real-world emergence of nirsevimab resistance in RSV-B breakthrough infections</b> <i>S. Fourati* (Créteil, France), A. Reslan, J. Bourret, J.S. Casalegno, Y. Rahou, L. Softic, L. Chollet, P. Tremeaux, B.M. Imbert-Marcille, S. Pillet, N. Veyrenche, A. Boudet, L. Deroche, S. Burrel, L. Mouna, T. Cocherie, A. Schnuriger, C. Pronier, L. Handala, F. Gallais, S. Larrat, A. Regueme, N.C. Dossou, A. Henry, E. Gault, C. Hartard, S. Brichler, A. Moisan, V. Avettand-Fenoel, C. Lefevre, I. Engelmann, S. Castelain, A. Mirand, M. Salmona, M.C. Jaffar-Bandjee, P. Cappy, C. Rodriguez, G. Dos Santos, S. Berreira Ibrahim, K. Da Silva, A. Recoing, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti</i>
00190	15:21	<b>Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan</b> <i>L. Kostanyan* (Cambridge, United States), H. Fukase, A. Rumyantsev, O. Kogawara, K. Hashizume, S. Osibajo</i>
00191	15:33	<b>High-dose vs standard-dose influenza vaccination across laboratory-confirmed influenza severity levels in older adults: the DANFLU-2 randomised trial</b> <i>F.S. Davidovski* (Hellerup, Denmark), N.D. Johansen, N. Shaikh, R. Harris, D. Modin, P.S. Wolff, K.G. Skaarup, C.S. Søndergaard, M. Loiacono, Y. Huang, J. Bartelt-Hofer, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B. Claggett, K. Janstrup, R. Jessen, N. Steenhard, K. Bartholdy, K. Bernholm, J. Borchsenius, L. Davodian, M. Dons, L. Duus, C. Espersen, F. Fussing, A.M. Jensen, N. Landler, A. Langhoff, M. Lassen, A.B. Nielsen, C. Ottosen, M. Sengeløv, S. Solomon, M. Landray, G. Gislason, L. Køber, P. Sivapalan, C. Martel, J.U. Jensen, T.B. Sørensen</i>

OS026 14:45 - 15:45 Hall ICM 13a



1-hour Oral Session

**Redefining care in bacterial meningitis: new approaches and emerging clinical evidence**

*Chairs Tuyen Nguyen (Laval, Canada) Charlotte Sriruttan-Nel (Johannesburg, South Africa)*

00192	14:45	<b>Continuous intracranial pressure monitoring in acute bacterial meningitis: a nationwide multi-centre cohort study</b> <i>J. Karlsson Valik* (Stockholm, Sweden), A. Grahn, M. Veje, P. Almqvist, C. Åkerlund, J. Widén, G. Westman</i>
00193	14:57	<b>Addition of daptomycin in the treatment of pneumococcal meningitis in adults: results of the phase II AddaMap trial</b> <i>T. Sixt* (Dijon, France), T. Sixt*, I. Fournel, A. Bourredjem, M. Blot, B. Mourvillier*, D. Grandgirard*, S. Leib*, X. Duval, L. Piroth, P. Chavanet*</i>
00194	15:09	<b>Effectiveness of ceftriaxone in the management of neurosyphilis: experience of a UK tertiary centre</b> <i>L. Carson* (Cambridge, United Kingdom), B. Warne, O. Sule, M. Routledge</i>
00195	15:21	<b>Early oral step-down therapy in pyogenic brain abscesses: a bicentric retrospective study</b> <i>J. Brouard* (Clichy, France), D. Morizet, R. Rahlj, A. Lefort, P. Decq, H. Kimseng, A.L. Munier, V. De Lastours</i>
00196	15:33	<b>Continued corticosteroids for non-pneumococcal bacterial meningitis in adults: a target trial emulation</b> <i>E. Eriksen* (Aalborg, Denmark), K.F. Greve, S.Ø. Larsen, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, J. Bodilsen</i>

**From overuse to optimisation: smarter diagnostics in practice**

*Chairs Gloria Cordoba (Copenhagen, Denmark) Polona Maver Vodcar (Ljubljana, Slovenia)*

00197	14:45	<b>The implementation of electronic clinical decision tools to reduce inappropriate urine and swab requests: a diagnostic stewardship intervention to reduce the environmental impact of laboratory testing</b> <i>R. Shorten* (Manchester, United Kingdom), S. Shafiq, L. Roberts, G. Williams</i>
00198	14:57	<b>Diagnostic stewardship in critical care: should overexpressed AmpC Enterobacterales detected on rectal screening be reported? predictive value for infection and comparison with ESBL</b> <i>A. Mizrahi* (Paris, France), G. Péan De Ponfilly, M. Holub, T. Genty, F. Philippart, C. Couzigou, B. Pilmis, A. Le Monnier</i>
00199	15:09	<b>Development of an infectious diseases diagnostic excellence program using the centres for Disease Control and Prevention (CDC) core elements</b> <i>T. Jenkins* (Denver, United States), M. Cooper, K. Shihadeh, L. Triplett, L. Fish, M. Wolfe, A. Penick, M. Wilson</i>
00200	15:21	<b>Optimising blood cultures: a diagnostic stewardship intervention</b> <i>L. Mejdoubi* (Vienna, Austria)</i>
00201	15:33	<b>Reducing CoNStant testing: Impact of a diagnostic stewardship intervention targeting coagulase-negative staphylococci in blood cultures on vancomycin, daptomycin and linezolid consumption</b> <i>K. Tanida* (Hamburg, Germany), B. Berinson, M. Florey, L. Middendorf, C. Sommer, M. Aepfelbacher, H. Rohde, M. Christner</i>

SY060 14:45 - 15:45 Hall A2-2



1-hour Symposium

**Precision diagnostics for neonatal sepsis: from biomarkers to the bedside**

*Chairs Ilias P. Iosifidis (Thessaloniki, Greece) Birgit Willinger (Vienna, Austria)*

S0123	14:45	<b>Rapid diagnostic tools for neonatal sepsis: from biomarkers to AI-powered screening</b> <i>Mohan Pammi (Bellaire, United States)</i>
S0124	15:15	<b>How to differentiate viral vs. bacterial infections in neonates?</b> <i>Marieke Emonts (Newcastle Upon Tyne, United Kingdom)</i>

SY061 14:45 - 15:45 Hall A3-1



1-hour Symposium

**Bridging the gap: aligning EUCAST standards with antimicrobial stewardship practice**

*Chairs Esther Calbo (Terrassa, Spain) Paul Christoffer Lindemann (Bergen, Norway)*

S0125	14:45	<b>From report to treatment: challenges in applying AST results in clinical practice</b> <i>Benedikt Huttner (Geneva, Switzerland)</i>
S0126	15:15	<b>Enhancing clinical relevance: EUCAST's vision for improving AST interpretability</b> <i>Amara Marlene (Paris, France)</i>

SY062 14:45 - 15:45 Hall A3-2



1-hour Symposium

**Closing the antiviral gap: broadening treatment options for emerging and neglected viruses**

*Chairs Julie Bines (Parkville, Australia) Jan Felix Drexler (Berlin, Germany)*

S0127	14:45	<b>New host-directed approaches against emerging viral infections</b> <i>Rainer Koenig (Jena, Germany)</i>
-------	-------	--

S0128 15:15 Outlook of new antiviral molecules in the pipeline Javier Sánchez Céspedes (Seville, Spain)

SY059 14:45 - 15:45 Hall B0-1

1-hour Symposium

PHEI

Climate change, biodiversity loss, and the future of infectious diseases

Chairs Marion Koopmans (Rotterdam, The Netherlands)  
Tyra Grove Krause (Copenhagen, Denmark)

S0121 14:45 Impact of climate change on infections Kimberly Fornace (Singapore, Singapore)

S0122 15:15 Biodiversity loss and risk of spill-over events and epidemics Carsten Rahbek (Copenhagen, Denmark)

SY058 14:45 - 15:45 Hall ICM 1

1-hour Symposium

CLN DX PHEI

Chemsex, HIV and STIs: so little time, so much to do

Chairs Ivana Gmizic (Belgrade, Serbia)  
Lorenzo Rabbi (Berlin, Germany)

S0119 14:45 Chemsex plus STIs syndemic: how to test and how to treat Zulma Vanessa Rueda (Winnipeg, Canada)

S0120 15:15 Chemsex and the costs of its ignorance: example from Central and Eastern Europe Sime Zekan (Zagreb, Croatia)

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Viral Hepatitis (ESGVH), Euroguidelines in Central and Eastern Europe Network Group

EF031 14:45 - 15:45 Arena 1

ePoster Flash Session

CLN TRN

Infection risk, response, and recovery in the immunocompromised host

Chair Michael Boeckh (Seattle, United States)

E0202 14:45 Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy N. Lambert\* (Liège, Belgium), M. El Moussaoui, A. Le Guilloux, M. Joly, M.D.C. Garcia Martearena, R. Bernard-Valnet, C. Pinnetti, K.F. Greve, X. Brousse, W.F. Westendorp, M.T. Wijburg, L. Grote-Levi, N. Moehn, V. Pourcher, S. Gressens, C.V. Cruz, V. Van Pesch, M. Vidal, C. Morvan, A. Makinson, A.M. Konitsioti, B. Hoellinger, L. Nitsch, D.E. Ney, E. Faure, K.B. Alstadhaug, M. Martinot, F. Genderini, J. Legras, M. Garzaro, S. Blanchi, S. Gazaigues, S. Borrelli, S. Patrat-Delon, D. Vydrář, P. Nicolas-Vullierme, M. Moutel, T. Cartau, F. London, A. Cabié, K. Bouiller, A. Montcuquet, P. Loubet, N. Sayre, P. Maquet, G. Darcis, M. Le Marechal, D.B. Clifford, T. Skripuletz, M.C. Brouwer, J. Bodilsen, R. Du Pasquier, P. Cinque, A. Sommet, G. Martin-Blondel

E0203 14:51 Pritelivir demonstrated superior lesion healing with extended treatment compared to investigator's choice for refractory herpes simplex virus infection in immunocompromised patients in the PRIOH-1 phase III trial R. Chemaly\* (Houston, United States), J.M. Molina, K. Workowski, R. Avery, Y.J. Lee, K. Peggs, D. Neofytos, M. Yong, J. Sasadeusz, R. Maves, B. Gaborit, D. Teschner, A. Perez-Rios, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, A. Wald, G.A. Papanicolaou

E0204 14:57 Impaired type I interferon response early after SARS-CoV-2 infection is associated with the occurrence of persistent COVID-19 in solid organ transplanted recipients Q. Richier\* (Paris, France), K. Lacombe, D. Duffy, K. Zafilaza, M. Briard, V. Bondet, M. Robert, V. Leducq, A. Fauchois, E. Ghidaoui, S. Sayon, C. Dorival, C. Lusivika-Nzinga, Y. Yordanov, G. Martin-Blondel, F. Carrat, A.G. Marcelin, C. Soulie

E0205 15:03 Blood virome and acute graft vs host disease K. Hosszu-Fellous\* (Geneva, Switzerland), S. Cordey, M. Gumowski, F. Laubscher, L. Royston, S. Masouridi-Levrat, Y. Chalandon, D. Neofytos, L. Kaiser

E0206 15:09 Towards personalised empirical antibiotic therapy in febrile neutropenia: a theoretical model based on machine learning and prior colonisation with multidrug-resistant Gram-negative bacilli A. Gallardo-Pizarro\* (Barcelona, Spain), C. Teijón-Lumbreras, T.F. Aiello, P. Monzó-Gallo, A. Martínez-Urrea, C. Terrones-Campos, A. Castiella, G. Cuervo, L. Morata, P. Castro, C. Casals, M. Espasa, J. Esteve, J.M. Nicolas, J. Mensa, A. Soriano, C. Garcia-Vidal

E0207 15:15 Burden and clinical outcomes of hospital-coded respiratory virus infection in patients with haematological malignancy: a longitudinal multi-centre cohort study from 2011-2023 V. Hall\* (Melbourne, Australia), T. Spelman, A.P. Ng, M.K. Yong, M.A. Slavin, B.W. Teh

E0208 15:21 Steroid-linked invasive fungal infections after CAR-T: Insights from a national Australian cohort G. Reynolds\* (Heidelberg, Australia), M. Dowling, S. Belbachir, N. Perera, J. Li, J. Valencia-Klug, B.W. Teh, M.A. Anderson, A. Barraclough, C. Tam, P.J. Ho, S.J. Harrison, A.S. Henden, M. Slavin

E0209 15:27 Role of colonising multidrug-resistant bacteria in haematological patients: a retrospective observational study A. Lovecchio\* (Trieste, Italy), N. Benvenuto, S. Babich, A. Misin, S. Mohamed, G. Sanson, S. Di Bella

E0210 15:33 Serious infection risk with advanced therapies across immune-mediated inflammatory diseases V. Allen\* (London, United Kingdom), I. Muzafar, R. Chavali, S. Muzafar, N. Suresh, Y. Yoon, L. De Gracia, M. Gibson, M. Russell, K. Bechman, M. Adas, S. Norton, D. Phillipppo, A. Goodman, J. Galloway

EF032 14:45 - 15:45 Arena 2

ePoster Flash Session

CLN DX

Beyond the culture plate: a multi-modal overview of recent advances in gastrointestinal testing

Chair Mauricio Farfan (Santiago, Chile)

E0211 14:45 Evaluation of Copan FecalSwab™ Collection and Transport device for molecular applications F. Bonometti\* (Brescia, Italy), S. Savi, C. Sabelli

E0212 14:51 Efficient and easy preparation of stool specimens for molecular diagnostics without nucleic acid purification T. Schuurman\* (Dordrecht, The Netherlands), M. Pellikaan, I. Huijskens

E0213 14:57 A multi-centre clinical trial evaluating molecular mini-panels for bacterial gastrointestinal pathogen detection A. Nenninger\* (San Diego, United States), C. Remillard, Y. Liu, A. Menez

E0214 15:03 Diagnostic efficacy of two immunochromatographic tests for the rapid detection of rotavirus, adenovirus, and norovirus compare G. Sánchez De Luis\* (Madrid, Spain), R. Blázquez Batanero, A.I. Peñalver López, H. Bermúdez Marval, V.A. Robles Curvelo, C. Rescalvo-Casas, M. Hernando-Gozaló, A. Rojas Díaz, F. Pérez-García, Á. Irigoyen-Von-Sierakowski, B. Rodríguez-Ponga, J.A. Cuadros-González, R. Pérez-Tanoira

E0215 15:09 Comparative evaluation of diagnostic methods for Entamoeba histolytica: A Four-Year retrospective study B. Dinç\* (Ankara, Türkiye), F. Demirel, S. Cebeci, U. Berberoğlu, B. Dinç

E0216 15:15 Bristol-scale guided using a POCT vs non-POCT molecular syndromic testing and clinical outcomes in traveler's diarrhoea M. Bugés Bascompte\* (Barcelona (Spain), Spain), M. Bugés-Bascompte, S.M. San José Villar, N. Vila-Olmo, P. García-Mellado, M. Muixi-Duran, I. Oliveira-Souto, P. Nadal-Barón, M. Vicente-Ciurans, A. Canals, V. Rodríguez-Garrido, C. Arconada-Rojano, C. Rubio-Maturana, L. Goterris-Bonet, E. Sulleiro

E0217 15:21 Optimising bacterial stool diagnostics: PCR-guided culture improves sensitivity and accelerates result reporting G. Hagn\* (Munich, Germany), T. Fleige

E0218 15:27 Clinical validation of the BB-ELISA for predicting recurrent Clostridioides difficile infection study E. Basseres\* (Houston, United States), H. Yu, R. Lee, S. Kumari, J. Fowler, A. Saint Fleur, T. Eubank, Y. Zhang, E. Von Rosenvinge, K. Garey, Z. Yang, H. Feng

EF033 14:45 - 15:45 Arena 3

## Preclinical data and fundamental science on fungi and antifungals

Chair	<i>Lysangela Ronalte Alves (Curitiba, Brazil)</i>	
E0220	14:45	<b>Impact of azithromycin on neutrophil-mediated immune responses against <i>Aspergillus fumigatus</i> R. Manchon*</b> (Paris, France), E. Dudoignon, A. Agathe, W. Sarah, G. Jessica, D. Sarah
E0221	14:51	<b>A novel infection model to study immunobiology, antifungal pharmacotherapy, and immunomodulatory therapy of invasive pulmonary aspergillosis in mice with acute myeloid leukemia S. Wurster*</b> (Houston, United States), N.D. Albert, J. Pantaleon Garcia, L. Matula, S. Evans, D.P. Kontoyiannis
E0222	14:57	<b>Efficacy of BAL2062 in immunosuppressed mice infected with azole-sensitive and azole-resistant <i>Aspergillus fumigatus</i> A. Ibrahim*</b> (Allschwil, Switzerland), T. Gebremariam, S. Alkharaji, Y. Gu, E. Youssef, S. Nabeela, T. Elsayed, S. Dolati, K. Litherland
E0223	15:03	<b>Invasive pulmonary mucormycosis is associated with siderophore secretion, neutrophil recruitment, and lipid remodelling in the lungs D. Luptáková*</b> (Prague 4, Czechia), T. Hřivnová Juříková, M. Petřík, K. Dvořáková Bendová, B. Neužilová, H. Marešová, A. Palyzová, M. Lackner, P. Hubáček, V. Havlíček
E0224	15:09	<b>Once-daily SCY-247 as oral and intravenous formulations has linear pharmacokinetics and is efficacious in a murine model of invasive <i>Candida glabrata</i> infection N. Wiederhold*</b> (San Antonio, United States), L. Najvar, S. Wring, K. Borroto-Esoda, D. Angulo, R. Jaramillo, M. Olivo, T. Patterson
E0225	15:15	<b>Phenotypic and genotypic characterisation of multiple <i>Candida albicans</i> laboratory-induced drug resistant isolates reveals convergent and divergent responses to resistance R. Khalaf*</b> (Byblos, Lebanon), M. Abbas, S. El Hachem, C. Chedraoui, I. Bitar, N. Fattouh
E0226	15:21	<b>Engineered CAR-T Cells Targeting Fungal Cell Wall Show Limited Antifungal Activity E. Dolader Ballesteros*</b> (Zaragoza, Spain), E. Dolader-Ballesteros, S. Redrado, D. Sánchez-Navarro, M.P. Domingo, P. Esteban, M. Arias, J. Paul-Bernal, V. Taleb, A. Ramírez, R. Hurtado, J. Pardo, E.M. Gálvez
E0227	15:27	<b>Azole-induced in-host microevolution of <i>Candida parapsilosis</i> drives MRR1-mediated antifungal resistance R. Zhang*</b> (Beijing, China)

EF034 14:45 - 15:45 Arena 4

ePoster Flash Session

AMR ANT IPC

## Innovations in antimicrobial stewardship across diverse settings

Chair	<i>Nathan Peiffer-Smadja (Paris, France)</i>	
E0229	14:45	<b>Strengthening infection control and antimicrobial stewardship through quality improvement in a refugee-serving hospital: lessons from Nakivale, Uganda Z. Nahumuza*</b> (Entebbe, Uganda), M. Umar
E0230	14:51	<b>From culture positives to positive culture: changing behaviour around ASB treatment M. Arandjelovic*</b> (Aveiro, Portugal), L. Maia, A. Ribeiro, T. Mariano, M. Santos, F. Freitas
E0231	14:57	<b>"No breakpoints? no problem!" evaluating gentamicin perioperative prophylaxis for <i>Pseudomonas aeruginosa</i> asymptomatic bacteriuria before urological surgery N. Reidy*</b> (London, United Kingdom), S. Dewan, A. Saiyed, A. Raza, D. Smith, A. Lima Soares, G. Pollara, R. Ghani
E0232	15:03	<b>A multi-seasonal mixed-method point-prevalence study of antibiotic prescription patterns in a tertiary healthcare facility in India V. Modgil*</b> (New Delhi, India), R. Surial, O. Sinha, S. Kumar, S. Raina, R. Chauhan, A. Mukherjee, S. Sahay
E0233	15:09	<b>TDM (Therapeutic Drug Monitoring)-guided meropenem therapy for bone and joint infections caused by Gram-negative bacilli M. Sanz De Mena*</b> (Barcelona, Spain), M. Sanz-De Mena, S. Luque, L. Sorli, D. Pérez-Prieto, A. Alier, G. Rodríguez-Cabalé, I. Pelegrín, M. Montero, J.P. Horcajada, J. Gómez-Junyent
E0234	15:15	<b>Antimicrobial Stewardship (AMS) program in</b>

**Lombardy Region: analysis of effectiveness and costs G. Renisi\*** (Milano, Italy), A. Comelli, L. Scudeller, A. Mazzone, G. Macaluso, M. Zanforlini, S. Schiatti, D. Cereda, G. Del Castillo, U. Restelli, S. Silvola, N. De Fazio, P. Bonfanti, M. Bartoletti, A. Tebaldi, S. Piconi, M. Puoti, A. Castagna, P. Grossi, G.C. Marchetti, A. Regazzetti, F. Castelli, A. Zoncada, B. Castiglioni, L. Pusterla, R. Bruno, S. Rusconi, S. Antinori, A. Muscatello, A. Gori, A. Bandera, S. Chiappetta

E0235	15:21	<b>Disparities in Infection Prevention and Control, and Antimicrobial Stewardship Practices across Healthcare Settings with Varied Resource Levels: Findings from the BALANCE Study R. Farzana*</b> (Oxford, United Kingdom), N. Haque, S.B. Shahid, G. Ferdous, N. Haque, M. Rahman, S. Afroj, E. Carretto, D.B. Roatti, E. Kibaru, L. Kiguongo, G. Ganda, D. Adera, C. Achi, K. Iregbu, P. Nwajiobi-Princewill, O.E. Ben, A. Aminu, F.H. Auwal, I.N. Nwafia, O.S. Ukaegbu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, M. Nawaz, M. Idrees, M. Umair, A. Zukowska, A. Zukowska, M. Zukowski, M. Borowiak, O. Ergonul, L.S. Gucer, Ö.K. Azap, N. Sari, E.T. Tigen, B.E. Sengel, M. De Kraker, S. Harbarth, N. Hassoun-Kheir, K. Onjuro, E. Owinoh, T. Walsh
-------	-------	---

E0236	15:27	<b>Addressing prescribing behaviour to reduce broad-spectrum antibiotic use V. Chorro-Mari*</b> (Ashford, United Kingdom), A. Dalton, S. Yan, S. Glass, L. White
-------	-------	--

KN057 14:45 - 15:45 Hall ICM 14

Keynote lecture

CLN TRN

## From molecules to ministries: a life in the fight against malaria

Chairs *Anu Kantele (Helsinki, Finland)*  
*Carlos Seas (Lima, Peru)*

K0118 14:45 *Abdoulaye Djimde (Bamako, Mali)*

SY069 16:15 - 17:15 Hall A3-2

1-hour Symposium

TRN VAX

## Outsmarting ticks: decoding tick-host-pathogen interactions and advancing vaccines against tick-borne diseases

Chairs *Anna J. Henningsson (Jönköping, Sweden)*  
*Ryan Rego (Ceske Budejovice, Czechia)*

S0153 16:15 **Insights into tick immune-developmental pathways impacting vector biology and pathogen persistence Chrysoula Kitsou (College Park, United States)**

S0154 16:45 **Counter-attacking the tick bite: anti-tick vaccines to prevent tick-borne diseases Joppe Willem Robert Hovius (Amsterdam, The Netherlands)**

Co-organised with: ESCMID Study Group for Lyme Borrellosis (ESGBOR)

EW072 16:15 - 18:15 Hall A2-1

2-hour Educational Session

CLN TRN

## The microbiome and response to cancer treatment

Chairs *Nicolas Benezet (Lyon, France)*  
*Lina Cavaco (Copenhagen, Denmark)*

W0163 16:15 **How the microbiome can impact response to cancer treatment Gal Markel (Petach Tikva, Israel)**

W0164 16:35 **How antibiotic treatment can impact response to immunotherapy Lisa Derosa (Villejuif, France)**

W0165 16:55 **How to preserve the microbiome during infection management in cancer patients? Arielle Elkrief (Montréal, Canada)**

W0166 17:15 **How the gut microbiome influences chemotherapy tolerance and efficacy Cindy Neuzillet (Saint Cloud, France)**

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAM)

EW071 16:15 – 18:15 Hall B0-1  
2-hour Educational Session

CLN PRO

**Adaptive platform trials in infectious diseases**

*Chairs* Marc J.M. Bonten (Utrecht, The Netherlands)  
Dafna Yahav (Ramat-Gan, Israel)

W0159 16:15 One and the same, or two and different? History and definitions of adaptive and platform trials *Holly Jackson (Singapore, Singapore)*

W0160 16:35 BALANCE PLUS: a platform trial answering challenging questions on Gram-negative infections *Nick Daneman (Ontario, Canada)*

W0161 16:55 Keeping it going: lessons learned from REMAP-CAP *Lennie Derde (Utrecht, The Netherlands)*

W0162 17:15 Getting it off the ground: successes and failures from the SNAP platform *Josh Davis (Newcastle, Australia)*

Co-organised with: CMI Communications Board of Editors

EW070 16:15 – 18:15 Hall ICM 13b  
2-hour Educational Session

CLN IPC VAX

**Building a safer journey from candidate to organ transplant recipient**

*Chairs* Wanessa Clemente (Belo Horizonte, Brazil)  
Victoria Hall (Melbourne, Australia)

W0155 16:15 Ready for the fight: candidate evaluation and vaccination *Maha Alamri (Riyadh, Saudi Arabia)*

W0156 16:35 It starts with the donor: minimising the risk of donor-derived infections *Oscar Len (Barcelona, Spain)*

W0157 16:55 At the table: surgical and perioperative challenges for infection control *Maddalena Giannella (Bologna, Italy)*

W0158 17:15 Traveling the world and safe living post-transplant *Priscilla Rupali (Vellore, India)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGIH)

SY067 16:15 – 18:15 Hall A2-2  
2-hour Symposium

CLN PHEI

**Can you see me? HIV among underserved populations**

*Chairs* Magdalena Rosińska (Warsaw, Poland)  
Milena Stevanovikj (Skopje, North Macedonia)

S0145 16:15 Learning from Malta's experience on HIV care for refugees and migrants *Aaron Schembri (Attard, Malta)*

S0146 16:45 HIV transmission and intimate partner violence in South America *Claudia Cortes (Santiago, Chile)*

S0147 17:15 Can people in homelessness crisis be effectively treated for HIV? a voice from Canada *Yoav Keynan (Winnipeg, Manitoba, Canada)*

S0148 17:45 STIs, HIV and hepatitis in penitentiary system: how to test and treat them all? *Justyna Kowalska (Warsaw, Poland)*

SY068 16:15 – 18:15 Hall A3-1  
2-hour Symposium

IPC PED

**Novel approaches to preventing neonatal infections beyond antibiotics**

*Chairs* Angelika Berger (Vienna, Austria)  
Pablo Sanchez (Columbus, Ohio, United States)

S0149 16:15 Lactoferrin: a natural defense against neonatal sepsis and necrotising enterocolitis *Theresa J. Ochoa (Lima, Peru)*

S0150 16:45 Immunometabolic approaches to prevent neonatal sepsis *Duc Ninh Nguyen (Frederiksberg, Denmark)*

S0151 17:15 Human milk oligosaccharides and the microbiome in preterm infants: mechanisms and evidence for infection protection *Moran Yassour (Jerusalem, Israel)*

S0152 17:45 Human fortifier to prevent infections in preterm infants: clinical data and future perspectives *Boris Kramer (Poznan, Poland)*

SY066 16:15 – 18:15 Hall B0-2  
2-hour Symposium

AMR PHEI TRN

**Barriers, drivers and maintenance: molecular mechanisms behind AMR gene mobility**

*Chairs* Louise Roer (Copenhagen, Denmark)  
Jozsef Soki (Szeged, Hungary)

S0141 16:15 Classification and typing of plasmids carrying multi-drug resistance *Alessandra Carattoli (Rome, Italy)*

S0142 16:45 Plasmid-host co-evolution that stabilises antibiotic resistance *Javier De La Fuente (Barcelona, Spain)*

S0143 17:15 The evolution and transmission of multi-drug-resistant *Escherichia coli* and *Klebsiella pneumoniae*: complexity of clones and plasmids *Alan McNally (Birmingham, United Kingdom)*

S0144 17:45 Antibiotic resistance plasmids in a One Health context *Michael Brouwer (Utrecht, The Netherlands)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP)

SY063 16:15 – 18:15 Hall ICM 1  
2-hour Symposium

ANT CLN

**Cracking the phage code: from clinical insights to precision design**

*Chairs* Tristan Ferry (Lyon, France)  
Jean-Paul Pirnay (Brussels, Belgium)

S0129 16:15 Designing clinical trials around phage therapy *Pranita Tamma (Philadelphia, United States)*

S0130 16:45 Randomised controlled trials of phage therapy in diabetic foot ulcers *Ran Nir-Paz (Jerusalem, Israel)*

S0131 17:15 AI for host-phage interaction prediction *Michiel Stock (Ghent, Belgium)*

S0132 17:45 Towards cell-free production and selection of therapeutic phages *Antoine Levrier (Montpellier, France)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY064 16:15 – 18:15 Hall ICM 13a  
2-hour Symposium

CLN PED TRN

**Global perspectives on tuberculosis**

*Chairs* Laura Ferreras-Antolin (London, United Kingdom)  
Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)

S0133 16:15 Computer modelling to improve TB outcomes: progress and problems *Rada Savic (San Francisco, California, United States)*

S0134 16:45 Contribution of asymptomatic TB to the global TB burden *Haniif Esmail (London, United Kingdom)*

S0135 17:15 The Brazil-wide TBped study on active and latent tuberculosis in childhood *Marcelo Scotta (Porto Alegre, Brazil)*

S0136 17:45 Radical shortening of the duration of TB treatment: here and now? *Nicholas Paton (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), International Society of Pediatric Respiratory Diseases (INSPIRED)

SY065 16:15 – 18:15 Hall ICM 5  
2-hour Symposium

TRN VAX

**Harnessing antibody response against viral and bacterial infections**

*Chairs* Silvio Daniel Brugger (Zurich, Switzerland)  
Christine Kelly (Dublin, United Kingdom)



E0258	17:27	M.H. Hamid, S. Shabbir, M. Bashir, R. Temur, A. Balqees, A. Ali, T.R. Walsh, G. Zaborský, K. Sands <b>Environmental reservoir driving hospital endemicity of a multispecies <i>bla</i><sub>NDM-1</sub> IncC plasmid A.</b> Anantharajah* (Brussels, Belgium), F. Goormaghtigh, A. Vanderheeren, W. Abdel Hadi, M. Argudin, N. Olive, E. Nguvuyila Mantu, A. Demur, C. Schirvel, A. Verroken, F. Van Bambeke, H. Rodriguez-Villalobos
E0259	17:33	<b>Patient-environment transmission dynamics of multidrug resistant <i>Enterobacteriaceae</i> in two Dutch intensive care units: a longitudinal retrospective and prospective analysis in a non-outbreak setting</b> C. Rossel* (Sittard-Geleen, The Netherlands), E.R. Heddema, R.M. Koeck, P.H.M. Savelkoul, L.B. Van Alphen
E0260	17:39	<b>Genomic comparison of carbapenemase-producing <i>Enterobacter</i> species isolated from patients and hospital environments, 2019-2024, reveals striking overlap between these niches</b> E. Cronin* (Galway, Ireland), A. O'connor, M. Maguire, C. Clarke, A. Tuohy, M. Cormican, M.J. Dorman, L.P. Burke
E0261	17:45	<b>Bacteriophage-based environmental decontamination to reduce carbapenem-resistant <i>Klebsiella pneumoniae</i>: results from the FagoLimp, a cluster-randomised controlled crossover study</b> A. Gales* (Sao Paulo, Brazil), T. Fagolimp
E0262	17:51	<b>Gold nanocluster-based bactericidal surface coatings: A novel approach to combat healthcare-associated bacterial infections and antimicrobial resistance</b> K. Burdova* (London, United Kingdom), S. Ali, N. Kapil, M.O. Coppens
E0263	17:57	<b>Impact of probiotic-based cleaning in intensive care units on the acquisition of <i>Pseudomonas aeruginosa</i> and multidrug-resistant organisms: an interrupted time-series analysis</b> L.A. Denkel* (Berlin, Germany), F. Schwab, S. Wolke, G. Zakonsky, B. Raguse, P. Gastmeier, C. Geffers
E0264	18:03	<b>Underfloor heating as a potential ally against <i>Candida auris</i> and <i>Candida albicans</i> surface contamination: impact on cleaning and disinfection effectiveness</b> A. Clifford* (Vienna, Austria), B. Leeb-Zatorska, K. Nikolova, J. Zotti, E. Presterl

E038	17:15 - 18:15	Arena 3 ePoster Flash Session
------	---------------	----------------------------------

**Advances in clinical and pre-clinical PK/PD**  
Chair Iris K. Minichmayr (Vienna, Austria)

E0265	17:15	<b>Synergistic activity of Pep16 with cefiderocol against cefiderocol-resistant <i>Escherichia coli</i> I.</b> Bourdalis* (Paris, France), E. O Van Den Daele, I. El Meouche, S. Magreault, M.C. Verdier, F. Guerin, A. Jousset, A. Birgy, B. Fantin, V. Cattoir, V. De Lastours
E0266	17:21	<b>Pharmacodynamic evaluation of aztreonam/avibactam and aztreonam plus ceftazidime/avibactam against clinical <i>Stenotrophomonas maltophilia</i> isolates in hollow fibre infection models</b> C. Wu* (Lexington, United States), A. Kunz Coyne, R. Gray, P. Gonnabathula, E. May
E0267	17:27	<b>Microdialysis Assessment of Gentamicin for Second-Line Antimicrobial Prophylaxis in Abdominal Surgery</b> Q. Saint-Genis* (Poitiers, France), N. Gregoire, M. Boisson, S. Marchand, A. Chauzy, H. Mirfendereski
E0268	17:33	<b>Population pharmacokinetic model of ceftolozane/tazobactam and ceftazidime/avibactam in plasma and ELF administered by continuous infusion in ICU patients with nosocomial pneumonia: are the standard doses adequate?</b> S. Luque Pardos* (Barcelona, Spain), S. Luque, A. Benítez-Cano, A. Araiz, I. Ramos, R. Adalia, E. Navarrete, J.P. Horcajada, M. Montero, J. Gomez-Junyent, R. Barquin, A. Juanes, J. Roberts, L. Sorli
E0269	17:39	<b>Long-acting antibiotics in osteoarticular infections: clinical outcomes and the role of therapeutic drug monitoring and serum bactericidal titre</b> F. Petrucci* (Rome, Italy), G. Iaiani, D. De Meo, A. Lesina, M. Rivano Capparuccia, C. Luceri, A. Lorusso, B.M. Goffredo, S. Cairoli, M. Raponi, F. Sacco, C.M. Mastroianni, A. Oliva

E0270	17:45	<b>PK/PD-based optimisation of temocillin dosing for the treatment of complicated urinary tract infections in non-ICU patients according to their renal function</b> J. Erntraud* (Hamburg, Germany), G.J. Wijnant, F. Van Bambeke, S.G. Wicha, S. Vervaeke, W. Follens, L. Dedeene, L. Goeman, G. Devos, M. Boeykens, V. Miendjedeyi, A. Reschner, C. Necsoi, D. Konopnicki, S. Vandecasteele, V. Grootaert
E0271	17:51	<b>Daptomycin levels in vancomycin-resistant <i>Enterococcus</i> bloodstream infections (DELIVRE-BSI)</b> K. Cairns* (Melbourne, Australia), C.B. Landersdorfer, A.Y. Peleg, Z.X. Mun, A.A. Udy, T.N. Peel, M.J. Dooley, J. Coutsovvelis, S. Patil, B. Mcwhinney
E0272	17:57	<b>Adapting meropenem administration to the constraints of home nursing care for OPAT: PK/PD evaluation of a new regimen for the administration of 2g 3x/day in non-critically ill patients</b> F. Van Bambeke* (Brussels, Belgium), C. Briquet, P. Ngougni Pokem, J.C. Yombi, X. Liu, G.J. Wijnant, O. Cornu, H. Yildiz, A. Verroken, J.A. Roberts
E0273	18:03	<b>Piperacillin/tazobactam and meropenem exposure-outcomes relationship in patients with Gram-negative sepsis: results from the BLING III PK/PD sub-study</b> J. Roberts* (Brisbane, Australia)

Sunday, 19 April 2026

EW080	08:30 - 10:30	Hall A2-2 2-hour Educational Session
-------	---------------	---

**Modelling approaches to estimate and predict the burden of AMR**  
Chairs Anna Both (Hamburg, Germany)  
Tomislav Mestrovic (Varaždin, Croatia)

W0307	08:30	<b>Methodological approach and pressing data need to model the burden of AMR</b> Mohsen Naghavi (Seattle, United States)
W0308	08:50	<b>A comprehensive approach to estimate the AMR burden using IHME data</b> Gisela Robles Aguilar (Oxford, United Kingdom)
W0309	09:10	<b>Expanding use of AMR burden data to influence policy and practice - the experience of the Fleming Fund</b> Toby Joseph Leslie (London, United Kingdom)
W0310	09:30	<b>Interventions to improve targeted access to effective antibiotics</b> Ert Kalanxhi (Washington, United States)

Co-organised with: ESCMID AMR Action Subcommittee

EW079	08:30 - 10:30	Hall B0-2 2-hour Educational Session
-------	---------------	---

**Europe's overlooked threat: the rise of zoonotic hepatitis E**  
Chairs Gülşen Özkaya Şahin (Lund, Sweden)  
Sumit Kumar Rawat (Sagar, India)

W0303	08:30	<b>Zoonotic hepatitis E reservoirs and transmission in Europe from a One Health perspective</b> Hao Wang (Gothenburg, Sweden)
W0304	08:50	<b>When the liver is just the beginning: a zoonotic journey beyond the liver</b> Yasemin Balaban (Ankara, Türkiye)
W0305	09:10	<b>Epidemiological features of hepatitis E virus infection in Sub-Saharan Africa</b> Richard Njouom (Yaounde, Cameroon)
W0306	09:30	<b>The rise of rat HEV: a new zoonotic herpesvirus</b> Antonio Rivero-Juarez (Córdoba, Spain)

Co-organised with: ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Viral Hepatitis (ESGVH), Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology, Turkish Association for the Study of the Liver (TKAD), Society on Liver Diseases in Africa (SOLDA)

EW078	08:30 - 10:30	Hall ICM 1 2-hour Educational Session
-------	---------------	--

**Duration of IV antibiotics in older adults for various infections**

<i>Chairs</i>	<i>Efthymia Giannitsioti (Athens, Greece)</i> <i>Jordi Rello (Barcelona, Spain)</i>
W0299	08:30 Duration of therapy and oral switch for Gram-positive bacteraemia <i>Giusy Tiseo (Pisa, Italy)</i>
W0300	08:50 Duration of therapy and oral switch for mycobacterial and nocardial infections <i>Ili Margalit (Ramat Gan, Israel)</i>
W0301	09:10 Duration of therapy, suppressive therapy and oral switch for endovascular infections <i>Barbara Hasse (Zurich, Switzerland)</i>
W0302	09:30 Duration of therapy, suppressive therapy and oral switch for orthopaedic infections <i>Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)</i>

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE)

OS039	08:30 - 10:30	Hall A3-1
	2-hour Oral Session	

**Sepsis at the frontline: diagnosis, therapy, and outcome in critical care**

<i>Chairs</i>	<i>Despoina Koulenti (London, United Kingdom)</i> <i>Tim Rahmel (Bochum, Germany)</i>
O0274	08:30 Real-world longitudinal validation of high-income-country-derived sepsis endotypes in Sub-Saharan Africa: a nested prospective multi-centre study <i>O. Turgman* (Amsterdam, The Netherlands), J. Wiersinga, S. Jacob, J. Butler, P. Haguma, S. Nyesiga, J. Phulusa, L. Carey, J. Rylance, T. Van Der Poll</i>
O0275	08:42 ARMOR-BSI: a nationwide analysis of the incidence and risk factors of ICU-acquired bloodstream infections in a multidrug-resistant organisms endemic country <i>C. Genovese* (Milan, Italy), M. Offer, S. Finazzi, M. Colaneri, E. Palomba, G. Scaglione, F. Dore, G. Montrucchio, G. Monti, B. Viaggi, A. Gori</i>
O0276	08:54 Multi-centre quality improvement intervention to optimise blood culture use among adults in medical intensive care units and wards at four university hospitals <i>V. Fabre* (Baltimore, United States), Y.J. Hsu, A. Xie, A. Salinas, E. Gettler, J.K. Johnson, R. Moehring, A. Ressler, G. Rodriguez-Nava, J. Salinas, G. Schrank, A. Wasylyshyn, S. Cosgrove</i>
O0277	09:06 Diagnostic efficacy and impacts on antibiotic use of digital droplet PCR in patients with suspected sepsis: the PROGRESS randomised, open-labeled, multi-centre trial <i>X. Xu* (Shanghai, China), H. Zhang, K. Lin, J. Ai, R. Wang, W. Zhang</i>
O0278	09:18 Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bloodstream infections: a case-control study <i>R. Morena* (Catanzaro, Italy), S. Rotundo, A. Russo, A. Quirino, F. Serapide, E. Garofalo, H.L. Morrone, G. Mazza, G. Neri, N. Marascio, A. Bruni, G. Matera</i>
O0279	09:30 Differential expression of miRNAs involved in shock are able to characterise mortality <i>I. Rebollo Mato* (Valladolid, Spain), A. Garcia Concejo, L. Polo Sánchez, R.D. Prieto Utrera, P.J. Martínez De Paz, M. Álvarez Bardón, J. Matesanz Isabel, H. Gonzalo Benito, R.M. Cobo Zubia, E. Gómez Sánchez, M. Martín Fernández, E. Tamayo Gómez</i>
O0280	09:42 High-dose vs standard-dose intermittent meropenem in critically ill patients: an observational cohort study <i>F. Bergmann* (Vienna, Austria), M. Prager, L. Pracher, K. Kumpf, M. Zeitlinger, A. Jorda</i>
O0281	09:54 Impact of appropriateness and type of empirical antibiotic therapy on outcomes of intensive care unit patients with bacteraemia by carbapenem-resistant <i>A. baumannii</i> <i>S. Karakonstantis* (Heraklion, Greece), E. Kritsotakis, E. Petrakis, N.R. Tziolos, D. Kypraiou, S. Papazisi, S. Anagnostou, E. Kondili, D. Kofteridis</i>
O0282	10:06 Therapeutic approaches and predictors of mortality in colistin-resistant <i>Klebsiella</i> bloodstream infections: a real-world study <i>G. Kul* (Ankara, Türkiye), N. Korkmaz, G.Ç. Şentürk, F. Aycan, B. Gündoğan, H.M. Yılmaz, F.Z. Şahin, H. Ertekin, A.H. Solay, S. Kuzi, D. Bulut, E.E. Tütüncü</i>
O0283	10:18 Mortality attributable to mismatch with <i>in vitro</i>

susceptibility of empirical antibiotics in patients with bacterial bloodstream infections *G.K. Zheng\* (Hong Kong, Hong Kong), W. Zhang, J. Blais, P. Wu, B. Cowling*

OS040	08:30 - 10:30	Hall A3-2
	2-hour Oral Session	

**Expanding the antimicrobial arsenal: from dual-action compounds to predictive AI**

<i>Chairs</i>	<i>Shampa Das (Liverpool, United Kingdom)</i> <i>Markus Zeitlinger (Vienna, Austria)</i>	
O0284	08:30 3A11, an antibacterial molecule that reveals a dual mechanism of action <i>A. Jouault* (Rennes, France), B. Durand, N. Amiot, S. Ray, V. Bordeau, Y. Augagneur, G. Lina, V. Cattoir</i>	
O0285	08:42 <i>In vitro</i> activity of a new antibiotic derivative of the lactivicin class, FPI-2119, tested against a challenge set of multidrug-resistant Enterobacteriales clinical isolates <i>R. Mendes* (North Liberty, United States), G. Morgan, R. Jankowska, Y. Edah, R. Brianna, S. Charbon, S. Salama</i>	
O0286	08:54 Antimicrobial activity of short ionic peptides is defined by fibre architecture, not charge <i>N. Dad* (Manchester, United Kingdom), G. Humphreys, A. Pluen, M. Elsayy, A. Mcbain</i>	
O0287	09:06 OMN6: a novel antimicrobial peptide demonstrating LPS sequestration and <i>in vivo</i> efficacy in LPS-induced sepsis model <i>N. Bachnoff* (Jerusalem, Israel), O. Heyman, O. Mayost Lev-Ari, N. Nur Maymon, S. Mandel, J. Zazoun, A. Ben Dror, T. Shachar, M. Cohen-Kutner</i>	
O0288	09:18 Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway against <i>Klebsiella pneumoniae</i> , <i>Pseudomonas aeruginosa</i> , <i>Streptococcus pneumoniae</i> , and <i>Neisseria meningitidis</i> <i>T. Walsh* (Richmond, United States), Y.M. Ali, M. Yabuki, C. Arachchilage, K. Priyanka, N.J. Lynch, S. Bruchmann, A. Weimann, K. Brown, R.A. Floto, J. Parhill, D.E. Briles, L.S. Macdaniel, H. Utsugi, G. Gragerova, R. Petraitiene, V. Petraitis, A. Misquith, C. Doulami, G. Demopoulos, W. Schwaeble</i>	
O0289	09:30 Chalcone-based scaffolds as promising antibacterial agents against clinical <i>Staphylococcus aureus</i> strains <i>A. Israyilova* (Baku, Azerbaijan), M. Uygun, N. Atac, A. Huseynzada, K. Shahverdiyeva, F. Can, U. Hasanova</i>	
O0290	09:42 Fighting Carbapenem-resistant <i>Klebsiella pneumoniae</i> (CR-Kp): mechanistic insights into a novel metal-based complex <i>R. Almeida* (Oeiras, Portugal), N.A. Faria, B. Royo, O. Lenis-Rojas, M. Miragaia</i>	
O0291	09:54 Reviving antibiotic potency: pharmacological assessment of JS238 a newly designed potentiator against <i>P. aeruginosa</i> <i>P. Rasouli* (Brussels, Belgium), J.M. Brunel, H. Rodriguez-Villalobos, J.H. Lorent, F. Van Bambeke</i>	
O0292	10:06 Integrating <i>in vitro</i> , <i>in silico</i> , and machine learning approaches to identify potent phytochemicals from <i>Phyllanthus amarus</i> leaf extracts with activity against multidrug-resistant pathogens <i>A. Adeniyi* (Kano, Nigeria), O. Olumide, A. Temiloluwa, A. Peter, A. Bolanle, B. Damilola</i>	
O0293	10:18 A hypergraph neural-network framework for predicting synergistic and antagonistic antimicrobial combinations: a triplet-based approach integrating antimicrobial peptides, antibiotics, and bacterial taxonomy <i>A. Khavaran* (Philadelphia, United States), F. Midjani, M. Malekpour, A.H. Rajabi, F.Z. Keshkar, F. Golabi, A. Abbasi, M. Farhadi, B. Khosravi, A. Amanati</i>	
SY077	08:30 - 10:30	Hall A2-1
	2-hour Symposium	
<i>Chairs</i>	<i>Yesim Besli (Istanbul, Türkiye)</i> <i>Merica Carev (Split, Croatia)</i>	
S0295	08:30 Global risk mapping of XDR Typhoid: from genomic	

**insights to possible threats** *Megan Carey (Amsterdam, The Netherlands)*

**S0296 09:00** **Global resistance trend of *Campylobacter*, predictive modelling and novel intervention strategies** *Bruno Lopes (Middlesbrough, United Kingdom)*

**S0297 09:30** **Exploring the rise of AMR in invasive NTS: mechanisms, mobility, and global trends** *Sandra Van Puyvelde (Wilrijk, Belgium)*

**S0298 10:00** **Silent spreaders: tracking carbapenemase-producing Enterobacteriales in the food chain** *Valeria Bortolaia (Copenhagen, Denmark)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

**SY076 08:30 - 10:30** **Hall B0-1**

2-hour Symposium

**What drugs are missing? Exploring adjuvant therapies in immunosuppressed patients**

*Chairs* *Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*  
*Nina Khanna (Basel, Switzerland)*

**S0291 08:30** **Immunotherapy meets infection: the case for host-directed treatment strategies** *Patrizia Comoli (Pavia, Italy)*

**S0292 09:00** **Too little or too much? Balancing immune modulation in transplant and oncology patients** *Carlota Gudiol (Barcelona, Spain)*

**S0293 09:30** **Adjuvant therapies in practice: lessons from mycobacteria** *Graeme Ayton Meintjes (Observatory, South Africa)*

**S0294 10:00** **What drugs are missing? Unmet needs and promising directions in the immunocompromised host** *Michael Boeckh (Seattle, United States)*

**SY073 08:30 - 10:30** **Hall ICM 13a**

2-hour Symposium

**Infections with no borders: challenges in South and Central-Eastern Europe in the context of travel, migration and war**

*Chairs* *Marco Falcone (Pisa, Italy)*  
*Christian Wejse (Aarhus, Denmark)*

**S0279 08:30** **Epidemiology and burden of imported travel related infectious diseases in the CEE region** *Botond Lakatos (Budapest, Hungary)*

**S0280 09:00** **The impact of armed conflicts and migration on antimicrobial resistance** *Vodiany Arkadii (Kyiv, Ukraine)*

**S0281 09:30** **Leishmaniasis outbreaks in conflict zones** *Aula Abbara (London, United Kingdom)*

**S0282 10:00** **"Threat of spread": vaccine preventable diseases in the CEE region** *Simona Ruta (Bucharest, Romania)*

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), Hungarian Society of Infectious Diseases and Clinical Microbiology, International Society of Antimicrobial Chemotherapy (ISAC), ESCMID Study Group for Epidemiological Markers (ESGEM)

**SY074 08:30 - 10:30** **Hall ICM 13b**

2-hour Symposium

**The rise of tick-borne diseases: why are things changing?**

*Chairs* *Sally Jane Cutler (London, United Kingdom)*  
*Alice Raffetin (Villeneuve-Saint-Georges, France)*

**S0283 08:30** **Urban green spaces, fragmented forests and the transmission of tick-borne pathogens** *Olaf Kahl (Berlin, Germany)*

**S0284 09:00** **Automated classification of disease vectors** *Rodrigo Gurgel-Gonçalves (Brasília, Brazil)*

**S0285 09:30** **Hitching a ride: role of migratory birds in transferring ticks to new habitats** *Ilaria Pascucci (Pesaro, Italy)*

**S0286 10:00** **'Seek and thou shall find': harnessing the power of**

citizen science *Gabor Foldvari (Budapest, Hungary)*  
Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

**SY075 08:30 - 10:30** **Hall ICM 5**

2-hour Symposium

**Protecting the most vulnerable: infection prevention in neonatal and paediatric critical care**

*Chairs* *Bianca Albers (Zurich, Switzerland)*  
*Angelika Berger (Vienna, Austria)*

**S0287 08:30** **Biofilm related infections in children** *Ojan Assadian (Wiener Neustadt, Austria)*

**S0288 09:00** **Multidrug-resistant infections in the neonatal and paediatric ICU: how can we prevent outbreaks?** *Pablo Sanchez (Columbus, Ohio, United States)*

**S0289 09:30** **Surveillance and stewardship in the NICU/PICU: what works and what doesn't?** *Julia Anna Bielicki (London, United Kingdom)*

**S0290 10:00** **Neonatal skin, device, and environmental hygiene: how to translate evidence into practice?** *Andreas F. Widmer (Füllinsdorf, Switzerland)*

**EF041 08:30 - 09:30** **Arena 2**

ePoster Flash Session

**Short- and long-term consequences of viral infections**

*Chair* *Bettie Voordouw (Culemborg, The Netherlands)*

**E0294 08:30** **Breath-based volatile organic compound signatures for long COVID identification: a machine learning approach for differential diagnosis** *P. Esteban Sánchez\* (Zaragoza, Spain), S. Letona, M.P. Domingo, D. Recalde, E. Morte, G. Pellejero, A. Ramirez, R. Sanz-Pamplona, J. Pardo, J.R. Paño, E. Del Corral Beamonte, E.M. Gálvez*

**E0295 08:36** **Time-stratified, variant-specific risks of major adverse cardiovascular events following COVID-19 across  $\alpha$ -omicron variants: a nationwide matched cohort study in Japan** *K. Ikeuchi\* (Tokyo, Japan), S. Harada, R. Sekiya, Y. Arisato, S. Matsumoto, T. Kishida, A. Kado, K. Okushin, H. Yotsuyanagi, T. Tsutsumi*

**E0296 08:42** **Metformin and ursodeoxycholic acid for the treatment of post-acute sequelae of COVID-19: a randomised clinical trial** *S. Y. Lim\* (Seoul, Korea, Republic of), J. Lee, E. Chang, S.H. Kim, J.S. Kwon, C. Y. Jang, Y. Seo, J.J. Park, S.H. Na, H. Park, H.M. Jang, S.C. Yun*

**E0297 08:48** **T cell exhaustion and gut microbiota in HIV/SARS-CoV-2 co-infection** *X. Yan\* (Shanghai, China), X. Zhang, Y. Shen*

**E0298 08:54** **Maternal and fetal outcomes of Crimean-Congo haemorrhagic fever in pregnancy: an individual patient data meta-analysis** *D. Güllü\* (Istanbul, Türkiye), B. Donk, A.M. Cırık, H. Alay, F. Karakeçili, K. Özden, F. Kesmez Can, O. Barkay, N. Pshenichnaya, Ö. Ergönül*

**E0299 09:00** **Myocarditis in chikungunya virus infection: a systematic review and meta-analysis** *S. Shah\* (Kathmandu, Nepal)*

**E0300 09:06** **Predictors and clinical spectrum of long-term sequelae after tick-borne encephalitis: results of a prospective multi-centre cohort study** *M. Slížek\* (Prague, Czechia), D. Smišková, O. Džupová, L. Chovanec, V. Pražák, A. Chrdle, K. Pohludková, L. Petroušová, J. Sečník*

**E0301 09:12** **Epidemiological, clinical, and virological findings in 1600 patients with West Nile virus infection, Northern Italy, 2008–2025** *L. Barzon\* (Padua, Italy), M. Pacenti, S. Vogiatzis, C. Lucca, E. Dal Molin, A. Sinigaglia, A. Giaretta, V. Lisi, S. Simonato, S. Satto, J. Rampazzo, C. Boldrin, M. Cattai*

**E0302 09:18** **Mpox-related ocular disease: a prospective cohort study in South-Kivu, Democratic Republic of Congo** *C. Van Dijck\* (Antwerp, Belgium), T. Kabesha, S. Mudwanga, S. Houben, Y. Mujula Kanundey, P. Munganga, S. Yeh, N. Kabedi, V. Nussenblatt, O. Tshiani Mbaya, I. Crozier, S. Sabiti Nundu, J.*

EF042	08:30 - 09:30	Arena 3
	ePoster Flash Session	
	<span style="background-color: #800080; color: white; padding: 2px;">DX</span> <span style="background-color: #800080; color: white; padding: 2px;">PED</span> <span style="background-color: #800080; color: white; padding: 2px;">TRN</span>	
<b>How viral and host genomics shape infection and immune response</b>		
Chair	Victoria Hall (Melbourne, Australia)	
E0303	08:30	Distinct antigenic signatures and neutralising antibody responses following MVA-BN vaccination and monkeypox virus infection U.M. Chan* (Taipei, Taiwan), T.L. Chao, W.D. Liu, C.C. Hung, S.Y. Chang
E0304	08:36	NGS sequencing with application of different methods and phylogenetic analyses in MPXV positive samples in Berlin 2022 to 2025 M. Obermeier* (Berlin, Germany), Ö. Yildirim, M. Lautner, M. Prentice, R. Ehret
E0305	08:42	Emerging human spillovers of H5N1: viral adaptations and pandemic preparedness J. Acosta España* (Quito, Ecuador), J.D. Acosta-España, J.B. Altamirano-Jara, D.K. Bonilla-Aldana, A. Rodríguez-Morales
E0306	08:48	Clinical significance of viral DNA findings by mNGS in a large cohort of patients T. Schroeder* (Nuertingen, Germany), J. Baake, M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stüdle
E0307	08:54	Prediction of conserved long-range RNA-RNA interactions in the hepatitis E virus genome B. Y. Alhatlani* (Buraydah, Saudi Arabia)
E0308	09:00	Molecular evidence of active Dengue virus transmission and DENV-2/DENV-3 circulation in Ondo, South-West Nigeria: implications for malaria-coendemic settings S. Kayode* (Ondo, Nigeria), B. Onoja, F. Akinkunmi, R. Nwuba
E0309	09:06	Acute hepatitis of unknown origin in the paediatric population: clinical, virological and genetic characterisation in a prospective case series D. Henares* (Barcelona, Spain), A. Avellon, I. Loverdos, M. Pons-Espinal, M. Muñoz-Chimeno, A. Garcia-Soler, E. Ruiz De Pedro, C. Molera, P. Brotons, M.F. De Sevilla, J. Martinez-Laso, C. Muñoz-Almagro
E0310	09:12	From pol to whole genome: advancing HIV drug resistance testing F. Stefanelli* (Genoa, Italy), N. Randazzo, G. Guarona, B. Galano, S. Ferrari, R. Qosja, A. Di Biagio, A. Domnich, N. Nigro, B. Bruzzone
EF043	09:30 - 10:30	Arena 1
	ePoster Flash Session	
	<span style="background-color: #800080; color: white; padding: 2px;">IPC</span> <span style="background-color: #800080; color: white; padding: 2px;">PHEI</span>	
<b>Tracking respiratory virus outbreaks in a changing world: from hospitals to wastewater</b>		
Chair	Magdalena Rosińska (Warsaw, Poland)	
E0312	09:30	Comparing COVID-19, influenza, and RSV positivity from a longitudinal cohort with US national surveillance data D. Nash* (New York, United States), M.S. Rane, K. Penrose, K.E. Allen, F.R. Ernst, A. Srivastava, Y. Shen, M.M. Robertson, J. Zamparo, S.G. Kulkarni, L. Puzniak
E0313	09:36	Pandemic-induced reorganisation of respiratory virus ecology: seven-year analysis of COVID-19, influenza, and RSV hospitalisation dynamics from RESP-NET surveillance (2018-2025) P. Kilgore* (Detroit, United States)
E0314	09:42	Hospitalisation and healthcare consumption burden of respiratory syncytial virus (RSV) in older adults in France M. Vacheret* (Paris, France), S. Fievez, E. Blanc, L. Watier, L. Baschet, C. Bignon-Favary, P. Mckelvie-Sebileau, P. Loubet
E0315	09:48	Incidence of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among adults 50 years and older in the outpatient setting in the US: interim results from the ARIA study M. Schmidt* (Portland, Or, United States), J. Kuntz, H. Groom, N. Smith, J. Meece, R. Mularski, W. Hu, M. O'keeffe-Rosetti, N. Klein, K. Jacobson, C. Oxandale, A. Wiesner, L. Glasser, S. Venkatesan, C. Talarico
E0316	09:54	Using latent class analysis to improve classification of

nosocomial SARS-CoV-2 infections in Ontario, Canada N. Wilson\* (Toronto, Canada), C.E. Lee, D. Fisman

E0317	10:00	Hospital outbreaks predict community COVID-19 spread: evidence for healthcare-driven transmission N. Wilson* (Toronto, Canada), C. Lee, D. Fisman
E0318	10:06	Self-testing for five respiratory viruses in adults =50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections J.A. Nacov* (Cologne, Germany), J. Salmanton-Garcia, J. Jakobs, M. Anggitakirana, S. Grimm, J. Leckler, K. Köbe, L. Cremer, P. Wipfler, J. Stemler, H.J. Schmitt, U. Bethe, O. Cornely
E0319	10:12	Comparison of emergency department indoor air and citywide wastewater for respiratory and enteric virus surveillance using hybrid-capture viral metagenomics M. Karatas* (Leuven, Belgium), S. Gorissen, C. Geenen, J. Swinnen, E. Hosten, K. Van Dyck, L. Cuypers, M. Bloemen, E. Wollants, M. Van Ranst, B. Verschuere, M. Sabbe, J. Matthijssens, E. André
E0320	10:18	Detection of SARS-CoV-2 variants of concern in Swiss wastewater without prior lineage classification R. Kociurzynski* (Freiburg, Germany), T. Donker

KN081	09:30 - 10:30	Hall ICM 14
-------	---------------	-------------

Keynote Scientific Interview

	<span style="background-color: #800080; color: white; padding: 2px;">DX</span> <span style="background-color: #800080; color: white; padding: 2px;">PHEI</span> <span style="background-color: #800080; color: white; padding: 2px;">VAX</span>
<b>Integrating technology and capacity building to strengthen disease surveillance and prevention in low-resource settings</b>	
Chair	Jon S. Friedland (London, United Kingdom)

K0311	09:30	Senjuti Saha (Dhaka, Bangladesh)
-------	-------	----------------------------------

OS044	11:00 - 12:00	Hall A1-1
	1-hour Oral Session	

#### Mechanisms of pathogenesis across different pathogens

Chairs	Elisa Borghi (Milan, Italy) Anna Norrby-Teglund (Stockholm, Sweden)	
O0321	11:00	A systems serology approach to identify antibodies to PfEMP1 that correlate with protection from paediatric cerebral malaria in Malawi P. Banda* (Blantyre, Malawi), I. Walker, C. Juwawo, W. Hasang, D. Mathanga, T. Taylor, T. Nyirenda, E. Aitken, S. Rogerson, K. Seydel
O0322	11:12	Wzi modulates immune evasion of hypervirulent <i>Klebsiella pneumoniae</i> in a CPS-dependent and independent manner K. Zhou* (Shenzhen, China), S. Wei, T. Xu
O0323	11:24	Binding of host glycans and vitronectin drive <i>Neisseria gonorrhoeae</i> pathogenesis and reveal potential vaccine targets E. Macdonald* (Bristol, United Kingdom), S. Savino, W. Pansegrau, D. Hill
O0324	11:36	A 3D-Bioprinted human skin model to study <i>Candida</i> colonisation and species-dependent phenotypes M. Cacaci* (Rome, Italy), D. Squitieri, G. Artemi, F. Bugli, R. Torelli, M. Papi, V. Palmieri, A. Augello, C. Perilli, M. De Spirito, R. Benvenuto, E. Stigliano, E. Benini, P. Fazi, M. Sanguinetti
O0325	11:48	Host-specific platelet-activating factor acetylhydrolase selectively remodels diacylglycerophospholipids to control schistosome development F.U. Prodjinotho* (Munich, Germany), J. Ertl, Z. Rao, A. Anisuzzaman, J. Schluckebier, Y. Hamway, P. Baar, M. Haslbeck, C.G. Grevelding, S. Haeberlein, F.H. Falcone, S. Schulz, A. Koeberle, C. Prazeres Da Costa

OS045	11:00 - 12:00	Hall A1-3
	1-hour Oral Session	

#### Invasive fungal infections: therapeutic strategies and emerging options

Chairs	Oliver A. Cornely (Cologne, Germany) Cornelia Lass-Flörl (Innsbruck, Austria)	
--------	--	--

00326	11:00	<b>Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Case-Control Study</b> <i>B.S. Bisono Garcia*</i> (Rochester, United States), <i>K.G. Rabe, S.A. Parikh, P. Vergidis</i>
00327	11:12	<b>Olorofim for the treatment of invasive <i>Aspergillus</i> in haematology patients with limited or no treatment options: sub-analysis of an open-label, single-arm, phase IIb trial (Study32; NCT03583164)</b> <i>J. Maertens*</i> (Leuven, Belgium), <i>S. Hammond, G. Rahav, A. Bruns, O. Uspenskaya, M. Chayakulkeeree, V. Mehra, A. Spec, J.M. Aguado, J. Fortun, C. Heath, M.H. Nguyen, J. Schaenman, S. Schwartz, M. Miceli, M. Moussa, O. Marin Fernandez, D. Zinzi, J. Rex</i>
00328	11:24	<b>Fosmanogepix expanded access in patients with invasive mould infections from Germany, Austria, and Switzerland</b> <i>J. Stemler*</i> (Cologne, Germany), <i>J. Prattes, N. Khanna, H. Schlamm</i>
00329	11:36	<b>Immunisation against <i>Aspergillus</i> is associated to poor outcome and higher mortality in patients with idiopathic pulmonary fibrosis: The Asp-IPF study</b> <i>J.P. Gangneux*</i> (Rennes, France), <i>H. Guegan, F. Reizine, P. Chauvin, F. Robert-Gangneux, M. De Saint Jore, T. Guy, A. Mabo, Y. Bazin, M. Kerjouan, S. Jounneau</i>
00330	11:48	<b>Oteseconazole concentrations in plasma and CSF in HIV-related cryptococcal meningitis</b> <i>M. Nicol*</i> (Minneapolis, United States), <i>M. Rutakingirwa, M. Kabahubya, T. Mugabi, J. Gakuru, S. Namombwe, F. Ssekindi, S. Kimuda, C.P. Skipper, M. Abassi, S.R. Brand, D.B. Meya, D.R. Boulware</i>

OS046	11:00 – 12:00	Hall A1-4
	1-hour Oral Session	

**Translational science in mycobacterial infections**

<i>Chairs</i>	<i>Deborah Chong (London, United Kingdom)</i> <i>Delia Goletti (Rome, Italy)</i>	
00331	11:00	<b>Increased cAMP levels compromise cell wall integrity by promoting the production of reactive oxygen species in <i>Mycobacterium tuberculosis</i></b> <i>Y. Li*</i> (Guangzhou, China), <i>J. Wan, X. Xia, X. Deng, G. Tian, L. Zhong, S. Feng</i>
00332	11:12	<b>Spatial single-cell transcriptomic analysis reveals elevated platelet-neutrophil interaction and platelet-derived MMP-1 secretion in human CNS-TB granulomas</b> <i>Y.H. Wong*</i> (Singapore, Singapore), <i>H. Lee, F.K. Loh, B. Chen, T.H. Hu, H.T. Chong, C.L. Tan, A.F. Vallejo, C.W.M. Ong</i>
00333	11:24	<b>Characterisation and genetic engineering of a novel mycobacteriophage for therapeutic use</b> <i>A. Bonacorsi*</i> (Pisa, Italy), <i>A. Fusco, D. Manessi, F. Filippini, G. Delogu, I. Palucci, M. Lai, G. Freer, S. Dominici, F. Pratesi, G. Hatfull, A. Tavanti, L. Rindi, M. Di Luca</i>
00334	11:36	<b>BCG vaccination induces partial NK cell tolerance in people with HIV-1 on suppressive ART</b> <i>C. Dollé*</i> (Zurich, Switzerland), <i>T. Tutumlu, D. Russenberger, M. Zeeb, E. West, D. Braun, H. Günthard, J. Nemeth</i>
00335	11:48	<b>Persistor cells are highly prevalent across <i>Mycobacterium abscessus</i> clinical isolates</b> <i>L. Geerts*</i> (Wilrijk, Belgium), <i>L. De Vooght, G.J. Wijnant, E. André, N. Lorent, P. Cos</i>

OS047	11:00 – 12:00	Hall A1-5
	1-hour Oral Session	

**Diagnosing respiratory infections: from PCR to metagenomics**

<i>Chairs</i>	<i>Gilbert Greub (Lausanne, Switzerland)</i> <i>Qiwen Yang (Beijing, China)</i>	
00336	11:00	<b>Machine learning-driven daily VAP risk stratification for real-time ICU decision support</b> <i>Y. Fromage*</i> (Limoges, France), <i>A. Hernandez Padilla, J. Vaidie, H. Sayadi, A. Barac, O. Cremer, D. Garot, A. Rouzé, T. Daix, L. Vintcent, H. Jackson, M. De Karker, H. Van Werkhoven, J.B. Woillard, B. François</i>
00337	11:12	<b>Novel thermo-induced switching probes enable dual-target detection per fluorescence channel for seven respiratory viral targets in a one-tube multiplex PCR assay</b> <i>J. Lee*</i> (Jeonju, Korea, Republic of), <i>J. Yoon, H.</i>

Kim

00338	11:24	<b>The first national EQA for clinical metagenomics: design, delivery and results</b> <i>A. Alcolea Medina*</i> (London, United Kingdom), <i>L.B. Snell, R. Doyle, V. Patel, R. Chang, M. Gumbanmarasigan, V. Vorslava, B. Leta, D. Ward, J. Brown, A. Kopec, S. Rock, M. Valappil, K. Laws, S. Parmar, S. May, P. Patel, M. Ibrahim, S. Green, K. Saeed, N. Norton, C. Reid, A. Every, A. Hughes, A. Kottara, K. Nelson, B. Browne, P. Grant, G. Nebbia, R. Batra, J. Edgeworth, A. Alcolea-Medina</i>
00339	11:36	<b>Whole genome sequencing of <i>Mycoplasma pneumoniae</i> directly from clinical samples using a novel target sequence capture probe panel</b> <i>C. Dixon*</i> (Cardiff, United Kingdom), <i>N. Couto, M. Ramirez, R. Mamede, H. Milton, M. Maiwald, C. Moore, S. Sidorov, J. Flipse, R. Nir-Paz, A. Michael-Gayego, J. Moran-Gilad, D. Kese, G. Greub, P.M. Meyer Sauteur, M.L. Beeton</i>
00340	11:48	<b>Diagnostic performance of clinical metagenomics in pneumonia for blood and respiratory specimens: a single centre study</b> <i>C. Bode*</i> (Bonn, Germany), <i>A. Sauer, K. Peukert, S. Mazzitelli, M. Parcina, C. Putensen, T. Muders, J. Poth, F. Lehmann, B. Seeliger, S. Grumaz</i>

OS048	11:00 – 12:00	Hall A2-1
	1-hour Oral Session	

**Field investigations of community-acquired infections**

<i>Chairs</i>	<i>Aula Abbara (London, United Kingdom)</i> <i>Steen Ethelberg (Copenhagen, Denmark)</i>	
00341	11:00	<b>Rapid deployment of a large epidemiological investigation: lessons learnt from a mains water outbreak of <i>Cryptosporidium parvum</i>, South West UK, 2024</b> <i>P. Charlotte*</i> (London, United Kingdom), <i>C. Patterson, B. Winer, M. Bardsley, F. Halford, S. Bird, N. Verlander, R. Chalmers, E. Smout, R. Kwiatowska, N. Young</i>
00342	11:12	<b>A national iatrogenic botulism outbreak associated with cosmetic procedures in England, 2025</b> <i>V. Wong*</i> (London, United Kingdom), <i>S. Gokool, D. Rajendram, B. Ahmed, R. Pebody, I. Hayden, G. Godbole</i>
00344	11:36	<b>Epidemiological characteristics and outcomes of the 2023–2024 cholera outbreak in South Yemen: a retrospective descriptive study from MSF-supported centres</b> <i>M. Sallam*</i> (Aden, Yemen), <i>N.O. Abdulgany, A.M. Farhan, M. Shomasi, A. Abdulhaq, U.Z. Khan, D. Dela Cruz-Diaz, H. De Clerck, S. Lim, K. Moussally, P. Garcia-Vello</i>
00345	11:48	<b>Echoes of <i>Vibrio</i> seasonal context variables, microbial signatures, and critical illness in cholera infections</b> <i>P. Thummalagunta*</i> (Mangalagiri, India), <i>M. Kumar, A. De Debabrata, C.N. Chithra, H. G. S.V. Kutty, R. Upparakadiyala, A. Rajeev</i>

OS049	11:00 – 12:00	Hall A2-2
	1-hour Oral Session	

**From silent malaria infections to severe disease in a globalised world**

<i>Chairs</i>	<i>Emmanuel Bottieau (Antwerp, Belgium)</i> <i>Fitsum Tadesse (Addis Ababa, Ethiopia)</i>	
00346	11:00	<b>Late treatment failures of artemisinin-based combination therapies in imported <i>Plasmodium falciparum</i> malaria in France (2013–2024): a case-control and genomic investigation</b> <i>S. Boufares*</i> (Paris, France), <i>R. Coppee, A. Cosson, N. Mathieux, S. Anthony, Z. Rizwana, S. Veronique, T. Nicolas, H. Sandrine</i>
00347	11:12	<b>Prevalence of truly asymptomatic malaria and its determinants in a high burden rural district in India: a community-based study from Uttar Pradesh</b> <i>R.S. Rath*</i> (Gorakhpur, India), <i>G.R. Dwivedi, H.S. Joshi, A. Singh, P. Kharya, N.M. Agarwal, M. Bisht, D. Upadhyaya, A.R. Koparkar, A.M. Dixit</i>
00348	11:24	<b>Outpatient management of imported non-severe malaria in the UK: a multi-site clinical safety evaluation</b> <i>J. Milburn*</i> (London, United Kingdom), <i>A. Williamson, S. Baljekar, R. Rachman, A. Daunt, N.</i>

		<i>Richardson, F. Olcott, C. Rodrigues, R. Thangarajah, S. Yeung, M. Arias, C. Jennings, A. Delmonte Sen, J.L. Klein, A. Odedra, N. Jacobs, C. Drapeau, C. Van Halsema, G. O'hara, A. Checkley</i>
00349	11:36	<b>Host and parasite biomarkers to trigger intravenous antimalarials and prioritise ICU admission in severe imported <i>Plasmodium falciparum</i> malaria patients</b> <i>D. Camprubi-Ferrer* (Barcelona, Spain), J. Pedreira-Rincon, C. Bertran-Cobo, M. Alguacil, L. Balerdi Sarasola, M.J. Alvarez-Martinez, J. Muñoz, C. Parolo, D. Camprubi Ferrer</i>
00350	11:48	<b>Whole genome sequencing to inform the epidemiology of <i>Plasmodium falciparum</i> malaria in the elimination setting of Malaysia</b> <i>K. Tan* (London, United Kingdom), N. Billows, P. Divis, C. Daneshvar, J. Edgeworth, J. Cox-Singh, S. Campino, T. Clark</i>

OS050 11:00 - 12:00 Hall A3-1

1-hour Oral Session

AMR CLN PED

**Personalised approaches to infectious diseases in high-risk haematologic and transplant patients**

*Chairs* *Andreas H. Groll (Münster, Germany) Stefan Schwartz (Berlin, Germany)*

00351	11:00	<b>The role of rectal swabs in driving empirical antibiotic therapy in febrile neutropenic patients: a quasi-experimental multi-centre study within the REVERSE project</b> <i>R. Scardellato* (Verona, Italy), M. Morra, M. Tebon, A.M. Azzini, M.C. Negulescu, A.L. Mohorea-Neata, A. Araujo, M.T. Pérez-Rodríguez, G. Nadali, C. Tecchio, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi Garcia, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara</i>
-------	-------	--

00352	11:12	<b>Antibiotic discontinuation in paediatric low-risk febrile neutropenia: a multi-centre randomised trial (eSTOP)</b> <i>N. Mendoza Palomar* (Barcelona, Spain), N. Mendoza-Palomar, L. Valero-Arrese, B. Espinosa-López, M. Sancosmed-Ron, N. Wörner, S. Melendo-Pérez, M.N. Larrosa-Escartín, M.B. Viñado-Pérez, J. Esperalba-Esquerria, S. Simó-Nebot, P. Mazorra-Roig, A. Faura-Morros, C. Grasa, P. Guerra-García, C. Echeopar-Parente, E. Cendejas-Bueno, B. Herrero-Velasco, D. Quintero-García, M.T. García-Ascaso, M. González-Amores, P. Soler-Palacin</i>
-------	-------	--

00353	11:24	<b>Efficacy and safety of peri-transplant probiotic supplementation among allogeneic stem cell transplant recipients: a phase IIb randomised controlled trial</b> <i>S. Selvakumar* (Vellore, Tamil Nadu, India), A. Arumugam, N. Veerasamy, S. Selva Kumar, J.S. John, S. Selvarajan, K. Lakshmi, B. George, P. Rupali</i>
-------	-------	---

00354	11:36	<b>Quantitative assessment of associations between early antibacterial drug exposure and late infective and noninfective complications after allogeneic stem cell transplantation</b> <i>M. Yakubovsky* (Tel-Aviv, Israel), R. Ram, R. Ben-Ami</i>
-------	-------	--

00355	11:48	<b>Infections after invasive biliary procedures in liver transplant recipients: a retrospective single-centre analysis</b> <i>A. Lombardi* (Milan, Italy), A. Tonizzo, L. Alagna, G.E. Tontini, M. Michelon, A. Murru, B. Antonelli, G. Viero, A. Celotti, S. Colombo, M. Sagasta, F. Lozio, C. Dibenedetto, V. Scaravilli, P. Lampertico, G. Grasselli, C. Quintini, F. Caprioli, A. Bandera</i>
-------	-------	---

LB003 11:00 - 12:00 Hall B0-2

1-hour Oral Session

ANT CLN

**Late-breaking antiviral drug trials**

*Chairs* *Laurent Kaiser (Geneva, Switzerland) Marta Mora-Rillo (Madrid, Spain)*

L0016	11:00	<b>Positive treatment response of pritelivir achieved in refractory HSV infections in immunocompromised patients, including haematopoietic stem cell and solid organ transplant recipients and oncology patients: PRIOH-1 phase III trial</b> <i>R. Chemaly* (Houston, United States), K. Peggs, D. Neofytos, K. Workowski, R. Avery, Y.J. Lee, R. Maves, O. Cornely, J. Stemler, D. Teschner, M. Yong, J. Sasadeusz, S. Dadwal, J. Dickter, A. Birkmann, C. Wat, D.C. Herath, A. Marini,</i>
-------	-------	---

L0017	11:12	<i>B. Surujbally, M. Sumner, G.A. Papanicolaou</i> <b>Implementing a controlled human infection model (CHIM) with a reverse genetics H3N2 (A/Texas/71/2017, clade 3C.3a) influenza challenge virus in healthy volunteers</b> <i>V. Cnossen* (Leiden, The Netherlands), G. Groeneveld, O. Engelhardt, J. Samolej, G. Piccini, S. Jochems, N. Huisman, T. Muster, M. Roestenberg, I. Kamerling</i>
-------	-------	---

L0018	11:24	<b>UMIT-1, Phase IB Trial: IV favipiravir and ribavirin for the treatment of CCHF</b> <i>I. Bozkurt* (Samsun, Türkiye), H. Bodur, M. Ertek, F. Altuntaş, N. Elaldi, G. Iskender, D. Mert, Y. Cosgun, E. Beren Tanik, E. Challenger, C.R. Thompson, L. Read, L. Else, L. Marsh, S.A. Büyüktuna, H. Can Bilek, H. Karadeniz, H. Oksuzoglu, A. Haykır Solay, E. Türkoğlu, M. Arslan, A. Torun, S. Kulari, J. Read, C. Rawcliffe, M. Yıldız, S. Khoo, T. Fletcher</i>
-------	-------	---

L0019	11:36	<b>Long-term viral suppression, and cardiometabolic benefits of switch to alicuvirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study</b> <i>Z. Jie* (Beijing, China)</i>
-------	-------	---

L0020	11:40	<b>Rivaroxaban, colchicine and famotidine/loratadine with integrated clinical care for Long COVID, a multi-site, open-label randomised controlled trial</b> <i>E. Wall* (London, United Kingdom), M. Heightman, A. Banerjee, G. Prescott, H. Dehbi, C. Watkins</i>
-------	-------	--

SY086 11:00 - 12:00 Hall A1-2

1-hour Symposium

AMR ANT CLN

**Therapeutic management of carbapenem-resistant Gram-negative infections: where are we globally?**

*Chairs* *Yin Mo (Singapore, Singapore) Pranita Tamma (Philadelphia, United States)*

S0233	11:00	<b>Treating carbapenem-resistant Enterobacterales in HIC and LMIC</b> <i>Anupa Thampy (Vellore, Tamil Nadu, India)</i>
-------	-------	--

S0234	11:30	<b>Beyond Enterobacterales: advances in the management of carbapenem resistant non-fermenters</b> <i>Michele Bartoletti (Milan, Italy)</i>
-------	-------	--

**Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Critically Ill Patients (ESGCIPI), European Society of Intensive Care Medicine**

SY087 11:00 - 12:00 Hall A3-2

1-hour Symposium

PED VAX

**The role of the microbiota in vaccine response**

*Chairs* *Zitta Barrella Harboe (Hillerød, Denmark) Ed J. Kuijper (Leiden, The Netherlands)*

S0235	11:00	<b>The impact of intestinal microbiota on vaccine response</b> <i>Petra Zimmermann (Lucerne, Switzerland)</i>
-------	-------	---

S0236	11:30	<b>Early-life gut microbiome and infant vaccination</b> <i>Julie Bines (Parkville, Australia)</i>
-------	-------	---

**Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Vaccine Study Group (EVASG)**

SY083 11:00 - 12:00 Hall ICM 1

1-hour Symposium

DX TRN

**Can large language models (LLMs) transform clinical diagnostics from start to finish?**

*Chairs* *Bram Lestrade (Roermond, The Netherlands) Mario Ramirez (Lisbon, Portugal)*

S0227	11:00	<b>LLM validation and integration for AST</b> <i>Christian Giske (Stockholm, Sweden)</i>
-------	-------	--

S0228	11:30	<b>LLM models in clinical diagnostics: from lab results to patient care</b> <i>De Vito Andrea (Sassari, Italy)</i>
-------	-------	--

**Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), Swiss Society for Microbiology (SSM)**

SY084	11:00 – 12:00	Hall ICM 13a	Damato* (London, United Kingdom), H. Armstrong, R. Lawlor, T. Wilsdon, D. Zhou
	1-hour Symposium		
PRO			
<b>Moving towards patient-centered evidence in infectious diseases</b>			
Chairs	Colin R. Mackenzie (Neuss, Germany) Luigia Scudeller (Pavia, Italy)		
S0229	11:00	Can AI help us to incorporate the patients' perspective into clinical research and guidelines? Bernardo Sousa-Pinto (Porto, Portugal)	
S0230	11:30	Our fight too: empowering patients against AMR Vanessa Carter (Altrincham, United Kingdom)	
Co-organised with: ESCMID Guidelines Subcommittee			
SY085	11:00 – 12:00	Hall ICM 13b	
	1-hour Symposium		
CLN PED			
<b>Early-life respiratory infections and their association with chronic lung disease</b>			
Chairs	Susanna Esposito (Parma, Italy) Chrysanthi Skevaki (Marburg, Germany)		
S0231	11:00	Long-term impact of early-life exposures including RSV disease on lung function Shaakira Chaya (Cape Town, South Africa)	
S0232	11:30	Rhinovirus infections and asthma in children: mechanisms and at-risk phenotypes Manuel E. Soto-Martinez (San Jose, Costa Rica)	
Co-organised with: International Society of Pediatric Respiratory Diseases (INSPIRED)			
EF051	11:00 – 12:00	Arena 2	
	ePoster Flash Session		
AMR ANT			
<b>Antibiotic use, misuse and stewardship across settings</b>			
Chair	Rita Murri (Rome, Italy)		
E0356	11:00	Understanding factors associated with antibiotic misuse among persons living with HIV at two large HIV clinics in Uganda F. Magololo Mutesi* (Kampala, Uganda), N. Mukiza, R. Nakalega, E. Twinomuhwezi, H. Mackline, A. Twimukye, F. Kakooza, A. Kambugu, D.M. Byonanebye, H. Kajumbula	
E0357	11:06	The global spatiotemporal distribution of substandard and falsified antibiotic medicines L. Adipo* (Oxford, United Kingdom), S. Cavany, C. Caillet, J. Mendes, S.M. Nanyonga, N. Stoesser, C. Dolecek, P. Newton, B. Cooper	
E0358	11:12	EU Joint Clinical Assessments: a missed opportunity to recognise the wider benefits of novel antimicrobials? M. Hofer* (London, United Kingdom), A. Macfarlane, G. Bray, E. Hamson, G. Hampson	
E0359	11:18	Profile of high-volume antibiotic prescribers, a population-based study from the French National Health Data System, 2023 G. Beraud* (Orleans, France), H. Desmars, A.I. Lecuyer, F. Coustillères, E. Laurent, C. Carvalho, L. Grammatico-Guillon	
E0360	11:24	In search of innovative 'alter-biotic treatments': non-traditional therapies and the sociotechnical frameworks they require C. Haddad* (Vienna, Austria), A. Albiez, K. Bentley, E. Paterson	
E0361	11:30	Laboratory-based antimicrobial stewardship: an Australian and New Zealand perspective K. Ryan* (St Leonards, Australia), J. Elvy, M. Otormin, M. Jayawardena, M. Graham	
E0362	11:36	European multidisciplinary AMR modified Delphi panel: root causes of undervaluation of novel antibiotics and opportunities for alternative payment models E. Broughton* (Berlin, Germany), H. Armstrong, J. Benítez Rodríguez, C. Capdevila, S. Capri, S. Delgado-Collins, L. Diamond, M. Gheorghe, C. Hng, S. Kelly, K.E. Kypreos, M. Laruem, E. Rinaki, N.V. Sipsas, J.P. Stahl, P. Tilleul, J. Torre-Cisneros, A. Townsend, J.A. Valles Callo	
E0363	11:42	Achieving Europe's fair share: the need for European countries to complement EU-level pull incentives with national provisions for novel antimicrobials E.	
E0364	11:48	Off-label antibiotic consumption behaviour increases the threat of antimicrobial resistance D. Batheja* (Hyderabad, India), S. Reddy, C. Achar	
EF052	11:00 – 12:00	Arena 3	
	ePoster Flash Session		
AMR CLN			
<b>From epidemiology to clinical impact of infections in solid organ transplant recipients</b>			
Chair	Patricia Munoz Garcia-Paredes (Madrid, Spain)		
E0365	11:00	Tuberculosis incidence in solid organ transplant recipients in Europe: a multi-centre TBnet cohort study T.T. Brehm* (Borstel, Germany), B. Lange, S.M. Arend, M. Arias-Guillén, M. Bakker, C. Berastegui, M. Babiker, R. Charif, R. Duarte, H. Flick, R.W. Hofland, J. Ismail, D. Kniepeiss, J. Krepel, N. Krishnan, D. Kuijpers, H. Kunst, F. Van Leth, V. Lezaic, I. Los-Arcos, J. Machová, H. Milburn, S.A. Morais, O.M. Kon, C. Osoro-Suarez, H. Pessegueiro Miranda, D.P. Pesut, A. Rahman, T. Reischig, A. Sánchez-Montalvá, H.E. Spohn, M.T. Stegenga, A.P.J. De Vries, D. Wagner, R. Wobser, C. Lange, M. Sester	
E0366	11:06	Comparative risk of tuberculosis in solid organ transplant recipients and matched general population controls S. Hosseini-Moghaddam* (Toronto, Canada), H.M. Seyed M., D. Fridman, S.S.M. Drover, S.K. Brode, T.K. Marras, F.B. Jamieson, S. Husain, J.C. Kwong	
E0367	11:12	Bacterial respiratory infections in solid organ transplant recipients with a focus on atypical pathogens: data from a prospective national cohort J. Bisch-Karatas* (Bern, Switzerland), I. Abela, A. Boyd, P. Kohler, N. Khanna, A. Koutsokera, M. Schuurmans, O. Manuel, C. Van Delden, N.J. Mueller, C. Hirzel, L.N. Walti	
E0368	11:18	Transplantation confers improved survival in ESBL-E BSI compared with non-transplant patients: insights from two multinational matched cohorts (INCREMENT vs INCREMENT-SOT) E. Ruiz Arabi* (Lausanne, Switzerland), E. Ruiz-Arabi, E. Pérez-Nadales, J.A. Marín-Sanz, J.J. Castón, I. Machuca, A. Cano, M. Marín-Sanz, B. Gutiérrez-Gutiérrez, J. Torre-Cisneros	
E0369	11:24	Epidemiological patterns of carbapenem resistance in solid organ transplantation: a contemporary multi-centre analysis T. Yanik Yalçın* (Ankara, Türkiye), T. Yanik-Yalçın, A. Ö. Mete, Ş. Acar, T. Arslan-Gülen, G. Çınar, I. Hasanoğlu, E. Olcucuoglu, E. Günel, T. Turunç, V. Avkan-Oguz, M.C. Ergon, M. Yavuz-Çolak, Ö. Azap, H. Aslan	
E0370	11:30	Infections in paediatric liver transplantation: risk factors and clinical outcomes L. Romani* (Rome, Italy), M. De Luca, A.C. Epifani, F. Fini, C. Tripiciano, S. Mercadante, S. Bernardi, G. Spagnoletti, A.M. Fratti, R. Somma, V. Tuccio Guarna Assanti Vanessa, L. Dei Giudici, T. Alterio, D. Liccardo, F. Chiusolo, C.F. Perno, A. Pietrobattista, M. Spada	
E0371	11:36	Risk factor analysis for early and late invasive <i>Candida</i> infections in solid organ transplant recipients D. Neofytos* (Geneva, Switzerland), L. Meyer, J. Frossard, P. Schreiber, O. Manuel, F. Lamoth, N. Khanna, K. Boggian, L. Walti, C. Garzoni, C. Van Delden, N. Mueller	
E0372	11:42	Durability of RSV-specific IgG, neutralising activity and T-cell responses after respiratory syncytial virus vaccination in kidney transplant recipients S. Bronder* (Homburg, Germany), H. Gruell, S. Lennartz, R. Urschel, D. Fliser, T. Schmidt, D. Schmit, M. Sester	
E0373	11:48	Systemic absorption and epithelial lining fluid concentration of inhaled vancomycin in lung transplant recipients G. Escudero Arnés* (Barcelona, Spain), G. Escudero, I. Los-Arcos, J. Sacanell, A. Pau, Y. Villena, C. Berastegui, J. Rosado, D. Campany, L. Castellote, B. Saez, L. Domenech, M.T. Martin, M. Culebras, C. Laborda, R. Barquín, S. Luque, O. Len, J. Gavalda	
EF053	11:00 – 12:00	Arena 4	

## Carbapenem resistance: surveillance, mechanisms, and clinical implications

Chair Rafael Canton (Madrid, Spain)

- E0374** 11:00 **A nationwide survey of carbapenemase-producing Gram-negative bacilli in bloodstream infections in a paediatric population (2015–2024)** *C. Kiffer\** (São Paulo, Brazil), *P.Z. Charf, D. Testoni Costa-Nobre, E. Carmo, C.B. Wagner, T.T.F. Rezende, A.S.S. Marinonio, A.P.C. Assef, C.L. Pessoa-Silva, R. Peral, D. Kulek, L. Kraft, M. Pilonetto*
- E0375** 11:06 **Diffusion of OXA-23 producing *Acinetobacter baumannii* in Zagreb post-pandemic** *B. Bedenić\** (Zagreb, Croatia), *B. Bedenić, D. Bandić-Pavlović, M. Nađ, M. Kasalo, D. Varda-Brkić, N. Beader, V. Bratić, M. Dobrić, H. Car, J. Vraneš*
- E0376** 11:12 **Determination of meropenem heteroresistance in a diverse collection of OXA-48-producing *Klebsiella pneumoniae* clinical isolates** *M. Alcalde-Rico\** (Seville, Spain), *A. Angós, F. Docobo-Pérez, M. Delgado-Valverde, J.M. Rodríguez-Martínez, L. López-Cerero, Á. Pascual*
- E0377** 11:18 **Human serum albumin (HSA) modulates cefiderocol activity in carbapenem-resistant (CR) pathogens** *M.S. Ramirez\** (Fullerton, United States), *A. Varnado, S. Moheb, K. Lopez, C. Rodriguez, S.D. Sanchez, G. Traglia, F. Pasteran, M.E. Tolmasky, R.A. Bonomo, L.A. Actis, G. Rao*
- E0378** 11:24 **Sigma E factor transcriptional regulates the expression of metallo- $\beta$ -lactamase NDM and mediates heteroresistance** *Y. Wang\** (Hangzhou, China), *W. Huang, Q. Shi, J. Zhou, R. Weng, H. Hu, J. Quan, Y. Jiang, Y. Yu*
- E0379** 11:30 **The role of colistin resistance genes in the formation of colistin-induced tolerant and persister cells in clinical isolates of *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*** *G. Ozcan Kuyucu\** (Ankara, Türkiye), *G. Ozcan, C. Vatansever, J. Boral, A. Akpınar, S. Menekse, M. Gonen, F. Can*
- E0380** 11:36 **Does use of ceftazidime/avibactam increase the risk of in vivo emergence of ceftazidime/avibactam and cefiderocol cross-resistance in KPC-producing *Klebsiella pneumoniae*: a case-control study** *Y.T. Lin\** (Taipei, Taiwan), *C. Chuang, S.Y. Liu, Y.C. Ho, S.H. Chou, Y.R. Huang, W. Chin, N.W. Hsu, L. Chen*
- E0381** 11:42 **Aztreonam/avibactam resistance due to synergistic interplay of ampC-related mutations in carbapenem-resistant Enterobacter spp.** *Y. Zeng\** (Chengdu, China), *Y. He, Z. Zong*

KN082 11:00 – 12:00 Hall ICM 14

Keynote lecture

CLN DX

## Rickettsioses: widespread and neglected

Chairs *Li Yang Hsu* (Singapore, Singapore)  
*Xavier Lescure* (Paris, France)K0226 11:00 *Nicholas Day* (Bangkok, Thailand)

ME089 11:00 – 12:00 Hall B0-1

Meet-the-Expert

CLN DX

## Global health on the move: advances and strategies in travel medicine

M0239 11:00 *German Henostroza* (Lima, Peru)M0240 11:12 *Andreas Neumayr* (Basel, Switzerland)

ME088 11:00 – 12:00 Hall ICM 5

Meet-the-Expert

ANT TRN

## To model or not to model? A debate on the role of modelling and simulation in clinical PK trials

M0237 11:00 *Markus Zeitlinger* (Vienna, Austria)M0238 11:12 *Lena Friberg* (Uppsala, Sweden)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

FO090 11:00 – 12:00 Arena 1  
Open Forum

IPC

## IPC nurses corner: building bridges across Europe

Chair *Ermira Tartari* (Msida, Malta)

- F0241** 11:00 **Training the invisible workforce: what (still) makes sense in cleaning staff education?** *Veronica Weterings* (Breda, The Netherlands)
- F0242** 11:10 **From recipient to partner: patient involvement in infection prevention** *Erik Briers* (Antwerp, Belgium)
- F0243** 11:20 **Simulation-based IPC training: the real-life test lab** *Constantinos Tsioutis* (Nicosia, Cyprus)
- F0244** 11:30 **Reinventing the wheel: hand hygiene meets AI innovation** *Silvana Gastaldi* (Mazzano, Italy)

Co-organised with: EUCIC Steering Committee

OS056 13:30 – 14:30 Hall A2-2  
1-hour Case Session

CLN PHEI

## Not the consult I expected this morning...

Chairs *Flaminia Olearo* (Berlin, Germany)  
*Ryan Rego* (Ceske Budejovice, Czechia)

- O0383** 13:30 **Hidden pathogen: *Mycoplasma hominis* as the cause of a prosthetic vascular infection** *M. Bettencourt Silva\** (Lisbon, Portugal), *A. Duarte, A.L. Silva, A. Lopes, P. Amorim, L. Mendes Pedro, L. Mendonça, D. Mendes Pedro*
- O0384** 13:41 **Non-typhoidal *Salmonella* brain abscesses in a newly-diagnosed HIV patient: a case report** *E.K. Barreda\** (Metro Manila, Philippines), *A. Estuart, C. Valdez, M.F. Tayzon, M. Saniel*
- O0385** 13:52 **A novel case of non-imported *Rickettsia akari* infection in Ireland** *T. Coyne\** (Dublin, Ireland), *A. Brown*
- O0386** 14:03 **When you hear hoofbeats, sometimes it's camels not horses** *J. Anderson\** (Edinburgh, United Kingdom), *E. Vink, S. Woolley, J. Jervis, R. Sutherland*
- O0387** 14:14 **Identification of *Pigmentibacter ruber* in the peripheral blood of a drowning patient: a case report and literature review** *H. Jiang\** (Changsha, China), *L. Xie, T. Li*

OS057 13:30 – 14:30 Hall A3-2  
1-hour Case Session

ANT CLN

## Mind your Ps: PK/PD

Chairs *Linda Aulin* (Leiden, The Netherlands)  
*Joseph Meletiadis* (Athens, Greece)

- O0388** 13:30 **PK/PD-optimised eravacycline for vancomycin-resistant *Enterococcus faecium* in a liver transplant recipient** *J. Qu\** (Changsha, China)
- O0389** 13:41 **Therapeutic drug monitoring-guided antimicrobial optimisation in thoraco-omphalopagus twins with partially shared hepatic circulation undergoing surgical separation** *B. Monti\** (Monza, Italy), *A. Mesini, E. Ricci, M. Mariani, G. Mattioli, F. Palo, G. Cangemi, A. Cafaro, C. Saffioti, A. Wolfier, G. Spiga, E. Castagnola, A. Moscatelli*
- O0390** 13:52 **First clinical case of aztreonam/avibactam during venovenous ECMO support: is standard dosing adequate?** *A. Pau Parra\** (Barcelona, Spain), *A. Pau-Parra, S. Luque, L. Doménech Moral, M. Martínez Pla, X. Nuvials, M. Sosa, I. Los-Arcos, A. Conto, F. Lasteros, E. Gallart, O. Castillo, A. Sánchez, S. García, E. Del Barrio, M.Q. Gorgas Torner, R. Ferrer, J. Riera*
- O0391** 14:03 **TDM-guided antibiotic therapy in a patient with recurrent *Listeria monocytogenes* meningitis and augmented renal clearance (ARC): from**

- hospitalisation to oral home therapy *D. Aquilino\** (Naples, Italy), *P. Grimaldi, L. Alessio, S. De Pascalis, C. Ricozzi, K. Gjeloši, S. Imbriani, M. Macera, C. Monari, L. Onorato, M. Pisaturo, N. Coppola*
- 00392 14:14** **Virological failure of long-acting cabotegravir/rilpivirine: a multifactorial case involving low drug exposure, high viral reservoir and rapid weight loss** *A. Andrianaki\** (Zurich, Switzerland), *P. Thoueille, C. Marzolini, M. Huber, H.F. Günthard, I.A. Abela*

**OS055 13:30 - 14:30** **Hall A2-1**  
1-hour Oral Session

**Susceptibility testing of phages**

*Chairs Annika Yanina Classen (Cologne, Germany) Marjolein Hensgens (Utrecht, The Netherlands)*

- 00393 13:30** **Mechanisms of phage-driven resensitisation to aztreonam/avibactam in *Escherichia coli* C.** *Tellapragada\** (Stockholm, Sweden), *M. Razavi, S. Patpatia, A. Garcia Navarro, A.M. Örmälä-Tiznado, C.G. Giske*
- 00394 13:42** **Impact of antimicrobials on bacteriophage-host interactions in *Pseudomonas aeruginosa* Y. Chikhani\*** (São Paulo, Brazil), *C. Siqueira, C. Rubio, R. Farzana, E. Portal, K. Sands, O. Spiller, A. Gales, W. Martins*
- 00395 13:54** **Two years (2024–2025) of bacteriophage susceptibility testing of bacterial isolates from persistent bacterial infections: results from the Israeli Phage Therapy Centre** *R. Braunstein\** (Jerusalem, Israel), *O. Yerushalmy, L. Khalifa, A. Rimon, S. Copenhagen-Glazer, R. Hazan, R. Nir-Paz*
- 00396 14:06** **Tigecycline-selected tyrosine kinase mutation in *Klebsiella pneumoniae* triggers metabolic rewiring and increased phage susceptibility without affecting virulence** *N.N. Rakhi\** (Oxford, United Kingdom), *A.K. Lankapalli, W. Martins, T. Lanyon-Hogg, T.R. Walsh*
- 00397 14:18** **Broth microdilution-based phage/antibiotic synergy in Gram-negative pathogens** *A.M. Örmälä-Tiznado\** (Stockholm, Sweden), *A. Williamson, E. Loo, S. Patpatia, C. Tellapragada, C. Giske*

**OS054 13:30 - 14:30** **Hall B0-2**  
1-hour Oral Session

**Harnessing artificial intelligence against AMR**

*Chairs Fusun Can (Istanbul, Türkiye) Lorena Lopez Cerero (Seville, Spain)*

- 00398 13:30** **A machine-learning workflow to investigate cefiderocol uptake defects arising from mutations in the siderophore receptor** *M. Mohammad\** (Stockholm, Sweden), *M. Razavi, C. Tellapragada, C.G. Giske*
- 00399 13:42** **Prediction of bacterial antimicrobial resistance based on resistance determinants and whole genome annotation neural networks algorithms** *M.R. Pulido\** (Seville, Spain), *F. Sola, D. Ayala, L. Monge-Olivares, R. Ayala, I. Portillo-Calderón, I. Hernández, D. Ruiz, L. López-Cerero*
- 00400 13:54** **Seven loci, one threat: Decoding and predicting azithromycin resistance in *Neisseria gonorrhoeae* with machine learning** *M. Krisna\** (Oxford, United Kingdom), *F. Rudi, A. Unitt, K. Jolley, O. Harrison*
- 00401 14:06** **Domain-aware vs machine-learning imputation for sparse antimicrobial susceptibility data** *F. Mutisya\** (Strasbourg, France), *C. Moore, M. Raad, K. Taylor, S. Alavi, T. Yokoyama, S. Boujaafar, P. Berger, C. De Turckheim*
- 00402 14:18** **Predicting risk of multidrug-resistant tuberculosis using long short-term memory (LSTM) and multimodal programmatic data in the Philippines** *M.I. Saldañas\** (Metro Manila, Philippines), *I.P. Mendoza, G.D. Sison, R. Destura, M. Kato-Maeda, F. Jiang, K.E. Henson, R. Basilio, J.E. Bascaña*

**SY092 13:30 - 14:30** **Hall A3-1**

**PHEI** 1-hour Symposium  
**Fungi in the flow: wastewater as a hidden threat**  
*Chairs Mihai Mares (Iasi, Romania) Esther Segal (Tel Aviv, Israel)*

- S0214 13:30** **New EU wastewater directive: why fungi must be included** *Joao Brandao (Lisbon, Portugal)*
- S0215 14:00** ***Candida* and *Aspergillus* in the environment: resistance starts here** *Monika Novak Babič (Ljubljana, Slovenia)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Israel Society for Medical Mycology (ISMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Hellenic Society of Medical Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED)

**EW095 13:30 - 15:30** **Hall ICM 13b**  
2-hour Educational Session

**Updates on emerging and re-emerging vector-borne viral infections**

*Chairs Xavier Lescure (Paris, France) Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

- W0220 13:30** **Global epidemiological situation and diagnostic challenges of vector-borne viral infections** *Marta Giovanetti (Rome, Italy)*
- W0221 13:50** **Translational advances about West Nile virus** *Anna Papa-Konidari (Thessaloniki, Greece)*
- W0222 14:10** **Oropouche virus and its emergence** *Felipe Naveca (Manaus, Brazil)*
- W0223 14:30** **Changing epidemiology of Dengue: a global outlook** *Gathsaurie Neelika Malavige (Nugegoda, Sri Lanka)*

Co-organised with: SBI, Colombian Association of Infectious Diseases, Latin American Society for Travel Medicine, API, Dominican Society of ID, Ecuatorian Society for MM and Pediatric ID, ESCMID Emerging Infections Subcommittee, ESCMID Scientific Affairs Subcommittee

**SY091 13:30 - 15:30** **Hall B0-1**  
2-hour Symposium

**Screening for multidrug-resistant pathogens in various populations: are we doing good?**

*Chairs Rita Ng (Hong Kong, Hong Kong) Spyros Pournaras (Athens, Greece)*

- S0210 08:30** **Rectal screening and perioperative prophylaxis** *Elda Righi (London, United Kingdom)*
- S0211 09:00** **Implications of positive MDR bacterial screen for clinical practice: algorithm for treatment** *Marco Falcone (Pisa, Italy)*
- S0212 09:30** **Screening for MDR bacteria and *Candida auris*: lab methods** *Yesim Besli (Istanbul, Türkiye)*
- S0213 10:00** **Rectal screen for MDR bacteria in haematological and solid organ transplant patients** *Michael Satlin (New York, United States)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Infections in the Elderly (ESGIE)

**EF058 13:30 - 14:30** **Arena 1**  
ePoster Flash Session

**Predicting complications and outcome of sepsis**

*Chair Despoina Koulenti (London, United Kingdom)*

- E0403 13:30** **The epidemiology of severe clinical manifestations caused by Group A streptococci in Denmark** *C. Evald-Schelde\** (Copenhagen, Denmark), *T.B. Johannesen, S. Hoffmann, P.H. Andersen, S. Hermann, Z.B. Harboe, M. Stegger, L.S. Vestergaard, U. Nygaard*
- E0404 13:36** **Subphenotype and complication-guided adjunctive**

E0405	13:42	<b>fosfomycin therapy for <i>Staphylococcus aureus</i> bacteraemia: pooled analysis of two randomised trials</b> J. García-Larrauri* (L'hospitalet De Llobregat, Spain), F. Escriva-Vidal, J. Carratalá, B. Gutiérrez-Gutiérrez, J. López-Contreras, G. Euba, A. Vázquez, S. Gómez-Zorrilla, L.E. López-Cortés, O. Gasch, E. Aparicio-Minguijón, R. Escudero-Sánchez, M.T. Pérez-Rodríguez, M.D. Rodríguez Pardo, A. Jover-Sáenz, G. García-Pardo, J. Rodríguez-Baño, M. Pujol
E0406	13:48	<b>Burkholderia as a silent antimicrobial resistance driver in lower-middle-income countries: genomic insights from the BALANCE study</b> K.J. Hoog* (Oxford, United Kingdom), R. Farzana, N. Haque, M. Sultana, J.B. Joyee, F. Humayra, M.R. Tasfia, S. Afroj, C. Abdellaoui, R. Zahra, M. Hamza, B. Hassan, K. Shafique, G. Fatima, K. Onjuro, H. Nerima, C.R. Achi, K. Iregbu, P. Nwajiobi-Princewill, I.N. Nwafia, E. Carretto, T.R. Walsh
E0407	13:54	<b>Antimicrobial resistance and risk-stratified empiric therapy in community-onset sepsis</b> W. Lee* (London, United Kingdom), H. Rastad, B. Hernandez, N. Zhu, D. Ming, R. Wilson, M. Gilchrist, A. Holmes, V. Cornelius, T. Rawson
E0408	14:00	<b>The role of serum cholinesterase levels in monitoring covert immunosuppression in critically ill patients with septic shock: evidence from a monocentric retrospective analysis</b> A. Frattari* (Pescara, Italy), F. Cedrone, E. Polilli, R. Zocaro, P. Fazio, V. Fortunato, G. Parruti
E0409	14:06	<b>Risk of dementia after bloodstream infection: propensity score matched cohort study</b> J. Underwood* (Cardiff, United Kingdom), D. Farewell, D. Gillespie, A. Akbari, N. Harrison, H. Ahmed
E0410	14:12	<b>Predicting in-hospital mortality in sepsis patients using machine learning methods in low- and middle-income country (LMIC) settings</b> S. Awan* (Karachi, Pakistan), N. Aziz, Z. Nasim, N. Nasir
E0411	14:18	<b>Integrated immune and endothelial profiling predicts 90-day mortality in postoperative sepsis and septic shock</b> R.D. Prieto Utrera* (Valladolid, Spain), M. Bardají-Carrillo1, A. García-Concejo, E. Tamayo, D. Bernardo

EF059 13:30 - 14:30 Arena 2

ePoster Flash Session  
 CLN TRN VAX  
**Decoding herpesviruses: from bench to bedside**  
 Chair Sylviane Defres (Liverpool, United Kingdom)

E0412	13:30	<b>LY6C+ monocyte derived macrophages contribute to pathological neuroinflammation in herpes simplex encephalitis</b> Q. Xue* (Shanghai, China), Z. Shen
E0413	13:36	<b>Development of a risk score to predict encephalitis by herpes simplex virus and varicella zoster virus</b> R. Hasbun* (Houston, United States), J. Portugal, A. Heck, P. Bean, R. Habis, J. Probasco, A. Venkatesan
E0414	13:42	<b>Clinical determinants of outcome in chronic active Epstein-Barr virus infection: derivation of a risk stratification score</b> Q. Yang* (Shanghai, China), Z. Zhou
E0415	13:48	<b>CXCL9, CXCL10, and CXCL11: sensitive predictors of acute EBV infection</b> A. Nikčević* (Zagreb, Croatia), A. Nikčević, K. Bodulić, S. Židovec Lepej, L. Radmanić Matotek, G. Tešović
E0416	13:54	<b>Distinguishing clinical significance from latent infection: establishing mNGS-based EBV diagnostic cut-offs in blood and CSF</b> Y. Cao* (Shanghai, China), X. Li, Y. Qingluan
E0417	14:00	<b>Using QuantiFERON-EBV to measure EBV-specific T-Cell function in thoracic transplant recipients</b> Y. Zhao* (Groningen, The Netherlands), L. Gard, K. Damman, E. Verschuuren, V.L.B. Coretta
E0418	14:06	<b>Digital PCR enables high-resolution quantification of HCMV UL123 in clinical and experimental samples</b> A.R. Silvain* (Limoges, France), M. Mayeras, E. Guerin, T. Reishig, O. Bestard, L. Cousi,

E0419	14:12	<b>Real-world effectiveness of recombinant zoster vaccine in high-risk adult populations in Greece</b> V. Petrakis* (Alexandroupolis, Greece), P. Rafailidis, N. Mpampaka, G. Karagiannis, V. Kyrgiannaki, D. Papapazoglou, P. Panagopoulos
E0420	14:18	<b>The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera</b> V. Leguizamón* (Madrid, Spain), B. Astibia-Mahillo, E. Mateos, M. Torres, N. Armenteros, A. Fernández-Chávez, M.C. Luengo-Martínez, N. Daza, M. Coiras, V. García-Gutiérrez

EF060 13:30 - 14:30 Arena 4

ePoster Flash Session  
 CLN PHEI

**Zoonotic infections: expect the unexpected**  
 Chair Manuela Carugati (Durham, United States)

E0421	13:30	<b>Clinical characteristics and treatment strategies in a cohort of patients with tularemia: a retrospective multi-centre analysis of 65 cases in Germany</b> C. Lübbert* (Leipzig, Germany), B. Arnold, N. Kellner, H. Trawinski, H.M. Orth, D. Tominski, A. Mikolajewska, K. Rothfuss, G. Grupe, D. Ruf, F. Reichert, K. Marx, K. Heuner, D. Jacob
E0422	13:36	<b>Characterisation of tularaemia cases in Southwest Germany and identification of two natural transmission clusters in a clinical high-endemic region Tuniberg/Kaiserstuhl (TuniKa)</b> D. Hornuss* (Freiburg i. Breisgau, Germany), S. Rieg, J. Borde, H. Von Buttlar, V. Goetz, P. Mathé, J. Klein, M. Leibenguth, L. Chitimia-Dobler, A.S. Claus, M. Scherer-Lorenzen, G. Dobler
E0423	13:42	<b>Paediatric tularemia: clinical outcomes and immunological insights from an endemic region in Türkiye</b> K. Aykac* (Ankara, Türkiye), O. Cakici, B.E. Seyrek, İ.C. Yılmaz, O.O. Demir, İ. Evçili, T. Canavar Yildirim, M. Yildirim, E.H. Erdeniz, S.Y. Durmus, A. Sahin, S. Ocal Demir, A.B. Cengiz, M. Gürsel, İ. Gürsel, Y. Ozsurekci
E0424	13:48	<b>Phylogenetic diversity of Mediterranean spotted fever group Rickettsiales: species-level sequencing in a Spanish tertiary hospital (2021-2025)</b> E. Gremaldos Mira* (Valencia, Spain), E. Cortés Giménez, J.M. Sahuquillo Arce, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz
E0425	13:54	<b>Diversity of <i>Rickettsia</i> species identified by metagenomics in ticks collected from a Brazilian University</b> F. Carvalho* (São Carlos, Brazil), D.S.F. Guedes, G. Montenegro De Campos, A. Sarana Da Silva, C.V.P. Hernandez, B.M. Begalli, L.C. Barci, J.M. Penedo, R.G.D.S. Taliassaqui, T.K.S. Felipe, S.J. Badra, F.D.F. Anibal, S.N. Slavov
E0426	14:00	<b>Epidemiology of toxigenic <i>Corynebacterium ulcerans</i> infections in England</b> K. Harman* (London, United Kingdom), C. Robin, E. Mugwagwa, T. Patel, R. Cordery, D. Litt, S. Neale, A. Mackintosh, D. Chudasama, R. Pudney
E0427	14:06	<b>First insights into the wild, wild west of <i>Borrelia</i> plasmids</b> S. Hefner* (Oberschleissheim, Germany), R.E. Rollins, E. Mourkas, K. Kuleshov, S. Casjens, W. Qiu, A. Dangel, D. Velázquez, S.Y. Kovalev, A. Wieser, J. Hübner, A. Sing, V. Fingerle, G. Margos
E0428	14:12	<b>The impact of previous brucellosis treatment on the clinical course of neurobrucellosis: a multi-centre retrospective study</b> O. Evlice* (Van, Türkiye), Y. Ezgi, H. Kir, S. Incecik, D. Ertürk, M. Aydın, A.S. İnal, Y. Çakır, Z. Karazeybek, B.B. Sivrikaya, B. Turaç, E. İnci, S.Y. Kaya, Z. Çelik, A. Şabablı Çetin, İ.D. Alırcı, Ö. Özgen, H. Özüt, M. Çelik, S. Alkan, S. Surme, A. Mert
E0429	14:18	<b>Early markers of severe leptospirosis in French Amazonia, 2007-2022</b> L. Epelboin* (Cayenne, French Guiana), P. Le Turnier, M. Zenou, A. Fremery, H. Kallel, N. Higel, A. Kpangon, P. Abboud, F. Djossou, M. Boutrou, M. Nacher

JS002 13:30 - 14:30 Hall ICM 5

Journal Session  
 AMR CLN

**Late-breaking research from CMI & CMI Comms: on invasive infections and antimicrobial resistance**

*Chairs Andre Kalil (Omaha, United States)  
Anne-Grete Mårtson (Leiden, The Netherlands)*

J0005	13:30	Estimating antibiotic resistance following antibiotic treatment in outpatients: a retrospective study <i>Michal Chowers (Kfar-Saba, Israel)</i>
J0006	13:40	Clinical utility of the DENOVA score for predicting infective endocarditis in <i>Enterococcus faecalis</i> bacteraemia: external validation with decision curve analysis <i>Benedetta Varisco (Milan, Italy)</i>
J0007	13:50	Challenges in nasal and throat microbiota composition during and after mupirocin and chlorhexidine decolonisation treatment in asymptomatic MRSA carriers: a longitudinal observational study <i>Sofie Marie Edslev (Copenhagen, Denmark)</i>
J0008	14:00	A multicentre evaluation of metagenomic sequencing for pathogen detection in central nervous system infections <i>Rui Zhang (Beijing, China)</i>
J0009	14:10	Prevalence of submicroscopic malaria parasitemia among migrant pregnant women: a prospective cohort study <i>Léa Docquier (Brussels, Belgium)</i>
J0010	14:20	Antenatal corticosteroid treatment and infectious diseases in children and adolescents aged 5–16 years <i>Katri Räikkönen (Helsinki, Finland)</i>

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors

ME093 13:30 – 14:30 Hall ICM 1

ANT CLN IPC Meet-the-Expert

**Novel therapeutics for *C. difficile* infection**

M0216	13:30	<i>Eugenie Basseres (Houston, United States)</i>
M0217	13:42	<i>Marek Duricek (Prague, Czechia)</i>

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

ME094 13:30 – 14:30 Hall ICM 13a

CLN PED Meet-the-Expert

**Recent evidence on the role of steroids in paediatric bacterial infections: focus on meningitis and pneumonia**

M0218	13:30	<i>George A. Syrogiannopoulos (Larissa, Greece)</i>
M0219	13:42	<i>Susanna Esposito (Parma, Italy)</i>

FO096 13:30 – 14:30 Arena 3

PRO Open Forum

**Communicating science today: new media, new platforms***Chair Angela Huttner (Geneva, Switzerland)*

F0224	13:30	Influencing in infectious diseases and clinical microbiology: tweet or fly? <i>Neil Stone (London, United Kingdom)</i>
F0225	13:40	Starting and sustaining a podcast <i>Erin McCreary (Pittsburgh, United States)</i>

Co-organised with: CMI Communications Board of Editors

WT005 13:30 – 14:30 Poster area

CLN VAX Poster Walkthrough

**Navigating through infections in immunocompromised hosts***Chair Simona Ruta (Bucharest, Romania)*

R0041	P4194 - Long-term outcomes of isoniazid prophylaxis in allogeneic haematopoietic stem-cell transplant recipients: a 15-year cohort study <i>Keon Oh (Seoul, Korea, Republic of)</i>
-------	---

R0042	P4138 - Human microRNA hsa-125a-5p as biomarker for predicting late CMV infection in high-risk D+/R-kidney transplant recipients <i>Natalia Redondo (Madrid, Spain)</i>
-------	---

R0043	P4166 - Epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and vancomycin-resistant <i>Enterococcus</i> spp. (VRE) in Swiss solid organ transplant recipients <i>Peter W Schreiber (Zurich, Switzerland)</i>
-------	---

R0044	P4217 - Impact of HHV-6B reactivation on engraftment and outcomes after allogeneic HSCT <i>Seyed M (sasan) Hosseini-Moghaddam (Toronto, Canada)</i>
-------	---

R0045	P4236 - Central venous catheter (CVC)-related bloodstream infections (CRBSI) in patients with solid tumours (ST) and haematological malignancies (HM): a propensity-score matched (PSM), non-inferiority, registry-based comparison <i>Enrico Schalk (Magdeburg, Germany)</i>
-------	---

R0046	P4146 - Identification and validation of clinical phenotypes in liver transplant donors and recipients to predict early infections and mortality <i>Cecilia Bonazzetti (Bologna, Italy)</i>
-------	---

R0047	P4152 - A retrospective analysis of patients receiving organs from HHV-8 positive donors at a large transplant centre <i>Benjamin Ravenhill (Cambridge, United Kingdom)</i>
-------	---

R0048	P4189 - Long-term outcomes in liver transplant recipients: comparison between patients living with and without HIV infection <i>Adriana Cervo (Modena, Italy)</i>
-------	---

R0049	P4218 - Antibiotic-induced microbiome disturbances in haematological patients undergoing haematopoietic stem cell transplantation: a prospective observational study <i>Hanna Montelin (Uppsala, Sweden)</i>
-------	--

R0050	P4148 - Infections and outcomes in elderly solid organ transplant recipients: a multi-centre cohort from Türkiye <i>Sibel Altunisik Toplu (Malatya, Türkiye)</i>
-------	--

WT008 13:30 – 14:30 Poster area

AMR PED Poster Walkthrough

**Optimising diagnosis and antimicrobial management in paediatric infectious diseases***Chair Ilias P. Iosifidis (Thessaloniki, Greece)*

R0071	P2866 - Pharmacokinetics, safety, and tolerability of ceftiderocol in paediatric patients aged three months to <18 years with suspected or confirmed Gram-negative bacterial infections in the phase Ib-2 APEKS-PEDI study <i>Emmanuel Roilides (Thessaloniki, Greece)</i>
-------	--

R0072	P0700 - Sputum-independent T cell activation-based diagnosis of paediatric tuberculosis: a prospective diagnostic accuracy study in five low- and middle-income countries <i>Alia Razid (Munich, Germany)</i>
-------	---

R0073	P0591 - A clinical prediction score for radiological severity of pulmonary tuberculosis in children: an individual participant data analysis <i>Akshita Gupta (Munich, Germany)</i>
-------	---

R0074	P0809 - Causes of neonatal sepsis in low- and middle-income countries: a multi-site international cohort study <i>Kirsty Sands (Oxford, United Kingdom)</i>
-------	---

R0075	P0818 - Referral of febrile children in a resource-constrained community settings in Asia (spot sepsis) <i>Arjun Chandna (London, United Kingdom)</i>
-------	---

R0076	P2821 - Population pharmacokinetics modelling of daptomycin in paediatric patients <i>Sylvain Goutelle (Lyon, France)</i>
-------	---

R0077	P4240 - Gut colonisation with MDR Gram-negative organisms and its impact on bacteraemia and sepsis development among children with haematological malignancies <i>Reham Khedr (Cairo, Egypt)</i>
-------	--

R0078	P1167 - Comparative effectiveness of clarithromycin and azithromycin for the treatment of pertussis in hospitalised infants: a multi-centre retrospective cohort study in Italy <i>Cristina Moracas (Napoli, Italy)</i>
-------	---

R0079	P3024 - Digital training for IPC and AMS in paediatric inpatient units: multicountry implementation and outcomes from TEAM-COACH project <i>Olaf Neth (Sevilla, Spain)</i>
-------	--

R0080	P0977 - Incidence of parapneumonic pleural effusion/empyema in children before, during, and after the COVID-19 pandemic (Germany, 2010/11-2024/25) <i>Andrea Streng (Würzburg, Germany)</i>
-------	---

WT006	13:30 – 14:30	Poster area
	Poster Walkthrough	
<b>Severe infections in ICU: from novel antibiotics to precision monitoring</b>		
Chair	<i>Antonios Katsounas (Bochum, Germany)</i>	
R0051	P0753 - Distinct temporal dynamics of host transcriptomic response between patients with persistent and resolving <i>Staphylococcus aureus</i> bacteraemia <i>Karishma Chhugani (Los Angeles, United States)</i>	
R0052	P2610 - Impact of acquired broad-spectrum $\beta$ -lactamases on susceptibility to oral cephalosporin (ceftibuten) and oral carbapenem (tebipenem) in combination with new $\beta$ -lactamase inhibitors ledaborbactam and xeruborbactam in <i>Escherichia coli</i> <i>Christophe Le Terrier (Fribourg, Switzerland)</i>	
R0053	P2602 - Activity of cefiderocol/xeruborbactam against NDM-producing <i>Escherichia coli</i> isolates with PBP3 insertions and decreased susceptibility or resistance to aztreonam/avibactam, cefiderocol, and cefepime/taniborbactam <i>Tania Blanco Martín (A Coruña, Spain)</i>	
R0054	P2826 - Population pharmacokinetics of piperacillin/tazobactam in plasma and epithelial lining fluid of ICU patients with pneumonia: the PNEUDOS study <i>Mohd-Hafiz Abdul-Aziz (Brisbane, Australia)</i>	
R0055	P0884 - NETosis-inducing <i>Staphylococcus aureus</i> correlate with mortality and elevated IL-10 <i>Warren Rose (Madison, United States)</i>	
R0056	P2669 - Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in <i>Escherichia coli</i> <i>Jiao Xie (Xi'an, China)</i>	
R0057	P2777 - Population pharmacokinetic analysis of piperacillin in critically ill women based on multi-centre data <i>Uwe Liebchen (Munich, Germany)</i>	
R0058	P2876 - Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of Integral-1 study <i>Sota Iyama (Tokyo, Japan)</i>	
R0059	P2883 - Pharmacokinetics, safety and tolerability of ANT3310 combined with meropenem in participants with impaired renal function <i>Justine Dao (Labège, France)</i>	
R0060	P0797 - Continuous vs intermittent infusion of high-dose meropenem in critically ill patients: an observational cohort study <i>Anselm Jorda (Vienna, Austria)</i>	

WT007	13:30 – 14:30	Poster area
	Poster Walkthrough	

**Digital or traditional Antimicrobial Stewardship interventions**

Chair	<i>Rita Murri (Rome, Italy)</i>	
R0061	P2907 - Global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): monitoring effectiveness of an EMR-assisted pre-authorisation requirement for non-guideline compliant surgical antimicrobial prophylaxis prescriptions at a tertiary hospital in the Philippines <i>Janelle Gagelonia (Taguig, Philippines)</i>	
R0062	P2933 - Implementation experience of an antimicrobial stewardship program in a resource-limited setting: MSF-MOH collaboration in a Mozambican hospital <i>Shehezady Cruz (Beira, Mozambique)</i>	
R0063	P2964 - A mixed-method evaluation and impact assessment of national secondary care (hospitals) antimicrobial stewardship (AMS) tools <i>Bee Yean Ng (London, United Kingdom)</i>	
R0064	P2978 - Hybrid AI2D and rule-based approach for prospective audit feedback (PAF) of piperacillin/tazobactam in suspected acute bacterial lower respiratory tract infections (ablRTI) <i>Yvonne Zhou (Singapore, Singapore)</i>	
R0065	P2915 - Sustained improvement in private practice dentists' antibiotic prescribing following stewardship education and electronic antibiotic dashboards <i>Debbie Goff (Westerville, Ohio, United States)</i>	

R0066	P2969 - From data silos to strategic action: developing a real-time dashboard to inform a local antimicrobial stewardship (AMS) programme <i>Mark Gilchrist (London, United Kingdom)</i>	
R0067	P3010 - Impact of a networked antimicrobial stewardship program with multi-site computer decision support on antibiotic consumption and resistance in four major Australian teaching hospitals 2012-2024 <i>Pamela Konecny (Sydney, Australia)</i>	
R0068	P2912 - Optimising antibiotic use in Nigerian secondary hospitals: prescribing patterns, consumption rate and drivers of inappropriate therapy <i>Justin Onyebuchi Nwofe (Abuja, Nigeria)</i>	
R0069	P2946 - From restrictive antibiotic stewardship to a handshake model: early outcomes from the REVERSE project in a tertiary hospital in Northern Italy <i>Amina Zaffagnini (Verona, Italy)</i>	
R0070	P3071 - Evaluation and knowledge mobilisation of the annual English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report <i>Diane Ashiru-Oredope (London, United Kingdom)</i>	

SEL	13:30 – 15:30	Hall ICM 14
	Special Session	

**Selective Pressure**

Chairs	<i>Niessen Annabel (Utrecht, The Netherlands)</i> <i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Josh Nosanchuk (Bronx, United States)</i> <i>José Ramón Paño-Pardo (Zaragoza, Spain)</i> <i>Jesús Rodríguez-Baño (Seville, Spain)</i> <i>Anja Šterbenc (Ljubljana, Slovenia)</i> <i>David Van Duin (Chapel Hill, United States)</i>	
--------	--	--

OS063	14:45 – 15:45	Hall A2-1
	1-hour Case Session	

**Malicious Mycobacteria**

Chairs	<i>Raquel Duarte (Porto, Portugal)</i> <i>Anupa Thampy (Vellore, Tamil Nadu, India)</i>	
--------	--	--

OO430	14:45	Donor-derived renal allograft tuberculosis detected by plasma metagenomic sequencing in two kidney transplant recipients <i>A. Diaz Arumir Vergara* (Jackson, United States), A. Diaz-Arumir Vergara</i>
-------	-------	--

OO431	14:56	Leprosy in an Indonesian patient diagnosed after childbirth in a tertiary hospital in Germany <i>A. Frenz* (Dresden, Germany), R. Kardashi, K. De With, S. Meisterfeld, P. Spornraft-Ragaller</i>
-------	-------	---

OO432	15:07	XDR-Tuberculosis meningitis in patient with advanced HIV infection: therapeutic challenge with limited treatment options <i>M. Schiuma* (Milan, Italy), F. Fama, A. Piubello, F. Saluzzo, D. Bernasconi, M. Schiavini, A. Covizzi, B. Caloni, D. Zizzo, D. Maddalena, M. Bognetti, A. Rizzo, F. Salari, A. Civati, M. Galimberti, A. Riva, S. Antinori, D. Cirillo, A. Gori, A. Torre</i>
-------	-------	---

OO433	15:18	An unexpected case of disseminated MAC infection in a non-HIV immunocompromised thymoma patient <i>L. Vos* (Utrecht, The Netherlands), A. Bruns</i>
-------	-------	---

OO434	15:29	<i>Mycobacterium ryadhense</i> : a rare emerging NTM in a TB endemic country <i>B. Kumar* (Jodhpur, India), A. Sarangal, D. Meena, N. Midha, G. Bohra</i>
-------	-------	---

OS062	14:45 – 15:45	Hall ICM 5
	1-hour Case Session	

**Puzzling parasites**

Chairs	<i>Rodrigo Gurgel-Gonçalves (Brasília, Brazil)</i> <i>Tin Tin Myaing (Bangkok, Thailand)</i>	
--------	---	--

OO435	14:45	Rapidly progressive parasitic meningoencephalitis: diagnostic challenges <i>C. Silva* (Vila Nova De Gaia, Portugal), C. Nunes-Silva, A. Silva-Pinto, A.S. Santos, C. Gonçalves, R. Baptista, A. Ferreira, S. Xerinda, L. Andrade, J. Ganicho, P. Figueiredo, A. Sarmento, A.</i>
-------	-------	--

Costa, C. Reis, S. Rebelo, S. Guimarães, L. Santos

- 00436 14:56 **Double trouble in the liver: amoebic and staphylococcal abscess in a Belgian MSM without travel history** *M. Moretti\* (Jette, Belgium), N. M'rabet, K. Demeyer*
- 00437 15:07 **Eosinophilic liver abscess caused by invasive *Fasciola*** *B. Uadomsataporn\* (Bangkok 10330, Thailand), O. Putcharoen*
- 00438 15:18 **Learning from the unusual: three autochthonous paediatric cases of *Entamoeba histolytica* colitis in Southern Italy suggesting a new challenge for clinical practice and public health** *R. Astorri\* (Casamassima (bari), Italy), M. Bartiromo, R. Melone, A. Di Martino, P. Marzuillo*
- 00439 15:29 **Reactivation of *Trypanosoma cruzi* with medullary tropism: an unexpected turn in a patient with HIV** *J. Mateo Gonzalez\* (Valencia, Spain), J.I. Mateo-Gonzalez, M. Garcia-Rodriguez, M. Martinez-Serrano, M.D. Ocete-Mochon, V. Abriil-Lopez-De-Medrano, E. Ballester-Belda, C. Ricart-Olmos, M. Garcia-Deltoro*

OS064 14:45 - 15:45 Hall A2-2

1-hour Oral Session

CLN TRN

**Rattle my bones - bone and joint infections**

*Chairs Parham Sendi (Bern, Switzerland) Andrej Trampuz (Brisbane, Australia)*

- 00440 14:45 **Validation of the KLIC score and development of a new predictive model in a multi-centre cohort of prosthetic joint infections treated with debridement and implant retention** *G. Zumbo\* (Seville, Spain), I. Martínez Alemany, J.M. Bravo Ferrer, I. Nieto Diaz De Los Bernardos, J. Praena, A. Del Arco, N. Enrique, C.D. Juan Enrique, B. Francisco, C. Natera, A. Romero Palacios, B. Sobrino, J. Rodriguez Baño, M.D. Del Toro Lopez*
- 00441 14:57 **Hypoxia-driven sdhB-mediated antibiotic tolerance impairs prophylactic antibiotics against MRSA in a mouse prosthetic joint infection model** *O. Gordon\* (Jerusalem, Israel)*
- 00442 15:09 **The use of [<sup>18</sup>F]FDG-PET/CT and magnetic resonance imaging in the diagnosis of pyogenic vertebral osteomyelitis secondary to *Staphylococcus aureus* bacteraemia** *I. Johansen\* (Odense C, Denmark), S. Olaf Lindvig, T. Benfield, I. Pedersen, S. Hess, F. Rosenvinge, M. Kehrler, I. Somuncu Johansen*
- 00443 15:21 **Fatty acid profiling of biofilms formed by *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*** *E. Torrecilla-Sádaba\* (Madrid, Spain), D. Carrizo-Gallardo, L. Sánchez-García, L. Salar-Vidal, J. Esteban, J.J. Aguilera-Correa*
- 00444 15:33 **Investigation of *Staphylococcus aureus* infections in human-derived musculoskeletal *ex vivo* tissue slices** *K. Strenger\* (Basel, Switzerland), M. Morgenstern, M. Clauss, R. Kühl, A.K. Woischnig, L. Sauter, D. Bumann, N. Khanna*

OS065 14:45 - 15:45 Hall A3-1

1-hour Oral Session

IPC TRN

**Engineering the gut microbiome: new therapeutics and clinical practice**

*Chairs Markus Arnoldini (Zurich, Switzerland) Fidelma Fitzpatrick (Dublin, Ireland)*

- 00445 14:45 **Randomised double-blinded clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin vs placebo in the prevention of recurrence of *Clostridioides difficile* infection in patients receiving systemic antibiotic therapy (PREVAN TRIAL)** *R. San-Juan\* (Madrid, Spain), J. Origüen, M. Fernández-Ruiz, K. Campion, J.T. Silva, F. Lopez-Medrano, J. Villa, B. Diaz-Pollan, A. Callejas, G. Candela, J. Boan, E. Aparicio-Minguñon, M.A. Perez-Jacoiste, I. Rodriguez-Goncer, C. Martin-Arriscado, M. Martínez-Uña, J.M. Ferrari, J.M. Aguado*
- 00446 14:57 **Longitudinal tracking of microbial restoration after faecal microbiota transplantation (FMT)** *D. Guevara Nuñez\* (Barcelona, Spain), P. Camps-Massa, L. Saiz-Escobedo, A. Carrera-Salinas, S. Antón, J. Orobítg, M. Bonilla, A. González-Díaz, C. Arajol, J. Guardiola, M.A.*

Dominguez, S. Marti

- 00447 15:09 **VE707, a live biotherapeutic product, reduces intestinal vancomycin resistant enterococci in a murine model of pathogen colonisation** *G. Medlock\* (Cambridge, United States), C. Russell, C. Felix, W. Alsharif, L. Cornacchione, M. Schinn, A. Watson, S. Bedard-Shurtleff, J. Norman, J. Faith, E. Kuijper, B. Olle, S. Caballero*
- 00448 15:21 **Single-donor lyophilised encapsulated faecal microbiota transplant (cFMT) supports home dosing with dose-to-dose heterogeneity driven by inter-donor microbiome differences** *B. Merrick\* (Harrow, United Kingdom), D. Prossomariti, N.M.M. Zain, B. Forbes, C. Sergaki, S.D. Goldenberg*
- 00449 15:33 ***Clostridioides difficile* infection recurrence and antibiotic utilisation following treatment with Food and Drug Administration-approved faecal microbiota products: a multi-centre analysis using Epic Cosmos** *S. Boettcher\* (Detroit, United States), R. Kenney, N. Everson, I. Kashat, G. Tengler, A. Soyad, S. Davis, M. Veve*

OS061 14:45 - 15:45 Hall ICM 13a

1-hour Oral Session

PRO

**AI applications in CM/ID: speaking the new language (model)**

*Chairs Riina Richardson (Manchester, United Kingdom) Bernardo Sousa-Pinto (Porto, Portugal)*

- 00450 14:45 **Assessing Large Language Model (LLM) performance in abstract screening for an infection-focused systematic review with >16,000 records** *D. Ashiru-Oredope\* (London, United Kingdom), O. Quinn, G. Shannon, H. Ollie, L. Timothy, F. Felix, H. Joshua, L. Leo, N. Toby*
- 00451 14:57 **Development of an ESCMID Global AI-based abstract categorisation tool** *G. De Angelis\* (Basel, Switzerland), E. Dexter, J. Moran-Gilad*
- 00452 15:09 **AI-assisted infectious disease consultation: concordance analysis between a custom GPT model and specialist recommendations** *S. Karunakara Ramesh\* (Tamil Nadu, India), K. Sarika, D. Suresh Kumar, M. Indumathi, B. Rithik Dharan*
- 00453 15:21 **Performance of large language models in management of complex infectious diseases cases** *A. Pradhan\* (Oxford, United Kingdom), B.J. Waxse, W. Matias, K. Bowman, C. Nutt, S. Mercado, S. Kanjilal, J. Hillis*
- 00454 15:33 **Multimodal artificial intelligence using entire electronic health record and complete pathogen genome data to predict clinical outcomes from life-threatening infection: the SuperbugAI platform** *A. Peleg\* (Melbourne, Australia), S. Tyagi, Y. Ramakrishnaiah, J. Hawkey, J. Wisniewski, T. Christian, V. Sikiric, G. Webb, C. Bain, J. Song, A. Stewardson, T. Peel, N. Macesic*

SY097 14:45 - 15:45 Hall A3-2

1-hour Symposium

IPC PHEI

**Capacity strengthening in antimicrobial stewardship and infection, prevention and control in LMICs**

*Chairs Gloria Cordoba (Copenhagen, Denmark) Syed Faisal Mahmood (Karachi, Pakistan)*

- S0245 14:45 **What is drive-AMS and what have we learned?** *Jeroen Schouten (Nijmegen, The Netherlands)*
- S0246 15:15 **Drive AMS East Africa, inducing behaviour change in resource-constrained settings** *Igizeneza Acsa (Kigali, Rwanda)*

Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS), ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

EF066 14:45 - 15:45 Arena 1

ePoster Flash Session

DX

**The escalating problem of antifungal resistance**

*Chair Ana Alastruey (Madrid, Spain)*

E0455	14:45	<b>Azole fungicides promote <i>C. auris</i> resistance to manogepix: a new One Health concern</b> <i>A. Boutillier*</i> (Poitiers, France), <i>A. Baillod, J. Moreau, S. Marchand, J. Clarhaut, K. Brunet</i>
E0456	14:51	<b>Clonal emergence and mechanistic insights into amphotericin B resistance in <i>Candida auris</i> from Indian hospitals</b> <i>P. Kagra*</i> (Delhi, India), <i>S. Yadav, N. Shukla, K. Jain, S. Srivastava, S.L. Kelly, M.F. Alomair, D.C. Lamb, N. Chauhan, A. Chowdhary</i>
E0457	14:57	<b>Clinically relevant gene flow leads to substantial loss of antifungal susceptibility in a rare invasive fungal pathogen</b> <i>R. Dai*</i> (Beijing, China), <i>Y. Huang, Y. Xu, M. Zhou, M. Xiao</i>
E0458	15:03	<b>Epidemiological trends and genomic insights from national surveillance of <i>Candida auris</i> in Singapore</b> <i>K.N. Sein Tun*</i> (Singapore, Singapore), <i>G. Lee, B. Tan, G. Toh, X.Y. Ong, L. Cui, M. Ang, Z. Said, C. Huang, K. Marimuthu</i>
E0459	15:09	<b>Detection of fluconazole resistant <i>C. parapsilosis</i> clinical isolates bearing both Y132F and S862C substitutions at MALDI-TOF analysis</b> <i>I. Franconi*</i> (Pisa, Italy), <i>B. Tuvo, L. Maltinti, M. Falcone, L. Mancera, A. Lupetti</i>
E0460	15:15	<b>Tandem gene duplications driven rising azole resistance in expanding <i>Candida orthopsilosis</i> population</b> <i>Y.T. Ning*</i> (Beijing, China), <i>R.C. Dai, Y.C. Xu, T.S. Sun, L. Zhang</i>
E0461	15:21	<b>Nationwide multi-centre surveillance of species distribution and antifungal resistance in <i>Candida</i> and <i>Candida</i> related-bloodstream isolates in Brazil (2023–2025)</b> <i>F. Guinsburg Hamburger*</i> (São Paulo, Brazil), <i>F. De Camargo Ribeiro, K. Rosa Fernandes Beraldo, R. Tigulini De Souza Bogo, A.L. De Abreu, A.P. D'Alincourt Carvalho Assaf, J. Nóbrega De Almeida Júnior, A.L. Colombo</i>
E0462	15:27	<b>Unique genetic clades and frequent zoonotic transmission of <i>Sporothrix brasiliensis</i> with reduced itraconazole susceptibility</b> <i>E.F.J. Meijer*</i> (Nijmegen, The Netherlands), <i>M. Orzechowski Xavier, M. Rodrigues Trápaga, B. Spruijtenburg, J. Estefânia Dávila Hidalgo, B. JacomeI, I. Martins Madrid, D. Isabel Brayer Pereira, A. Souza Mattei, A. Reis Gomes, R. Osório De Faria, F. Silveira, C. Bittencourt Severo, V. Rodrigues Aquino, A. Paula Giolo Franz, S. De Ávila Botton, R. Maria Zancopé-Oliveira, V. Rodrigues Poester, T. De Groot</i>
E0463	15:33	<b>High triazole resistance rates of <i>Aspergillus fumigatus</i> in Belgian composting facilities</b> <i>L. Cuyppers*</i> (Leuven, Belgium), <i>L. Vinken, R. Merckx, A. Reséndiz-Sharpe, G. Vande Velde, K. Lagrou</i>

EF067	14:45 – 15:45	Arena 2
ePoster Flash Session		
ANT IPC PED		

### Infection control and antimicrobial stewardship in neonatal and pediatric critical care

Chair	<i>Irja Lutsar (Tartu, Estonia)</i>	
E0464	14:45	<b>Colonisation pressure is associated with infant acquisition of ESBL genes on the neonatal unit</b> <i>A. Cook*</i> (London, United Kingdom), <i>M. Berkell, D.R.M. Smith, H. Van Werkhoven, E. Sieswerda, C. Minotti, L. Van Heirstraeten, S. Malhotra-Kumar, J.A. Bielicki</i>
E0465	14:51	<b>First report of a neonatal intensive care unit outbreak linked to <i>Serratia sarumani</i> in Latin America: insights from WGS and IR Biotyper</b> <i>P. Orlandi Barth*</i> (Porto Alegre, Brazil), <i>W. Latosinski Matos, L. Lutz, L. Rita Konkewicz, D. Castro Pereira, L. Czekster Antochewis, J.V. Barboza Cardoso, L. Quadro Stein, A.L. Barth, A. Francisco Martins</i>
E0466	14:57	<b>Infection prevention surveillance across 29 neonatal units: methods and initial analyses from the NeoIPC Surveillance Network</b> <i>G. Karadağ*</i> (Berlin, Germany), <i>A. Bekker, A. Dramowski, B. Loureiro, J. Pérez López, J.I. Pijoan Zubizarreta, P.T. Heath, B. Piening</i>
E0467	15:03	<b>What do surveillance cultures really tell us in neonates?</b> <i>P. Favier*</i> (Valencia, Spain), <i>P. Suarez-Urquiza, A. Valentin-Martin, A. Pinilla-González, M. Marco-Piá, M. Gomis-Sánchez, E.M. González-</i>

E0468	15:09	<b>Rapid nanopore sequencing and Average Nucleotide Identity (ANI) to guide a <i>Serratia marcescens</i> complex outbreak in a neonatal ward</b> <i>R. Sierra*</i> (Geneva, Switzerland), <i>C. Cave, L. Munoz, C. Ougier Riccio, A. Borghesi, R. Pfister, N. Buetti, D. Andrey</i>
E0469	15:15	<b>Searching for the needle in the haystack with the right lens: impact of chromogenic <i>Serratia</i> spp. agar to neonatal ICU surveillance</b> <i>P. Favier*</i> (Valencia, Spain), <i>P. Suárez-Urquiza, A. Valentin-Martin, A. Pinilla-González, M. Marco-Piá, M. Gomis-Sánchez, M. Cernada-Badía, E.M. González-Barberá</i>
E0470	15:21	<b>The caveats and (im)possibilities of tracking outbreaks directly from swabs in neonates</b> <i>S. Ayala Montaña*</i> (Freiburg Im Breisgau, Germany), <i>S. Ayala-Montaña, A.O. Afolayan, I.J. Akintayo, R. Kociurzynski, L. Duarte Dos Santos, C. Schneider, T. Nguyen, M. Kuntz, H. Fuchs, G.A. Häcker, S. Reuter</i>
E0471	15:27	<b>Impact of BARNARDS II: Introduction of standard diagnostic protocols on antibiotic stewardship and neonatal outcomes in a NICU</b> <i>S. Naqvi*</i> (Islamabad, Pakistan), <i>S. Riaz, M.A. Khan, R. Zahra, E. Rashid, K. Thomson, T. Walsh, B. Hassan</i>
E0472	15:33	<b>Cefiderocol use in paediatric intensive care and neonatal intensive care units: real-world use, safety, and clinical outcomes in a tertiary hospital</b> <i>A. Estevez Prieto*</i> (Madrid, Spain), <i>A. Estévez, F. Camero, J. Serrano-Lobo, C. Redondo Galán, M. Slöcker-Barrio, E. Zamora-Flores, M. Sánchez-Luna, P. Muñoz</i>

EF068	14:45 – 15:45	Arena 3
ePoster Flash Session		
ANT CLN		

### Saving lives, preserving antibiotics: stewardship in the ICU

Chair	<i>Bhanu Sinha (Groningen, The Netherlands)</i>	
E0473	14:45	<b>Beyond acceptance rates: what makes antimicrobial stewardship work in intensive care?</b> <i>S. Camilleri*</i> (Melbourne, Australia), <i>S. Khumra, A. Thomas, S. Vogrin, A. Batrouney, M. Devchand, S. Motaganahalli, S.J. Warrillow, J.A. Trubiano, G.K. Reynolds, S. Narayanasamy</i>
E0474	14:51	<b>Beyond the 'antibiotic police': ICU clinicians' perspectives on effective antimicrobial stewardship communication</b> <i>S. Khumra*</i> (Melbourne, Australia), <i>S. Camilleri, A. Thomas, A. Batrouney, M. Devchand, S. Motaganahalli, S. Warrillow, J. Trubiano, G. Reynolds, S. Narayanasamy</i>
E0475	14:57	<b>Optimising intravenous to oral antibiotic switch in intensive care units: a multi-site audit using UKHSA IVOS criteria across three West Midlands NHS Trusts</b> <i>N. Agravedi*</i> (Birmingham, United Kingdom), <i>A. Jenkins, A. Brush, S. Gilani</i>
E0476	15:03	<b>Optimising Prospective Audit Feedback (PAF): hybrid approach combining AI2D (Augmented Intelligence in Infectious Diseases) and rule-based algorithm</b> <i>Y. Zhou*</i> (Singapore, Singapore), <i>J.L. Lim, S. Tang, J.S. Chung, Y.B. Wang, A. Kwa</i>
E0477	15:09	<b>Antimicrobial stewardship implementation across intensive care units: insights from a national survey</b> <i>A. Van Boekel*</i> (Leiden, The Netherlands), <i>B. Bolhuis, R. Bentvelsen, C. Van Den Berg, L. Van Bodegom-Vos, N. Deetman, D. Dongelmans, W. Falkenburg, E. Van De Garde, J. Haringman, E. De Jong, M. Lambregts, D. De Lange, J. Schouten, C. Den Uil, S. Arbous, M. De Boer, J. Van Paassen</i>
E0478	15:15	<b>Long-term impact of a high-intensity multimodal antimicrobial stewardship programme on broad-spectrum antibiotic consumption and resistance in an adult intensive care unit: an interrupted time series analysis (2013–2025)</b> <i>G. Roncancio Villamil*</i> (Medellín, Antioquia, Colombia), <i>G.E. Roncancio-Villamil, A.A. Pineda-Florez, D.A. Diaz-Ospina, A.R. Vargas-Garcia, A.M. Montoya-Duque, C.I. Garcia-Rincon, C.G. Garces-Zamudio</i>
E0479	15:21	<b>Overcoming implementation challenges: achieving sustained excellence in antimicrobial prescribing through prospective audit and feedback in intensive care units</b> <i>N. Sandoval*</i> (Guatemala, Guatemala), <i>G. Ozaeta, G. Reyes, C. Karla, P. Abdi, C. Alessandra</i>
E0480	15:27	<b>Reassessing risk in critical illness: antibiotic de-escalation remains a safe practice without decreasing</b>

adverse events or mortality *M. Inan Hekimoğlu\** (Ankara, Türkiye), *E. Gülten, E.M. Sarcaoglu, A.H. Elhan, F. Yörük*

**E0481 15:33** **Effect of clinical pharmacist-led antibiotic optimisation in a resource limited tertiary ICU in South India lacking dedicated infectious disease physician support** *A. Mohamed Mohideen\** (Chengalpattu, India), *D. Ganesh, F. Jose, S. Kurian Mathew, M. George*

**EF069 14:45 - 15:45** **Arena 4**  
ePoster Flash Session

**AI-powered pathogen detection and AMR prediction**  
*Chair Belen Rodriguez-Sanchez (Madrid, Spain)*

**E0482 14:45** **Leveraging machine learning for predicting urine culture outcomes: a multi-centre prospective study** *Q. Yi\** (Beijing, China), *X. Zhou, Y. Guo, Y.C. Xu*

**E0483 14:51** **Pilot study for the differentiation of *Clostridium botulinum* group I and *Clostridium sporogenes* using MALDI-TOF MS and unsupervised machine learning** *F. Dematheis\** (Munich, Germany), *R. Schneider, D. Amort, H. Von Buttler, S. Zange*

**E0484 14:57** **A data-driven framework for *Streptococcus pneumoniae* serotype prediction from mass spectrometry profiles** *J. Zintgraff\** (Barracas, Argentina), *N. Sánchez Eluchans, M.A. Moscoloni, C.S. Lara*

**E0485 15:03** **Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistant *Acinetobacter baumannii* from whole genome sequencing and gene expression** *H. Jia\** (Hangzhou, China), *X. Li, Y. Zhuang, Q. Yang, Z. Ruan*

**E0486 15:09** **Predicting genomics-based antibiotic susceptibilities and treatment-emergent resistance in *Acinetobacter baumannii*** *K. Hall\** (San Diego, Ca, United States), *E. Solares, L. Bledsoe, L. Williams, R. Shields*

**E0487 15:15** **stackPred: AI boosted AMR phenotype prediction for multiple species and antimicrobial agents** *J. Welling\** (Essen, Germany), *M. Balzer, L. Consten, S. Bletz, J. Buer, V. Chapot, D. Harmsen, E. Heintschel Von Heinegg, A. Mellmann, W. Pölking, F. Salhöfer, F. Schaumburg, N. Scherff, N. Wiesmann, F. Meyer*

**E0488 15:21** **Interpretable machine learning predicts antimicrobial resistance and reveals regulatory mechanisms in ESKAPEE pathogens** *A. Skoulakis\** (Lamia, Greece), *K. Daniilidis, S. Digenis, C.G. Gkountinoudis, E. Petinaki, A. Hatzigeorgiou*

**E0489 15:27** **MicroBIS: a novel artificial intelligence and machine learning-based digital platform for rapid bacterial identification and antimicrobial resistance prediction to strengthen diagnostics, clinical decision-making, and surveillance in resource-limited healthcare settings across Africa** *A.M. Martin\** (Nairobi, Kenya), *D. Otieno, K. Sam*

**E0490 15:33** **A scalable machine learning-based approach to enhance AMR surveillance in LMICs** *T. Agboeze\** (Ibadan, Nigeria), *O. Daramola, R. Adediji, A. Akomolafe*

**ME099 14:45 - 15:45** **Hall B0-2**  
Meet-the-Expert  
**Pathogens and people: modelling epidemics for preparedness**

**M0249 14:45** *William Hanage (Boston, United States)*  
**M0250 14:57** *Vittoria Colizza (Paris, France)*

**ME098 14:45 - 15:45** **Hall ICM 1**  
Meet-the-Expert  
**What's new in Antimicrobial Susceptibility Testing (AST)**

**M0247 14:45** *Erika Matuschek (Växjö, Sweden)*  
**M0248 14:57** *Rafael Canton (Madrid, Spain)*

Co-organised with: EUCAST Steering Committee

**OS070 16:15 - 17:15** **Hall A3-2**  
1-hour Oral Session

**Turning mechanisms into clinical strategies in chronic viral hepatitis**  
*Chairs Ruxandra Calin (Paris, France)*  
*Yogesh Kumar Gupta (Jaipur, India)*

**O0491 16:15** **NTCP-based HBV infection model to define ncRNA drivers of post-transplant HCC recurrence** *S. Aksoy\** (Bursa, Türkiye), *S. Ak-Aksoy, İ. Sağlık*

**O0492 16:27** **Distinct hepatitis B virus mutational patterns in hepatocellular carcinoma patients vs chronic hepatitis B patients highlight potential biomarkers for cancer progression** *E. Gupta\** (Delhi, India), *S. Maniraj, R. Agarwal, P. Gautam, C. Bihari, M. Sharma*

**O0493 16:39** **Prophylaxis for hepatitis B virus reactivation in patients undergoing immunosuppressive therapy: is there a continued role for lamivudine?** *G. De Simone\** (Rome, Italy), *L. Campogiani, V. Malagnino, E. Teti, T. Mulas, M. Compagno, D. Checchi, A.M. Geretti, L. Sarmati*

**O0494 16:51** **Hepatitis C virus reactivation in cancer patients receiving Bruton tyrosine kinase inhibitors** *T. Harrys\** (Houston, United States), *J. Arvelaez Pasucci, K. Mustafayev, P. Jain, Y. Jiang, E. Yopez Guevara*

**O0495 17:03** **Bulevirtide treatment of HBV-HDV coinfecting patients: 12 months of real-life experience** *G.S. Gherlan\** (Bucharest, Romania), *R.M. Cretu, A. Blidaru, D.S. Lazar, A. Culinescu, A. Condurache, S.M. Ruta, S.A. Florescu, C.P. Popescu*

**LB004 16:15 - 17:15** **Hall B0-2**  
1-hour Oral Session

**Recent and ongoing high impact outbreaks**  
*Chairs Daniel Grupel (Jerusalem, Israel)*  
*Barbara Juliane Holzknicht (Copenhagen, Denmark)*

**L0021 16:15** **The January 2026 Nipah virus outbreak investigation and successful containment in West Bengal, India: direct report from the field** *S. Banerjee\** (Kalyani, India), *A. Das, R. Basu, S. Maharatna, R. Sahay, M.K. Kundu, P. Yadav*

**L0023 16:27** **Uncovering a multi-centre outbreak of *Candida viswanathii* candidaemia caused by contaminated milrhone in Italy** *A. Mesini\** (Genoa, Italy), *V. Di Pilato, D. Contu, M. Castignone, M.L. Ciofi Degli Atti, G. Vrenna, L. Ricotta, C. D'amore, V. Fox, P. Bernaschi, G. Travi, M. Merli, C. Vismara, E. Matarazzo, G. Vento, V. Arena, E. Nardi, A. Marchese, R. Bandettini, G. Spiga, E. Castagnola*

**L0022 16:39** **A complete soil-water-air transmission network for urban melioidosis: source identification and successful intervention in Hong Kong** *T.F. Wong\** (Hung Hom, Hong Kong), *K.H.G. Siu, W.N.F. Chow*

**L0024 16:51** **Outbreak of NDM-1-producing *Burkholderia contaminans* bloodstream infections linked to contaminated intravenous metoprolol** *M. Fantoni\** (Rome, Italy), *P. Laurenti, B. Fiori, S. Vincenti, M. Di Donato, R. Murri, M. Wachocka, F. De Maio, M. Cioce, N. Mores, R. Campopiano, C. Pais, G. Vetrugno, T. D'inzeo, B. Posteraro, C. Torti, M. Sanguinetti*

**L0025 17:03** **Ongoing outbreak of *Burkholderia stabilis* ST480 linked to non-sterile cleansing wipes in the United Kingdom: investigation findings and mitigating patient safety risks** *R. Stretch\** (London, United Kingdom), *A. Carroll, S. Milligan, J. Elston, D. Blackman, A. Popay, D. Kenna, M. Day, C. Willis, K. Staniforth, D. Williams, K. Osman, G. Russell, J. Pappill, J. Gordon-Brown, G. Fear, M. Mirfenderesky, D. Jeyaratnam, I. Sinha, C. Searle, C. Patterson, R. Peabody, C. Brown, E. Betts*

**LB005 16:15 - 17:15** **Hall ICM 1**  
1-hour Oral Session

**New drugs and anti-infective solutions**  
*Chairs Shampa Das (Liverpool, United Kingdom)*

L0026	<b>A chimeric CXCL8(3–72) K11R/G31P–BPI233 protein modulates neutrophil-driven inflammation and protects against carbapenem-resistant Gram-negative bacteria</b> <i>D. Pu*</i> (Beijing, China), <i>J. Zhao, B. Cao</i>
L0027	<b>Breaking bacterial communication signals: Anti-QS antibodies to block pathogenicity</b> <i>T. Posvai*</i> (Barcelona, Spain), <i>L. Vilaplana, M.P. Marco</i>
L0028	<b>In vivo efficacy and PK/PD of OSUAB-0284: a preclinical candidate for MRSA</b> <i>M. Mitton-Fry*</i> (Columbus, United States), <i>P. Srivastava, A. Landgraf, J. West, C. Mann, R. Kebriaei, T. Murphy, D. Andes</i>
L0029	<b>Enzybiotic therapy for species-selective eradication of staphylococcal biofilms</b> <i>M. Yousefi*</i> (Warsaw, Poland), <i>P. Haniewicz, M. Zaród, M. Korzeniowska, J. Kornatowski, E. Jagielska, I. Sabala</i>
L0030	<b>Investigating the antiviral activity of (±)Bay K8644 against Enterovirus D68</b> <i>J.A. Lee*</i> (Taipei, Taiwan), <i>K.C. Yang, L. Jin-Yi</i>

SY103	<b>16:15 – 17:15</b>	<b>Hall A2-1</b>
	1-hour Symposium	

### Implementation of WHO Fungal Priority Pathogens List: landscape and challenges

<i>Chairs</i>	<i>Katrien Lagrou (Leuven, Belgium)</i> <i>Rita Oladele (Lagos, Nigeria)</i>
S0258	<b>16:15</b> <b>Pilot implementation of WHO's global surveillance system for monitoring antimicrobial resistance (GLASS-AMR) in fungal diseases</b> <i>Silvia Bertagnolio</i> (Geneva, Switzerland)
S0259	<b>16:45</b> <b>WHO global blueprint for the implementation of the Fungal Priority Pathogens List</b> <i>Nelesh Govender</i> (Johannesburg, South Africa)

SY102	<b>16:15 – 17:15</b>	<b>Hall B0-1</b>
	1-hour Symposium	

### The future of clinical phage susceptibility testing

<i>Chairs</i>	<i>Saima Aslam (San Diego, United States)</i> <i>Frédéric Laurent (Lyon, France)</i>
S0256	<b>16:15</b> <b>Bacteriophage potency and quality control: guidelines vs. real life</b> <i>Pieter-Jan Ceysens</i> (Brussels, Belgium)
S0257	<b>16:45</b> <b>Bacteriophage susceptibility testing: EUCAST perspectives on standardisation</b> <i>Annika Yanina Classen</i> (Cologne, Germany)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), EUCAST Steering Committee

SY101	<b>16:15 – 18:15</b>	<b>Hall A3-1</b>
	2-hour Symposium	

### Pertussis resurgence: understanding epidemiological trends, immune and vaccine challenges, and policy responses

<i>Chairs</i>	<i>Tina Tan (Chicago, United States)</i> <i>Julie Toubiana (Paris, France)</i>
S0252	<b>16:15</b> <b>Pertussis in its most severe forms: risks, realities, and responses</b> <i>Carla Rodrigues</i> (Paris, France)
S0253	<b>16:45</b> <b>Tracking pertussis: epidemiological trends and global patterns</b> <i>Gayatri Amirthalingam</i> (London, United Kingdom)
S0254	<b>17:15</b> <b>Genomic surveillance and emerging strains</b> <i>Noémie Lefrancq</i> (Basel, Switzerland)
S0255	<b>17:45</b> <b>Rethinking pertussis immunity: challenges and innovations in vaccine strategy</b> <i>Dimitri Diavatopoulos</i> (Nijmegen, The Netherlands)

EF071	<b>16:15 – 17:15</b>	<b>Arena 1</b>
-------	----------------------	----------------

### Risky business: preventing respiratory virus infection in high-risk groups

<i>Chair</i>	<i>Vana Spoulou (Athens, Greece)</i>
E0496	<b>16:15</b> <b>Real-world effectiveness of maternal influenza vaccination in children under six months: a retrospective cohort study in a tropical setting</b> <i>N. Goh*</i> (Singapore, Singapore), <i>E.W. Liang, R. Ho, C. Chiew, R. Li, D. Lye, K. Tan</i>
E0497	<b>16:21</b> <b>Two-year real-world impact and effectiveness of universal RSVpreF vaccination during pregnancy in preventing infant RSV-related hospitalisations in the metropolitan area of Buenos Aires</b> <i>M. Caballero*</i> (Buenos Aires, Argentina), <i>J. Dvorkin, D. Parada, G. Guinazu</i>
E0498	<b>16:27</b> <b>Two-season impact of nirsevimab against RSV hospitalisation in Galicia: findings from the NIRSE-GAL study</b> <i>F. Martínón-Torres*</i> (Santiago De Compostela, Spain), <i>J.L. Razzini, I. Giné-Vázquez, J. Jin, N. Mallah, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzaneres-Casteleiro, A.I. Dacosta-Urbieto, C. Álvarez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo</i>
E0499	<b>16:33</b> <b>RSV prefusion F vaccine effectiveness in older adults according to Charlson Comorbidity Index: A prespecified analysis of the DAN-RSV trial</b> <i>K. Feldballe Bernholm*</i> (Copenhagen, Denmark), <i>M.C.H. Lassen, N. Dyrby Johansen, S. H. Christensen, N. Aliabadi, K.G. Skaarup, D. Modin, K. Hyldekær Janstrup, B. L. Claggett, C. S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. G. Lindholm, A.M. Reimer Jensen, M. Dons, F. Soeskov Davidovskij, L. S. Duus, C. I. Ottosen, A. B. Nielsen, J. H. Borchsenius, C. Espersen, G. Köse, F. H. Fussing, L. Køber, S. D. Solomon, J.U. Stæhr Jensen, C. Jean-Marie Martel, M. Goeijenbier, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B. D. Gessner, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, E. Begier, T. Biering-Sørensen</i>
E0500	<b>16:39</b> <b>Immune response and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (adjuvanted RSVPreF3) in immunocompromised (IC) adults with lung or kidney transplant compared to non-IC adults up to 12 months post-vaccination</b> <i>K. Oluwayi*</i> (London, United Kingdom), <i>C. Small, D. Kumar, A. Abbas, A. Sánchez-Fructuoso, S. Yamanaga, V.L. Pérez-González, H. Karakizlis, M. Nissen, P.G. Choe, V. Paloschi, S. Chadban, H.A. Hailemariam, C. Gerard, M.P. David, D. Descamps, C. Agutu, V. Hulstrøm</i>
E0501	<b>16:45</b> <b>Effectiveness of the adapted XBB.1.5. COVID-19 vaccine received as a 2023 autumn dose among immunocompromised persons in six EU/EEA countries, a VEBIS EHR network study</b> <i>A. Blake*</i> (Paris, France), <i>J. Humphreys, N. Nicolay, T. Braeys, I. Van Evercooren, C. Holm Hansen, I. Rask, M. Fabiani, A. Mateo-Urdiales, J. Castilla, I. Martínez Baz, A. Machado, A. Brito, R. Ljung, N. Pihlström, S. Monge, K. Olsson, B. Nunes</i>
E0502	<b>16:51</b> <b>Interim analysis of the effectiveness of conventional and self-amplifying JN.1-adapted mRNA COVID-19 vaccines against symptomatic infection in adults aged 60 years, Japan</b> <i>H. Maeda*</i> (Nagasaki, Japan), <i>A. Igarashi, S. Mitsui, K. Suzuki, T. Kutomi, H. Fujino, T. Onoe, T. Kimura, Y. Ichigi, H. Kozai, T. Komazaki, S. Kida, K. Morimoto</i>
E0503	<b>16:57</b> <b>A novel approach assessing the impact of SARS-CoV-2 variant drift on effectiveness and durability of an XBB.1.5-adapted COVID-19 vaccine using the id.DRIVE platform</b> <i>H.R. Volkman*</i> (New York, United States), <i>J.L. Nguyen, K. Bollaerts, T.M.P. Tran, M.M. Mustapha, L. De Munter, C. Marques, H. Dunford, J.V. Hernandez-Villena, M. Mitrata, A. Antón, I. Casas Garcia, B. Gruner, G. Icardi, G. Luit Ten Kate, C. Martin, A. Mira-Iglesias, A. Orrico-Sanchez, S. Otero-Romero, G. Rohde</i>
E0504	<b>17:03</b> <b>Safety, tolerability, pharmacokinetics, and immunogenicity in a phase I first-in-human study with VYD2311, a SARS-CoV-2-directed monoclonal antibody</b> <i>P. Richmond*</i> (Nedlands, Australia), <i>L. Hu, K. Narayan, K. Tosh, R. Gerlach, I. Yacin, D. Wilfret, M. Wingertzahn</i>

EF072	16:15 – 17:15	Arena 3
	ePoster Flash Session	
DX		
<b>Advances in sepsis diagnostics: improving speed and accuracy</b>		
Chair	Özlem Kurt Azap (Ankara, Türkiye)	
E0505	16:15	True bacteraemia vs contamination in positive blood cultures: development of a prediction model E. Nannini* (Rosario, Argentina), M. Dumas Marucci, J.I. Rodriguez Lia, M. Pallotta, C. Scipione, R. Bonifacio, M. Rinaudo
E0506	16:21	Epidemiology and interpretation of positive blood cultures when polymerase-chain reaction-based blood culture results are “not detected” S. Boettcher* (Detroit, United States), R. Kenney, R. Tibbetts, L. Samuel, S. Davis, M. Veve
E0507	16:27	Modeling a point-of-care diagnostic panel implementation for rapid bloodstream infection identification in remote settings: a cost-effectiveness analysis K. Bagge* (Copenhagen, Denmark), F.H. Jensen, J.G. Lisby
E0508	16:33	Patient factors associated with circulating bacterial DNA in critically ill sepsis patients C. Lannsjö* (Stockholm, Sweden), B. Stammler Jaliff, D. Yu, S. Cajander, A. Bäckman, E. Tina, A. Somell, H. Alpkvist, M. Ullberg, C. Jorns, J. Wernerman, V. Özenci, K. Strålin
E0509	16:39	Culture-free detection of bloodstream bacteria in ICU patients within six hours A. Wijen* (Maastricht, The Netherlands), C. Von Wintersdorff, R. Driessen, S. Van Mens, D. Bergmans, P. Savelkoul
E0510	16:45	From culture to clarity in four hours: accelerating clinical management of bloodstream infections R. Ahmad* (Hamar, Norway), J. Ali, A. Basavaraj Bellankimath, S. Therese Opgård, E. Varman Manivannan, G. Skov Simonsen
E0511	16:51	Rapid pathogen and antimicrobial resistance detection in bloodstream infections using short subculture and nanopore sequencing M. Pitombeira Liborio* (Brisbane, Australia), P. Harris, C. Ravi, K. Ramsay, T. Da Silva Duarte, A. Irwin
E0512	16:57	Rapid identification of bacteraemia-causing microorganisms using MALDI-TOF MS: a comparative study of three in-house methods with two matrices Z.C. Karahan* (Ankara, Türkiye), R. Waheed Osman
E0513	17:03	Four-day vs five-day blood culture incubation: a retrospective study of diagnostic performance using the BACT/ALERT VIRTUO system K. Tron* (Newcastle, United Kingdom), C. Cullerton, J. Lupton, P. Mpwilu, J. Samuel, D. Weiland

EF073	16:15 – 17:15	Arena 4
	ePoster Flash Session	
ANT CLN PHEI		

**Surveillance of antimicrobial use around the world**

Chair	Kalisvar Marimuthu (Singapore, Singapore)	
E0514	16:15	The ECRAID Emerging Resistance Index by European region: assessing the index's applicability in different epidemiological contexts J. Garlasco* (Verona, Italy), F. Arieti, M. Morra, D.E. Ortiz, E. Addis, M. Tebon, O. Awwad, K. Odoj, M.D. Pezzani, S. Harbarth, E. Prestler, G. Kahlmeter, A. Cassini, A. Savoldi, E. Tacconelli
E0515	16:21	Antibiotic use, rapid escalation practices and access in neonatal sepsis across LMIC tertiary care hospitals: findings from the BARNARDS II cohort K. Thomson* (Oxford, United Kingdom), K. Sands, J. Oduwo, C. Achi, R. Farzana, B. Hassan, E. Owinoh, M. Nziliani, A. Ko, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, N. Ukaegbu, C. Nzurumike, T. Amin, S. Arefin, T.N. Shatu, A.T. Promi, T. Haque, R. Tasnim, R. Zahra, E. Rashid, M.I. Shah, S. Riaz, S. Naqvi, S. Naeem, M. Haroon Hamid, S. Shabbir, U. Hussain, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, T.R.

		Walsh
E0516	16:27	Global antibiotic use (AMU) patterns in 2023: insights from WHO's global AMU surveillance system (GLASS-AMU) D. Tong* (Geneva, Switzerland), M. Escher, A. Muller, V. Ivanovska, D. O'doherty, B. Huttner
E0517	16:33	Scaling a national antimicrobial prescribing surveillance programme incorporating an appropriateness assessment to drive policy and practice R. James* (Melbourne, Australia), C. Chen, K. Thursky
E0518	16:39	Being more AWaRe: assessing appropriateness of antimicrobial prescribing against the World Health Organization AWaRe classifications C. Chen* (Melbourne, Australia), L. Hall, K. Thursky, N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson
E0519	16:45	How do we define 'appropriate antimicrobial use' in One Health? A global Delphi survey R. Scarborough* (Parkville, Australia), C. Ierano, K. Bailey, G. Browning, K. Thursky, R. Biezen, B. Hur, B. Mc Mullan, L. Dowson, A. Schermuly, L. Teoh, L. Hardefeldt
E0521	16:57	Real-world use of novel $\beta$ -lactams in fragile patients with multidrug-resistant Gram-negative infections: insights from an Italian retrospective cohort M. Bognetti* (Milan, Italy), F. Fama, M. Colaneri, E. Palomba, C. Conflitti, F. Brivio, M. Piscaglia, M. Schiavini, M.V. Cossu, S. Vimercati, E. Rossin, C. Paganì, S.G. Rimoldi, A. Gori
E0522	17:03	Strengthening antimicrobial stewardship across Europe: EU-JAMRAI2 on frameworks, implementation, and collaborative action on human health M. Nunez-Nunez* (Granada, Spain), M. Nuñez Nuñez, B. Bradley-Valdenebro, J.L. Trillo-Contreras, A. López-Navas, R. Fernández-Urrusuno

KN100	16:15 – 17:15	Hall ICM 14
	Keynote lecture	
CLN		

**From post-mortem discoveries to precision care: the evolution of opportunistic fungal infection management in haematological malignancies**

Chairs	Murat Akova (Ankara, Türkiye) Anuradha Chowdhary (Delhi, India)	
K0251	16:15	Dimitrios P. Kontoyiannis (Houston, United States)

ME104	16:15 – 17:15	Hall ICM 13a
	Meet-the-Expert	
CLN PHEI		

**Crimean-Congo haemorrhagic fever: best practices and advances in therapeutics and vaccines**

M0260	16:15	Önder Ergönül (Istanbul, Türkiye)
M0261	16:27	Ali Mirazimi (Stockholm, Sweden)
Co-organised with: ESCMID Emerging Infections Subcommittee		

FO105	16:15 – 17:15	Arena 2
	Open Forum	
CLN PRO		

**Science in action: implementation science for effective CM/ID practice in diverse settings**

Chair	Marlies Hulscher (Nijmegen, The Netherlands)	
F0262	16:15	Implementation science fundamentals: a toolkit for CM/ID practice Fabiana Lorençatto (London, United Kingdom)
F0263	16:25	Measuring success: metrics that matter José Molina Gil-Bermejo (Seville, Spain)
F0264	16:35	Implementing infection control best practices across diverse resource settings Raheelah Ahmad (London, United Kingdom)
Co-organised with: ESCMID Education Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee		

OS076 17:30 – 18:30 Hall A3-2

1-hour Case Session

CLN

**A zoonotic carnival: masquerade syndromes and unusual presentations**

*Chairs* Loïc Epelboin (Cayenne, French Guiana)  
Joseph Papaparaskevas (Athens, Greece)

00523 17:30 **Buffalopox beyond borders: first imported human case in Europe** L. Soldevila Langa\* (Badalona, Spain), L. Soldevila, L. Valerio, A. Plana, X. Vallès, E. Fernández-Pedregal, S. Roure

00524 17:41 **Fulminant multisystem anthrax with delayed haemorrhagic gastrointestinal involvement: a clinically unique case from an endemic region** M. Javakhadze\* (Tbilisi, Georgia), M. Kobakhidze, L. Goliadze, E. Choladze, M. Kanashvili

00525 17:52 **Imported round cavitory pneumonia: an unusual presentation of murine typhus** J.R. Le Henaff\* (Toulouse, France), G. Grouteau, G. Martin-Blondel, D. Pierre, A. Merckx, G. Moulis, L. Cavalié, P. Floch, R. Gueneau

00526 18:03 **A spectacular differential diagnosis of lung cancer and the elucidation of its origin** S. Zange\* (Munich, Germany), K. Kösters, F. Löhr, E. Mantel, M. Hohls, C. Hinz, F. Dematheis, T. Hoffmann, K. Silberreis, M. Seidel, M. Walter, H. Scholz, W. Roman, D. Lang

00527 18:14 **Seeing the unexpected: intraretinal dirofilariasis** H. Aldhaferi\* (Abu Dhabi, United Arab Emirates), G. Rashwan, Z.O.E. Babiker, A.P. Srinivasulu, R.S. Ganeshan

OS074 17:30 – 18:30 Hall ICM 13a

1-hour Oral Session

CLN PHEI TRN

**Innovations in vector-borne and zoonotic viral infections**

*Chairs* Casandra Bulescu (Bucharest, Romania)  
Ines Ushiro-Lumb (Marlow, United Kingdom)

00528 17:30 **The role of the host genetic background in tick-borne encephalitis** S. Grygorczuk\* (Białystok, Poland), M. Parczewski, J. Dunaj, P. Czupryna, J. Adamczuk, W. Pawlak-Zalewska, A. Moniuszko-Malinowska

00529 17:42 **Phenotypic characterisation of emerging neurotropic viruses using embryonic stem cell-derived neural cells and brain organoids** S. Vogiatzis\* (Padua, Italy), E. Dal Molin, G. Gori Savellini, R. Pia Falco, M. Severa, C. Lucca, A. Sinigaglia, A. Gianella, G. Ceolotto, M. Bogacheva, I. Weinstein, O. Vapalahti, M. Pacenti, M. Trevisan, E. Coccia, M.G. Cusi, L. Barzon

00530 17:54 **Exploring haematocrit, platelet and leukocyte count trajectories associated with dengue: pooled analysis from Vietnam** N.L. Vuong\* (Ho Chi Minh City, Vietnam), D.T. Trung, T.V. Ngoc, N.M. Nguyet, D.T.H. Tam, N.T. Truong, H.T.L. Duyen, N.T.H. Quyen, N.T.T. Kieu, N.V.V. Chau, L.T.H. Tai, N.T.H. Lan, P.K. Lam, C.P. Simmons, S. Yacoub, R.B. Geskus, B.A. Willis

00531 18:06 **A novel ARPE-19 cell-based assay for assessing interferon-mediated protection and autoantibody neutralisation in ZIKV infection** A. Ferrari\* (Pavia, Italy), I. Cassaniti, F. Rovida, D. Lilleri, S. Croce, F. Trespidi, A. Gervais, S.Y. Zhang, J.L. Casanova, A. Borghesi, F. Baldanti

00532 18:18 **One health investigation of Tahyna and Batai orthobunyaviruses and Sindbis alphavirus in Northern Italy, 2021-2024** E. Dal Molin\* (Padua, Italy), M. Pacenti, D. Murova, A. Sinigaglia, A. Giaretta, A. Lavazza, D. Lelli, F. Gobbo, F. Montarsi, L. Barzon

OS075 17:30 – 18:30 Hall ICM 13b

1-hour Oral Session

ANT CLN

**Primary care and long-term care facilities: what's going on in stewardship?**

*Chair* Bradley Langford (Etobicoke, Canada)  
TBA

00533 17:30 **Evaluation of a national training roll out implementing a stewardship toolkit in primary care in England: a quasi-experimental analysis using hybrid time series**

modelling M.X. Lee\* (Gloucester, United Kingdom), N.J. Zhu, J. Meadows, R. Ahamad, D.M. Lecky

00534 17:42 **Between-practice differences, rather than patient case-mix, drive variation in antibiotic prescribing in UK primary care: evidence from a three-way variance decomposition** V. Nguyen\* (Oxford, United Kingdom), J.V. Robotham, A.S. Walker, D. Eyre, R. Hope, C. Butler, G. Hayward, M. Sharland, K.B. Pouwels

00535 17:54 **Antimicrobial use and stewardship activities in Swiss long-term care facilities: data from a national point-prevalence survey** S. Toppino\* (St. Gallen, Switzerland), P. Kohler, D. Flury, F. Grässli, S. Kuster, E. Glampedakis, C. Gardiol, T. Kudrnovsky, V. Piezzi, M. Schlegel

00536 18:06 **Assessment of antibiotic prescribing and AWaRe classification compliance in Dutch nursing homes using national surveillance data** A. Zondag\* (Bilthoven, The Netherlands), M. Biesheuvel, J. Polman, K. Halonen, A.P.J. Haenen, S.C. De Greeff

00537 18:18 **Impact of an antimicrobial stewardship intervention in residential aged care: a multi-centre, stepped-wedge cluster randomised trial (START Trial)** N. Jokanovic\* (Melbourne, Australia), S.J. Lee, T. Haines, S. Hilmer, Y.H. Jeon, D. Ayton, R.L. Stuart, A. Cheng, A.J. Stewardson, T.N. Peel, A. Y. Peleg

SY111 17:30 – 18:30 Hall A2-1

1-hour Symposium

PED VAX

**How to tackle congenital viral infections**

*Chairs* Susanne Gjeruldsen Dudman (Oslo, Norway)  
Boris Kramer (Poznan, Poland)

S0275 17:30 **Congenital CMV screening: lessons and implications for prevention** Dana Wolf (Jerusalem, Israel)

S0276 18:00 **Opportunities and challenges of vaccination in pregnancy** Chrissie Jones (Southampton, United Kingdom)

SY109 17:30 – 18:30 Hall B0-1

1-hour Symposium

CLN DX

**New evidence challenging the UTI paradigm**

*Chairs* Merel Lambregts (Leiden, The Netherlands)  
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0271 17:30 **Urobiomics: detection and utility in the UTI universe** Nicole De Nisco (Richardson, Texas, United States)

S0272 18:00 **Complicated UTI: diagnosis and treatment strategies** Florian Wagenlehner (Giessen, Germany)

Co-organised with: ESCMID Scientific Affairs Subcommittee, ESCMID Study Group for Urinary Tract Infections (ESGUTI)

SY110 17:30 – 18:30 Hall B0-2

1-hour Symposium

CLN DX

**Dosing by breakpoints vs guidelines: are S/I/R results based on the focus of infection best practice or source of confusion?**

*Chairs* Iva Butic (Zagreb, Croatia)  
Sören Gatermann (Bochum, Germany)

S0273 17:30 **Pro: make AST reports as informative as possible, add different S/I/R results per indication** Mandy Wootton (Cardiff, United Kingdom)

S0274 18:00 **Con: don't confuse clinical colleagues, keep S/I/R fixed and add dosages in the guidelines** Miquel Ekkelenkamp (Utrecht, The Netherlands)

Co-organised with: Dutch Committee on Antimicrobial Policy

SY107 17:30 – 18:30 Hall ICM 1

1-hour Symposium

CLN DX

**Machine learning to fight against MDR *Acinetobacter baumannii***

*Chairs* Hege Vangstein Amot (Lørenskog, Norway)

Abhilasha Karkey (Kathmandu, Nepal)

S0267 17:30 AI approaches to improve diagnosis and treatment of MDR-Ab Anton Peleg (Melbourne, Australia)

S0268 18:00 ML algorithms for distinguishing colonisation from infection by MDR-AB Gert Marais (Cape Town, South Africa)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID)

SY106 17:30 - 18:30 Hall ICM 14  
1-hour Symposium

DX

### Year in clinical microbiology

Chairs Brigitte Lamy (Bobigny, France)  
Holger Rohde (Hamburg, Germany)

S0265 17:30 - Belen Rodríguez-Sánchez (Madrid, Spain)

S0266 18:00 - Surbhi Malhotra-Kumar (Antwerp, Belgium)

SY108 17:30 - 18:30 Hall ICM 5  
1-hour Symposium

TRN VAX

### Immunological determinants of host-pathogen interactions in inflammation and immune compromise

Chairs Silvio Daniel Brugger (Zurich, Switzerland)  
Anna Norrby-Teglund (Stockholm, Sweden)

S0269 17:30 Human genetics as a compass to understand the host-microbe interactions

S0270 18:00 Modulation of granulocyte effector response in patients with inflammatory and immunodeficiency disorders Srikanth Mairpady Shambat (Zurich, Germany)

EF077 17:30 - 18:30 Arena 1  
ePoster Flash Session

CLN DX PHEI

### Diagnosing mycobacterial infections across the globe

Chair Jakko Van Ingen (Nijmegen, The Netherlands)

E0538 17:30 Clinical and microbiological correlation of NTM PCR N. Shah\* (Svs Road, Mahim West, India), K. Ajbani, A. Sunavala, S. Shirole, B. Jadeja, S. Gore, S. Ganta, S. Naik, C. Rodrigues, S. Basu, A. Bijwe, U. Agrawal

E0539 17:36 Improving tuberculosis diagnosis through AI (CAD4TB) and Stool-Xpert MTB/RIF: a prospective study from Oromia, Ethiopia G. Guido\* (Bari, Italy), B. Gulo, S. Cotugno, W. Nigussa, K. Bobosha, F.V. Segala, B. Zauli, B. Kenate Sori, G. Putoto, F. Cavallin, G. Madeddu, F.A. Bobbio, N. Veronese, A. Biset Asmare, A. Reta, R. Iatta, S. Abata, M. Miressa, F. Gobbi, L. Guglielmetti, M. Tilahun, A. Saracino, A. Alemseged, F. Manenti, F. Di Gennaro

E0540 17:42 A \$26 gold standard *Mycobacterium tuberculosis* complete genome using long read sequencing A. Osmaston\* (London, United Kingdom), C. Leon, O. Romero, D. Taquiri, P. Avellaneda, J.B. Raez Pereyra, J.L. Perez, S. Huaman, J. Coronel, W. Solano, R. Gilman, A. Torres-Ortiz, G. Tan, B. Sobkowiak, P. Sheen, M. Zimic, L. Grandjean

E0541 17:48 Whole genome sequencing-based clonality assessment of *Mycobacterium simiae* isolates from Lebanon M. Antar\* (Beirut, Lebanon), Z. Awad, S. Agsous, L. Tabet, C. Allam, M. Abifadel, F. Mougari, J. Najjar-Pellet, E. Cambau

E0542 17:54 Machine learning-assisted differentiation of *Mycobacterium tuberculosis* complex species from MALDI-TOF mass spectra M. Gutiérrez-Pareja\* (Madrid, Spain), F. Alcaide, L. Herrera, D. Domingo, V. González-Galán, J. Viñuelas-Bayon, M. Simón-Sacristán, C. Castelló-Abietar, B. Fernández-Pérez, M. Oviaño, L. Fernández-Delgado, A. Candela, E. Abascal, M.J. Ruiz-Serrano, B. Rodríguez-Sánchez, D. Rodríguez-Temporal

E0544 18:06 Consensus-based diagnostic evaluation of a novel tuberculosis IGRA in a low-endemic population K. Callebaut\* (Bruges, Belgium), T. Chin, V. Verbeke, A. Muyltermans, M. Verhulst, M. Reynders

E0545 18:12 Evaluation of *Mycobacterium tuberculosis* derived cell-free DNA (CF-DNA) based multi-targeted real-time PCR (MRTPCR) from extrapulmonary (EPTB) samples for diagnosis of extrapulmonary tuberculosis (EPTB) K. Sharma\* (Chandigarh, India), M. Modi

E0546 18:18 Targeted next-generation sequencing-a promising approach in the diagnosis of *Mycobacterium tuberculosis* and drug resistance X. Wu\* (Shanghai, China)

EF078 17:30 - 18:30 Arena 2  
ePoster Flash Session

CLN IPC TRN

### Prevention and management of implant-associated infections: biofilm control and beyond

Chair Biljana Carevic (Oslo, Norway)

E0547 17:30 Preventing bacterial colonisation of synthetic bone grafts using nanostructured hydroxyapatite and cold atmospheric plasma-treated liquids A. Ruiz Sorribas\* (Barcelona, Spain), F. Tampieri, C. Canal, M.P. Ginebra

E0548 17:36 Supercritical CO2 as an innovative method to inactivate biofilms on orthopaedic implants R. Hafian Al-Homsj\* (Madrid, Spain), A. Cabañas, L. Calvo, R. Hafian, P. Sanz

E0549 17:42 Bilayer sol-gel coating prevents *Staphylococcus aureus* prosthetic joint infection and improves bone integration in mice J. Aguilera Correa\* (Madrid, Spain), B. Toirac, J.J. Aguilera-Correa, Á. Solís-Garrido, A. Mediero, F. Mulero, O. Velyt-Vepryk, J. Esteban, A. Jiménez-Morales

E0550 17:48 Risk factors for early infection after spinal instrumentation surgery: a multi-centre case-control study M. Muelas-Fernandez\* (Barcelona, Spain), J.A. Iribarren, E. Benavent, A. Marron, J.M. Bravo-Ferrer, H. Vilchez, D. Rodríguez-Montserrat, N. Sopena, M. Riera, O. Gasch, A. Lersundi, M.D. Del Toro, O. Murillo

E0551 17:54 Risk stratification and clinical impact of Gram-negative fracture-related infections F. Petrucci\* (Rome, Italy), D. De Meo, P. Martini, M. Rivano Capparuccia, G. Iaiani, S. Gumina, C.M. Mastroianni, A. Oliva

E0552 18:00 Keeping it clean when things inflate: evidence gaps in antimicrobial strategies for penile prosthesis surgery R. Ghani\* (London, United Kingdom), P. Sangster, W.G. Lee, S. Dewan, P. Panesar, G. Satta

E0553 18:06 Rifampicin combination therapy fails to enhance clearance and induces growth delay in a rat model of *Staphylococcus aureus* vascular graft infection E. Faddy\* (Aarhus N, Denmark), J. Bär, M.I. Johansen, C. Gadeberg, L.B. Carstens, L. Østergaard, L.T. Erikstrup, S. Mairpady Shambat, A. Zinkernagel, R.L. Meyer, N.P. Jørgensen

E0554 18:12 Characteristics, management and outcomes of vascular graft and endograft infections in Eastern Denmark: a retrospective cohort study A.J. Christensen\* (Hillerød, Denmark), S. Bjerrum, K. Sörelius, I.H.M. Mathiesen, C. Moser, J. Helweg-Larsen, B.V. Sandholt, D. Faurholt-Jepsen, C. Kraef

E0555 18:18 Antibiotic and surgical treatment in staphylococcal ventriculoperitoneal shunt infections in adults I. Pelegrín Senent\* (Barcelona, Spain), I. Pelegrín, M. Sanz De Mena, J. Gómez-Junyent, C. Iglesias, M.M. Moreno, A. Siverio, S. Gómez-Zorrilla, L. Sorli, M.M. Montero, J.P. Horcajada

EF079 17:30 - 18:30 Arena 3  
ePoster Flash Session

AMR

### Molecular epidemiology and genomic evolution of high-priority MDROs

Chair Helena Zemlickova (Prague, Czechia)

E0556 17:30 Antimicrobial susceptibility and molecular

		characterisation of carbapenem-resistant Enterobacteriales (CRE) from European medical centres stratified by country (2020-2024) <i>H.S. Sader*</i> (North Liberty, United States), <i>J.H. Kimbrough, G. Stone, K. Perez, R. Mendes, M. Castanheira</i>	
E0557	17:36	Emergence of new variants of OXA-48 in France <i>L. Bientz*</i> (Le Kremlin-Bicêtre, France), <i>R. Nermont, C. Emeraud, T. Naas, R.A. Bonnin, L. Dortet</i>	
E0558	17:42	Spread of carbapenemase-producing <i>Serratia</i> spp. in France from 2016 to 2024: a comparative genomic study <i>L. Dortet*</i> (Le Kremlin-Bicêtre, France), <i>I. Rezzoug, S. Bernabeau, K. Oucel, A. Birer, A. Jousset, L.M. Gerald, E. Cécile, D. Laurent</i>	
E0559	17:48	Molecular epidemiology and resistance of carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates from five referral centres in South Africa <i>G. Marais*</i> (Cape Town, South Africa), <i>S. Africa, F. Patel, E. Geza, E. Du Toit, F. Franceschi, R.M.A. Da Costa, A. Brink</i>	
E0560	17:54	Emergence of vancomycin-variable <i>Enterococcus faecium</i> following the expansion of Vancomycin-resistant <i>E. faecium</i> in Taiwan <i>W.C. Hung*</i> (Kaohsiung, Taiwan)	
E0561	18:00	Increase in OXA-48-like carbapenemase-producing Enterobacteriales driven by clonal expansion and plasmid dissemination in the Netherlands, 2019-2024 <i>A. Hendrickx*</i> (Bilthoven, The Netherlands), <i>S. Lansu, A. De Haan, S. Witteveen, J. Bos, F. Landman, C.C.H. Wielders, S.C. De Greeff, D.W. Notermans</i>	
E0562	18:06	Plasmid population analysis of <i>Klebsiella pneumoniae</i> spanning two decades <i>M. Martin*</i> (Silver Spring, United States), <i>E. Nguyen, A. Sapre, T. Luo, B. Jones, V. Rollins, R. Maybank, A. Ong, Y. Kwak, J. Bennett, P. Mc Gann, F. Lebreton</i>	
E0563	18:12	High prevalence of ESBL Enterobacteriales colonisation in elderly people with high care needs in Liverpool, UK <i>J.M. Lewis*</i> (Liverpool, United Kingdom), <i>S. Gallichan, E. Picton-Barlow, C. Mckeown, S. Forrest, M. Moore, S. Todd, M. Taegtmeier, F.E. Graf, N.A. Feasey</i>	

EF080	17:30 - 18:30	Arena 4
	ePoster Flash Session	

**Beyond the cocktail: advances in phage therapy**

Chair *Maria Vehreschild (Frankfurt Am Main, Germany)*

E0565	17:30	Capsule-independent entry route for <i>Acinetobacter baumannii</i> phage infection <i>H. Oliveira*</i> (Braga, Portugal), <i>S. Lorenz, D. Turner</i>	
E0566	17:36	Mechanistic insights and clinical implications of cross-reactive anti-phage antibodies on phage therapeutic failure <i>A. Peleg*</i> (Melbourne, Australia), <i>F. Gordillo Altamirano, D. Subedi, B. Gardiner, J. Hawkey, J. Barr</i>	
E0567	17:42	Exploiting the natural power of phage lysins as novel enzyme-based antibiotics to treat polymicrobial Gram-negative infections <i>G. Vandermarliere*</i> (Ghent, Belgium), <i>G. Hermans, D. Grimon, Y. Briers, R. Vázquez, V. Stove, J. De Waele</i>	
E0568	17:48	Hidden lytic potential of human gut phages: discovery of thousands of endolysins and holins <i>M. Khan Mirzaei*</i> (Neuherberg, Germany), <i>A.H.A. Elbeheri, S. Abdullah, B. Neumann, M.K. Mirzaei, L. Deng</i>	
E0569	17:54	Engineered phage therapy using parenteral and intravesical delivery of CRISPR-Cas armed phages (SNIPRO01) in mice increase survival and reduces infection? <i>A. Gram*</i> (Copenhagen, Denmark), <i>A. Østergaard Petersen, J. Krause Haaber, E. Van Der Helm, A. Troy, J. Hink, C. Grøndahl</i>	
E0570	18:00	Rational selection of a synergistic phage combination enabled clearance of mouse gut colonisation by carbapenemase-producing <i>Escherichia coli</i> ST131 <i>F. Laumay*</i> (Lyon, France), <i>R. Bonnin, R. Bonnet, F. Laurent, G. Dalmasso, R. Beyrouthy, C. Baeza, B. Lapras, M. Bonhomme, P. Martins-Simoes, E. Helluin, L. Blazere, V. Bonnin, L. Guillouard, R. Froissart, M. Medina, C. Kolenda, F. Pirot, L. Dortet</i>	
E0571	18:06	Exploring phage-amikacin combination against metallo-β-lactamase Gram-negative bacteria in a murine thigh infection model <i>P. Paranos*</i> (Athens, Greece), <i>P.C. Georgiou, S. Pournaras, J. Meletiadis</i>	
E0572	18:12	A phage cocktail promotes intestinal decolonisation	

E0573	18:18	of multidrug-resistant <i>Klebsiella pneumoniae</i> : insights from a 3D <i>in vitro</i> microbiota model <i>M. Calvigioni*</i> (Pisa, Italy), <i>E. Fausti, C. Ferretti, G. Vozzi, E. Ghelardi, M. Di Luca</i>	
		Regional therapeutic phages and genomic correlates of susceptibility in refractory/resistant <i>Pseudomonas</i> infections: findings from a multi-centre Asian cohort <i>A. Kwa*</i> (Singapore, Singapore), <i>Y. Liu, S. Thong, Z.S. Chong, S.H. Tan, Y. Zhong, A. Chan, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo</i>	

ME112	17:30 - 18:30	Hall A2-2
	Meet-the-Expert	

**Immunisation strategies for vaccine-preventable arboviral diseases: recent advances and future directions**

M0277	17:30	<i>Alfonso J. Rodriguez-Morales (Pereira, Colombia)</i>
M0278	17:42	<i>Antonio Carlos De Albuquerque Bandeira (Lauro De Freitas, Brazil)</i>

Co-organised with: ESCMID Vaccine Study Group (EVASG)

**Monday, 20 April 2026**

EW120	08:30 - 10:30	Hall A2-2
	2-hour Educational Session	

**Future of fungi: biomarkers, big data and mycobiome**

Chairs *Methee Chayakulkeeree (Bangkok, Thailand)*  
*Oliver A. Cornely (Cologne, Germany)*

W0390	08:30	Next-gen biomarkers for invasive fungal disease <i>Laura Alcazar Fuoli (Madrid, Spain)</i>
W0391	08:50	AI in action: big data and models in fungal infections <i>Daniele Roberto Giacobbe (Genoa, Italy)</i>
W0392	09:10	Pulmonary mycobiome: a missing link in lung health? <i>Cecile Angebault (Creteil, France)</i>
W0393	09:30	Steroids and risk: quantifying IFI susceptibility <i>Andrés Henao (Aurora, United States)</i>

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Austrian Society for Medical Mycology (ÖGMM), Belgian Society of Human and Animal Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED), Asia Fungal Working Group (AFWG), Taiwan Society of Microbiology

EW118	08:30 - 10:30	Hall ICM 13a
	2-hour Educational Session	

**Integrating IPC into hospital design: a collaborative approach to safer hospitals**

Chairs *Sabiha Essack (Durban, South Africa)*  
*Constantinos Tsioutis (Nicosia, Cyprus)*

W0382	08:30	Building safer hospitals: what is the role of the IPC? <i>Margreet C. Vos (Rotterdam, The Netherlands)</i>
W0383	08:50	Consult your architect: optimising infection control through hospital layout and design <i>Marco Gola (Milan, Italy)</i>
W0384	09:10	Collaborating with operations: HVAC systems in healthcare, balancing airflow and infection control <i>Jeffrey Siegel (Toronto, Canada)</i>
W0385	09:30	Consult your water hygienist: engineering and planning aspects of water systems for safe patient care <i>Evdokia Katsemi (Frankfurt, Germany)</i>

EW119	08:30 - 10:30	Hall ICM 13b
	2-hour Educational Session	

**Your attention, please! Parasitic infections in immunocompromised patients**

<i>Chairs</i>	<i>Miriam José Alvarez Martinez (Barcelona, Spain)</i> <i>Hanne Brekke (Oslo, Norway)</i>
<b>W0386</b>	<b>08:30</b> <b>A deadly duo: immunosuppression and alveolar echinococcosis</b> <i>Ansgar Deibel (Zurich, Switzerland)</i>
<b>W0387</b>	<b>08:50</b> <b>Please, do not forget: <i>Strongyloides</i> and immunosuppression</b> <i>Dora Buonfrate (Negrar, Italy)</i>
<b>W0388</b>	<b>09:10</b> <b>Management of visceral leishmaniasis in the immunocompromised</b> <i>Jaya Tapadar Née Chakravarty (Varanasi, India)</i>
<b>W0389</b>	<b>09:30</b> <b>Double challenge: Chagas diseases and immunosuppression</b> <i>Marisa Liliána Fernandez (Ciudad Autónoma De Buenos Aires, Argentina)</i>

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), Latin American Society for Travel Medicine, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

<b>OS081</b>	<b>08:30 – 10:30</b>	<b>Hall B0-2</b>
	2-hour Oral Session	

**Hot topics in tuberculosis**

<i>Chairs</i>	<i>Emmanuelle Cambau (Paris, France)</i> <i>Christian Wejse (Aarhus, Denmark)</i>
<b>00574</b>	<b>08:30</b> <b>A 3D-bioprinted granuloma platform with controlled syringe-based infection for studying Mtb drug response and host-pathogen interactions</b> <i>R. Sorrentino* (Milan, Italy), C. Scielzo, D.M. Cirillo, R. Pinos, P. Miotto, A. Ghodousi, F. Saluzzo, A. Muscetti</i>
<b>00575</b>	<b>08:42</b> <b>Airway microbiome signatures accurately discriminate <i>Mycobacterium tuberculosis</i> infection status</b> <i>G. Olweny* (Kampala, Uganda), A. Kayongo, M.L. Ntai</i>
<b>00576</b>	<b>08:54</b> <b>A platelet activation signature defines the CSF compartment in early tuberculous meningitis</b> <i>K. Skolimowska* (London, United Kingdom), A.G. Davis, T. Reid, N. Bangani, C. Stek, P. Renner, M. Panchoo, R.J. Wilkinson, J.S. Friedland</i>
<b>00577</b>	<b>09:06</b> <b>A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment</b> <i>J. Donovan* (Ho Chi Minh City, Vietnam), N.T.T. Hiep, T.T. Hung, H.D.T. Nghia, L.H.B. Ngoc, N.D. Bang, K. Maharani, P.K.N. Oanh, E. Riwanti, N.T.T. Thuong, E. Kestelyn, D. Imran, R.L. Hamers, R.B. Geskus, N.H. Phu, G.E. Thwaites</i>
<b>00578</b>	<b>09:18</b> <b>Genomic epidemiology as a high-resolution tool to investigate local tuberculosis outbreaks</b> <i>M.G. López* (Valencia, Spain), A. Blasco-Molla, P. Cano-Jiménez, J.C. Gascó-Laborda, I. Gómez-Navarro, V. Furió, M. Torres-Puente, F.J. Roig-Sena, J. Bellido-Blasco, I. Comas</i>
<b>00579</b>	<b>09:30</b> <b>Assessing the diagnostic accuracy of TB transcriptomic signatures in children: insights from the RaPaed-TB study</b> <i>A. Razid* (Munich, Germany), O. Baranov, M. McClean, Z. Franckling-Smith, H. Zar, C. Khosa, D. Banze, I. Sabi, N. Ntinginya, M. Nliwasa, E. Corbett, R. Semphere, V. Verghese, J. Michael, M. Ninan, E. Saathoff, T. Mchugh, S. Graham, R. Song, P. Nabeta, A. Trollip, M. Nicol, M. Ahmed, M. Hoelscher, N. Heinrich, L. Olbrich, C. Geldmacher, K. Held</i>
<b>00580</b>	<b>09:42</b> <b>Tuberculosis infections among rifampicin-resistant tuberculosis household contact persons: a multi-central prospective cohort study (TCCT study)</b> <i>F. Zhou* (Shanghai, China), Y. Lan, Q. Yang, W. Zhang, Q. Ruan</i>
<b>00581</b>	<b>09:54</b> <b>Phenotypic drug susceptibility testing of <i>Mycobacterium tuberculosis</i> in less than a day</b> <i>B.M. Tran* (Uppsala, Sweden), J. Larsson, E. Amselem, P. Knagge, J. Elf</i>
<b>00582</b>	<b>10:06</b> <b>Are WHO recommended rapid diagnostic tests a panacea for the diagnosis of multidrug-resistant tuberculosis?</b> <i>N. Mvelase* (Durban, South Africa), G. Vadelu, R. Singh, Y. Mahabeer</i>
<b>00583</b>	<b>10:18</b> <b>Inadequate access to TB and MDR-TB therapies in the EU and the European economic area: the role of regulatory pathways</b> <i>M. Van Der Heijden* (London, United Kingdom), R. Otto-Knapp, C. Årdal</i>

<b>SY116</b>	<b>08:30 – 10:30</b>	<b>Hall A3-1</b>
	2-hour Symposium	

**Mobile elements and plasmids in Gram-positive pathogens: new frontiers in structure, function and clinical impact**

<i>Chairs</i>	<i>Kristin Hegstad (Tromso, Norway)</i> <i>Marc Stegger (Copenhagen, Denmark)</i>
<b>S0374</b>	<b>08:30</b> <b>Conjugation and host-range in Gram-positive plasmids: barriers and bridges</b> <i>Elisabeth Grohmann (Berlin, Germany)</i>
<b>S0375</b>	<b>09:00</b> <b><i>Enterococcus faecium</i>: mobile elements and AMR spread</b> <i>Jia Qi Beh (Melbourne, Australia)</i>
<b>S0376</b>	<b>09:30</b> <b>The adaptation of <i>Staphylococci</i> for clonal success</b> <i>Maria Miragaia (Oeiras, Portugal)</i>
<b>S0377</b>	<b>10:00</b> <b>Resolving mobile elements and plasmids in Gram-positive pathogens: what new genomics reveals</b> <i>Jukka Corander (Oslo, Norway)</i>

Co-organised with: ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

<b>SY117</b>	<b>08:30 – 10:30</b>	<b>Hall A3-2</b>
	2-hour Symposium	

**How to maintain the microbial safety of transfusion and transplantation?**

<i>Chairs</i>	<i>Oscar Len (Barcelona, Spain)</i> <i>Anna Papa-Konidari (Thessaloniki, Greece)</i>
<b>S0378</b>	<b>08:30</b> <b>Emerging infections and blood safety: urgent matter</b> <i>Helvi Harvala (Turku, Finland)</i>
<b>S0379</b>	<b>09:00</b> <b>Are syphilis and other sexually-transmitted infections a problem for blood safety?</b> <i>Thijs Van De Laar (Amsterdam, The Netherlands)</i>
<b>S0380</b>	<b>09:30</b> <b>Tools to prevent transmission of HHV-8 via organ transplantation</b> <i>Ines Ushiro-Lumb (Marlow, United Kingdom)</i>
<b>S0381</b>	<b>10:00</b> <b>Amyloid beta as a novel transmissible agent</b> <i>John Collinge (London, United Kingdom)</i>

Co-organised with: European Society for Clinical Virology (ESCV)

<b>SY115</b>	<b>08:30 – 10:30</b>	<b>Hall B0-1</b>
	2-hour Symposium	

**Interconnected microbiomes and resistomes across One Health**

<i>Chairs</i>	<i>Debby Bogaert (Edinburgh, United Kingdom)</i> <i>John W. A. Rossen (Groningen, The Netherlands)</i>
<b>S0370</b>	<b>08:30</b> <b>Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention</b> <i>Amy Mathers (Charlottesville, United States)</i>
<b>S0371</b>	<b>09:00</b> <b>Silent transmission: the genetic bridges between worlds</b> <i>Bruno Gonzalez-Zorn (Madrid, Spain)</i>
<b>S0372</b>	<b>09:30</b> <b>Into the wild: connectivity of wildlife resistomes and antimicrobial resistance across sectors</b> <i>Jacob Moran-Gilad (Beer Sheva, Israel)</i>
<b>S0373</b>	<b>10:00</b> <b>From barn to city: environmental transmission of livestock-associated microbiota and antimicrobial resistance</b> <i>Myrna Maria Theresia De Rooij (Utrecht, The Netherlands)</i>

<b>SY113</b>	<b>08:30 – 10:30</b>	<b>Hall ICM 1</b>
	2-hour Symposium	

**Sepsis 2026: practice-changing insights you can't ignore**

<i>Chairs</i>	<i>Thierry Calandra (Epalinges, Lausanne, Switzerland)</i> <i>Robin Patel (Rochester, Minnesota, United States)</i>
<b>S0361</b>	<b>08:30</b> <b>ISF-ESCMID Sepsis Award</b>
<b>S0362</b>	<b>08:45</b> <b>Reversing sepsis mortality in Uganda's refugee settlements: a solar-powered diagnostic revolution</b> <i>U. Muhumuza* (Kampala, Uganda), Z. Nahumuza, B.B.</i>

		<i>Nanyange</i>	
S0363	09:00	<b>The new surviving sepsis campaign 2026 guidelines</b> <i>Willem Joost Wiersinga (Amsterdam, The Netherlands)</i>	
S0364	09:30	<b>Immunotherapy for sepsis: finally there!</b> <i>Eleni Karakike (Athens, Greece)</i>	
S0365	10:00	<b>Sepsis: year in review</b> <i>Annelies Zinkernagel (Zurich, Switzerland)</i>	

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY114	08:30 – 10:30	Hall ICM 5
	2-hour Symposium	

### Barriers to infectious disease control and treatment in resource-limited settings

<i>Chairs</i>	<i>Nitin Gupta (Manipal, India)</i> <i>Priscilla Rupali (Vellore, India)</i>
S0366	08:30 <b>Scrub typhus: a neglected tropical disease</b> <i>Winsley Rose (Vellore, India)</i>
S0367	09:00 <b>The impact of recent severe flooding events and global funding shifts on HIV in Malawi</b> <i>Sam Phiri (Lilongwe, Malawi)</i>
S0368	09:30 <b>Polio eradication in Pakistan: health services, violence, and the 'Long Goodbye'</b> <i>Svea Closser (Baltimore, Maryland, United States)</i>
S0369	10:00 <b>Barriers to cholera control in Malawi amidst climate disasters</b> <i>Anat Rosenthal (Beer Sheva, Israel)</i>

EF082	08:30 – 09:30	Arena 2
	ePoster Flash Session	

### Chasing resistance to anti(retro)virals

<i>Chair</i>	<i>Snjezana Zidovec Lepej (Zagreb, Croatia)</i>
E0584	08:30 <b>Emergence and persistence of RSV-B resistant variants under monoclonal antibody pressure: evidence in a 3D human airway model</b> <i>A. Caillault* (Créteil, France), A. Ly, P. Cappy, A. Soulier, J.M. Pawlowsky, L. Softic, S. Fourati</i>
E0585	08:36 <b>Resistance mutations on M2 gene of A(H5N1) viruses: are adamantanes still useful against avian influenza?</b> <i>I. Sanz* (Valladolid, Spain), I. Sanz-Muñoz, A. Martín-Toribio, M. Toquero-Asensio, S. Galindo-Carretero, L. Sanchez-De Prada, J. Sánchez-Martínez, C. Rodríguez-Crespo, R. Iglesia-Aparicio, C. López-Gonzalo, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, J.M. Eiros</i>
E0586	08:42 <b>Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in influenza A viruses circulating in China, 2018–2025</b> <i>B. Sun* (Shanghai, China), H. Wang, X. Zhao, J. Ai, W. Zhang</i>
E0587	08:48 <b>Tracking RSV fusion protein variability across seven decades: risks of resistance to prophylactic antibodies</b> <i>F. Serrano Cano* (Antwerp, Belgium), F.I. Serrano-Cano, K. Stobbelaar, S. Van Looy, K. Van Hoorenbeek, R. Sanjuán, P. Delputte</i>
E0588	08:54 <b>Integrated viral resistance analysis in participants with COVID-19 treated with remdesivir across six phase III clinical studies</b> <i>C. Hedskog* (Foster City, Ca, United States), L. Rodriguez, J. Moshiri, D. Han, N. Peinovich, T. Aeschbacher, J. Li, R. Martin, J.K. Perry, R.H. Hyland</i>
E0589	09:00 <b>Ensitrelvir treatment of COVID-19 across multiple global phase III trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound</b> <i>A. Hurt* (England, United Kingdom), H. Nobori, H. Sakaguchi, A. Luetkemeyer, D. Verdi, F. Draica, S. Portsmouth, T. Uehara</i>
E0590	09:06 <b>Identification of epitope mutation in HBV mono-infection and HBV-HDV coinfection</b> <i>M.S. Mehmood* (Karachi, Pakistan), S.H. Abidi</i>
E0591	09:12 <b>APOBEC-context mutations vs true HIV resistance: evidence from a hospital population in Quito, Ecuador</b> <i>G. Sevillano* (Quito, Ecuador), C. Moreno-Izquierdo, M. Granja, J. Zurita, C. Zurita-Salinas</i>
E0592	09:18 <b>Limited emergence of dolutegravir-associated</b>

**resistance mutations in HIV-1 across Africa** *P. Appiah\* (Accra, Ghana), M. Adusei-Poku, B.M. Obeng, R. Osei-Yeboah, E.T. Norgbe, P. Omoniyi, M. Akuka, L. Mac-Ankrah, I. Jamfaru, S. Ankamah, K.O. Duedu, K.W.C. Sagoe*

PM001	08:30 – 10:30	Hall A2-1
	Pipeline Symposium	

### AI in infectious diseases: the future is now

<i>Chairs</i>	<i>Giorgia Carra (Lausanne, Switzerland)</i> <i>Oliver Nolte (Zürich, Switzerland)</i>
D0001	08:30 <b>AI: risks and opportunities</b> <i>Bram Lestrade (Roermond, The Netherlands)</i>
D0002	09:00 <b>AI: experiences in drug discovery</b> <i>Stephan Sieber (Munich, Germany)</i>
D0003	09:30 <b>AI: modelling epidemics and analysing disease outbreaks</b> <i>Moritz U. G. Kraemer (United Kingdom)</i>
D0004	10:00 <b>AI in the regulatory field</b> <i>Radu Botgros (Amsterdam, The Netherlands)</i>

SY121	09:30 – 10:30	Hall ICM 14
	1-hour Symposium	

### Year in public health

<i>Chairs</i>	<i>Alexandra Mailles (Saint-Maurice, France)</i> <i>Rita Oladele (Lagos, Nigeria)</i>
S0394	09:30 - <i>David Fisman (Toronto, Canada)</i>
S0395	10:00 - <i>Kurt Hanevik (Bergen, Norway)</i>

EF083	09:30 – 10:30	Arena 1
	ePoster Flash Session	

### Expanding the role of genomics and proteomics against AMR

<i>Chair</i>	<i>Lorena Lopez Cerero (Seville, Spain)</i>
E0593	09:30 <b>Benchmarking antimicrobial resistance gene prediction tools from metagenomic sequencing data of positive blood cultures</b> <i>K. To* (Hong Kong, Hong Kong), A. Li, D. Buhl, A. Chu, W.M. Chan</i>
E0594	09:36 <b>Molecular characterisation of the first CTX-M-15 and OXA-9 <math>\beta</math>-lactamase-producing <i>Haemophilus influenzae</i> isolates in the Iberian Peninsula</b> <i>A. González-Díaz* (Barcelona, Spain), M. Pinto, I. Cadenas-Jiménez, S. Duarte, C. Ardanuy, M.M. Ribeiro, S. Martí, P. Bajanca-Lavado</i>
E0595	09:42 <b>Genomic surveillance uncovers polyphyletic, high-risk <i>Escherichia coli</i> lineages in apparently healthy children and household livestock</b> <i>N. Okumu* (Nairobi, Kenya), J. Juma, D. Muloi, E. Cook, O. Cumming, A. Moodley, S. Oyola, J. Ngeranwa</i>
E0596	09:48 <b><i>In vitro</i> activity of ceftiderocol against carbapenemase-producing <i>E. coli</i> phenomics vs genomics for antimicrobial susceptibility prediction</b> <i>C. Tellapragada* (Stockholm, Sweden), M. Razavi, P. Jonsson, C. Giske</i>
E0597	09:54 <b>Quantifying the association of resistance with antimicrobial resistance genes in <i>Escherichia coli</i> for new <math>\beta</math>-lactam/<math>\beta</math>-lactamase-inhibitor/enhancer combinations</b> <i>J. Takata* (Oxford, United Kingdom), D. Nagy, V. Pennetta, K. Hopkins, A. Roohi, D. Karageorgopoulos, M.B. Avison, A. Mathers, R. Hope, D. Williams, A. Ledda, J. Robotham, C.S. Brown, P. Bejon, G. Mcvieve, A.S. Walker, K.L. Hopkins, S. Lipworth, N. Stoesser</i>
E0598	10:00 <b>K-MARVEL: K-Mer-based antimicrobial resistance virtual exploration lab</b> <i>R. Ahmad* (Hamar, Norway), N.S. Mahar, S. Branders, M.G. Grabherr, I. Gupta</i>
E0599	10:06 <b>Early antimicrobial resistance prediction using urinary proteomics and machine learning</b> <i>E. Lemann* (Gothenburg, Sweden), A. Marchi, R. Karlsson, A. Polster</i>
E0600	10:12 <b>Genomic characterisation of carbapenem-resistant Enterobacterales (CRE) reveals high-risk clones and</b>

**patient-environment transmission in a Nigerian tertiary hospital** *B.A. Olanipekun\* (Ilorin, Kwara State, Nigeria), A. Afolayan, A. Keller, S. Becker, L.A. Molano, J. Rehner, P. Jung, R. Raheem, A. Fadeyi, A. Shittu, C. Nwabuisi*

**E0601 10:18 A Next-generation platform for culture-free AMR gene identification in human infections** *T. Mehrotra\* (Faridabad, India), B. Das*

**EF084 09:30 - 10:30 Arena 3**  
ePoster Flash Session

**From virus to host and back again: exploring retroviruses**  
Chair *Anna Maria Geretti (London, United Kingdom)*

**E0602 09:30 Defining the contribution of T lymphocyte activation and proliferation to the HIV reservoir** *L. Santinelli\* (Rome, Italy), L. Bortolani, L. Maddaloni, M. Andreotti, Z. Michelini, C. Falvino, G. Ceccarelli, C.M. Mastroianni, G. D' Ettore*

**E0603 09:36 Unexpected high prevalence of HTLV-1 in HIV-1 positive patients: a looming crisis?** *G. Zahra\* (Tehran, Iran, Islamic Republic of), A. Letafati, L. Abbasian, S. Sadeghipour Marvi, S.H. Mozghani, B. Sarshari*

**E0604 09:42 Immune checkpoint LAG3 overexpression reflects T cell dysfunction in PLWH with low CD4/CD8 ratio** *G. Nunnari\* (Catania, Italy), S. Spampinato, G. Scuderi, M. Pinzone, N.L. Parrinello, M. Di Rosa, F. Condorelli, E. Venanzi Rul, A. Marino, R. Bruno, B. Caccopardo, B.M. Celesia, F. Di Raimondo, P. Fagone*

**E0605 09:48 Near full genome sequencing of HIV-2** *Ö. Yildirim\* (Berlin, Germany), M. Prentice, R. Ehret, M. Obermeier*

**E0606 09:54 Altered gene expression in migration and angiogenesis pathways of HTLV-1 infected individuals: implications for disease progression in asymptomatic carriers** *A. Letafati\* (Tehran, Iran, Islamic Republic of), S.H. Mozghani*

**E0607 10:00 Exploring immune correlates of low viral reservoir burden in people living with HIV following early ART initiation: a retrospective longitudinal study from the DZIF TOP-HIV cohort** *M. Figueroa Orozco\* (Munich, Germany), E. Grüner, M. Münchhoff, R. Cohen, T. Trenkner, M. Beiersdorfer, A. Hölzemer, J. Roeder*

**E0608 10:06 HIV-1 Subtype definition in the era of whole genome sequencing** *F. Stefanelli\* (Genoa, Italy), N. Randazzo, N. Nigro, S. Varesano, M. Ferraris, E. Massaro, V. Paolozzi, M. Ogliastrò, L. Taramasso, V. Ricucci*

**E0609 10:12 Comparison of HIV clusters in metropolitan France and overseas territories** *B. Visseaux\* (Frepillon, France), N. Rybak, G. Wartel, L. Nguyen, M. Niang, E. Hedbaut, S. Teixeira, V. Kailainathan, K. Diallo, S. Lasteré*

**LB006 11:00 - 12:00 Hall A1-1**  
1-hour Oral Session

**Late-breaking disease surveillance approaches**  
Chairs *Megan Carey (Amsterdam, The Netherlands), Carla Rodrigues (Paris, France)*

**L0031 11:00 Inferring the global risk of dengue outbreaks** *V. Cabrini\* (Singapore, Singapore), M.K.B. Mohamad Rosle, E.L.W. Choo, Y. Chen, J.T. Lim*

**L0032 11:12 A climate-responsive emerging disease risk projection platform: version 1 release and early adoption opportunities** *J. Abbate\* (Montpellier, France), V. Heurteaux*

**L0033 11:24 Evaluation of a host-based, pathogen-agnostic viral biomarker for early outbreak detection** *R. Mehta\* (London, United Kingdom), H. Hopkins, D. Mabey, E. Fitchett, P. Randell, A. Mohamed, M. Mayxay, Q. Bassat, J. Chipanga, C. Christopher, L. Papargyris, H. Wagstaff, S. Ascough, S. Hamilton, M. Levine, J. Herberg, O. Ioana-Diana, L. Maslen, M. Valdivia-Garcia, C. Anthony, E. Chekmeneva, S. Sriskandan*

**L0034 11:36 Metagenomics surveillance collaboration and analysis programme (mSCAPE): preliminary results from a national metagenomics surveillance pilot** *S. Rokadiya\* (London, United Kingdom), N.J. Loman, M.*

*Chand, N. Groves, R. Graham, A. Aryee, C. Rodrigues, R. Cohring, C. Houlihan, R. Puleston, S.A.J. Wilkinson, T. Brier, J. James, A. Banyard, D. Ward, R. Batra, J. Edgeworth*

**L0035 11:48 Sustained mpox clade I human-to-human spread in DRC calls for continuous variant monitoring** *E. Kinganda-Lusamaki\* (Kinshasa, Congo, the Democratic Republic of the), A. Amuri-Aziza, J.C. Makangara Cigolo, R. Lumembe-Numbi, G. Kabamba-Lungenyi, G. Luakanda-Ndelemo, P. Akil-Bandali, T. Wawina-Bokalanga, S. Ahuka Mundeke, J.J. Muyembe-Tamfum, A. Ayouba, E. Delaporte, M. Peeters, P. Mbala-Kingebeni*

**OS087 11:00 - 12:00 Hall A1-2**  
1-hour Oral Session

**Hospital- and ventilator-associated pneumonia: new insights on prevention, diagnosis and treatment**

Chairs *Elisabeth Presterl (Vienna, Austria), Jeroen Schouten (Nijmegen, The Netherlands)*

**O0611 11:00 The hospital acquired pneumonia prevention (HAPPEN) study: a multi-centre randomised controlled trial** *B. Mitchell\* (Gosford, Australia), N. White, P. Russo, A. Cheng, M. Kiernan*

**O0612 11:12 Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): secondary analysis using desirable outcome ranking with response adjusted for duration antibiotic risk and generalised pairwise comparison** *A. Blanco Arévalo\* (Barcelona, Spain), A. Blanco-Arevalo, N.A. Binte Mohamed, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchoisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo*

**O0613 11:24 Antibiotic duration-response curve for ventilator-associated pneumonia using a target trial emulation** *W.C. Tan\* (Singapore, Singapore), J. Quah, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, L. Yie Hui, P. Chetchoisakd, D. Limmathurotsakul, P.A. Tambyah, J. Chaisurote, P. Poomthong, A. Kawiwangsanon, K. Semram, S. Kitsaran, P. Wongsrikaew, N. Wetchagama, S. Patamatham, A. Rujisirasankul, A. Narmwong, C. Sodapak, S. Nuntalohit, S. Boonsong, J. Nilsakul, J. Moolasart, A. Phunmanee, A. Panitchote, P. Duangthongphon, P. Pisuttimarn, N. Srisurat, Y. Hwee Seng, G. Maclaren, T.W. Lim, K.L. Chew, S.L. Lim, B.W. Teo, T.J. Lim, L.J. Sun, S. Peng, N. Graves, Y.T. Chew, L.M. Ling, P.Y. Chia, Y.W. Chia, W. Huang, Y.K. Chan, P. Roshan, S. Anil, K. Abhilasha, D. Sabina, F.F. Tuon, B.S. Cooper, Y. Mo*

**O0614 11:36 Trimethoprim/sulfamethoxazole vs vancomycin for MRSA ventilator-associated pneumonia: a retrospective study** *F.F. Tuon\* (Curitiba, Brazil), A. Salomão, V. Sabbaga Amato, J.P. Telles*

**O0615 11:48 Impact of antimicrobial stewardship programmes on hospital-acquired and ventilator-associated pneumonia among adults: a systematic review and meta-analysis** *S. Rachina\* (Moscow, Russian Federation), N. Ablakimova, D. Strelkova, A. Suvorov, G. Smagulova*

**OS088 11:00 - 12:00 Hall A1-3**  
1-hour Oral Session

**Focus on Infective endocarditis: from pathogens to prognosis**

Chairs *Tatjana Lejko Zupanc (Ljubljana, Slovenia), Parham Sendi (Bern, Switzerland)*

**O0616 11:00 BlaZ-associated mortality in patients with Staphylococcus aureus endocarditis** *P. Mathé\* (Freiburg, Germany), M.T. Leibenguth, M. Hanke, S. Schuster, J. Camp, D. Hornuss, G. Peyerl-Hoffmann, A.J. Kaasch, I. Joost, H. Seifert, W. Kern, S. Rieg*

**O0617 11:12 Evaluation of different scores for the prediction of infective endocarditis among patients with Staphylococcus aureus bacteraemia** *Z. Dennebouy\* (Lausanne, Switzerland), M. Padrutt, P. Monney, G. Tzimas, M. Frank, L. Senn, L. Niclauss, M. Kirsch, M. Van Hemelrijck, O. Dzemali, B. Guery, B. Hasse, M. Papadimitriou-Olivgeris*

00618	11:24	<b>Removal of cardiac implanted electronic devices in patients with <i>Staphylococcus aureus</i> bacteraemia without endocarditis is not associated with improved survival</b> <i>D. Macfadden*</i> (Ottawa, Canada), <i>N. Daneman, L. Lau, S. Almoosawy, E. Athan, D. Birnie, J. Davis, W. Gold, M. Gollan, J. Johnstone, T. Lee, E. McDonald, D. Messika-Zeitoun, S. Ong, M. Cheng, S. Tong, H. Wijeyesundera, C. Yu</i>
00619	11:36	<b>Characteristics of infective endocarditis caused by <i>Enterococcus faecium</i>: a study from the GAMES cohort</b> <i>E. Aparicio-Minguijón*</i> (Madrid, Spain), <i>P. Muñoz, M. Machado-Vilchez, M. Valerio-Minero, A. Josune Goikoetxea-Agirre, M.J. Blanco-Vidal, M.Á. Rodríguez-Esteban, C. Hidalgo-Tenorio, G. Ojeda-Burgos, J.M. Miró, R. Parra-Fariñas, V.A. Hortigüela Martín, I. Diego Yagüe, F. López-Medrano</i>
00620	11:48	<b>Should we extend the use of oral antibiotics in infective endocarditis? the ENDO-ORAL study</b> <i>R. Pouy*</i> (Reims, France), <i>B. Rallet, C. Coutureau, M. Blot, F. Bani-Sadr, T. Sixt, M. Moutel, L. Piroth, M. Hentzien</i>

OS089	11:00 – 12:00	Hall A1-4
	1-hour Oral Session	

### Mechanistic insights into antimicrobial activity and resistance of Gram-negative bacteria

<i>Chairs</i>	<i>Kwame Ohene Buabeng (Ho, Ghana)</i> <i>Thomas Tängdén (Uppsala, Switzerland)</i>	
00621	11:00	<b>Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in <i>Escherichia coli</i></b> <i>M. Murillo Torres*</i> (Seville, Spain), <i>M. Murillo-Torres, K. Alexandre, Á. Pascual, F. Docobo-Pérez, J.M. Rodríguez-Martínez</i>
00622	11:12	<b>Characterising penicillin-binding protein 2 (PBP2) mutations causing zidebactam resistance in <i>Pseudomonas aeruginosa</i></b> <i>M.Á. Sastre-Femenia*</i> (Palma, Spain), <i>M.A. Gomis-Font, B. Moya, A. Oliver</i>
00623	11:24	<b>Spontaneous resistance to siderophore-conjugated <math>\beta</math>-lactams in <i>Klebsiella pneumoniae</i>: diverse mechanisms and fitness effects</b> <i>G. Zaborskyte*</i> (Oxford, United Kingdom), <i>G. Zaborskyté, A. Lankapalli, A.J.M. Farley, C.J. Schofield, T.R. Walsh</i>
00624	11:36	<b>Pre-existing <math>\beta</math>-lactamase gene diversity reduces ESBL-producing Enterobacterales colonisation risk in patients exposed to ceftriaxone</b> <i>Q. Le Bastard*</i> (Nantes, France), <i>M. Emmanuel, R. Etienne, R. Gschwind, J. Lao, M.A. Vibet, B. Eric, C. Stéphane</i>
00625	11:48	<b>Optimising the treatment regimen with phage cocktails and ceftolozane/tazobactam against carbapenem-resistant <i>Pseudomonas aeruginosa</i> endotracheal tube biofilms</b> <i>V. Oliveira*</i> (Barcelona, Spain), <i>A. Rocha, A. Soler-Comas, G. Macip, E. Watanabe, M. Ferrer, A. Torres, L. Fernandez-Barat</i>

OS090	11:00 – 12:00	Hall A1-5
	1-hour Oral Session	

### Overcoming diagnostic challenges in low resource settings

<i>Chairs</i>	<i>Nitin Gupta (Manipal, India)</i> <i>Juliette Severin (Rotterdam, The Netherlands)</i>	
00626	11:00	<b>BADLOCK: a rapid, portable, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings</b> <i>D. Roach*</i> (Somerville, United States), <i>P. Sangruji, S. Bhat, R. Bhattacharyya</i>
00627	11:12	<b>Accelerating bacteraemia management with molecular-AI vs molecular-phenotypic AI antimicrobial recommendations: a prospective study in a resource-limited setting</b> <i>J. Gomez De La Torre*</i> (Lima, Peru), <i>J.C. Gómez De La Torre, A. Frenkel, C. Chavez-Lencinas, A. Rendon, Y. Higuchi, L. Alvarado, J.A. Cáceres-Delaguila, D. Minchon-Vizconde, M. Hueda-Zavaleta</i>
00628	11:24	<b>Microbiology lab implementation in low-resource settings: does it help clinicians reducing antibiotic prescriptions for hospitalised patients?</b> <i>H. Nguyen Thi*</i> (Ha Noi, Vietnam), <i>T. Hoang Van, H. Tran Thi, C. Dang Quang, H. Tran Thi Bich, H. Phan Quoc, M. Nguyen Duy, H. Nguyen Ba, H. Phan Van, T. Pham Le,</i>

*G. Bui Thi Huong, T. Pham Thi Thanh, H. Nguyen Thi Thu, D. Pham Minh, H. Dinh Xuan, K. Bui Xuan, H. Nguyen Thi Bich, L. To Duc, H. Nguyen Ngoc, T. Van Dinh, H. Nguyen Thanh, Y. Nguyen Hai, P. Bui Bich, H. Vu Thi Lan, R. Van Doorn, T. Kesteman*

00629	11:36	<b>Addressing diagnostic limitations in enteric fever in resource-limited settings</b> <i>S. Dongol*</i> (Lalitpur, Nepal), <i>N. Maharjan, A. Karkey, C. Parry, B. Basnyat</i>
00630	11:48	<b>Evaluation of immunochromatographic assays for carbapenemase detection: a multi-centre study within the strengthening a Brazilian system for surveillance and prevention of antimicrobial resistance network (VigIRAM)</b> <i>M. Pillonetto*</i> (São José Dos Pinhais, Brazil), <i>L. Kraft, G.A. Gonçalves, H.R.S. D'espindula, D. Kulek, A.P.S. Chacon, J.M. Cieslinski, R.T. Souza, A.L. Abreu, A.P. Assef</i>

OS091	11:00 – 12:00	Hall A3-2
	1-hour Oral Session	

### Intracellular persistence of Gram-negative pathogens: immune evasion and implications for treatment

<i>Chairs</i>	<i>Christian Stephan Lentz (Tromsø, Norway)</i> <i>Nina Van Sorge (Amsterdam, The Netherlands)</i>	
00631	11:00	<b>OmpA controls intracellular survival of <i>Acinetobacter baumannii</i> through TFEB activation and lysosomal remodeling</b> <i>Á. Rey Hidalgo*</i> (Seville, Spain), <i>A. Rey-Hidalgo, M. Pérez-Pérez, G. Olgiati, C. Atalaya-Rey, I. Molina-Panadero, Y. Smani</i>
00632	11:12	<b>Intracellular invasion of osteoblasts by Gram-positive bacteria and the impact of vancomycin eluted from orthopaedic cement</b> <i>R. Brull Tuma*</i> (São Paulo, Brazil), <i>L. Batista Campos, M. Muniz De Andrade Silva, M. Neri Lucas Kurihara, I.N. Marcelino Santos, M.A. Midolli Vieira, R.D.C. Sinigaglia, T.A. Tardelli Gomes Do Amaral, M.J. Costa Salles</i>
00633	11:24	<b>T5SS-Mediated contact-dependent inhibition drives intracellular UPEC persists contributing to recurrent UTI</b> <i>M. Obrebski*</i> (Warsaw, Poland), <i>M. Obrebski, M. Kirzyc, M. Równicki, J. Piwowarski</i>
00634	11:36	<b>The intracellular state: a fortress of persistence for uropathogenic <i>Escherichia coli</i></b> <i>J. Atrissi*</i> (Brussels, Belgium), <i>J.F. Ouédraogo, F. Van Bambeke</i>
00635	11:48	<b>The human bladder microenvironment and urinary fluid dynamics modulate antibiotic and bacteriophage treatment against uropathogenic <i>Escherichia coli</i></b> <i>J. Rohn*</i> (London, United Kingdom), <i>R. Garcia Maset, A. Crowther, V. Chu, D. Di Grande, R.O.A. Jariah, J. Yoon, D. Blumgart, M.A.E. Hodek, N. Yuen, B.O. Murray, L. Pasquina-Lemonche, S.N.H. Alghamdi, A.D. Millard, G. Lutheryn, M.E.K. Haines, M.R.J. Clokier, E. Stride, D. Carugo</i>

OS085	11:00 – 12:00	Hall ICM 13a
	1-hour Oral Session	

### Artificial intelligence: emerging applications for medical mycology

<i>Chairs</i>	<i>Ronen Ben-Ami (Tel Aviv, Israel)</i> <i>Toni Gabaldón (Barcelona, Spain)</i>	
00636	11:00	<b>Machine learning-based predictive model for invasive mould infections in haematology patients: development and validation</b> <i>E. Gras*</i> (Barcelona, Spain), <i>C. Teijón-Lumbreras, P. Monzo-Gallo, B. Glemain, T.F. Aiello, A. Gallardo-Pizarro, A. Martínez-Urrea, C. Terrones, A. Castiella, A. Vergara, C. Martínez, M. Suarez-Lledó, J. Esteve, A. Soriano, C. Garcia-Vidal</i>
00637	11:12	<b>Machine learning for genomic antifungal susceptibility prediction in <i>Candidoizyia auris</i></b> <i>Y. Zhong*</i> (Liverpool, United Kingdom), <i>G. Alessandro, H. Alex, B. Charlie, H. William</i>
00638	11:24	<b>Advancing fungal disease impact assessment: development and pilot validation of a semi-automated AI-based surveillance algorithm for invasive aspergillosis</b> <i>S. Kleinsteuber*</i> (Leiden, The Netherlands), <i>M. Van Der Beek, J. Buil, P. Verweij, M. Reijers, R. Bruggemann, M. De Boer</i>
00639	11:36	<b>Evaluation of the performance of large language models in mycological diagnosis</b> <i>M. Aras*</i> (Istanbul, Türkiye), <i>M.I. Tosun, N. Samanci, I. Caklovica Kucukkaya, S.A.</i>

00640	11:48	<b>Machine learning-based gene screening unravels key determinants of caspofungin resistance</b> <i>Y. Su*</i> (Beijing, China), <i>Y. Xu</i>	
OS086	11:00 – 12:00	1-hour Oral Session	Hall ICM 13b
<b>Vaccines: landmark trials and preventive immunisation</b>			
<i>Chairs</i> <i>Joel Mossong (Luxembourg, Luxembourg)</i> <i>Oana Sandulescu (Bucharest, Romania)</i>			
00641	11:00	<b>Randomised phase III trial of a 9-valent vaccine (ExPEC9V) for prevention of invasive <i>Escherichia coli</i> disease (IED) in older adults (E.mbrace)</b> <i>K.A. Cohen*</i> (Titusville, United States), <i>C. Mclean, T. Day, M. Peeters, I. Scheys, M.G. Pau, J. Poolman, M. Bonten</i>	
00642	11:12	<b>Avian influenza A (H5N1) clade 2.3.4.4b haemagglutinin–Matrix-M nanoparticle vaccine (H5-MNP) induces neutralising responses and protection against H5N1 challenge in mice</b> <i>C. Bennett*</i> (Gaithersburg, United States), <i>R. Draghia Akli, J.F. Trost, B. Zhou, K. Pyles, T.L. Darling, A.C.M. Boon, G.E. Smith</i>	
00643	11:24	<b>Final results from a phase IIb randomised controlled trial assessing the efficacy and impact of full- and fractional-dose regimens of the RTS,S/AS01E malaria vaccine in Ashanti Region, Ghana and Siaya County, Kenya, September 2019 - November 2024</b> <i>D. Otieno*</i> (Kisumu, Kenya), <i>K. Sam</i>	
00644	11:36	<b>High-dose vs standard-dose influenza vaccine effectiveness according to frailty risk: a prespecified analysis of the DANFLU-2 trial</b> <i>C. Espersen*</i> (Hellerup, Denmark), <i>N.D. Johansen, D. Modin, K.H. Janstrup, M.M. Loliacono, R.C. Harris, Y. Huang, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovski, L.W. Davodian, M. Dons, L.S. Duus, F.H. Fussing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, G. Gavazzi, T. Biering-Sørensen</i>	
00645	11:48	<b>Effectiveness of PCV10 and PCV13 against invasive pneumococcal disease in Vietnamese children: a multi-centre matched case–control study</b> <i>C. Truong*</i> (Ho Chi Minh, Vietnam), <i>T. Nguyen, N. Speybroeck</i>	
SY124	11:00 – 12:00	1-hour Symposium	Hall A2-2
<b>Innovations in the management of tuberculosis and non-tuberculous mycobacteria</b>			
<i>Chairs</i> <i>Catherine Ong (Singapore, Singapore)</i> <i>Onya Opota (Lausanne, Switzerland)</i>			
S0323	11:00	<b>New diagnostics for mycobacterial infection</b> <i>Daniela Maria Cirillo (Milan, Italy)</i>	
S0324	11:30	<b>Applying pharmacokinetics for the optimisation of mycobacterial treatments</b> <i>Elin Svensson (Uppsala, Sweden)</i>	
Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)			
SY125	11:00 – 12:00	1-hour Symposium	Hall A3-1
<b>Surgical site infections after solid organ transplantation: an underestimated driver of transplant outcome</b>			
<i>Chairs</i> <i>Wanessa Clemente (Belo Horizonte, Brazil)</i> <i>Elda Righi (London, United Kingdom)</i>			
S0325	11:00	<b>SSIs after visceral transplantation</b> <i>Nicolas Mueller (Zurich, Switzerland)</i>	
S0326	11:30	<b>SSIs after thoracic transplantation</b> <i>Manuela Carugati (Durham, United States)</i>	

SY123	11:00 – 12:00	1-hour Symposium	Hall ICM 5
<b>Going super small: nano-technology in infectious diseases</b>			
<i>Chairs</i> <i>Elisa Borghi (Milan, Italy)</i> <i>Gregor Fuhrmann (Erlangen, Germany)</i>			
S0321	11:00	<b>Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery</b> <i>Eleanor Stride (Oxford, United Kingdom)</i>	
S0322	11:30	<b>Nanotechnologies for precision immunotherapy and infection treatment</b> <i>Willem Mulder (Eindhoven, The Netherlands)</i>	
EF092	11:00 – 12:00	ePoster Flash Session	Arena 2
<b>Antimicrobial stewardship in low resource countries: challenges and solutions</b>			
<i>Chair</i> <i>Igizeneza Acsa (Kigali, Rwanda)</i>			
E0646	11:00	<b>Antimicrobial prescribing in five primary healthcare centres in northern Syria: a global PPS based period prevalence survey</b> <i>F. Abdo*</i> (Amman, Jordan), <i>K. Parikh, Z. Ejielat, A. Boven, A. Versporten, I. Pauwels, E. Vlieghe, A. Luczynska, R. Esguerra, C. Roman</i>	
E0647	11:06	<b>Observed vs expected antibiotic use in MSF-supported primary outpatient MSF settings in North-West Syria</b> <i>C. Naim*</i> (Beirut, Lebanon), <i>A. Comelli, A. Farra, K. Moussally, P. Garcia-Vello, M. Khalife, C. Arias Vicente, A. Almohamad, Z. Ejielat, A. Wetti, B. Alonso, A. Ali, C. Roman, M. Yaacoub, M. Gazal</i>	
E0648	11:12	<b>A practical observational tool to measure antimicrobial stewardship and infection prevention behaviours in a low-resource hospital setting</b> <i>C. Bonaconsa*</i> (Cape Town, South Africa), <i>T. Makamu, A. Kona, M. Samkele, E. Charani</i>	
E0649	11:18	<b>Assessing implementation fidelity of Malawi's antimicrobial resistance policy: key findings from a cross-sectional qualitative study on policy practice and perceived impact</b> <i>A. Lubanga*</i> (Lilongwe, Malawi), <i>K. Kunmin, T. Daniel, Z. Peter, N. Thomas</i>	
E0650	11:24	<b>Tailoring empirical antibiotics to local resistance in severely malnourished hospitalised children in Niger: secondary analysis of a prospective cohort</b> <i>C. Langendorf*</i> (Paris, France), <i>B. Mollo, A. Delafon-Pariset, N. Peiffer-Smadja, R. Kanapathipillai, C.T. Andersen, S. Garba, N. Sayinzonga-Makombe, E.I. Tassiou, R. Daré, S. Isanaka, C. Amaris Hobson, M. Thy, C. Jimenez</i>	
E0651	11:30	<b>Factors influencing antibiotic use in patients without bacterial infections during the COVID-19 pandemic in a tertiary care centre in a low-middle-income country</b> <i>N. Nasir*</i> (Karachi, Pakistan), <i>W. Fazal, Z. Nasim, N.S. Khan</i>	
E0652	11:36	<b>Antimicrobial and corticosteroid prescribing for adults with suspected CNS infection in Botswana and Zimbabwe</b> <i>C. Coughlan*</i> (London, United Kingdom), <i>T. Mwarumba, R. Suresh, K. Ngoni, G. Manenji, R. Doyle, K. Boyd, C. Northcott, J. Penney, M. Kinsella, I. Mechie, S. Ensor, C. Williams, K. Lechiile, K. Siamisang, L. Owen, E. Gwakuba, T. Milton, T. Machiya, H.E. Barton, P. Ponatshego, K. Seatla, G. Boitshupo, I. Rulaganyang, L. Gwaunza, K. Kranzer, D. Grint, M.W. Tenforde, D.M. Goldfarb, M. Mokomane, M. Mine, G. Ngwende, C. Ndhlovu, J.N. Jarvis, J. Milburn</i>	
E0653	11:42	<b>Hospital pharmacists in antimicrobial stewardship in Latin America: roles and challenges</b> <i>E. Zavaleta*</i> (San Jose, Costa Rica), <i>J.P. Diaz, R. Mosmann, P. Lichtenberger, R. Quiros</i>	
E0654	11:48	<b>Effects of participatory learning and action with primary care doctors on antibiotic prescribing for acute respiratory infections in Vietnam: a pilot cluster randomised study</b> <i>M.D. Vu*</i> (Hanoi, Vietnam), <i>N.Y. Nguyen, N.T.H. Nguyen, P.B. Bui, V.T. Khuong, H.T.T. Duong, L.V. Le, G. Coact Investigators, H.R. Van Doorn, N.T.T. Do, S. Nagraj</i>	

EF093	11:00 – 12:00	Arena 3
	ePoster Flash Session	
	<b>AMR</b>	
<b>MDR pathogens around the globe: mechanisms, risk, and treatment optimisation</b>		
Chair	<i>Merica Carev (Split, Croatia)</i>	
E0655	11:00	
	<b>Clinical outcomes and risk factors for mortality in serious infections due to carbapenem-resistant <i>Acinetobacter baumannii</i> in Asia</b> <i>Y. Chang*</i> (Kaohsiung City, Taiwan), <i>A. Manesh, L. Mezzadri, X. Hao, Y. Ding, C. Yang, C. Yiyang, S. Kitsaran, H.H. Chua, B. Sotharith, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S.F. Mahmood, A.D. Roman, L. Thwaites, K.A. Nguyen, V.T. Phan, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O.R. Khalid, G.M.S. Mamun, G.S. Rajahram, H. Guterres, N.H. Huynh, V.G. Tran, N.T. Pham, A. Karkey, S. Gunasekara, R.L. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, L. Priya, Y. Doi, H. Hitoshi, B. Baljin, R. Asli, U. Gurjav, L. Ling, A. Dhungana, L.Y. Hsu, Y. Mo, D.L. Paterson</i>	
E0656	11:06	
	<b>Activity of cefiderocol against <i>Stenotrophomonas maltophilia</i> clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014 – 2019) and SENTRY (2020 – 2024)</b> <i>Y. Yamano*</i> (Osaka, Japan), <i>C. Longshaw, S.T. Nguen, J.M. Maher, R.E. Mendes, M. Hackel, H. Yamashiro, B.L.M. De Jonge</i>	
E0657	11:12	
	<b>Emergence and characterisation of multi-carbapenemase-producing <i>Klebsiella pneumoniae</i> in Italy: genomic features and <i>in vitro</i> therapeutic options</b> <i>A. Cornacchia*</i> (Teramo, Italy), <i>S. Comini, F. Pomilio, C. Costa, M. Boattini, G. Bianco</i>	
E0658	11:18	
	<b>Epidemiology of penicillin-binding protein 3 variants in carbapenem-resistant <i>Escherichia coli</i> isolates from France</b> <i>J. Mehidi*</i> (Le Kremlin-Bicêtre, France), <i>A. Birer, A. Jacquemin, A.B. Jousset, P. Glaser, R.A. Bonnin, L. Dortet, S. Oueslati, T. Naas</i>	
E0659	11:24	
	<b>Integrating the ECRAID Emerging Resistance Index (ERI) into antibiotic policy for new antibiotics targeting multidrug-resistant Gram-negative bacteria: a proof-of-concept analysis</b> <i>M.D. Pezzani*</i> (Verona, Italy), <i>J. Garlasco, D. Ortiz, K. Odoj, F. Arieti, A. Savoldi, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Prestler, G. Kahlmeter, E. Tacconelli</i>	
E0660	11:30	
	<b>Tracking <i>Clostridioides difficile</i> in Ireland: genomic landscape and antimicrobial resistance profiles of clinical isolates, 2022–present</b> <i>D. Espadinha*</i> (Dublin, Ireland), <i>N. O' Mara, A. Carroll, T.K. Teoh</i>	
E0661	11:36	
	<b>Profiling of dalbavancin resistance in clinical MRSA through a nationwide genomic survey in China: insights into resistance mechanisms</b> <i>Y. Hong*</i> (Hangzhou, China), <i>Y. Chen</i>	
E0662	11:42	
	<b>Molecular epidemiology and antimicrobial resistance of <i>Mycoplasma genitalium</i> in Tokyo, 2023–2025</b> <i>R. Omachi*</i> (Saitama, Japan), <i>K. Imai, T. Maeda, A. Sato, M. Tanaka, N. Mori</i>	
E0663	11:48	
	<b>Molecular antimicrobial resistance gene profiles in community-acquired, healthcare-associated, and hospital-onset <i>E. coli</i> and <i>K. pneumoniae</i> bacteraemia</b> <i>G. Korürek*</i> (Istanbul, Türkiye), <i>H. Tutan, U. Özgür, D.Y. Sevgi, B. Bayraktar</i>	
KN122	11:00 – 12:00	Hall ICM 14
	Keynote lecture	
	<b>PHEI</b> <b>TRN</b>	
<b>On virus origin, evolution, and the next pandemic threat</b>		
Chairs	<i>Giulia De Angelis (Rome, Italy)</i> <i>Jacob Moran-Gilad (Beer Sheva, Israel)</i>	
K0320	11:00	<i>Edward Holmes (Sydney, Australia)</i>

ME127	11:00 – 12:00	Hall B0-1
	Meet-the-Expert	
	<b>DX</b> <b>TRN</b>	

## Microbiome-based diagnostic tools, are we ready for prime-time?

M0329	11:00	<i>Debby Bogaert (Edinburgh, United Kingdom)</i>
M0330	11:12	<i>Gianluca Ianaro (Rome, Italy)</i>

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

ME128	11:00 – 12:00	Hall B0-2
	Meet-the-Expert	
	<b>CLN</b> <b>DX</b>	

**The returned traveler with eosinophilia: clinical, diagnostic and therapeutic approaches**

M0331	11:00	<i>Martin Montes (Lima, Peru)</i>
M0332	11:12	<i>Diana Ayoola Mabayoje (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

ME126	11:00 – 12:00	Hall ICM 1
	Meet-the-Expert	
	<b>AMR</b> <b>DX</b>	

**Applications of machine learning for predicting virulence and resistance by MALDI-TOF MS: opportunities and challenges**

M0327	11:00	<i>Adrian Egli (Zurich, Switzerland)</i>
M0328	11:12	<i>Jaroslav Hrabak (Plzen, Czechia)</i>

FO129	11:00 – 12:00	Arena 1
	Open Forum	
	<b>PRO</b>	

**Panic vs calm: the pivotal roles of trainees in infectious disease responses**

Chair *Casandra Bulescu (Bucharest, Romania)*

F0333	11:00	<b>Being in the frontline: shaping public messaging during outbreaks</b> <i>Ferenc Balázs Farkas (Budapest, Hungary)</i>
F0334	11:10	<b>From crisis to resilience: the role of early career researchers in outbreak response</b> <i>Jules Villa (Paris, France)</i>

F0335	11:20	<b>COVID-19 pandemic memories: what can we learn for future crises?</b> <i>Aleksandra Barac (Belgrade, Serbia)</i>
-------	-------	--

Co-organised with: ESCMID Emerging Infections Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

PM002	11:00 – 12:00	Hall A2-1
	Pipeline Symposium	
	<b>AMR</b> <b>PHEI</b>	

**Accelerating access: rethinking HTA to unlock AMR solutions**

Chairs *Maarten Postma (Groningen, The Netherlands)*  
*Charlotte Vernhes (Brussels, Belgium)*

D0005	11:00	<b>Data: what's available today and where are the key gaps?</b> <i>Marlieke De Kraker (Geneva, Switzerland)</i>
D0006	11:15	<b>Full economic value of AMR solutions in HTA</b> <i>Michele Cecchini (Paris, France)</i>
D0007	11:30	<b>EU HTA regulation and AMR solutions: lessons from vaccines</b> <i>Eliana Biundo (Wavre, Belgium)</i>

OS096	13:30 – 14:30	Hall A2-2
	1-hour Case Session	
	<b>CLN</b> <b>DX</b> <b>PHEI</b>	

**Protozoa and microsporidia: rare and emerging**

Chairs *Aleksandra Barac (Belgrade, Serbia)*  
*Emmanuel Bottieau (Antwerp, Belgium)*

O0664	13:30	<b>A <i>Plasmodium vivax</i> case identified only by use of</b>
-------	-------	---

		<b>next-generation sequencing</b> <i>C.R. Stensvold*</i> (Copenhagen S, Denmark), <i>H.V. Nielsen, J.K. White, J. Szeps, K. Wyss, S. Botero-Kleiven</i>
00665	13:41	<b>Leishmania (Mundinia) procaviensis as an emerging pathogen: first confirmed human infection identified by target-gene sequencing</b> <i>A. Andrianaki*</i> (Zurich, Switzerland), <i>D. Weller, F. Grimm, M. Concu, B. Nickel, A. Neumayr, M.B. Kälin</i>
00666	13:52	<b>Disseminated <i>Toxoplasma gondii</i> infection with haemophagocytic lymphohistiocytosis</b> <i>D. Walzer*</i> (Freiburg, Germany), <i>C. Kaech, S. Rieg</i>
00667	14:03	<b>Insights from a fatal case of disseminated albendazole refractory <i>Annacallia algerae</i> myositis</b> <i>T. Fernando*</i> (St Leonards, Australia), <i>S. McGinn, S. Ahmer, H.C. Soh, L. Tan, G. Kotsiou</i>
00668	14:14	<b>Non-resolving cerebral toxoplasmosis in an immunodeficient patient</b> <i>J. Olchowski*</i> (Haifa, Israel), <i>M. Paul</i>

OS094	13:30 – 14:30	Hall ICM 13a
	1-hour Case Session	

### Challenging and complicated viral infections

<i>Chairs</i>	<i>Niessen Annabel (Utrecht, The Netherlands)</i> <i>Alexandra Mailles (Saint-Maurice, France)</i>
---------------	---

00669	13:30	<b>Chronic herpes simplex virus type 2 necrotising granulomatous pachymeningitis after glofitamab: an unusual CNS infection in an immunocompromised patient</b> <i>N. Jain*</i> (Auckland, New Zealand), <i>B.S. Chen, L. Berkahn, M. Strauss, R. Lane</i>
00670	13:41	<b>First documented case of a fatal autochthonous Usutu virus infection in an immunocompromised patient in Hungary</b> <i>B. Szabo*</i> (Budapest, Hungary), <i>B.G. Szabó, A. Nagy, O. Nagy, A. Koroknai, N. Csonka, D. Korózs, K. Jeszenszky, A. Hardi, N. Deézi-Magyar, J. Sztikler, Z. Bódi, D. Cadar, G.E. Tóth, L. Veres, E. Barcsay, M. Takács, J. Sinkó</i>
00671	13:52	<b>But its got to be PML, right? chronic myeloencephalitis 14 year after heart transplant</b> <i>L. Lippert*</i> (Berlin, Germany), <i>S. Albus, D. Grund, M. Witzenrath, L. Sander</i>
00672	14:03	<b>Long-term survivor of BoDV-1 encephalitis: complex immunotherapy, neuroimaging signatures and late viral reactivation: a case report</b> <i>I. Masouris*</i> (Munich, Germany), <i>I. Wilkens, D. Grabova, F. Schöberl, M. Chen, H. Klauß, L. Keidel, D. Hauptstein, C. Eckert, V. Ruf, M. Schmutzer-Sondergeld, M. Brendel, R. Forbrig, G. Höglinger, A. Straube, F. Sörgel, M. Bauswein, D. Tappe</i>
00673	14:14	<b>Changing landscape of paediatric influenza-associated neurological complications: a single-centre case series from northern Italy (2024-2025)</b> <i>L. Franzetti*</i> (Milan, Italy), <i>C. Porro, S.M. Bova, C. Giovannini, A. Gadda, A. Rizzo, A. Lombardi, F. Salari, G. Zuccotti, E. Fusco, L. Folgiori</i>

OS095	13:30 – 14:30	Hall ICM 13b
	1-hour Oral Session	

### Precision pedagogy: AI-driven and data-driven education

<i>Chairs</i>	<i>Sarah Delliere (Paris, France)</i> <i>Mary Horgan (Dublin, Ireland)</i>
---------------	---

00674	13:30	<b>Large Language Model-assisted OSCE stations in infectious diseases: faster, high-quality, and well-received by faculty</b> <i>S. Villard*</i> (Paris, France), <i>C.A. Hobson, Y. Guedj, L. Khider, A. Mageau, J. Mesnier, M. Sanchez, S. Voicu, S. Peiffer-Smadja, N. Burnichon, A. Faye, T. Mirault, Y. Nguyen, B. Oules, A. Pellat, D. Bouzid, M. Thy, N. Peiffer-Smadja</i>
00675	13:42	<b>Intelligent multi-agent systems for antimicrobial stewardship training: a new paradigm in medical education</b> <i>Y. Chen*</i> (Hangzhou, China), <i>L. Sun, X. Du, F. Chiu, Y. Yu</i>
00676	13:54	<b>Large-scale artificial intelligence or medical residency: who achieves greater concordance with ID specialists in antibiogram-guided antibiotic selection?</b> <i>M. Lanna*</i> (São Paulo, Brazil), <i>N. Adiwardana, V. Marchetti, J. Verissimo</i>
00677	14:06	<b>InfectoCast: a digital ecosystem for infectious diseases education and science communication in Brazil</b> <i>K. Faico-Filho*</i> (São Paulo, Brazil), <i>W. Dunke, J. Prats, J. Pinheiro,</i>

00678	14:18	<b>List of Recommended Names (LoRN) for bacteria of medical importance</b> <i>E. Moore*</i> (Gothenburg, Sweden), <i>H. Christensen, V. Fingerle, M. Göker, M. Kostovski, G. Margos, A. Oren, S. Patrick, U. Reischl, J. Vazquez-Boland</i>
-------	-------	---

SY132	13:30 – 14:30	Hall A3-2
	1-hour Symposium	

### Innovative methodologies for advancing PK/PD studies

<i>Chairs</i>	<i>Birgit Koch (Rotterdam, The Netherlands)</i> <i>Sebastian Wicha (Hamburg, Germany)</i>
---------------	--

S0316	13:30	<b>Development and application of organs on chip to study infectious diseases</b> <i>Girija Goyal (Boston, United States)</i>
-------	-------	---

S0317	14:00	<b>Multi-omics approaches to personalise and improve antibiotic efficacy</b> <i>Gauri Rao (Rancho Palos Verdes, United States)</i>
-------	-------	--

SY130	13:30 – 14:30	Hall BO-1
	1-hour Symposium	

### Special issues of IFI in paediatrics

<i>Chairs</i>	<i>Andreas H. Groll (Münster, Germany)</i> <i>Aspasia Katragkou (Morristown, United States)</i>
---------------	--

S0312	13:30	<b>Antifungal prophylaxis in neonates in the era of increased resistance to fluconazole</b> <i>Paolo Manzoni (Turin, Italy)</i>
-------	-------	---

S0313	14:00	<b>Implementation of guidelines in different settings: challenges and solutions</b> <i>Laura Ferreras-Antolin (London, United Kingdom)</i>
-------	-------	--

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), German-Speaking Mycological Society, Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG)

SY131	13:30 – 14:30	Hall BO-2
	1-hour Symposium	

### Top papers in infections in immunosuppressed patients

<i>Chairs</i>	<i>Carlota Gudiol (Barcelona, Spain)</i> <i>Stefan Schwartz (Berlin, Germany)</i>
---------------	--

S0314	13:30	<b>Infections in immunocompromised patients: what you need to know</b> <i>Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)</i>
-------	-------	--

S0315	14:00	<b>Shifting evidence in transplant infectious diseases: key studies that change practice</b> <i>Oriol Manuel (Lausanne, Switzerland)</i>
-------	-------	--

LB007	13:30 – 15:30	Hall ICM 1
	2-hour Oral Session	

### The trial run

<i>Chairs</i>	<i>Angela Huttner (Geneva, Switzerland)</i> <i>David L. Paterson (Singapore, Singapore)</i> <i>Steven Tong (Melbourne, Australia)</i>
---------------	---

L0036	13:30	<b>PipEracillin Tazobactam vs mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacterales (PeterPen)</b> <i>M. Paul*</i> (Haifa, Israel), <i>Y. Dishon, D. Yahav, T.C. Lee, L. Leibovici, M. Kristen, K. Afra, C. Condin, T. Bai, J. Strahilevitz, V. Daïtch, R. Ben-Ami, M. Chowers, L. Neshier, M. Hershman, A. Carignan, P. Daley, P. Leighanne, J. Eastmond, T. Finn</i>
-------	-------	---

L0037	13:50	<b>Ertapenem vs meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: an ASTARTE post hoc analysis</b> <i>J. Rodríguez-Baño*</i> (Seville, Spain), <i>F. Cogliati Dezza, L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo</i>
-------	-------	---

		<i>Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J.M. Bravo-Ferrer, Z.R. Palacios-Baena, M.Á. López Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampín García, S. López Cardenas, M.C. Gómez Sánchez, I. Pérez Camacho, S.M. Martín Ramos, E. León Jiménez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M. Siller Ruiz, F. Arnaiz De Las Revillas Almajano, L. Gisbert Pérez, J. Goikoetxea Agirre, Á. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero-Sánchez, S. De La Villa, J.R. Yuste Ara, M.Á. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J.A. Fernández, A.M. Barrios Blandino, H.H. Vilchez-Rueda, R. Álvarez-Marín, A. Romero Palacios, E. García Vázquez, E. Nuño Álvarez, C. Rosso-Fernández, B. Gutiérrez-Gutiérrez, Á. Pascual, L. López-Cerero</i>
L0038	14:10	<b>A decade after the MERINO trial: refusing to grow up?</b> <i>David L. Paterson (Singapore, Singapore)</i>
L0039	14:20	<b>When the fairy dust settles: critical appraisal of presented trials</b> <i>Angela Huttner (Geneva, Switzerland)</i>
L0040	14:30	<b>Tick tock, AMR clock: how should I treat my next ESBL bacteraemia patient?</b> <i>Steven Tong (Melbourne, Australia)</i>

EF097	13:30 - 14:30	Arena 1
		ePoster Flash Session

**Fosfomycin for difficult-to-treat resistant pathogens: is it really a useful weapon?**

*Chair Andre Kalil (Omaha, United States)*

E0679	13:30	<b>Can the fosfomycin MIC value be used in the evaluation of response to treatment of carbapenemase-producing Enterobacterales infections with fosfomycin-containing regimens?</b> <i>M. Törüyenler Coskunpinar* (Ankara, Türkiye), D. Ocal, G. Cinar, L.E. Dogangul Doygun, Z. Tekbas</i>
-------	-------	--

E0680	13:36	<b>Effectiveness of antibiotic regimens for the treatment of bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i>: a national, multi-centre study</b> <i>F. Serapide* (Catanzaro, Italy), A. Russo, S.P. Gulli, A. Vena, L. Spadafora, M. Bernardi, S. Corcione, G. Ceccarelli, F. Alessandri, C.M. Mastroianni, A. Oliva, E. Venanzi-Rullo, G. Caviglia, A. Cortegiani, M.C. Ippolito, G. Nunnari, F. Di Gennaro, A. Saracino, A. Marino, B. Cacopardo, G. Tiseo, M. Falcone, V. Galfo, C. Iaria, G. Pipitone, A. Cascio, S. Carbonara, L. Montemurro, F.S. Serino, N. Boffa, M. Libanore, F.G. De Rosa, A. Mattei, A. Calabresi, M. Tumbarello, L. Fontanelli Sulekova, C. Pallotto, P. Brugnaro, R. Mascianà, B. Tiri, N. Coppola, G. Calabria, A. Bandera, A. Lombardi, P. Vassalini, N. Carannante, V. Scaglione, M. Meschiarì, O. Simonetti, A. Mularoni, F. Bar, C. Mussini, M. Bassetti, G. Biondi-Zoccai</i>
-------	-------	---

E0681	13:42	<b>Evaluation of fosfomycin including regimens in culture-confirmed carbapenem-resistant Gram-negative pneumonia: analysis of 53 cases</b> <i>M.B. Özkara* (Izmir, Türkiye), D. Kaya, M. Mert Vahabi, D. Akyol Seyhan, O. Acet, A. Kaya, A.M. Parmaksızoğlu Aydın, M. Ceylan, F.B. Arkan, S. İstek, D. Yaman, B. Süllü, D. Verendağ, H.A. Erdem, H. Sipahi, T. Yamazhan, B. Arda, Ş. Aydemir, O.R. Sipahi</i>
-------	-------	---

E0682	13:48	<b>How and why clinicians use intravenous (IV) fosfomycin in Canada: results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) registry</b> <i>G. Zhanel* (Winnipeg, Canada), M. Baxter, M. Wong, Y. Mirzanejad, A. Lee, R. Dhami, J. Kosar, D. Werry, N. Irfan, J.F. Tessier, G. Girouard, C. Tascini, T. Von Den Baumen, M. Savoie, A. Serebryanskyy, J. Chan, M. Kucey, A. Walkty, J. Karlowisky</i>
-------	-------	---

E0683	13:54	<b>Fosfomycin resistance in Enterobacterales: a comprehensive national surveillance in the Czech Republic</b> <i>K. Chudejova* (Plzen, Czechia), V. Mattioni Marchetti, S. Kanova, V. Zaccaria, I. Bitar, J. Hrabak</i>
-------	-------	---

E0684	14:00	<b>Synergistic activity of fosfomycin and temocillin against GES carbapenemase-producing <i>Enterobacteriaceae</i></b> <i>J.L. Rodríguez Ochoa* (Santander, Spain), N. Fraile-Valcárcel, S. García-García, M. Siller-Ruiz, D. Pablo-Marcos, S. García-</i>
-------	-------	--

E0685	14:06	<b>Evolution of the <i>in vitro</i> activity of fosfomycin against carbapenemase-producing microorganisms in Colombia</b> <i>G.A. Muñeton Lopez* (Bogota, Colombia), M.F. Rueda, N.C. Mendoza, J.C. Torres, D. Celis-Giraldo, H. Vergara</i>
E0686	14:12	<b>Discovery and characterisation of gfa, a novel fosfomycin resistance gene family already spread in environmental and clinical bacteria</b> <i>N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, A. Prieto, A. Carvalho, E. Vergara, J.A. Escudro</i>
E0687	14:18	<b>In vitro activity of fosfomycin against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i> isolated from urine specimens in Canada: CANWARD surveillance study 2007–2022</b> <i>J. Karlowisky* (Winnipeg, Canada), G. Zhanel, H. Adam, M. Baxter, A. Walkty, P. Lagacé-Wiens</i>

EF098	13:30 - 14:30	Arena 2
-------	---------------	---------

ePoster Flash Session

**First, do no harm: allergy, kidney safety and length of stay in antimicrobial stewardship**

*Chair Pilar Retamar Gentil (Seville, Spain)*

E0688	13:30	<b>ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy</b> <i>O. Joean* (Jena, Germany), K. Sermet, L. Ashkenazi-Hoffnung, Y. Cakir Kiyamaz, K. Blumenthal, C.M. Bonazzetti, A.M. Chiriac, S. Gomez-Zorrilla, E. Karakike, E. Khatamzas, N. Powell, J.A. Trubiano, R. Wijnakker, J. Sandoe, B. Nagavci, M.G.J. De Boer</i>
-------	-------	---

E0689	13:36	<b>Direct penicillin allergy de-labelling at a pre-anaesthesia consultation: picking the low-hanging fruit?</b> <i>S. Deryckere* (Ghent, Belgium), P. De Nocker, H. Lapeere, L. De Baerdemaeker, D. Huis In 't Veld</i>
-------	-------	---

E0690	13:42	<b>Implementation of a penicillin allergy delabelling service in a UK centre: measuring indicators of success</b> <i>B. Morris* (Cambridge, United Kingdom), U. Ahmed, R. Santos, C. Aherne, I. Lowings, X.Y. Thum, S. Nasser, P. Gurugama, T. Gouliouris</i>
-------	-------	---

E0691	13:48	<b>Penicillin allergy de-labelling by non-specialists in NHS acute care: A UK-wide survey and review of current practice by the PADL-UK survey A.</b> <i>Blanshard* (Manchester, United Kingdom), H. Lewis, N. Fleming, P. Howard, T. Locke, R. Payne</i>
-------	-------	---

E0692	13:54	<b>Patients' experiences of penicillin allergy evaluation and delabelling process in primary care</b> <i>T. Langeveld* (Bilthoven, The Netherlands), T. Schoffelen, A. Timen, M. Hulscher, N. Milevska-Kostova</i>
-------	-------	--

E0693	14:00	<b>Can vancomycin therapeutic drug monitoring detect acute kidney injury before serum creatinine?</b> <i>M. Scheetz* (Downers Grove, United States), S. Leech, A. Sathyanarayanan, S. Roy, P. Sabourenkov</i>
-------	-------	---

E0694	14:06	<b>Vancomycin-induced kidney injury in adult oncology: adjudicated incidence and a pragmatic dosing framework derived from AUC-guided care</b> <i>J.P. Telles* (São Paulo, Brazil), D. Coelho Jr, K. Migotto, D. Feriani Da Silva, R. Reghini, G.T. Daiane, F. Lima De Oliveira, P. Caruso, I. França E Silva</i>
-------	-------	---

E0695	14:12	<b>Development and validation of a prediction model for acute kidney injury risk in patients receiving concomitant vancomycin and piperacillin/tazobactam</b> <i>D. Chen* (Macau Sar, Macao), H. Zhang, X. Luo, M. Yu, J. Kan, A. Zhao, W. Ge</i>
-------	-------	---

E0696	14:18	<b>Saving beds and budgets: real-world efficacy, safety, and pharmacoeconomics of long-acting lipoglycopeptides in a day hospital setting</b> <i>A. Marino* (Catania, Italy), E. Venanzi Rullo, G. Pipitone, A. Albanese, A. Franzò, A. De Vito, N. Geremia, C. Iaria, G. Madeddu, B. Cacopardo, G. Nunnari</i>
-------	-------	---

EF099	13:30 - 14:30	Arena 3
-------	---------------	---------

ePoster Flash Session

**Ask AI how to manage antibiotics!**

*Chair Carolina Garcia Vidal (Barcelona, Spain)*

E0697	13:30	<b>Evaluating a machine learning-based decision</b>
-------	-------	---

support tool for early antibiotic discontinuation in Lower Respiratory Tract Infections (LRTI): a randomised controlled trial *S. Tang\** (Singapore, Singapore), *D. Yii, R. Lim, M.P. Chlebicki, J. Chung, A. Kwa*

(Göteborg, Sweden)

E0698	13:36	<b>Cost-effectiveness of a machine learning (ML) approach for reducing unnecessary antibiotic use in patients with suspected lower respiratory tract infections (LRTI): an economic analysis of a randomised clinical trial</b> <i>Y. Cai*</i> (Singapore, Singapore), <i>N. Nazeha, S. Tang, D. Yii, A.L. Kwa, N. Graves</i>
E0699	13:42	<b>Who's the smartest in the room? benchmarking large language models for antimicrobial stewardship support</b> <i>G. Pellejero*</i> (Zaragoza, Spain), <i>A. Abejz-Arrizabalaga, J. Schouten, T. Schoffelen, E. Morte-Romea, E. Ruizendaal, J. Origüen, M.T. Pérez-Rodríguez, P. Retamar-Gentil, N. Sisamón-Dolader, B. Franco-García, R. Del Hoyo, S. Letona-Giménez, J.R. Paño-Pardo</i>
E0700	13:48	<b>An antibiotic chatbot for providing guideline-based antimicrobial advice</b> <i>D. Eyre*</i> (Oxford, United Kingdom), <i>R. Corrigan, L. Hookham, S. Lumley, D. Clarke, K. Jeffery, L. Dunsmure, N. Jones</i>
E0701	13:54	<b>Antimicrobial stewardship programme: a data-driven approach to continuously optimised, locally adapted empirical antibiotic guidelines</b> <i>M. Raad*</i> (Sarrebouurg, France), <i>T. Yokoyama, S. Boujaafar, F. Mutisya, C. De Turckheim, P. Berger, L. Vezard, M. Valette, C. Moore</i>
E0702	14:00	<b>Investigating UK online antibiotic provision: a covert simulated patient ethnographic study</b> <i>S. Boyd*</i> (London, United Kingdom), <i>N. Zhu, R. Jain, A. Parmar, A. Matthews, A. Holmes, R. Ahmad</i>
E0703	14:06	<b>UK outpatient parenteral antimicrobial therapy (OPAT/COPAT) point prevalence dashboard</b> <i>S. Khan*</i> (London, United Kingdom), <i>J. Grayson, M. Gilchrist, A. Seaton</i>
E0704	14:12	<b>Performance of a clinical decision support tool on targeted antibiotic treatment in the emergency department: a retrospective study</b> <i>S. Nørgaard Sogaard*</i> (Aabenraa, Denmark), <i>S.N. Sogaard, L. Ward, M.L. Mogensen, C.B. Mogensen, M.B. Cartuliales, H. Skjøt-Arkl</i>
E0705	14:18	<b>Bayesian neural network (BNN) with uncertainty-thresholding for personalised empirical antibiotic guidance, compared to clinician prescribing</b> <i>A. Luk*</i> (Oxford, United Kingdom), <i>K. Yuan, J. Wei, S.A. Walker, D. Eyre</i>

JS003	13:30 - 14:30	Hall A3-1
	Journal Session	

GLN

**Late-breaking research from The Lancet: new interventions for more established pathogens**

<i>Chairs</i>		<i>Syeda Saleha Hassan</i> (London, United Kingdom) <i>Onisillos Sekkides</i> (London, United Kingdom)
J0011	13:30	<b>Clinical effectiveness and bacteriological eradication of three different short-course antibiotic regimens and single dose fosfomycin for uncomplicated lower urinary tract infections in adult women (SCOUT study): a pragmatic, multicentre, multi-arm, open-label, randomised clinical trial</b> <i>Carl Llor</i> (Barcelona, Spain)
J0012	13:42	<b>Maribavir for clinically significant cytomegalovirus infection in hematopoietic cell transplantation: a real-world retrospective international study of the Infectious Disease Working Party of EBMT</b> <i>Annalisa Paviglianiti</i> (Barcelona, Spain)
J0013	13:54	<b>Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an observational, cross-sectional analysis</b> <i>Rory De Vries</i> (Rotterdam, The Netherlands)
J0014	14:06	<b>Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blinded phase IV medical device trial</b> <i>Annelies Van Rie</i> (Wilrijk, Belgium)
J0015	14:18	<b>Adjunctive betamethasone treatment of hypoxemic adults hospitalised with mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial</b> <i>Karl Hagman</i>

ME133	13:30 - 14:30	Hall ICM 5
	Meet-the-Expert	

ANT TRN

**Membrane vesicles: pathogenic factor and emerging targets for antimicrobial therapies**

M0318	13:30	<i>Maria Kaparakis-Liaskos</i> (Melbourne, Australia)
M0319	13:42	<i>Gregor Fuhrmann</i> (Erlangen, Germany)

PM004	13:30 - 14:30	Hall A2-1
	Pipeline Symposium	

PRO PHEI

**Science under pressure: is it business as usual?**

<i>Chairs</i>	<i>Till T. Bachmann</i> (Edinburgh, United Kingdom) <i>Robert Leo Skov</i> (Copenhagen, Denmark)
---------------	---

D0010	13:30	<b>A funder's perspective</b> <i>Ghada Zoubiane</i> (London, United Kingdom)
D0011	14:00	<b>Industry perspective</b> <i>Marc Gitzinger</i> (Basel, Switzerland)

WT009	13:30 - 14:30	Poster area
	Poster Walkthrough	

AMR TRN

**Fundamental insights: a guided tour along the best-rated posters in fundamental microbiology and pathogenesis**

<i>Chair</i>	<i>Christian Stephan Lentz</i> (Tromsø, Norway)
--------------	---

R0082	<b>P3994 - Protective effects of Haemophilus influenzae on epithelial damage induced by Streptococcus pneumoniae</b> <i>Emi Tanaka</i> (Nagoya, Japan)
R0083	<b>P3961 - The biosurvival of Neisseria meningitidis in human saliva vs artificial saliva: nothing beats the real thing</b> <i>Mia Dierks-Treece</i> (Bristol, United Kingdom)
R0084	<b>P4007 - Adaptive evolution of carbapenem-resistant Klebsiella pneumoniae: altered virulence and extensive persistence in the GI tract</b> <i>Jing Wang</i> (Hong Kong, Hong Kong)
R0085	<b>P4134 - Immune correlates of protection in a first-in-human non-typhoidal Salmonella challenge study</b> <i>Anna Rydlova</i> (London, United Kingdom)
R0086	<b>P3991 - Effects of high-fat diet and ApoE gene deficiency on human Coronavirus infection in an ex vivo lung model</b> <i>Hsing-Yu Chen</i> (Taipei, Taiwan)
R0087	<b>P4042 - Synthetic wound fluid modulates antibiotic susceptibility and biofilm formation in wound pathogens</b> <i>Charlotte Morgan</i> (Swansea, United Kingdom)
R0090	<b>P4114 - Immunomodulators GM-CSF and plerixafor are advantageous in the treatment of Pseudomonas aeruginosa wound-derived sepsis in mice</b> <i>Lacie Werner</i> (Silver Spring, Maryland, United States)

WT010	13:30 - 14:30	Poster area
	Poster Walkthrough	

AMR TRN

**AMR in LMICs: from mechanisms to surveillance**

<i>Chair</i>	<i>Christina Obiero</i> (Kilifi, Kenya)
R0091	<b>P1631 - Diverse population of antimicrobial resistant plasmids carried by Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries</b> <i>Kirsty Sands</i> (Oxford, United Kingdom)
R0092	<b>P2004 - Comparison of mobile genetic elements found in carbapenemase-producing Enterobacterales isolated from conflict zone clinical samples</b> <i>Olena Moshynets</i> (Kyiv, Ukraine)
R0093	<b>P1441 - Building a national bacteriology and AMR surveillance network by leveraging the existing tuberculosis laboratory network in a resource limited</b>

setting: the Benin experience *Faridath Massou (Cotonou, Benin)*

R0094	P1357 - Pathogen distribution and antimicrobial resistance patterns in bloodstream infections across diverse healthcare settings: findings from the BALANCE study <i>Refath Farzana (Oxford, United Kingdom)</i>
R0095	P1944 - Molecular characteristics and antimicrobial resistance gene profiles of atypical and typical enteropathogenic <i>Escherichia coli</i> from clinical and environmental settings in South Africa <i>Veronica Ueckermann (Pretoria, South Africa)</i>
R0096	P1723 - Resistance plasmidome of neonatal sepsis pathogens in low- and middle-income countries <i>Ngoc Minh Nguyen (Antwerp, Belgium)</i>
R0097	P1965 - Carriage of antimicrobial resistant bacteria in filth flies collected from five hospital sites across Pakistan <i>Teresa Iannetelli (Oxford, United Kingdom)</i>
R0098	P1438 - Genomic characterisation of <i>Staphylococcus epidermidis</i> neonatal sepsis isolates across BARNARDS-II clinical sites in Pakistan and Nigeria <i>Jawaria Aziz (Cardiff, United Kingdom)</i>
R0099	P1261 - Changes in proportions of ESBL-producing <i>E. coli</i> by sequence type after return: a longitudinal follow-up <i>Arttu Nousiainen (Helsinki, Finland)</i>
R0100	P1404 - Prior antibiotic exposure as a hidden bias in neonatal AMR surveillance: evidence from a multicountry LMIC cohort <i>Kathryn Thomson (Oxford, United Kingdom)</i>

WT011 13:30 - 14:30 Poster area

Poster Walkthrough



Hospital transmission and emerging threats: *Candida auris*, environmental reservoirs, and genomic surveillance of antimicrobial resistance

Chair *Ermira Tartari (Msida, Malta)*

R0101	P3210 - Epidemiological trends in invasive <i>Candida</i> spp. infections before and after an extreme flooding event in Southern Brazil <i>Cezar Vinicius Würdig Riche (Porto Alegre, Brazil)</i>
R0102	P3305 - Characterisation of <i>Candida auris</i> ( <i>Candidozyma auris</i> ) from a worldwide surveillance program over 12 years <i>Marisa Winkler (North Liberty, United States)</i>
R0103	P3133 - A resistant invader in hospitals: national summary of <i>Candida auris</i> infections in Türkiye <i>Elif Ağüloğlu-Balı (Ankara, Türkiye)</i>
R0104	P1927 - Investigation of a rare human outbreak of mecC-MRSA in Belgium and its genomic links to animal-associated lineages <i>Nicolas Yin (Brussels, Belgium)</i>
R0105	P1987 - Distribution of antimicrobial resistance genes in hospital wastewater, WWTP effluent, and urban surface water in the northeastern part of the Netherlands <i>Carmen Stoffers (Groningen, The Netherlands)</i>
R0106	P2010 - Linking clinical and wastewater settings: a comparative genomic analysis of carbapenemase- and ESBL-producing Enterobacterales in Northern Spain <i>Mario Sergio Pino Hurtado (Logroño, Spain)</i>
R0107	P3158 - <i>Candidozyma auris</i> in the Netherlands: no evidence of nosocomial transmission supported by effective infection control policies <i>Chiara De Groot (Bilthoven, The Netherlands)</i>
R0108	P1268 - Effectiveness of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine <i>Jale Boral (Malmö, Sweden)</i>
R0109	P1199 - Comprehensive metagenomic surveillance uncovers last-resort antibiotic resistance genes in wastewater <i>Prerna Yadav (New Delhi, India)</i>
R0110	P2006 - Linking antimicrobial resistance between hospital and wastewater environments via plasmid systems <i>Meghana Srinivas (Maynooth, Ireland)</i>

WT012 13:30 - 14:30 Poster area

Poster Walkthrough



Novel insight into AMR epidemiology in One Health perspective

Chair *Helena Zemlickova (Prague, Czechia)*

R0111	P1714 - PlasmidNL: a web-based interface for tracking plasmid dissemination in the Netherlands <i>Gijs Teunis (Bilthoven, The Netherlands)</i>
R0112	P1975 - Stable plasmid populations in sewage spread antibiotic resistance <i>Alberto J. Martín-Rodríguez (Stockholm, Sweden)</i>
R0113	P2011 - Cross-domain plasmid mediated AMR transmission <i>Rebekka Koeck (Maastricht, The Netherlands)</i>
R0114	P2030 - Evolutionary dynamics and plasmid epidemiology of <i>Salmonella</i> infantis in Türkiye: focus on the pESI-like megaplasmid <i>Gultekin Unal (Ankara, Türkiye)</i>
R0115	P1511 - Predicting antimicrobial susceptibility after one hour of antibiotic exposure <i>Ben Nannings (Rotterdam, The Netherlands)</i>
R0116	P1573 - LC-MS reveals distinct degradation signatures for carbapenemases including $\beta$ -lactone formation by OXA-48-like enzymes <i>Veronika Pašková (Plzen, Czechia)</i>
R0117	P3255 - Molecular detection of <i>C. auris</i> : a comparative evaluation of commercial assays including a new selective <i>C. auris</i> broth for clinical laboratory use <i>Alexander Maximilian Aldejohann (Würzburg, Germany)</i>
R0118	P3308 - Activity of manogepix against <i>Candida auris</i>
R0119	P1559 - Towards a microfluidic PK/PD system for individualised phenotypic antimicrobial susceptibility testing <i>Jennifer Lawrence (London, United Kingdom)</i>
R0120	P2017 - Genomic wastewater surveillance program reveals emergence of cefiderocol-resistant Enterobacterales in South America <i>Johana Becerra (São Paulo, Brazil)</i>

OS103 14:45 - 15:45 Hall A2-2

1-hour Case Session



What did you get in the hospital?

Chairs *Christina König (Hamburg, Germany)*  
*Sara Tomczyk (Berlin, Germany)*

O0706	14:45	Hospital acquired tularemia: a case report of nosocomial transmission of <i>Francisella tularensis</i> O. Arce Garcia* (Pozuelo De Alarcon, Spain), M. Simon Sacristan, A. Collazos Blanco, M.F. Ramos Ferriol, M. Rozas Bellido, I. Darid Y Ceron, S. Sanchez Sanchez, G. Arán Toha, S. Medrano Pardo, M.T. Llorente Rodriguez, O. Arce, G. Ramirez Olivencia
O0707	14:56	<i>Gemella haemolysans</i> endocarditis in a southern Spain hospital P. Monroy* (Malaga, Spain), P. Monroy Moya, L. Balderas Fernández, L. Mora Navas, M.V. García López
O0708	15:07	Nosocomial myiasis: report of two cases and review of the literature D. Verendag* (Izmir, Türkiye), D. Verendağ, D. Kaya, H.A. Erdem, N. Bilgili Korkmaz, B. Arda, O.R. Sipahi
O0709	15:18	Difficult-to-treat Gram-positive health-care associated ventriculitis treated with combination antibiotic therapy including fosfomycin: a series of three cases A. Frattari* (Pescara, Italy), F. Spagnuolo, C. Di Iorio, E. Polilli, P. Fazi, G. Parruti
O0710	15:29	The unusual outbreak of sepsis in a cancer hospital caused by intrinsically contaminated heparin injection vials V. Bajpai Batra* (Varanasi, India), A. Kapoor

OS101 14:45 - 15:45 Hall BO-1

1-hour Case Session



Phage therapy for complex infections

Chairs *Zuzanna Drulis-Kawa (Wrocław, Poland)*  
*Spyros Pournaras (Athens, Greece)*

O0711	14:45	Personalised phage therapy for multidrug-resistant infections in thoracic organ transplant recipients C. Kuehn* (Hannover, Germany), E. Rubalskii, L. Sedlacek, S. Ruemke, N. Schwert, J. Gottlieb, A. Haverich, D. Schlüter, G. Hansen, A. Ruhparwar
-------	-------	---

00712	14:56	<b>Breaking the cycle of relapse: personalised phage therapy in MDR <i>Pseudomonas aeruginosa</i> LVAD infection</b> <i>S. Ferin*</i> (Udine, Italy), <i>S. Flammini</i> , <i>P. Della Siega</i> , <i>M. Merelli</i> , <i>D. Pecori</i> , <i>S. Giuliano</i> , <i>C. Tascini</i>
00713	15:07	<b>Novel antibiotic-phage therapy duo rapidly resolves XDR-AB pneumonia after liver transplant</b> <i>W. Wang*</i> (Xian, China)
00714	15:18	<b>Precision-matched bacteriophage therapy for prosthetic aortic graft infections: a single-centre observational case series</b> <i>E. Rubalskii*</i> (Hannover, Germany), <i>S. Ruemke</i> , <i>L. Sedlacek</i> , <i>A. Haverich</i> , <i>D. Schlüter</i> , <i>A. Ruhparwar</i> , <i>C. Kuehn</i>
00715	15:29	<b>Phage therapy for refractory, native joint <i>Staphylococcus aureus</i> arthritis with infected bone necrosis</b> <i>M. Dekel*</i> (Tel Aviv, Israel), <i>R. Nir Paz</i> , <i>R. Ben Ami</i> , <i>N. Bishouty</i> , <i>A. Khoury</i> , <i>N. Snir</i> , <i>T. Ben Tov</i>

OS104 14:45 - 15:45 Hall A3-1

1-hour Oral Session

AMR ANT CLN

**Emerging and repurposed therapeutic options in resistant Gram-negatives**

<i>Chairs</i>	<i>Jaroslav Hrabak</i> (Plzen, Czechia) <i>Giusy Tiseo</i> (Pisa, Italy)
00716	14:45 <b>Treatment strategies for CRKP central nervous system infections after neurosurgery: a prospective observational study comparing intravenous ceftazidime/avibactam and intraventricular/intrathecal polymyxin B sulphate injections</b> <i>M. Wang*</i> (Shanghai, China), <i>W. Mei-Hua</i> , <i>L. Yang</i> , <i>L. Nan-Yang</i> , <i>C. Wei</i> , <i>F. Ya-Xin</i> , <i>W. Gang</i> , <i>H. Jin</i> , <i>Z. Jing</i>
00717	14:57 <b>Clinical and genomic insights into emerging resistance to novel <math>\beta</math>-lactam/<math>\beta</math>-lactamase inhibitor combinations in KPC-producing <i>Klebsiella pneumoniae</i> (Italy, 2021–2024)</b> <i>M. Boattini*</i> (Turin, Italy), <i>S. Comini</i> , <i>G. Ricciardelli</i> , <i>R. Casale</i> , <i>L. Guarrasi</i> , <i>R. Cavallo</i> , <i>C. Costa</i> , <i>P. Gaibani</i> , <i>G. Bianco</i>
00718	15:09 <b>Clinical outcomes and treatment-emergent resistance of bloodstream infections due to AmpC <math>\beta</math>-lactamase-producing Enterobacterales</b> <i>S. Shah*</i> (Pittsburgh, United States), <i>J. Jawanda</i> , <i>M. O'donnell</i> , <i>R. Shields</i> , <i>L. Clarke</i> , <i>H. Creager</i> , <i>R. Marini</i> , <i>B. Falcione</i>
00719	15:21 <b>A multi-centre cohort study of tigecycline effectiveness and safety in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> and carbapenem-resistant <i>Acinetobacter baumannii</i> co-infection</b> <i>D. Chen*</i> (Nanjing, China), <i>S. Wang</i> , <i>N. Hu</i> , <i>P. Liang</i> , <i>J. Liu</i> , <i>H. Xie</i> , <i>H. Zhang</i> , <i>J. He</i>
00720	15:33 <b>Efficacy of minocycline-based combination therapy in <i>Stenotrophomonas maltophilia</i> infections from a randomised controlled trial, and the activity of antimicrobial combinations against isolates as determined by the checkerboard method</b> <i>A. Boonyasiri*</i> (Bangkok, Thailand), <i>T. Pongdumbun</i> , <i>S. Tiengrim</i> , <i>Y. Rongrungruang</i>

OS105 14:45 - 15:45 Hall A3-2

1-hour Oral Session

DX TRN

**Decoding inflammation and innovating diagnostics of parasitic diseases**

<i>Chairs</i>	<i>Pikka Jokelainen</i> (Copenhagen, Denmark) <i>Martin Montes</i> (Lima, Peru)
00721	14:45 <b>Monocyte-dependent antigen specific inflammation in neurocysticercosis is regulated by mitogen activated protein kinases</b> <i>L.M. Toribio*</i> (London, United Kingdom), <i>D.L. Chong</i> , <i>H.H. Garcia</i> , <i>J.S. Friedland</i>
00722	14:57 <b>First cases of male genital schistosomiasis reported in Zambia: a pilot study integrating semen-based parasitology, molecular diagnosis and portable ultrasonography</b> <i>S. España Cueto*</i> (Badalona, Spain), <i>E.C. Sergio</i> , <i>N. Bronwyn</i> , <i>M. Isaac</i> , <i>N. Rhoda</i> , <i>C. Lucas</i> , <i>A. Fiona</i> , <i>V.L. Lisette</i> , <i>W. Bonnie L.</i> , <i>C. Maina</i> , <i>M. Tegwen</i> , <i>H. Shinjiro</i> , <i>R. Silvia</i> , <i>P. Roger</i> , <i>K. Sekeleghe</i> , <i>S. J. Russell</i> , <i>S. Kwame</i> , <i>B. Amaya L.</i>
00723	15:09 <b>Evaluating the diagnostic performance of a recombinase polymerase amplification assay compared to polymerase chain reaction for the diagnosis of female genital schistosomiasis using</b>

		<b>cervicovaginal self-sample swabs</b> <i>N. Hrouda*</i> (London, United Kingdom), <i>S. Nanyinza</i> , <i>L. Smith</i> , <i>M. Cheeba</i> , <i>R. Ndubani</i> , <i>B. Neufeld</i> , <i>K. Shanaube</i> , <i>B. Webster</i> , <i>A. Bustinduy</i>
00724	15:21	<b>Diagnostic evaluation of parasite-derived microRNAs as serum biomarkers for cystic echinococcosis</b> <i>Y. Akyön Yilmaz*</i> (Ankara, Türkiye), <i>S. Orsten</i> , <i>I. Baysal</i> , <i>M. Sarıkaya</i> , <i>E. Yagmur</i> , <i>O. Bozkurt</i> , <i>E. Ünal</i> , <i>S. Yabanoglu Çiftçi</i> , <i>H.A. Dinçer</i> , <i>D. Dirim</i> , <i>D. Akıncı</i> , <i>A.B. Doğrul</i> , <i>E. Karaağaoğlu</i> , <i>M. Korkmaz</i> , <i>Y. Akyön</i> , <i>T. Çiftçi</i> , <i>O. Akhan</i>
00725	15:33	<b>Hookworm infection drives inflammation and tissue destruction in tuberculosis</b> <i>M. Loader*</i> (London, United Kingdom), <i>S.E. Vásquez Alves</i> , <i>M.R. Verástegui</i> , <i>R.H. Gilman</i> , <i>J.S. Friedland</i>

OS102 14:45 - 15:45 Hall BO-2

1-hour Oral Session

CLN

**Pitfalls in modern HIV therapy**

<i>Chairs</i>	<i>Justyna Kowalska</i> (Warsaw, Poland) <i>Milena Stevanovikj</i> (Skopje, North Macedonia)
00726	14:45 <b>A plasma proteomic aging clock reflects reversal of accelerated aging in people with HIV under antiretroviral therapy</b> <i>Barry Ryan</i> (Ecublens, Switzerland)
00727	14:57 <b>Effect of 1HP on dolutegravir concentrations</b> <i>M. Nicol*</i> (Minneapolis, United States), <i>A. Buzibye</i> , <i>A. Fieberg</i> , <i>B. Dai</i> , <i>P. Nerima</i> , <i>E. Ajilong</i> , <i>C. Waitt</i> , <i>D. Boulware</i> , <i>E. Nalintya</i> , <i>R. Rajasingham</i>
00728	15:09 <b>Renal function, HIV reservoir and immune marker changes after one year of long-acting ART</b> <i>L. Maddaloni*</i> (Rome, Italy), <i>L. De Martino</i> , <i>L. Santinelli</i> , <i>C. Falvino</i> , <i>G. Bugani</i> , <i>A. Lazzaro</i> , <i>R. Donà</i> , <i>L. Bortolani</i> , <i>M. Andreotti</i> , <i>Z. Michelini</i> , <i>G. Antonelli</i> , <i>C.M. Mastroianni</i> , <i>C. Scagnolari</i> , <i>G. D' Ettore</i>
00729	15:21 <b>Doravirine: two vs three-drugs based regimens, a multi-centre observational study</b> <i>F. Casari*</i> (Modena, Italy), <i>A. Cervo</i> , <i>A. Giacomelli</i> , <i>R. Rossotti</i> , <i>M. Menozzi</i> , <i>M. Albertini</i> , <i>G. Menegotto</i> , <i>E. Martini</i> , <i>M.V. Cossu</i> , <i>C. Mussini</i> , <i>G. Guaraldi</i> , <i>C. Gervasoni</i> , <i>B. Fontana</i>
00730	15:33 <b>No biomarker evidence of CNS injury after switching to dual therapy with dolutegravir/lamivudine in HIV</b> <i>L. Renborg*</i> (Gothenburg, Sweden), <i>A.L. Benedet</i> , <i>A. Yilmaz</i> , <i>S. Nilsson</i> , <i>K. Nyström</i> , <i>K. Blennow</i> , <i>H. Zetterberg</i> , <i>M. Gisslén</i>

OS100 14:45 - 15:45 Hall ICM 5


1-hour Oral Session

TRN

**Microbiome-host interplay in intestinal disease and under selection pressure**

<i>Chairs</i>	<i>Silvia Corcione</i> (Turin, Italy) <i>Ed J. Kuijper</i> (Leiden, The Netherlands)
00731	14:45 <b>A hit with a scar: amoxicillin alters the infant gut microbiome long-term but without fungal expansion</b> <i>J. Hurych*</i> (Helsinki, Finland), <i>R. Ventin-Holmberg</i> , <i>J. Honkanen</i> , <i>V. Castrén</i> , <i>A. Nikkonen</i> , <i>J. Koskimäki</i> , <i>V. Peltola</i> , <i>K. Korpela</i> , <i>P. Saavalainen</i> , <i>K.L. Kolho</i>
00732	14:57 <b>Protease-induced activation of colonic afferent neurons by gut bacterium <i>Phocaeicola vulgatus</i>, previously associated with inflammatory bowel disease</b> <i>R. Nakhle*</i> (Kingston, Canada), <i>H.M. Wood</i> , <i>K. Blazkova</i> , <i>F.F. Faucher</i> , <i>M. Farquhar</i> , <i>P.M. Sheth</i> , <i>B.L. Schmidt</i> , <i>S.J. Vanner</i> , <i>N.W. Bunnett</i> , <i>M. Bogyo</i> , <i>D.E. Reed</i> , <i>A.E. Lomax</i>
00733	15:09 <b>Recapturing individual inflammatory responses in IBD microbiomes using an <i>in vitro</i> colonic model (MiGut)</b> <i>I. Moura*</i> (Leeds, United Kingdom), <i>W. Davis Birch</i> , <i>N. Beauchemin</i> , <i>K. Bentley</i> , <i>M. Vulic</i> , <i>M. Henn</i> , <i>A. Buckley</i> , <i>C. Ford</i> , <i>N. Kapur</i> , <i>E. Halvorsen</i> , <i>I. B. Moura</i>
00734	15:21 <b>Development of antibiotic-associated diarrhea in sepsis patients is associated with dysbiosis at baseline</b> <i>E. Kyriazopoulou*</i> (Athens, Greece), <i>E. Stylianakis</i> , <i>G. Damoraki</i> , <i>A. Spyrou</i> , <i>S. Symbardi</i> , <i>G. Chrysos</i> , <i>G. Adamis</i> , <i>E. Giamarellos-Bourboulis</i>
00735	15:33 <b>Ecological instability of the gut microbiome during haematopoietic stem cell transplantation</b> <i>C. Hajjar*</i> (Beirut, Lebanon), <i>A. Ibrahim</i> , <i>A. Bazarbachi</i> , <i>M.</i>

SY135	14:45 – 15:45	Hall ICM 13b
	1-hour Symposium	
		
<b>Resistance redefined: how to analyse biofilms and anaerobes</b>		
Chairs	Tom Coenye (Ghent, Belgium) Efthymia Giannitsioti (Athens, Greece)	
S0338	14:45	Resistance in slow growing anaerobic communities Catalina Suzana Stingu (Leipzig, Germany)
S0339	15:15	What <i>in vitro</i> susceptibility testing does (not) tell you about <i>in vivo</i> anti-biofilm activity in the respiratory tract Valerie Waters (Toronto, Canada)
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Anaerobic Infections (ESGAI)		

SY134	14:45 – 15:45	Hall ICM 14
	1-hour Symposium	
		
<b>Year in infectious diseases</b>		
Chairs	Murat Akova (Ankara, Türkiye) Yoav Keynan (Winnipeg, Manitoba, Canada)	
S0336	14:45	- Dafna Yahav (Ramat-Gan, Israel)
S0337	15:15	- Margaret Ip (Hong Kong, Hong Kong)

EF106	14:45 – 15:45	Arena 1
	ePoster Flash Session	
		
<b>Latest trends in vaccinology: from current strategies to next-generation vaccines</b>		
Chair	David Chien Lye (Singapore, Singapore)	

E0736	14:45	Long-term impact of a single-dose inactivated hepatitis A vaccine in Korean military recruits: a nationwide cohort analysis (2011–2024) J.H. Im* (Incheon, Korea, Republic of), J.S. Lee, S. Cho, D.Y. Kang, D.Y. Lee
E0737	14:51	Effectiveness of high-dose vs standard-dose influenza vaccine against recurrent hospitalisations and through extended follow-up: a prespecified analysis of the DANFLU-2 trial N.D. Johansen* (Hellerup, Denmark), D. Modin, M.M. Loiacono, R.C. Harris, M. Dufournet, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovski, L.W. Davodian, M.F. Dons, L.S. Duus, C. Espersen, F.H. Fussing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, T. Biering-Sørensen
E0738	14:57	Effectiveness of high-dose vs standard-dose influenza vaccine in older adults according to age: a prespecified analysis of the FLUNITY-HD study K. Hosseini* (Copenhagen, Denmark), N. Dyrby Johansen, D. Modin, J. Pardo-Seco, C. Rodriguez-Tenreiro-Sánchez, M. M. Loiacono, R. C. Harris, R. Van Aalst, A. Chit, C. Schade Larsen, L. Larsen, M. Pareek, L. Wiese, M. Dalager-Pedersen, B. L. Claggett, K. Hyldekaer Janstrup, C. Duran-Parrondo, M. Piñeiro-Sotelo, M. Dufournet, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S. D. Solomon, P. Sivapalan, C. Jean-Marie Martel, J. Ulrik Stæhr Jensen, F. Martínón-Torres, T. Biering-Sørensen
E0739	15:03	Immunogenicity and safety of a higher-dose MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults ≥50 years of age: a phase III randomised controlled trial F.R. Albano* (Melbourne, Victoria, Australia), B.J. Essink, W. Vermeulen, C. Andrade, M. Mazur, C. Jamison, R. De Rooij, E. Heijnen, D. Casula, R. Xing, M. Piedrahita, V. Garner
E0740	15:09	Predicting COVID-19 vaccination decision-making

E0741	15:15	Intramuscular SARS-CoV-2 vaccination fails to induce de novo local antibodies in older adults: a Com-COV randomised substudy R. Shaw* (Oxford, United Kingdom), T. Dinesh, J. Alderson, S. Belij-Rammerstorfer, S. Bibi, E. Clutterbuck, M.R.N.U. Ramasamy, M. Snape, X. Liu, T. Lambe
E0742	15:21	Vaccines insight, beliefs, and experiences in school-aged children and parents: a questionnaire and structured interview in UK families (VIBES) W. Carroll* (Uttoxeter, United Kingdom), A. Jagadish, F. Gilchrist, R. Horne
E0743	15:27	Next-generation vaccines for hepatitis E virus J. Situ* (Hongkong, China), X. Ma, Y. Liang, S. Wu, S. Sridhar

EF107	14:45 – 15:45	Arena 2
	ePoster Flash Session	
		
<b>Infection control and prevention around the world: risks, behaviours, and solutions</b>		
Chair	Maria João Lopes (Amadora, Portugal)	

E0745	14:45	Perception vs practice in hospital cleaning: assessing task-prioritisation between hospital cleaning staff and IPC practitioners, an interim analysis A. Kearney* (Dublin, Ireland), M. Fallon, J. Doyle, B. Fletcher, A.F. Talento, R. Cunney, C. Cahir, D. Fitzgerald Hughes, B. Mitchell, M. Kiernan
E0746	14:51	Environmental reservoirs of carbapenemase-producing organisms (CPO) in intensive care unit (ICU) hand hygiene (HH) sinks and haemodialysis (HD) wall boxes: investigation and control measures J. Guerrero* (Scarborough, Canada), S. Paramalingam, J. Lerma, M. Pekelny, S. Arefin, A. Garga, M. O'connor, R. Lovinsky
E0747	14:57	Hospital surfaces as reservoirs of carbapenemase- and ESBL-producing bacteria in hospitals across Bangladesh, Nigeria and Pakistan A. Cooke* (Oxford, United Kingdom), J. Rzaska, R. Farzana, B. Hassan, C. Achi, M. Nieto-Rosado, L. Wilson, S. Langhorne, A. Sindhu, J. Oduwo, E. Owinoh, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, H. Naz, A. Muhammad, S. Ali, W. Sombul, M. Khan, S.U. Nisa, A. Khan, S. Riaz, S. Naqvi, J. Zafar, H. Hamid, A. Sajid, R. Razaq, K. Iregbu, N. Medugu, T. Akujobi, F.Z.Z. Abdu, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Pantti, O. Oduyebo, O. Olutekunbi, F. Okenla, I. Nwafia, P. Nwachukwu, S. Chukwuma, T. Sultana, S. Arefin, P.I. Disha, N. Tasnim, T. Hossain, T. Haque, T.R. Walsh, K. Sands, K.M. Thomson
E0748	15:03	CRE colonisation as a marker for CRE ventilator-associated pneumonia (VAP): insights from a 15-month ICU cohort in Rome L. Campogiani* (Rome, Italy), A.M.A. Crea, L. Alborghetti, P. Vitale, I. Spalliera, M. Zordan, A.M. Geretti, V. Malagnino, M. Iannetta, L. Sarmati
E0749	15:09	Behavioral insights and motivational challenges within infection control committees: mixed-methods study using COM-B and TDF frameworks T. Yanik Yalçın* (Ankara, Türkiye), A. Pehlivanlı, B. Gönülal, F. Callak Oku, B. Madran, E. Sargin Altunok, Ş. Keske, M. Aydin, Ö. Kurt Azap, Ö. Ergönül, H. Akalin
E0750	15:15	<i>Candidozyma auris</i> colonisation: point-prevalence and long-term outcomes in a tertiary university hospital M. Gamaletsou* (Athens, Greece), D. Basoulis, A. Karapanou, E. Apostolidi, S. Zerva, A.R. Andritsou, K. Panteli, C. Psarakis, K. Reppas, A. Rigatou, D. Stefaní, A. Strikou, D. Mpora, D. Petraki, M. Sampanis, S. Zagkavierou, K. Theodoridou, T. Koliou, S. Kritikou, A. Millioni, E. Giannitsioti, E. Mastrogianni, F. Ntziora, A. Anastasopoulou, M. Samarkos, M. Psychogiou, N.V. Sipsas, G. Vrioni
E0751	15:21	A 20-year single-centre retrospective study on the impact of hospital environmental factors on the incidence of candidaemia A. Bedini* (Modena, Italy), G. Franceschi, S. Esperti, S. Generoso, L. Benassi, U. Calvi, M. Meschiarì, E. Franceschini, C. Venturelli, C. Mussini
E0752	15:27	Swiss minimum requirements for infection prevention and control: results of a national survey A. Sonpar* (Zurich, Switzerland), C. Balmelli, M. Eder, A. Metsini, Z. Zhang, W. Zingg

**E0753** 15:33 **A multi-modal intervention with patient engagement to reduce Multidrug-Resistant Organisms (MDROs) in post-acute care** *L. Mody\** (Ann Arbor, United States), *M. Cassone, K. Gibson, G. Vijayasiri, E. Snitkin, S. Saint, S. Krein, M. Janevic, J. Thiel, A. Nguyen, T. Bej, O. Hicks, N. El Chakhtoura, L. Min, A. Galecki, T. Greene, M.C. Roghmann, L. Chigurupati, F. Perez, R. Jump*

**EF108** 14:45 - 15:45 **Arena 3**

ePoster Flash Session

CLN PED

**Little patients, big challenges: tackling bacterial infections in children**

*Chair* *Christina Obiero (Kilifi, Kenya)*

**E0754** 14:45 ***Klebsiella pneumoniae*: a leading cause of neonatal sepsis from 13 hospitals in Nigeria, Pakistan and Bangladesh** *K. Sands\** (Oxford, United Kingdom), *K. Thomsson, C. Achi, R. Farzana, B. Hassan, A. Cooke, J. Rzaska, A.K. Lankapalli, J. Oduwo, E. Owinoh, N. Haque, R. Farzana, T.A. Sumi, P.I. Disha, S.K. Sara, T. Haque, K. Iregbu, N. Medugu, T. Akujobi, K. Abdurraheem, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Adamu, O. Oduyebo, O. Olutekunbi, O. Ogunsanya, I. Nwafia, S. Chukwuma, P. Nwachukwu, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, S. Ali, S. Amin, M. Khan, S. Arif, S.U. Nisa, S. Riaz, S. Naqvi, I. Zeb, M. Haroon Hamid, U. Hussain, S. Shabbir, T.R. Walsh*

**E0755** 14:51 **Antibiotic dosing practices in neonates in low- and middle-income countries: model-based comparison with guidelines and implications for target attainment and toxicity** *W. Van Os\** (Leiden, The Netherlands), *K.M. Thomson, K. Sands, T.R. Walsh, C.R. Achi, B. Hassan, R. Farzana, E. Owinoh, J. Oduwo, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, S.M. Zainu, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, J. Unigwe, C. Onyejekwe, T.A. Sumi, B. Majumder, S.B. Proma, T. Haque, R. Khatun, T. Hossain, E. Rashid, R. Zahra, M.I. Shah, A. Mehboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, S. Riaz, S. Naqvi, R. Hamza, M.H. Hamid, M. Malik, R. Temur, R. Sajjad, J.G.C. Van Hasselt*

**E0756** 14:57 **Antibiotic resistance genes in meconium of newborns very early after admission to neonatal intensive care unit** *Argyro Ftergioti* (Thessaloniki, Greece)

**E0757** 15:03 **Stool-based real-time PCR platform as a non-invasive frontline diagnostic tool for paediatric pulmonary tuberculosis: a cross-sectional study from a tertiary care paediatric centre** *A. Soni\** (Noida, India), *S. Nandwani, S.B. Mathur, B. Kumar*

**E0758** 15:09 **Predictors of outcomes of paediatric diphtheria in sub-Saharan Africa: a systematic review and meta-analysis** *I.A. Rufai\** (Sokoto, Nigeria), *S. Abubakar, F. Shagari*

**E0759** 15:15 **Post-pandemic resurgence and epidemiology of group A *Streptococcus* infection in children** *N. Tan\** (Singapore, Singapore), *W.J.W.H. Goh, C.Y. Chong, J. Li, C.F. Yung, K.C. Thoon, K.Q. Kam, K.D. Nadua, C.W.X. Seow, Y. Yelen, M. Maiwald, S.B. Yusof, K.P.L. Wong, C.Y. Woo, N.W.S. Tee, L. Cui, M. Ang*

**E0760** 15:21 **IPSCC 2005 and Phoenix Sepsis Score in children under 60 days: strengths and diagnostic pitfalls** *L. Di Meglio\** (Rome, Italy), *G. Lorenzetti, M. Roversi, C. Tripiciano, S. Mercadante, M. Di Giuseppe, S. Chiurchiù, M. De Luca*

**E0761** 15:27 **An early mortality prediction tool for children with haematologic malignancy and Gram-negative bloodstream infection** *A. Ayad\** (Cairo, Egypt), *Y. Taher, M. Jamal, M. Mohammed, O. Ahmed, A. Alameldein, G. Ziad, Y. Madeny*

**E0762** 15:33 **Epidemiology and antibiotic use for pertussis and pertussis-like cough in Italian children: a population study (2010–2024, PEDIANET)** *E. Gres\** (Padua, Italy), *G. Sturniolo, S. Masenello, D. Dona, G. Brigadoi, A. Cantarutti, C. Giaquinto, V. Baldo, E. Barbieri*

**PM005** 14:45 - 15:45 **Hall A2-1**

Pipeline Symposium

PRO PHEI

**From AI for evidence synthesis to decision making**

*Chairs* *David Eyre (Oxford, United Kingdom)*  
*Holger Rohde (Hamburg, Germany)*

**D0012** 14:45 **AI decision support in antibiotic prescribing - novel aspects and direction** *Daniele Roberto Giacobbe* (Genoa, Italy)

**D0013** 15:15 **AI for ESCMID guideline development - a perspective on feasibility and safety** *José Molina Gil-Bermejo* (Seville, Spain)

**MOVIE** 14:45 - 18:30 **Hall ICM 13a**

Special Session

PRO PHEI

**Behind the scenes: don't look up**

*Chairs* *Diane Ashiru-Oredope (London, United Kingdom)*  
*Ana Raquel Freitas (Porto, Portugal)*  
*William Hanage (Boston, United States)*  
*Holger Rohde (Hamburg, Germany)*  
*Luigia Scudeller (Pavia, Italy)*  
*Sotirios Tsioupras (Athens, Greece)*

**OS110** 16:15 - 17:15 **Hall A2-2**

1-hour Case Session

ANT CLN TRN

**New and novel approaches to complex infections**

*Chairs* *Rekha Pai Mangalore (Melbourne, Australia)*  
*Jacques Simkins (Miami, United States)*

**O0763** 16:15 **Allogeneic cytomegalovirus-specific T cell therapy in a small-bowel transplant recipient with multidrug-resistant CMV infection** *L. Van Den Bogaart\** (Lyon, France), *E. Frobert, T. Antonini, J.H. Dalle, J.Y. Mabrut, T. Perpoint, L. Reppel, D. Bensoussan, F. Ader*

**O0764** 16:26 **Faecal Microbiota Transplantation (FMT) as a novel therapy for refractory chronic norovirus infection in immunocompromised hosts: clinical response and metagenomic analysis** *K. Chaw\** (Brisbane, Australia), *K. Garnham, M. Buller, S. Schlebusch, T. Badrick, V. Grey, M. Sullivan, A. Sai, B. Koh, I. Gosbell*

**O0765** 16:37 **Cycloheptasin: a novel antimicrobial peptide from *Periplaneta americana* for combating Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) I.** *Ihekukwumere\** (Uli, Nigeria)

**O0766** 16:48 **Daratumumab and belimumab for patients with neutralising anti-interferon- $\gamma$  autoantibodies mediated adult-onset immunodeficiency: a case series** *Y.T. Weng\** (Taipei, Taiwan), *M.T. Tsai, H.Y. Sun, K.Y. Lin, Y.S. Huang, W.T. Tsai, C.Y. Yao, B.C. Guo, J.T. Wang, S.C. Chang, A. Cheng*

**O0767** 16:59 **Refractory resistant *Salmonella* empyema successfully treated with compassionate adjunctive bacteriophage therapy** *J. Chung\** (Singapore, Singapore), *Y.Y. Chua, E.C.Y. Sng, J.M.F. Chien, A. Taha, W.M. Chew, K.J. Goh, S. Thong, N.G.S. Chua, A.L.H. Kwa*

**OS109** 16:15 - 17:15 **Hall ICM 13b**

1-hour Case Session

CLN PHEI

**Melioidosis finds new destinations**

*Chairs* *Yogesh Kumar Gupta (Jaipur, India)*  
*Maria João Lopes (Amadora, Portugal)*

**O0768** 16:15 **First documented blood culture-confirmed melioidosis case in Mozambique: implications for awareness, surveillance, and diagnosis** *S. Cruz\** (Beira, Mozambique), *C. Raimundo, L. Andela, N. Joao, J. Marcos, C. Joyce, Z. Seni, M. Barrios, A. Dicko, C. Monjane, A. Comelli, F. Gordillo, P. Garcia-Vello*

**O0769** 16:26 **Saving the spleen: importance of timely diagnosis in relapsing melioidosis** *W. Khot\** (Navimumbai, India)

00770	16:37	<b>Rhino-orbital melioidosis masquerading as invasive fungal sinusitis: a case report</b> <i>N. Kaur*</i> (Jodhpur, India), <i>T. Kanagiri, D. Kumar, V. Tak, G.K. Bohra</i>
00771	16:48	<b>Ruptured aneurysm unmasking disseminated melioidosis: a case report</b> <i>M.L. Panes*</i> (Manila, Philippines), <i>J. Poblete, C. Ramos</i>
00772	16:59	<b>A rare case of melioidosis reactivation in Germany twelve years after travel to Thailand</b> <i>T. Cronen*</i> (Berlin, Germany), <i>S. Schaber, F. Bremer, H. Müller-Redetzky, A. Uhrig</i>

OS111	16:15 - 17:15	Hall A3-2
	1-hour Oral Session	

AMR ANT DX

**Novel aspects of susceptibility testing methods**

*Chairs* *Arjana Tambic Andrasevic (Zagreb, Croatia)*  
*Andreas Voss (Groningen, The Netherlands)*

00773	16:15	<b>Prospective assessment of heteroresistance to first-line <math>\beta</math>-lactams in Gram-negative bloodstream infections</b> <i>D. Squitieri*</i> (Rome, Italy), <i>G. Menchinelli, B. Berinson, N. Degel-Brossmann, B. Posteraro, M. Sanguinetti, H. Rohde</i>
00774	16:27	<b>Comparative evaluation of agar dilution and Etest against broth microdilution for ceftobiprole susceptibility testing in methicillin-resistant <i>Staphylococcus aureus</i>: a multi-centre study in China</b> <i>F. Zhu*</i> (Hangzhou, China), <i>Y. Chen</i>
00775	16:39	<b>Implementation of cost-effective antimicrobial susceptibility testing in resource-constrained settings: lessons from the BALANCE study</b> <i>R. Farzana*</i> (Oxford, United Kingdom), <i>E. Carretto, N. Haque, M. Rahman, A. Monir, R.A. Ansary, S. Shahid, S.T. Reza, N. Haque, E. Kibaru, G. Ganda, D. Adera, K. Onjuro, C. Achi, K. Iregbu, P. Nwajobi-Princewill, K. Abdulraheem, F. Kilani, J. Udeh, A. Aminu, A.M. Idris, J.D. Joshua, I.N. Nwafia, A. Nkiruka, C.I. Chiedu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, G. Fatima, R. Siddiqi, M. Idrees, A. Khattak, N. Rehman, K. Hoog, C. Abdellaoui, S. Langhorne, A. Sindhu, M. Christodoulou, E. Owinoh, F. Demetrio, T.R. Walsh</i>
00776	16:51	<b>An innovative fluorogenic assay for reliable detection of staphylococcal penicillinase</b> <i>C. Dupieux*</i> (Lyon, France), <i>P. Martins-Simoes, B. Youenou, G. Antoniotti, F. Vandenesch, A. Tristan, F. Laurent</i>
00777	17:03	<b>Comparison of piperacillin/tazobactam susceptibility testing with a Microscan system and the novel rapid system QuickMIC</b> <i>L. Lopez Cerero*</i> (Seville, Spain), <i>M. Sánchez-Ruiz De La Muela, M. Oliva-Sánchez, L. Monge-Olivares, I. Portillo-Calderón, M. Pulido, L. López-Cerero, A. Pascual</i>

SY139	16:15 - 17:15	Hall A3-1
	1-hour Symposium	

PHEI

**Setbacks to strength: re-imagining global health partnerships at times of geopolitical uncertainty**

*Chairs* *Tetiana Melnyk (Paris, France)*  
*Marc Jean Struelens (Rocheftort, Belgium)*

S0347	16:15	<b>Effects on the global HIV pandemic</b> <i>Mosa Moshabela</i> (Cape Town, South Africa)
S0348	16:45	<b>Come back stronger: WHO's strategic plans for fighting infections in a globalised world</b> <i>Maria Van Kerkhove</i> (Geneva, Switzerland)

Co-organised with: Dutch Society for Medical Microbiology (NVMM), ESGPHM, ESGVM, Médecins Sans Frontières (MSF), European AIDS Clinical Society (EACS)

SY138	16:15 - 17:15	Hall B0-1
	1-hour Symposium	

AMR ANT CLN

**Bacteriophages in implant-related infections: translating a century-old concept into a modern solution for AMR**

*Chairs* *Gina Suh (Rochester, Minnesota, United States)*  
*Andrej Trampuz (Brisbane, Australia)*

S0345	16:15	<b>Bacteriophage therapy in cardiac and orthopaedic device-related infection</b> <i>Tristan Ferry</i> (Lyon, France)
S0346	16:45	<b>Challenges and future directions of phagotherapy in multidrug-resistant implant infections</b> <i>Thomas Fintan Moriarty</i> (Davos, Switzerland)

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY137	16:15 - 18:15	Hall B0-2
	2-hour Symposium	

AMR ANT

**Stronger together: rational design and use of antibiotic combination therapies**

*Chairs* *Sandrine Marchand (Poitiers, France)*  
*Anouk Edwina Muller (The Hague, The Netherlands)*

S0341	16:15	<b>Combination therapies in tuberculosis: how to design and evaluate new regimens</b> <i>Elin Svensson</i> (Uppsala, Sweden)
S0342	16:45	<b>Towards rational breakpoints for antibiotic combination therapies</b> <i>Sebastian Wicha</i> (Hamburg, Germany)
S0343	17:15	<b>Antibiotic combination therapies: can we suppress resistance?</b> <i>Linda Aulin</i> (Leiden, The Netherlands)
S0344	17:45	<b>Optimal off-patent antimicrobial combinations regimens for Gram-negative infections</b> <i>Joe Standing</i> (London, United Kingdom)

EF112	16:15 - 17:15	Arena 1
	ePoster Flash Session	

ANT CLN

**Respiratory bacterial infections: challenges and advances**

*Chair* *Margaret Ip* (Hong Kong, Hong Kong)

E0778	16:15	<b>Invasive pneumococcal disease in a Portuguese hospital: 19-year retrospective study</b> <i>C. Batista*</i> (Oporto, Portugal), <i>S. Araújo, C. Azeredo, C. Bacelar, J. Oliveira, F. Reis, L. Neto, T. Dos Santos, E. Pena, M.J. Gonçalves, F. Duarte, S. Rocha, S. Jordão, M. Guimarães, A. Read, R. Correia De Abreu, C. Soeiro</i>
E0779	16:21	<b>Re-emergence of Chlamydia pneumoniae after the COVID-19 pandemic: a retrospective PCR-based study in a Spanish tertiary hospital (2019-2025)</b> <i>P. Suárez Urquiza*</i> (Valencia, Spain), <i>E. Cortés Giménez, E. Gremaldos Mira, P. Suarez-Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz</i>
E0780	16:27	<b>Procalcitonin and lung ultrasonography-guided antibiotherapy in patients with lower respiratory tract infection in Swiss emergency departments: a pragmatic stepped-wedge cluster-randomised trial: The PLUS-IS-LESS study</b> <i>N. Boillat-Blanco*</i> (Lausanne, Switzerland), <i>C. Bessat, O. Hugli, E. Garcia, R. Bingisser, M. Schwendinger, T. Bulaty, Y. Fournier, V. Della Santa, M. Pfeil, D. Schwab, J. D. Leuppi, N. Geigy, S. Steuer, F. Roos, M. Christ, A. Sirova, A. Atzl, F. Napieralski, O. Manuel, I. Locatelli, W. Albrich</i>
E0781	16:33	<b>Effect of clarithromycin on inflammatory proteomic expression in community-acquired pneumonia: secondary analysis of the ACCESS trial</b> <i>E. Stylianakis*</i> (Athens, Greece), <i>K. Tsiakos, V. Tzavara, L. Skorda, K. Iliopoulou, G. Adamis, G. Niotis, K. Akinosoglou, N. Kakavoulis, G. Chrysos, S. Gerakari, T. Kontopoulou, G.N. Dalekos, I.C. Papanikolaou, M.G. Netea, V. Kumar, E.J. Giamarellos-Bourboulis</i>
E0782	16:39	<b>Antimicrobial-associated acute kidney injury in patients hospitalised with community-acquired pneumonia</b> <i>R.S. Knudsen*</i> (Hvidovre, Denmark), <i>C. Leding, H. Løvendahl Jørgensen, M. Fally, P. Ravn, L. Kolte, S. Bastrup Israelsen, T. Benfield</i>
E0783	16:45	<b>Efficacy of <math>\beta</math>-lactam monotherapy vs clindamycin or addition of metronidazole in peritonsillar abscess: an observational study with a focus on <i>Fusobacterium necrophorum</i></b> <i>D. Nygren*</i> (Lund, Sweden), <i>M. Loggarfve, E. Lindberg, K. Holm, M. Gisselson-Solén</i>
E0784	16:51	<b>A randomised, double-blind, placebo-controlled trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis participants</b>

		<b>chronically colonised with <i>Pseudomonas aeruginosa</i></b> P. Tamma* (Philadelphia, United States), T. Hamasaki, M. Souli, D. Van Tyne, D. Pride, S. Nayak, K. Moon, E. Raterman, K. Greenwood-Quaintance, D. Ellison, A. Filippov, M. Nikolich, T. Lodise, D. Conrad, A. Jaunarajs, Z. Wintrob, D. Albon, P. Allyn, T. Barto, J. Billings, L. Caverly, A. Graham, W. Hunt, R. Jain, J. Koff, K. Mcbennett, D. Miller, P. Mohabir, B. Morrissey, K. Patel, J. Wang, N. West, M. Bates, J. Leonard, G. Sah, M. Chiu, B. Evans, H. Geres, C. Koscianski, U. Rappo, J. Fackler, H. Chambers, S. Evans, R. Patel, V. Fowler, R. Schooley
<b>E0785</b>	<b>16:57</b>	<b>Evolution of the respiratory microbiological profile in people with cystic fibrosis undergoing treatment with elexacaftor/tezacaftor/ivacaftor</b> B.S. Orena* (Milan, Italy), F. Girardi, E. Tomassini, D. Girelli, M. D'accico, F. Blasi, V. Daccò, A. Callegaro, L. Cariani
<b>E0786</b>	<b>17:03</b>	<b>Nosocomial pneumonia in Georgia: a rising threat of multidrug-resistant pathogens</b> S. Khetsuriani* (Tbilisi, Georgia), G. Mgeladze, L. Gabunia, G. Janigashvili, L. Ratiani

**EF113** **16:15 - 17:15** **Arena 2**

ePoster Flash Session



**Parasitic diseases in a changing world: climate, mobility, and clinical impact**

Chair *Camilla Rothe (Munich, Germany)*

<b>E0788</b>	<b>16:21</b>	<b>Estimating unreported malaria cases in England: a capture-recapture study</b> P. Charlotte* (London, United Kingdom), C. Patterson, A. Simbo, D. Turner, S. Leinster, P. Katwa, P. Veal, A. Checkley, C. Redman, C.A. Gibb, C. Williams, P. Chiodini
<b>E0789</b>	<b>16:27</b>	<b>Paediatric imported malaria infections with a non-falciparum species: a 2011-2023 retrospective study in France</b> C. Melenotte* (Paris, France), P. Buffet, S. Houzé, V. Joste, M. Thellier, F. Gay, F. Sorge, J. Toubiana, O. Lortholary, F. Lanternier, P.H. Consigny, L. Musset, B. Pradines
<b>E0790</b>	<b>16:33</b>	<b>Effectiveness of intermittent preventive treatment for malaria in pregnancy in an area of high sulfadoxine/pyrimethamine resistance in northern Uganda: a directed acyclic graph-guided analysis</b> F.V. Segala* (Bari, Italy), J. Ichtho, R. Novara, N. Olung, G. Patti, R. Papagni, G. Atim, V. Totaro, L. Olal, E. De Vita, J. Adongo, M. L'episcopia, S. Okori, G. Dall'oglio, L. Pisani, A. Dondorp, G. Putoto, P. Lochoro, A. Saracino, F. Di Gennaro
<b>E0791</b>	<b>16:39</b>	<b>The PK6 project: a test-and-treat operational strategy for <i>Plasmodium vivax</i> elimination among hard-to-reach illegal gold miners in French Guiana</b> D. Patarot* (Cayenne, French Guiana), M. Oberlis, T. Levarato, M. Rozé, P. Feller, L. Houssais, A. Carfantan, M. Boutrou, Y. Lazrek, L. Musset, F. Mubenga, C. Michaud, L. Epelboin
<b>E0792</b>	<b>16:45</b>	<b>Leishmaniasis as an opportunistic infection in HIV patients in Europe: lack of guidelines harmonisation and limited diagnostic arsenal</b> G. Zaremba* (Warsaw, Poland), A. Papadopoulos, K. Protopapas, M. Stevanovikj, N. Yancheva, S. Dragaš, A.Ç. İnkaya, C. Oprea, J. Begovac, Z. Bartovská, M. Zlámal, O. Beran, D. Jilich, A. Schembri, R. Matulionyte, I. Gmizic, D. Maric, J. Tomažič, E. Golovco, H. Tiberiu, B. Lakatos, T. Balayan, A. Vassilenko, A. Verhaz, N. Bolokadze, V. Krasniqi, J. Kowalska, A. Harxhi
<b>E0793</b>	<b>16:51</b>	<b>Leishmaniasis in a Spanish tertiary hospital (2018-2025): epidemiological trends, clinical and diagnostic characteristics of a re-emerging disease</b> E. Gremaldos Mira* (Valencia, Spain), E. Cortés Giménez, A. Ruiz Gaitán, P. Suárez Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz
<b>E0794</b>	<b>16:57</b>	<b>Serum circulating anodic antigen as test-of-cure for schistosomiasis in migrants: what is the impact?</b> L.C. Vaccari* (London, United Kingdom), I. Chaudhry, J. Martin, C. Sen, N. Longley, G. Godbole, S. Eisen, L. Nabarro
<b>E0795</b>	<b>17:03</b>	<b>Three decades of echinococcosis in southern Madrid: insights into an endemic zoonosis</b> A.N. Ruiz Benito* (Leganes, Spain), V. Anton Berenguer, K.M. Pinto Tapia, M.D. Martín Rodrigo, S.M. Quevedo Soriano, S. Gómez De Frutos, F.J. Merino Fernández, J.M. Rubio Muñoz, M.D. Flores Chávez

**EF114** **16:15 - 17:15** **Arena 3**

ePoster Flash Session



**Controlling *Clostridioides difficile* infections and hospital related challenges**

Chair *Kerrie Davies (Leeds, United Kingdom)*

<b>E0796</b>	<b>16:15</b>	<b>Most recurrent <i>Clostridioides difficile</i> infections reflect persistent infection or repeat exposure: findings from whole genome sequencing in Wales</b> , UK R. Polani Chandrasekar* (Cardiff, United Kingdom), L. Campbell, T. Connor, N. Craine, V. Daniel, H. Hughes, V. McClure, T. Morris, M. Perry, R. Phillips, D. Williams, M. Morgan
<b>E0797</b>	<b>16:21</b>	<b>Evaluation and comparison of three methods for the detection of <i>Clostridioides difficile</i> toxin in faecal samples</b> R. Asif* (Cardiff, United Kingdom), P. Talagtag, F. Ismail, S. Mitchell, M. Perry, S. Jones
<b>E0798</b>	<b>16:27</b>	<b>Gut microbiome characterisation in inflammatory bowel disease and <i>Clostridioides difficile</i> infection</b> S. Vázquez-Cuesta* (Madrid, Spain), I. Marín, M. Díaz-Navarro, G. Álvarez-Calatayú, C. Sánchez, M. Guembe, A. Visedo, E. Bouza, P. Muñoz, L. Menchén, R. Samaniego, R. Bañares, E. Reigadas
<b>E0799</b>	<b>16:33</b>	<b>Screening for asymptomatic carriage of <i>Clostridium difficile</i>: results from a two year intervention</b> M. Gilboa* (Ramat Gan, Israel), N. Barde, E. Meltzer, Y. Peretz, I. Levy, S. Amit, G. Rahav, N. Pinas-Zade, B. Mechnik, G. Regev-Yochay
<b>E0800</b>	<b>16:39</b>	<b><i>Clostridioides difficile</i> infection in Europe: are we meeting best practices?</b> M. Krutova* (Prague, Czechia), J. Prehn, W.K. Smits, O. Burdunuc, M. Wilcox, E. Kuijper
<b>E0801</b>	<b>16:45</b>	<b>Epidemiological trends in <i>Clostridioides difficile</i> infections in France, 2019-2024: TRACE national population-based study</b> M. Decalonne* (Tours, France), M.H. Pham-Hi, C. Gaborit, C. Salpérier, N. Khanafer, C. Daniau, F. Barbut, L. Grammatico-Guillon
<b>E0802</b>	<b>16:51</b>	<b>Exploring patient experiences of infection prevention and control across a range of healthcare associated infections: the stories behind the numbers</b> M. Skally* (Dublin, Ireland), J. Strawbrige, C. Cox, J. Heritage, S. Rajesh, A. Walsh, C. Finn, P. Conran, K. Bennett, H. Humphreys, F. Fitzpatrick
<b>E0803</b>	<b>16:57</b>	<b>From insight to impact: leveraging opportunity mapping to drive system-wide reductions in CLABSI, CAUTI, <i>C. difficile</i>, and MRSA over a three-year period</b> G. Rosello* (Miami, United States), J. Somani, C. Ghaemmaghami, D. Zambrana, H. Clark, C. Biggs, L. Abbo
<b>E0804</b>	<b>17:03</b>	<b>Wipe-based solutions for hand hygiene: do they really work?</b> A. Barry* (Salisbury, United Kingdom), G. Moore

**KN136** **16:15 - 17:15** **Hall ICM 14**

Keynote lecture



**Viral infection in the immunocompromised: from discovery to emerging therapies**

Chairs *Maddalena Giannella (Bologna, Italy)*  
*Monica Slavin (Melbourne, Australia)*

**K0340** **16:15** *Hans H. Hirsch (Tromsø, Norway)*

**ME140** **16:15 - 17:15** **Hall ICM 1**

Meet-the-Expert



**Artificial intelligence in antimicrobial stewardship and infection control: from prediction to precision**

**M0349** **16:15** *Damien Ming (London, United Kingdom)*

**M0350** **16:27** *José Ramón Paño-Pardo (Zaragoza, Spain)*

**ME141** **16:15 - 17:15** **Hall ICM 5**

Meet-the-Expert



**Children are not small adults: interactive paediatric cases**

M0351 16:15 Julie Toubiana (Paris, France)  
 M0352 16:27 Sanjay Patel (Southampton, United Kingdom)

PM006 16:15 – 18:15 Hall A2-1  
 Pipeline Symposium

DX PHEI

**The value of diagnostics and enhancing utilisation**

Chairs Till T. Bachmann (Edinburgh, United Kingdom)  
 Betsy Wonderly Trainor (Boston, United States)

D0014 16:15 Adoption and implementation in infection diagnostics – the long and winding road Jane Freeman (Leeds, United Kingdom)

D0015 16:45 Beyond the test: social and organizational realities of implementing RTI diagnostics in primary care Sibyl Anthierens (Wilrijk, Belgium)

D0016 17:15 What are diagnostics actually worth? Rethinking value beyond accuracy Brooke Nichols (Boston, United States)

D0017 17:45 From great science to routine clinical use Matthew Mckillip (Chicago, United States)

LB008 17:30 – 18:30 Hall A1-4  
 1-hour Oral Session

CLN IPC

**Late-breaking trials in surgical infection prevention**

Chairs Ili Margalit (Ramat Gan, Israel)  
 Eli Perencevich (Iowa City, Iowa, United States)

L0041 17:30 Improvement in staff behavior during surgical procedures to prevent postoperative complications (ARIBO<sup>2</sup>): a cluster randomised trial. G. Birgand\* (Nantes, France), J.C. Lucet, B. Giraudeau, N. Jacquet, E. Tavernier, C. Gaborit, T. Haudebourg, N. Mauduit, C. Leux, D. Lepelletier, L. Grammatico-Guillon

L0042 17:42 Polyhexanide vs mupirocin and chlorhexidine for pre-operative *Staphylococcus aureus* decolonisation in elective spine surgery (SPADE): a pilot randomised controlled trial R. Sommerstein\* (Lucerne, Switzerland), J. Krebs, M. Grigorov, T. Poetzel, F. Michael, D. Bratelj, C. Capone, X. Zhou, J. Stoyanov

L0043 17:54 One day of antibiotic treatment is non-inferior to four to seven days in patients with acute cholangitis after adequate biliary drainage: a multi-centre randomised controlled trial (COBRA) A. Overdeest\* (Amsterdam, The Netherlands), E. Sieswerda, S. Haal, J.A. Bogaards, K.S. Boparai, F. Ter Borg, M.A. Brink, F. Van Delft, V.K. Dik, L.P.L. Gilissen, M. Hadithi, W.L. Hazen, F. Van Der Heide, W.J. Den Hollander, A. Inderson, P.J.F. De Jonge, S.D. Kuiken, J.M. Munneke, B. Opsteeg, L.E. Perk, A.C. Poen, J.W. Poley, R. Quispel, R.C.H. Scheffer, D.W. Schölvinck, E.J. Van Soest, A.C.I.T.L. Tan, W.J. Thijs, N.G. Venneman, R.C. Verdonk, F.P. Vleggaar, W. Van De Vrie, J.M. Vrolijk, R.L.J. Van Wanrooij, P.W. Weijnenborg, M.G.W. Dijkgraaf, J.M. Prins, R.P. Voermans

L0045 18:06 Effectiveness of an AI-based augmented reality tool for hand hygiene: preliminary findings of a cluster randomised controlled trial L. Yang\* (Hong Kong, Hong Kong), Y. Lai, J. Meng, Y. Li, J. Lu, S. Lu, J. Chen, C.F. Ho, E. Tartari, G. Birgand

L0044 18:18 Epidemiology, medical-surgical approach, and clinical and functional outcomes in fracture-related infection: an international multi-centre study from ESGIAI B. Dahiri Khattabi\* (Sevilla, Spain), B. Dahiri, R. García, M. Papadimitriou-Olivgeris, H. Ernandes, F. Almeida, J. Gomez-Junyent, O. Lesens, T. Martínez-Pascual, I. Contadini, D. Vaznaisiene, J.A. Iribarren-Loyarte, G. Euba, R. Escudero, J. Courjon, M.H. Ezzelarab, B. Sobrino-Díaz, A. Muñoz-Gómez, J. Rodríguez-Baño, M.D. Del Toro

OS116 17:30 – 18:30 Hall A2-2

1-hour Oral Session

AMR CLN TRN

**Challenging the status quo in herpesvirus therapy**

Chairs Sylviane Defres (Liverpool, United Kingdom)  
 Dionysios Neofytos (Geneva, Switzerland)

O0805 17:30 ABI-5366-101: a phase Ib study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpes M. Bloch\* (Sydney, New South Wales, Australia), E. Gane, C. Sellwood, A. Edwards, W. Hayter, T. Tonkin, K. Kaluhin, D. Smith, G. Wang, J. Liu, S. Knox, K. Zomorodi, K. Kitrinis, A. Gaggar, J. Sasadeusz

O0806 17:42 Helicase-primase inhibitor adibelvir (IM-250) shows potent antiviral activity against HSV clinical and acyclovir-resistant isolates and achieves therapeutic exposure in phase I/Ib studies G. Klyemann\* (Munich, Germany), A. Blank, M. Bergamino, J. Burhenne, D. Czock, C. Gege, Z. Haiying, A.C. Pérez-Osorio, B. Madarampalli, K.R. Jerome, N. Pretzsch, D. Huzly, V. Falcone, T. Hoffmann

O0807 17:54 Updated use of CHARMD, a comprehensive herpesviruses antiviral resistance mutation database and HSA tool for easy cytomegalovirus genotyping interpretation S. Alain\* (Limoges, France), V. Tilloy, D. Diaz-Gonzalez, S. Chou, G. Andrei, F. Baldanti, G. Boivin, H. Hirsch, T. Lazzarotto, M. Marcos-Angeles, D. Michel, W.D. Rawlinson, S. Hantz

O0808 18:06 Clinical experience of maribavir use for the treatment of refractory or resistant cytomegalovirus infection in solid-organ transplant recipients M. Jayne\* (London, United Kingdom), A. Stafford, K. Fung, G. Jones, R. Evans, M. Harber, R. Westbrook, J. Ryan, J. Potts, A. Marshall, M. Lanzman, N. Kanani Alvir, D. Cunningham, T. Haque, J. Hart, B. Patterson

O0809 18:18 Delayed treatment alters pharmacodynamics of anti-CMV drugs L. Sudarsono\* (Leiden, The Netherlands), K. Puspitasari, X. Liu, C. Van Hasselt, A.G. Mårtson

OS117 17:30 – 18:30 Hall A3-2

1-hour Oral Session

ANT CLN TRN

**PK/PD-based antimicrobial dosing optimisation in children**

Chairs William Couet (Poitiers, France)  
 Iris K. Minichmayr (Vienna, Austria)

O0810 17:30 Population pharmacokinetics of cefotaxime for optimising dosing in paediatric meningitis and bacteraemia Z.X. Mun\* (Melbourne, Australia), C. Landersdorfer, A. Gwee, A. Boast, A. Lei, A. Di Carlo, R. Chiletto, A. Daley, D. Fuhs, G. Gonis, B. Mcwhinney, A. Moody, R. Nation, J. Ungerer

O0811 17:42 Ceftazidime/avibactam in neonates and infants < three months old: population pharmacokinetic (PopPK) analysis and PopPK model application E. Soto\* (Sandwich, United Kingdom), J.L. Yan, P. Irani, R. England

O0812 17:54 Population pharmacokinetic/pharmacodynamic analyses of cefiderocol for paediatric patients D. Yamaguchi\* (Osaka, Japan), T. Katsube

O0813 18:06 Optimising posaconazole dosing in children through population PK modelling and simulation M.L. Vuong\* (Leuven, Belgium), O. Elkayal, J. Standing, S. Boonsathorn, Z. Kane, S. Bentley, A. Tragiannidis, A. Groll, J. Nickless, A. Brothers, A. Uyttebroeck, R. Valenzuela, J. Morales, I. Spriet, E. Dreesen

O0814 18:18 Evaluation of optimal empirical antibiotic combinations for neonatal sepsis in low- and middle-income countries: a pharmacokinetic/pharmacodynamic approach W. Van Os\* (Leiden, The Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, R. Zahra, G. Chan, D. Bekele, S. Solomon, A. Rucogoza, J.B. Mazarati, K. Iregbu, S.N.C. Uwaezuoke, A.B. Mairami, F.Z. Modibbo, L.I. Audu, S. Gambo, A. Aliyu, J.G.C. Van Hasselt

OS115 17:30 – 18:30 Hall ICM 1

1-hour Oral Session

CLN DX TRN

**Functional and translational advances in microbiome analysis**

Zinsstag (Basel, Switzerland)

<i>Chairs</i>		<i>Lena Biehl (Cologne, Germany)</i> <i>Maurizio Sanguinetti (Rome, Italy)</i>
00815	17:30	<b>Validation of microbiome-guided fluorescence <i>In situ</i> hybridisation (MG-FISH) in clinical microbiology: Integrating next-generation sequencing with molecular microbiome imaging</b> <i>J. Kikhney* (Leipzig, Germany), Z. Xiong, K. Sarbandi, M. Muchova, D. Von Schöning, A. Moter</i>
00816	17:42	<b>Machine learning-based optimisation of long-read 16S rRNA sequencing parameters enhances species-level microbiome classification</b> <i>A.K. Bari* (Groningen, The Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, B.J. Olij, J.H.E. De Lange, T.T. Severs</i>
00817	17:54	<b>Salivary host-microbe interactions reveal pathogenic signatures in early colorectal cancer</b> <i>S. Rezasoltani* (Aachen, Germany), H. Asadzadeh Aghdai, G. Conrads</i>
00818	18:06	<b>Culturomics-guided bacterial extracellular vesicle profiling reveals the gut microbiota's role in patients with CTLA4 deficiency</b> <i>R. Magdy Wasfy* (Montreal, Canada), C. Morin, M. Naegele Aranguren, C. Masse, J. Poudrier, E.L. Falcone</i>
00819	18:18	<b>Site-stratified multi-omics profiling reveals body site specific microbiome immune signatures for clinical state classification</b> <i>D. Sebukpor* (Chandigarh, India), I. Odezuligbo, M. Nagey, M. Chukwuka, O. Akinsuyi</i>

SY144 17:30 – 18:30 Hall A3-1

1-hour Symposium

**Update on STIs: epidemiology, drug resistance and role of DoxyPEP**

<i>Chairs</i>		<i>Arjan Harxhi (Tirana, Albania)</i> <i>Jean-Michel Molina (Paris, France)</i>
S0357	17:30	<b>The impact of travel on the global epidemiology of STIs</b> <i>Zofia Bartovska (Prague, Czechia)</i>
S0358	18:00	<b>Impact of DoxyPEP on the human microbiome and resistome</b> <i>Victoria Chu (San Francisco, California, United States)</i>

Co-organised with: ESCMID Education Subcommittee, ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

SY143 17:30 – 18:30 Hall B0-1

1-hour Symposium

**The future of pathogen surveillance: molecular data without borders**

<i>Chairs</i>		<i>Adrian Egli (Zurich, Switzerland)</i> <i>Paula Mölling (Örebro, Sweden)</i>
S0355	17:30	<b>The Swiss Pathogen Surveillance Platform: a model for international collaboration and data sharing</b> <i>Tim-Christoph Roloff (Zurich, Switzerland)</i>
S0356	18:00	<b>Lessons learned from the Trakka Data Sharing Ecosystem in Australia and beyond</b> <i>Benjamin Peter Howden (Melbourne, Australia)</i>

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)

SY142 17:30 – 18:30 Hall ICM 13b

1-hour Symposium

**Redefining One Health**

<i>Chairs</i>		<i>Pikka Jokelainen (Copenhagen, Denmark)</i> <i>Sonja Lofmark Behrendtz (Solna, Sweden)</i>
S0353	17:30	<b>New theoretical frameworks for One Health</b> <i>Julianne Meisner (Seattle, United States)</i>
S0354	18:00	<b>New operational frameworks for One Health</b> <i>Jakob</i>

EF118 17:30 – 18:30 Arena 1

ePoster Flash Session

**Beyond culture: spectroscopy for pathogen identification and typing**

<i>Chair</i>		<i>Angela Novais (Porto, Portugal)</i>
E0820	17:30	<b>FTIR spectral fingerprinting for rapid identification of high-risk Shiga toxin-producing <i>Escherichia coli</i> serotypes</b> <i>L. Díaz-Formoso* (A Coruna, Spain), S. Sánchez, G. Bou, M. Oviaño</i>
E0821	17:36	<b>Automated discrimination of <i>E. coli</i> from <i>Shigella</i> spp. using FT-IR spectroscopy and machine learning</b> <i>M. Cordovana* (Bremen, Germany), N. Mauder, A.B. Pranada, C. Hess, W. Geissdoerfer, F. Pankok, U. Loderstaedt, S. Scheithauer, D. Dekker, A.E. Zautner, J. Overhoff, M. Werner, A. Wille, P. Warnke, T. Koeller, P. Morales, M. Suleiman, A. Perez-Lopez, J. Jiménez-Rodríguez, P. Garcia, G. Da Silva Collar, N. Kehl Moreira, A.L. Barth, J. Caierao, O. Join-Lambert, A.A. Muntean, C. Ghitulescu, C. Daniela, M.I. Popa, R.M. Hagen, U. Schotte, H. Frickmann</i>
E0822	17:42	<b>Accelerated identification of high-risk <i>E. coli</i>/ST131 isolates via Fourier-transform infrared (FTIR) spectroscopy and neural network analysis</b> <i>N. Rakovitsky* (Tel Aviv, Israel), M. Bechor, A. Keren-Paz, Y. Carmeli</i>
E0823	17:48	<b>Development of surface-enhanced Raman spectra coupled with machine learning analysis for differentiation of closely related species within <i>Enterobacter cloacae</i> complex</b> <i>Y. Li* (Beijing, China), M. Zhou, X. Xu, Y. Xu, B. Gu, J. Gu</i>
E0824	17:54	<b>Discriminating old from new: application of Fourier-transform infrared spectroscopy (FTIR) to the reappearance of <i>Pseudomonas aeruginosa</i> in cystic fibrosis and primary ciliary dyskinesia</b> <i>M. Rossitto* (Rome, Italy), S. Raimondi, M. Cristiano, G. Vrenna, V. Fox, V. Tuccio Guarna Assanti, N. Essa, M.S. Lepanto, G. Foglietta, E. Montemiro, F. Alghisi, F. Majo, L. Cristiani, A. Boni, N. Ullmann, R. Cutrera, C.F. Perno, P. Bernaschi</i>
E0825	18:00	<b>Performance of a machine learning algorithm for FTIR-based typing of NDM-producing <i>Klebsiella pneumoniae</i> in a hospital outbreak</b> <i>C. Garrido* (Santiago, Chile), J. Jimenez, M. Lecerasi, A. Wozniak, G. Arratia, P. Garcia</i>
E0826	18:06	<b>Serotyping of <i>Haemophilus influenzae</i> strains and <i>Yersinia enterocolitica</i> by Fourier-transform infrared (FTIR) spectroscopy</b> <i>S. Zimmermann* (Heidelberg, Germany), C. Janssen, J. Rau, M. Cordovana, N. Mauder, T.T. Lam</i>
E0827	18:12	<b>Fourier-transform infrared spectroscopy as a tool for <i>Streptococcus pneumoniae</i> serotyping: optimisation of the PCV15-classifier (Version 2.0)</b> <i>J. Caierão* (Porto Alegre, Brazil), G. Rosa Da Cunha, C. Tondolo Romero, N. Kehl Moreira, A.L. De Oliveira Gonçalves, J. Cover Salvador, A. Luis Barth, C.A. Gomes Dias</i>
E0828	18:18	<b>Comparative evaluation of FTIR spectroscopy and whole genome sequencing for typing <i>Salmonella enteritidis</i></b> <i>S. Suto* (Zagreb, Croatia), S. Šuto, N. Pražić, T. De Zan, M. Kvaternik Celjak, J. Knežević, J. Vranes</i>

EF119 17:30 – 18:30 Arena 2

ePoster Flash Session

**When fungi break the rules: rare pathogens in unusual sites**

<i>Chair</i>		<i>Johan Maertens (Leuven, Belgium)</i>
E0829	17:30	<b><i>Candida</i> prosthetic joint infections, including multidrug-resistant <i>Candida auris</i>, at Hospital La Fe: a 15-patient 15-year experience (2010–2025)</b> <i>L. Brusca Vidao* (Valencia, Spain), S. Giner Almaraz, J. Frasset, P. Suárez Urquiza, P. Muñoz Brell, E. Gremaldos, C. Castillo Martínez, J.L. López Hontangas, A. Ruiz-Gaitán</i>
E0830	17:36	<b>Clinical features and outcomes of cryptococcosis associated with Bruton tyrosine kinase inhibitors: a multi-centre retrospective study and literature review</b> <i>R. Manchon* (Paris, France), C. Julien, D.</i>

		<i>Roos-Weil, B. Elodie, B. Charlotte, P. Thomas, O. Lortholary, C. Sharon, F. Lanternier, S. Monica, O. Paccoud</i>
E0831	17:42	<b>Beyond hepatosplenic candidiasis: the changing face of paediatric chronic disseminated yeast infection</b> <i>M. Husain*</i> (Paris, France), <i>F. Alby Laurent, J. Guitard, M. Gits-Muselli, B. Brethon, F. Lanternier</i>
E0832	17:48	<b>Rezafungin for <i>Candida</i> osteoarticular infections: the REZ-GEIO project</b> <i>S. De La villa Martínez*</i> (Madrid, Spain), <i>S. De La Villa, J. Guinea, J. Gómez Junyent, L. Ramos Merino, R. Escudero Sánchez, B. Sobrino, M.J. Moya, A. Muñoz, E. Múñez, M. Sánchez Somolinos, P. Sanz Ruiz, P. Muñoz</i>
E0833	17:54	<b>From detection to decision-making: clinical utility of plasma microbial cell-free DNA sequencing for invasive mould infections</b> <i>M. Al Mohajer*</i> (Houston, United States), <i>R. Berger, N. Howard, S. Grant</i>
E0834	18:00	<b>Prospective evaluation of itraconazole for the treatment of Jorge Lobo's disease (lobomycosis)</b> <i>A. Nishikaku*</i> (São Paulo, Brazil), <i>J. Nobrega De Almeida Jr, F. Gonçalves, R.R. Durlacher, M.R. De Sousa Trindade, A. Panizza Jalkh, M. De Melo Teixeira, M.D.V. Martino, A. Satie Nishikaku</i>
E0835	18:06	<b>Severe histoplasmosis in intensive care units: a multi-centre retrospective study in France</b> <i>L. Chantelot*</i> (Paris, France), <i>H. Kallel, L. Camous, E. Dufranc, L. Zafrani, T. Urbina, A. Curtiaud, F. Boissier, P. Szychowiak, D. Roux, A. Rouze, A. Robert, N. Heming, F. Pene, R. Sonnevill, S. Hraiech, G. Voiriot, G. Martin Blondel, J. Hayon, G. Jolly, N. Issa, E. Blanchard, F. Ader, M. Decavele, B. Peiffer, F. Botterel, A. Adenis, F. Lanternier, K. Razazi</i>
E0836	18:12	<b>Multi-centre outbreak of both <i>Magnusiomyces capitatus</i> and <i>Magnusiomyces clavata</i> in Italy</b> <i>B. Spruijtenburg*</i> (Nijmegen, The Netherlands), <i>E. De Carolis, C. Magri, M. Sanguinetti, T. De Groot, V. Di Pilato, M. Mikulska, J.B. Buil, E.F.J. Meijer</i>

EF120 17:30 – 18:30 Arena 3

AMR DX

ePoster Flash Session

#### Advances in AMR diagnostics

<i>Chair</i>		<i>Tomislav Kostyanev (Esbjerg, Denmark)</i>
E0838	17:30	<b>Evaluation of a new CRISPR-Cas-based assay for the detection of <i>bla</i>KPC in bacterial isolates</b> <i>A. Valêncio Siqueira*</i> (Massachusetts, United States), <i>A. VALÊNCIO Siqueira, A.C. Gales, P.J.M. Bispo</i>
E0840	17:42	<b>PathCrisp: a next-generation CRISPR diagnostic platform for rapid detection of antimicrobial resistance</b> <i>M. Naik*</i> (English, India), <i>K. Bs, R. Arora, S. Annes, D. Hafiz, D. Bhagchandani, V. Hegde, V. Chandru, V. Gupta</i>
E0841	17:48	<b>Rapid aptamer-based biosensor for identifying <i>K. pneumoniae</i> strains and testing meropenem-collistin susceptibility</b> <i>K.N. Yilmaz*</i> (Kars, Türkiye), <i>N. Ciftci, Z.O. Uygun</i>
E0842	17:54	<b>Digital AST Annotator: standardising Kirby-Bauer reading with an open-source app</b> <i>A. Guerrero-López*</i> (Zurich, Switzerland), <i>A. Diversi, E. Sosa, A.G. Monsalve, A. Egli</i>
E0843	18:00	<b>Comparative evaluation of a real-time PCR assay vs conventional culture for detecting carbapenemase-producing Gram-negative bacteria in rectal swabs</b> <i>A. Tychala*</i> (Thessaloniki, Greece), <i>P. Trikoupi, Z. Sereni, Z. Tsinaris, G. Kagkalou, O. Vasilaki, K. Kouirouxis, P. Mantzana, E. Protonotariou, L. Skoura</i>
E0844	18:06	<b>MIC creep in the shadows: an interactive dashboard for forecasting MIC trends in newer antimicrobials against MDR pathogens across WHO regions</b> <i>N. Nityadarshini*</i> (New Delhi, India), <i>J. Biswas, T. Bordoloi</i>
E0845	18:12	<b>Explaining phenotypic carbapenem resistance in GeneXpert-negative Gram-negative bacteria and evaluating concordance with whole genome sequencing</b> <i>S. Alotaibi*</i> (Riyadh, Saudi Arabia), <i>A. Alomani, S. Alharbi, M. Alghoribi, L. Faqih, T. Abdulrahman, F. Alasmari</i>
E0846	18:18	<b>Genomic surveillance in an LMIC: convergent collistin resistance in epidemic <i>Klebsiella pneumoniae</i> (ST11, ST147) in Peshawar, Pakistan</b> <i>M. Khan*</i> (Peshawar, Pakistan)

ME145 17:30 – 18:30 Hall ICM 5  
Meet-the-Expert

CLN DX VAX

#### Implementing WHO hepatitis guidelines in LMICs: challenges and perspectives

M0359 17:30 *Olufunmilayo Lesi (Geneva, Switzerland)*  
M0360 17:42 *Zeinab Said (Cairo, Egypt)*

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Society for the Study of liver Diseases in Africa (SOLDA), Slovenian Society for Infectious Diseases, British Infection Association (BIA)

PM007 17:30 – 18:30 Arena 4  
Policy Forum

AMR PHEI

#### From global research priorities to national and local impact: implementing AMR priority research agendas

*Chair* *Benedikt Huttner (Geneva, Switzerland)*

D0018 17:30 **Challenges and opportunities on the implementation of the OHPRA** *Sabiha Essack (Durban, South Africa)*  
D0019 17:45 **Implementing global research agendas on AMR: tracking research projects and activities** *Lesley Ann Ogilvie (Berlin, Germany)*  
D0020 18:00 **Aligning national research projects with global research agendas** *Gloria Cordoba (Copenhagen, Denmark)*  
D0021 18:15 **Promoting global research agendas for policy makers** *Geneviève Boily-Larouche (Toronto, Canada)*

## Tuesday, 21 April 2026

OS122 08:30 – 09:30 Hall A1-2  
1-hour Oral Session

CLN DX

#### Moving from culture to molecular diagnostics in implant-associated infections

*Chairs* *Thomas Fintan Moriarty (Davos, Switzerland)*  
*Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)*

O0847 08:30 **Rapid novel molecular method for enhanced detection of periprosthetic joint infection** *E. Morreel\** (Maastricht, The Netherlands), *P. Savelkoul, I. Van Loo*  
O0848 08:42 **Enhancing diagnostics in orthopaedic infections: clinical impact of syndromic multiplex PCR compared to traditional culture** *F. De Winter\** (Turnhout, Belgium), *N. Van Beek, J. Frans, T. Goegebuer, W. Schuermans, E. Van Even, P. Verbeeck, D. Van Der Beek, H. Nalils*  
O0849 08:54 **Optimising culture strategies in chronic orthopedic device-related infections: do blood culture bottles deliver?** *J. Van Heuverswyn\** (Ghent, Belgium), *H. Hamerlinck, D. Huis In 't Veld, S. Vandendriessche, B. Verhasselt, J. Boelens*  
O0850 09:06 **Pathogen spectrum of aortic graft infections uncovered by combined microbiologic testing and *in situ* metagenomic sequencing** *Q. Miao\** (Shanghai, China), *J. Yue, Y. Chen, Y. Luo, H. Liu, Y. Kan, B. Hu*  
O0851 09:18 **Utility of metagenomic sequencing of microbial cell-free DNA as a diagnostic tool in vascular graft and endograft infections: a cross-sectional study** *M. Eneberg\** (Aalborg, Denmark), *R.A. Nielsen, A.M.F. Eskildsen, M. Albertsen, N.P. Jørgensen, J. Budtz-Lilly, H.L. Nielsen, L.J. Østergaard, N.B. Stærke*

LB009 08:30 – 09:30 Hall A1-3  
1-hour Oral Session

CLN

#### Late-breaking clinical trials in sepsis management

*Chairs* *Jean-Francois Timsit (Paris, France)*  
*Steven Tong (Melbourne, Australia)*

L0046	08:30	<b>Imipenem/cilastatin-funobactam for hospital-acquired/ventilator-associated bacterial pneumonia: a multinational phase III trial (REITAB-2)</b> <i>K. Chang*</i> (Beijing, China), <i>Y. Wang, C. Wang, Z. Tang, J. Yin, J. Zhao, Y. Wang, B. Cao, T. Mei, A. Li, H. Li, Q. Jiang, P. Wang, F. Ye, L. Ding, Z. Liu, F. Yin, X. Mo, H. Qu, Y. Xia, J. Wang, J. Wu, S. Yang, R. Lin, G. Lv, H. Luo, B. Liu, J. Gu, F. Wei, J. Zhu, H. Liang, S. Qiu, H. Mai, X. Zhu, R. Yu, G. Han, T. Lou, H. Wang, J. Zhang, Y. Li, H. Wang, H. Lu, T. Xin, C. Li, X. Wang, X. Zhang, H. Gao, H. Wang, A. Pan, Q. Wang, J. Cao, Y. Zhu, Z. Xiao, L. Pan, S. Peng, X. Ding, Q. Chi, H. Xu, F. Liu, A. Guo, J. Zhan, Q. Zhang, R. Guo, J. Li, D. Zhu, H. Zhao, A. Cano Yuste, T. Huynh, I. Biney, K. Remy</i>	W0477	09:10	<b>Zoonotic influenza: from signals to public health response actions</b> <i>Angeliki Melidou</i> (Stockholm, Sweden)
L0047	08:42	<b>Low-dose CT cOmPared to Lung UltraSonography vs standard of care-based strategies for the diagnosis of pneumonia in the elderly: a multi-centre randomised controlled trial (OCTOPLUS)</b> <i>V. Prendki*</i> (Geneva, Switzerland), <i>J. Stirnemann, W. Hautz, N. Garin, A. Platon, E. Bernasconi, T. Ruder, A. Poncet</i>	W0478	09:30	<b>Antivirals and vaccines: readiness for a future influenza pandemic</b> <i>Marco Cavaleri</i> (Amsterdam, Belgium)
L0048	08:54	<b>A multi-centre, randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in severely ill neonates and children: BENEFICIAL trial</b> <i>P. De Cock*</i> (Ghent, Belgium), <i>R. Colman, A. Smits, F. Piersigilli, M. Renard, A. Van Damme, A. Clarysse, E. Dhont, S. Vanhaesebrouck, V. Bordon, L. Boland, B. De Wilde, A. Amza, L. Vanlanduyt, T.V.A. Nguyen, F. Cools, J. Van Der Werff Ten Bosch, D. Vens, F. Derriks, L. Houtekie, M. Reiner, D. Van Der Linden, P. Schelstraete</i>	<p>Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV), European Centre for Disease Prevention and Control (ECDC)</p> <hr/> <p>OS121</p> <p>08:30 - 10:30</p> <p>Hall BO-1</p> <p>2-hour Oral Session</p> <p>AMR</p> <p><b>Genomic epidemiology and emerging bacterial resistance</b></p> <p><i>Chairs</i> <i>Valeria Bortolaia</i> (Copenhagen, Denmark) <i>João Pires</i> (Oslo, Norway)</p>		
L0049	09:06	<b>Use of procalcitonin point-of-care test to guide de-escalation of empiric antibiotic therapy in adult patients with sepsis in a tertiary hospital in Bangladesh (PROCALBAN): a randomised, controlled, open-label trial</b> <i>F.U.H. Chowdhury*</i> (Oxford, United Kingdom), <i>R.A.M.E. Uddin, M. Ali, P.K. Dutta, D. Das, A.H. Hanif, M. Kar, F.B. Jahangir, S.I. Khan, M.M. Huq, A.A. Sayeed, M.H.O. Roshid, N.U. Chy, M.A. Hossain, M.A. Sattar, M. Schilstra, E. De Jong, C. Schultsz, M. Nijsten, M.J. Uddin, A. Ghose, K. Plewes, L. Pisani, P. Guerin, M. Mukaka, A.M. Dondorp</i>			
L0050	09:18	<b>Adjunctive clindamycin for treatment of <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial within the S. aureus Network Adaptive Platform (SNAP)</b> <i>A. Bowen*</i> (Wembley, Australia)	O0852	08:30	<b>Long-term persistence and cross-reservoir transmission of antimicrobial resistant <i>Serratia marcescens</i>: a genomic epidemiology study</b> <i>J. Lay*</i> (Melbourne, Australia), <i>B. Vezina, N. Macesic, J. Lacey, R. Patwa, A.Y. Peleg</i>
EW152	08:30 - 10:30	Hall A3-1	O0853	08:42	<b>High prevalence of NDM-5-producing <i>Escherichia coli</i> with Penicillin-Binding Protein 3 Mutations in Germany: An emerging threat?</b> <i>J.B. Hans*</i> (Berlin, Germany), <i>L.M. Höfken, S. Haller, S. Gatermann, S. Möller, N. Pfennigwerth, F. Reichert, M. Sandfort, M.A. Fischer, T. Semmler, T. Eckmanns, G. Werner</i>
<p>2-hour Educational Session</p> <p>PED VAX</p> <p><b>Vaccination during pregnancy: for the mother, and for the child</b></p> <p><i>Chairs</i> <i>Olivier Epaulard</i> (Grenoble, France) <i>Ulrich Heininger</i> (Basel, Switzerland)</p>		O0854	08:54	<b>A decade of evolving <i>Pseudomonas aeruginosa</i> resistance: epidemiology and antimicrobial trends (2014-2024)</b> <i>D. Mendes Pedro*</i> (Lisbon, Portugal), <i>M. Meneses, C. Mimoso Santos, A. Bruschy Fonseca, Á. Ayres Pereira, E. Valadas, J. Melo Cristino, C. Caneiras</i>	
W0479	08:30	<b>Burden of vaccine-preventable infections in pregnant women</b> <i>Shamez Ladhani</i> (London, United Kingdom)	O0855	09:06	<b>Associations between antidepressant prescribing and antibiotic resistance in <i>Escherichia coli</i> urinary tract infections in Scotland</b> <i>L. Ciaccio*</i> (Dundee, United Kingdom), <i>K.N. Barnett, C.A. Marwick, B.J. Parcell, H. Wang, J. Danial, F. Kerr, J. McEwen, A. Morrison, D. O'driscoll, A. Seaton</i>
W0480	08:50	<b>Mother-to-child transmission of antibodies: how and when</b> <i>Marta Nunes</i> (Lyon, France)	O0856	09:18	<b>Integrated genomic surveillance of carbapenemase-producing <i>Klebsiella pneumoniae</i> in Germany in 2023-2024 revealed frequent case imports from abroad and local outbreaks</b> <i>M. Sandfort*</i> (Berlin, Germany), <i>L.M. Höfken, F. Reichert, M.A. Fischer, S. Möller, J.B. Hans, H. Öhler, D. Said, N. Pfennigwerth, T. Eckmanns, G. Werner, S.G. Gatermann, S. Haller</i>
W0481	09:10	<b>Vaccination of pregnant women to protect the child: successes and hurdles</b> <i>Pawel Stefanoff</i> (Stockholm, Sweden)	O0857	09:30	<b>The emergence and spread of NDM-type carbapenemase-producing <i>Acinetobacter baumannii</i> clones in Hungary</b> <i>A. Hanczvikkel*</i> (Budapest, Hungary), <i>D. Göbhardtter, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Holub, L. Majoros, K. Kamotsay, M. Farkas, A. Kark, K. Mályi, B. Roskó, M.A. Peti, Á. Tóth</i>
W0482	09:30	<b>Vaccination during pregnancy: from doctors to mother-to-be, who is hesitant?</b> <i>Emilie Karafillakis</i> (London, United Kingdom)	O0858	09:42	<b>Clonal complex 398 emerging as community- and healthcare-associated methicillin-resistant <i>Staphylococcus aureus</i> in the Czech Republic 2017-2024</b> <i>J. Tkadlec*</i> (Prague, Czechia), <i>A. Rozsypalkova, S. Polivkova, P. Drevinek, J. Gooskens, M. Krutova</i>
<p>Co-organised with: ESCMID Vaccine Study Group (EVASG)</p>		O0859	09:54	<b>Epidemiological and molecular insights of community- and hospital-acquired MRSA in Antwerp, Belgium</b> <i>D. De Smet*</i> (Antwerp, Belgium), <i>B.B. Xavier, S. Van Goethem, P. Van Lint, W. Verstrepen, R. Naesens</i>	
EW151	08:30 - 10:30	Hall ICM 13a	O0860	10:06	<b>Antimicrobial resistance in the zoonotic pathogen <i>Capnocytophaga canimorsus</i>: global distribution of resistance genes and their phenotypic impact</b> <i>Z. Germuskova*</i> (Zurich, Switzerland), <i>E. Pronzini, T. Roloff, H. Seth-Smith, K.K. Sagaard, E.M. Broens, F. Renzi, A. Egli</i>
<p>2-hour Educational Session</p> <p>DX PHEI</p> <p><b>Bird flu is no longer just for birds: from strategic planning to public health readiness</b></p> <p><i>Chairs</i> <i>Edoardo Colzani</i> (Solna, Sweden) <i>Barbara Rath</i> (New Orleans, United States)</p>		O0861	10:18	<b>Comprehensive genomic surveillance of invasive <i>Salmonella</i> in India reveals plasmid evolution and expanding antimicrobial resistance</b> <i>V. Shamanna*</i> (Bengaluru, India), <i>P.R. Sowmya, S. Varun, C. Natacha, N. Geetha, K.L. Ravikumar</i>	
W0475	08:30	<b>What drives pandemic risk? Virus, population and policy factors influencing Influenza H5N1 spread</b> <i>Benjamin Cowling</i> (Pokfulam, Hong Kong)	SY148	08:30 - 10:30	Hall A1-1
W0476	08:50	<b>Surveillance in action: diagnostic tools for early</b>	<p>2-hour Symposium</p> <p>CLN DX</p> <p><b>Advancing diagnostic strategies for detecting bacteraemia across the globe</b></p> <p><i>Chairs</i> <i>Christina Obiero</i> (Kilifi, Kenya)</p>		

Agnes Maria Sonnevend (Pécs, Hungary)

- S0463 08:30 Rethinking bacteraemia: how diagnostic innovation is improving outcomes *Kai Sohn (Stuttgart, Germany)*
- S0464 09:00 From PCR to whole genome: the molecular revolution in bacteraemia diagnosis *Kwan Ki Karrie Ko (Singapore, Singapore)*
- S0465 09:30 Low-tech blood culture techniques and protocols: what is truly necessary? *Liselotte Hardy (Antwerp, Belgium)*
- S0466 10:00 Needs and barriers for performing blood cultures in resource limited settings *Makeda Semret (Montreal, Canada)*

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

SY149 08:30 - 10:30 Hall A2-1  
2-hour Symposium

CLN TRN

### The role of the microbiome in shaping clinical outcomes in immunocompromised patients

Chairs *Nicolas Benech (Lyon, France)*  
*Silvia Corcione (Turin, Italy)*

- S0467 08:30 The role of the microbiome in immune reconstitution after cancer therapy *Kate Markey (Seattle, United States)*
- S0468 09:00 Targeting the gut microbiome: an emerging trend in haematopoietic stem cell transplantation *Jonathan Peled (New York, United States)*
- S0469 09:30 Optimising cancer treatment through gut microbiome modulation *Maria Rescigno (Pieve Emanuele, Italy)*
- S0470 10:00 Role of microbiome in GVHD *Mette Hazenberg (Amsterdam, The Netherlands)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY150 08:30 - 10:30 Hall A2-2  
2-hour Symposium

DX

### The real-world impact of IVDR on patient care: threat or opportunity?

Chairs *Antti Hakanen (Turku, Finland)*  
*David Ong (Rotterdam, The Netherlands)*

- S0471 08:30 Implications of IVDR on clinical decision making and patient care *Erlangga Yusuf (Rotterdam, The Netherlands)*
- S0472 09:00 IVDR impact on molecular diagnostic workflows *Maurizio Sanguinetti (Rome, Italy)*
- S0473 09:30 How metrology can support IVDR and outbreak response *Esmeralda Valiente (Berlin, Germany)*
- S0474 10:00 IVDR from a European policy perspective *Gülşen Özkaya Şahin (Lund, Sweden)*

Co-organised with: Clinical Microbiologists of Finland, Dutch Society for Medical Microbiology (NVMM), ESCMID Ethics Advisory Committee, ESCMID Professional Affairs Subcommittee, Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), UEMS, Biomed Alliance

SY147 08:30 - 10:30 Hall ICM 1  
2-hour Symposium

ANT CLN

### The what and how of using AI in antimicrobial stewardship

Chairs *Mark G. J. De Boer (Leiden, The Netherlands)*  
*Mark Gilchrist (London, United Kingdom)*

- S0459 08:30 An introduction and overview of the evolving use of AI in antimicrobial stewardship *Bradley Langford (Etobicoke, Canada)*
- S0460 09:00 Responsible use of AI in prediction modeling for real-life clinical practice tools *Pontus Naucler (Stockholm, Sweden)*
- S0461 09:30 The role of ChatGPT and AI chatbots in optimising

antibiotic therapy: believe or disbelieve? *Alexis Maillard (Paris, France)*

- S0462 10:00 Is AI the key to acceleration of Antimicrobial Stewardship in LMICs? *Mike Nsubuga (Bristol, United Kingdom)*

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Society of Infectious Diseases Pharmacists (SIDP)

SY146 08:30 - 10:30 Hall ICM 5  
2-hour Symposium

CLN DX TRN

### Fungal OMICS: from bench to bedside

Chairs *Lottie Brown (London, United Kingdom)*  
*Josh Nosanchuk (Bronx, United States)*

- S0455 08:30 Evolutionary genomics of emerging fungal pathogens *Toni Gabaldón (Barcelona, Spain)*
- S0456 09:00 Host transcriptome response to *Candida auris* extracellular vesicles *Lysangela Ronalte Alves (Curitiba, Brazil)*
- S0457 09:30 How *Candida* drives oral cancers: host and pathogen omics *Attila Gacser (Szeged, Hungary)*
- S0458 10:00 Functional consequences of mycobiota on host immunity *Tobias Hohl (New York, United States)*

EF123 08:30 - 09:30 Arena 2  
ePoster Flash Session

CLN

### Novel aspects on epidemiology and therapeutics of urinary tract infections

Chair *Suzanne Geerlings (Amsterdam, The Netherlands)*

- E0862 08:30 Incidence of urinary tract infections among diabetic and non-diabetic patients following treatment with SGLT-2 inhibitors compared with GLP-1 receptor agonists *O. Biham\* (Lehavim, Israel), L. Hassan, N. Burrack, L. Neshet*
- E0863 08:36 Characterising complicated urinary tract infections (POS-cUTI): preliminary results of a multinational prospective cohort (POST-cUTI / ECRAID) *J.M. Bravo-Ferrer\* (Seville, Spain), E. Rubio Martin, N. Maldonado, B. Gallego, E. Moreno, F. Cogliati Dezza, R. Compagnone, I. Portillo, A. Barac, F. Arieti, O. Awwad, P. De Nardo, A. Cano, P. Clevenbergh, N. Merchante, A. Hernandez-Torres, E. Frangou, E. Merino, T. Lafon, T. Ten Doesschate, O. Sandulescu, B. Koprivica, P. Andrade, A. Ternhag, M. Samarkos, M. Bokhari, A. Bandera, L. Jacquín, E. Iosifidis, E. Durante-Mangoni, D. Chadwick, J. Rupp, P. Muñoz-García, A. Røder, D. Viglino, J. Van Laethem, B. Kjurchikj, G. Marchetti, S. Tsiodras, M. David, A.R. Veiga-Ferraz, J.R. Paño-Pardo, C. Kirakli, N. Catorze, M. Tumbarello, M. Akova, I. Gentile, A. Bartoloni, L. Radulovic, C. Constantinou, M. Bonten, L.P.G. Derde, E. Cappelli, E. Tacconelli, J. Rodríguez-Baño*
- E0864 08:42 Clinical effectiveness of four different short-course antibiotic regimens in adult women with bacteriological confirmation of urinary tract infection *R. Monfà\* (Barcelona, Spain), R. Monfà, A. García-Sangenis, R. Morros, C. Llor, D. Ouchi, S. Fernández-García, C. Miranda-Jiménez, A. Moragas, M. Aguilar-Sánchez, A. Leiva, A. Troncoso-Mariño, J. Marín-Cañada, R. Rodríguez, J.M. Molero, M.A. Sánchez-Calavera*
- E0865 08:48 Proteomic endotypes in patients with *Escherichia coli* pyelonephritis *L. Bolinder\* (Stockholm, Sweden), T. Sutantiwanichkul, A. Reepalu, A. Linder, L. Mellhammar, M. Sundqvist, D. Nestor, C. Unge, A. Färnert, H. Janols, M. Lipcsey, J. Sundén-Cullberg, S. Cajander, M. Uhlén, F. Edfors, K. Strålin*
- E0866 08:54 Predicting antibiotic resistance risk in urinary tract infections using machine learning to support safer empirical prescribing in hospitalised children and adults *L. Aerts\* (Basel, Switzerland), D. Malpetti, S. Bouizaguen, C. Berchtold, P. Neuschwander, G. Greub, L. Azzimont, J.A. Bielecki*
- E0867 09:00 Nitrofurantoin for *Neisseria gonorrhoeae* urethritis? an *in vitro* and *in vivo* study in *Galleria mellonella* *C. Kenyon\* (Antwerp, Belgium), S. Manoharan-Basil, I. Kanesaka, I. De Baetselier, S. Abdellati, T. De Block, T.*

*Vanbaelen, R. Naesens, B. Britto Xavier*

E0868	09:06	<b>The effectiveness of a weekly antimicrobial stewardship intervention on antibiotic prescriptions in Dutch nursing homes: a randomised controlled trial</b> <i>L. Van Buul* (Amsterdam, The Netherlands), K. Paap, M. Schim Van Der Loeff, S. Kuil</i>
E0869	09:12	<b>In private facilities, expensive medications are sometimes used as a first choice: attitudes and practice of health care workers in the management of UTIs in Kampala, Uganda</b> <i>D. Ekusai Sebatia* (Kampala, Uganda), D. Ekusai-Sebatia, N. Miriam, P. Kirabo, J. Enomot, M. Iwami, H. Kajumbula, F. Kitutu, J. Kapisi, C.E. Moore</i>
E0870	09:18	<b>Clinical symptom improvement and resolution following uUTI treatment with gepotidacin: a post-hoc subgroup analysis</b> <i>J. Diaz-Regañon* (Madrid, Spain), K. Gupta, D. Powell, R. Banerjee, J. Bablani, S. Janmohamed, M. Ramirez</i>

**CGR** **08:30 - 10:30** **Hall ICM 14**  
Special Session

**Clinical grand rounds**

*Chair* *Robert C. Read (Southampton, United Kingdom)*

*Chairs* *Yoav Keynan (Winnipeg, Manitoba, Canada)*  
*Nina Khanna (Basel, Switzerland)*  
*Dimitrios P. Kontoyiannis (Houston, United States)*  
*David L. Paterson (Singapore, Singapore)*  
*Priscilla Rupali (Vellore, India)*  
*Monica Slavin (Melbourne, Australia)*

- CGR01** **Case 1** *Tom Cartau (Caen, France)*
- CGR02** **Case 2** *Paul M. I. Chabert (Dumbéa, New Caledonia)*
- CGR03** **Case 3** *Johanna Erber (Munich, Germany)*
- CGR04** **Case 4** *Rotem Gorfinkel (Kibbutz Beer, Israel)*
- CGR05** **Case 5** *Rohan Patel (London, United Kingdom)*
- CGR06** **Case 6** *Lauren Saint (Chapel Hill, North Carolina, United States)*
- CGR07** **Case 7** *Samuel Showalter (Aurora, United States)*
- Co-organised with: Infectious Disease Society of America (IDSA)

**OS125** **09:30 - 10:30** **Hall A1-4**  
1-hour Oral Session

**Regulatory, metabolic, and evolutionary mechanisms shaping *Staphylococcus aureus* pathogenesis**

*Chairs* *Frédéric Laurent (Lyon, France)*  
*Marc Stegger (Copenhagen, Denmark)*

- O0871** **09:30** **Investigating antibiotic tolerance among clonal pairs of *Staphylococcus aureus* derived from cystic fibrosis lung infections** *A. Deventer\* (St Andrews, United Kingdom), J. Pearson, J. Hobbs*
- O0872** **09:42** **Whole genome CRISPRi-seq reveals a cation-proton antiporter as a critical determinant of *Staphylococcus aureus* survival in monocytes like cells** *A. Iizuka\* (Basel, Switzerland), M.V. Mazzuoli, E. Demirbilek, A.K. Woischnig, D. Bumann, J.W. Veening, A. Zinkernagel, N. Khanna*
- O0873** **09:54** **Integrating phylogenetics and GWAS to uncover drivers of methicillin-sensitive *Staphylococcus aureus* bacteraemia and colonisation** *D. Aggarwal\* (London, United Kingdom), A.J. Van Tonder, L. Du Plessis, W. Figueroa, B. Blane, K.L. Bellis, C. Raisen, X. Ba, E. Lay, E. Nickerson, L. Bedford, R. Sanderson, W. Smith, B. Warne, T. Gouliouris, M.E. Torok, M.A. Holmes, J. Parkhill, F. Coll, S.J. Peacock, E.M. Harrison*
- O0874** **10:06** ***Streptococcus pneumoniae* weaponises its own electrical signature to launch ROS attack against *Staphylococcus aureus*** *X. Wu\* (Hangzhou, China), L. Liu, Y. Wang, Y. Jiang, Y. Yu*
- O0875** **10:18** **Simple sequence repeats power *Staphylococcus aureus* adaptation** *R. Guérrillot\* (Melbourne, Australia), A.S. Hayes, A. Hachani, S.G. Giulieri, L. Donovan, L.M. Judd, L.K. Sharkey, A. Gonçalves Da Silva, T. Seemann, T.P. Stinear, B.P. Howden*

**OS124** **09:30 - 10:30** **Hall ICM 13b**  
1-hour Oral Session

**Facing severe bacterial infections in neonates and children**

*Chairs* *Dana Danino (Beer Sheva, Israel)*  
*Johannes Hübner (Munich, Germany)*

- O0876** **09:30** **Appropriateness of empirical antibiotic therapy and mortality in neonatal sepsis across LMIC hospitals** *K. Thomson\* (Oxford, United Kingdom), C. Achi, B. Hassan, R. Farzana, K. Sands, O.B. Spiller, L.C. Jones, J. Rzaska, A. Cooke, J. Aziz, C. Farley, C. Phillips, J. Spencer, J. Oduwo, E. Owinoh, K. Iregbu, N. Medugu, C. Chieze, K. Abdulraheem, F.Z. Zango Abdi, A. Aminu, R. Y. Khalid, M. Bello, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyobo, O. Olutekunbi, A. Odedina, I. Nwafia, S. Ihezuruoha, U. Ibekwe, N. Haque, S.B. Proma, S. Arefin, S. Khatun Sara, R. Khatun, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, S. Arif, S. Riaz, S.S. Gul, S. Naqvi, H. Hamid, R. Sajjad, A. Sajid, T.R. Walsh*
- O0877** **09:42** **Revising vancomycin dosing recommendations in critically ill children using a population PK approach based on unbound concentrations** *A.T.V. Nguyen\* (Ghent, Belgium), S. Carter, F. Klopogge, J. Standing, V. Stove, D. Sarah, E. Dhont, D. Vens, P. De Paepe, P. De Cock*
- O0878** **09:54** **Epidemiology and vaccine coverage of group B streptococcal disease in infants zero-three months old in the Netherlands, 1987-2023** *M. Groenvelde\* (Amsterdam, The Netherlands), D. Jamroz, M.C. Brouwer, D.H. Visser, D. Van De Beek, M.W. Bijlsma, N.M. Van Sorge*
- O0879** **10:06** **Population validation of Phoenix criteria for identifying paediatric sepsis** *S.H. He\* (Hong Kong, China), J.Z. Zhang, L.C.N. Chan, A. Lin, K.Y. Yeung, M.C.I. Kuok, J.W.C.H. Cheng, D.C.Y. Au, C.Y. Chow, T.W. Wong, W.K. Wong, E. Chan, H.M. Young, E.M. Wong, K.M. Ho, A. Lee, C. Rhee, H.S. Lam, L. Ling*
- O0880** **10:18** **Oral step-down antibiotic therapy in children with infective endocarditis: the EndoChild retrospective study** *M. Husain\* (Paris, France), M. Potie, P. Labe, P. Parize, J. Cohen, E. Bille, D. Khraiche, J. Toubiana*

**SY153** **09:30 - 10:30** **Hall A3-2**  
1-hour Symposium

**Pro/con debate: is One Health essential or a distraction in AMR related policies?**

*Chairs* *Elena Carrara (Verona, Italy)*  
*Timothy R. Walsh (Oxford, United Kingdom)*

- S0483** **09:30** **AMR is the quintessential One Health issue** *Sabiha Essack (Durban, South Africa)*
- S0484** **10:00** **One Health is distracting us from addressing policy gaps** *Heiman Wertheim (Nijmegen, The Netherlands)*

**EF126** **09:30 - 10:30** **Arena 1**  
ePoster Flash Session

**Clinical and diagnostic insights into invasive fungal diseases**

*Chair* *Cecile Angebault (Creteil, France)*

- E0881** **09:30** **Detection of Mucorales antigen in serum samples using a newly developed lateral-flow device** *J. Rousselot\* (Besançon, France), L. Millon, E. Scherer, A.P. Bellanger, C.R. Thornton*
- E0882** **09:36** **High rates of *Candida* colonisation in European neonates: a sub-analysis of the NeoVanc randomised controlled trial** *L.F. Hill\* (London, United Kingdom), L. Ferreras-Antolin, M.N. Clements, F. Shahed, J. Fermin Luque, I. Monahan, T. Planche, M.A. Turner, I. Lutsar, E. Roilides, M. Sharland, J.A. Lindsay, P.T. Heath*
- E0883** **09:42** **Epidemiology, resistance patterns, and outcomes of candidaemia acquired in Italian intensive care units: Insights from the GIVITI Network (2020-**

		2024) <i>G. Scaglione*</i> (Milan, Italy), <i>M. Colaneri, M. Offer, G. Montrucchio, C.G.I. Genovese, B. Viaggi, F. Dore, G. Tricella, L. Dalfino, G. Monti, A. Gori, E.P.I. Palomba, S. Finazzi</i>	E0896	10:06	Genomic epidemiology of multidrug-resistant <i>Enterobacteriaceae</i> in intensive care units: a one year prospective study in adult intensive care units of three French university hospitals <i>F. Gravey*</i> (Caen, France), <i>C. Bernachot, K. Le Neindre, D. Ducheyron, J.B. Decros, F. Tamion, S. Boyer, T. Clavier, J. Maizel, H. Dupont, N. Lemaitre, J. Brochart, H. Marini, S. Galopin, M. Godet, S. Le Hello, C. Jeanne-Leroy, O. Join-Lambert</i>
E0884	09:48	CandEYE: serial non-mydriatic fundoscopy in patients with candidaemia <i>I. Reinhold*</i> (Cologne, Germany), <i>J. Müller, L. Altay, A. Lentzsch, K. Löw, E. Mackevic, J. Salmanton-García, C. Cursiefen, O.A. Cornely, R. Sprute</i>	E0897	10:12	Evaluation of the applicability of nanopore-only whole genome sequencing for <i>Pseudomonas aeruginosa</i> outbreak investigation in the ICU setting: a multi-centre study <i>J. Dingemans*</i> (Hasselt, Belgium), <i>S. Vandersanden, P. Hilkens, F. Crombé, D. De Geyter, A.M. Van Den Abeele, P. Bruynseels, J. Frans, P. Vandecandelaere, A. Boel, R. Cartuyvels, K. Magerman</i>
E0885	09:54	Clinical, laboratory and financial evaluation of diagnostic testing for Invasive <i>Aspergillus</i> infections in haemato-oncology patients with neutropenic fever in a large U.K. teaching hospital <i>J. Moore*</i> (Cambridge, United Kingdom), <i>W. Hamilton, P. Patel, A. King, J. Mason, D. Enoch</i>	E0898	10:18	<i>Pseudomonas aeruginosa</i> genome adaptations in bleached sink traps <i>D. Hocquet*</i> (Besançon, France), <i>T. Chautrand, L. Masson, C. Couchoud, B. Valot</i>
E0886	09:54	Diagnostic value of galactomannan in tracheobronchial aspirate for <i>Aspergillus</i> infection in lung transplant recipients (the GALACTBAS study) <i>A. Monforte Pallares*</i> (Barcelona, Spain), <i>A. Monforte, M.T. Martín-Gómez, C. Berastegui, E. Márquez-Algaba, J. Sacanell, J. Rosado, A. Falcó-Roget, G. Escudero, J. Casanovas, C. Kirkegaard-Biosca, B. Sáez-Giménez, V. Monforte, J. Gavaldá, O. Len, I. Los-Arcos</i>	EF128	09:30 - 10:30	Arena 4
E0887	10:00	Fungal diagnostic approach among hospitalised patients receiving polyene vs azole in US, 2021-2024 <i>E. Harvey*</i> (Baltimore, United States), <i>M. Zilberberg, A. Knee, Q. Andan, B. Nathanson, T. Sandison, K. Marr, A. Shorr</i>			ePoster Flash Session
E0888	10:12	<i>Pneumocystis jirovecii</i> pneumonia in solid organ transplant recipients: a cross-sectional study in France <i>A. Alanio*</i> (Paris, France), <i>K. Sitbon, T. Obadia, M. Desnos-Ollivier, D. García-Hermoso, V. Bru, G. Desoubreux, E. Guemas, M.F. Durieux, F. Morio, F. Robert-Gangneux, J. Bonhomme, F. Lanternier, O. Lortholary</i>			CLN PED TRN
E0889	10:18	A qPCR identification scheme to detect the most common mycetoma causative agents in Africa <i>W. Van De sanDe*</i> (Rotterdam, The Netherlands), <i>A. Watson, S. Bakhiet, E. Siddig, C. Pab Minlekib, R. Mohammed, W. Zandjick, M. Konings, A. Fahal, M. Faye, F. Mazraati Tajabadi, J. Errington, D. Sow</i>	CNS infections at a crossroad: rising lineages, host susceptibility and novel mechanisms		
			Chair	<i>Emmanuelle Varon</i> (Creteil, France)	
EF127	09:30 - 10:30	Arena 3	E0899	09:30	Epidemiology, clinical characteristics and outcomes of invasive meningococcal disease caused by two hypervirulent serogroup W strains belonging to the ST11 clonal complex in England (2010-2019) <i>I. Isitt*</i> (Stockholm, Sweden), <i>H. Campbell, J. Lucidarme, S. Clark, P.T. Heath, R. Borrow, S.N. Ladhani</i>
		ePoster Flash Session	E0900	09:36	Antimicrobial exposure but not vaccination predicts oropharyngeal <i>Neisseria meningitidis</i> clearance among men who have sex with men <i>M.F. Lucente*</i> (Milan, Italy), <i>F. Ranaldi, A.R. Raccagni, N. Capra, R. Lolatto, C. Candela, M. Ripa, G. Catalano, A. Castagna, S. Nozza</i>
		AMR DX IPC	E0901	09:42	Global expansion of a CTX-M-15-chromosomally integrated <i>Escherichia coli</i> /ST1193 sublineage (ST1193-B1-Rx) identified in neonatal meningitis in France, 2000-2023 <i>Y. Benhadid-Brahmi*</i> (Paris, France), <i>K. La, G. Geslain, J. De Larminat, P. Bidet, A. Cointe, L. Armand, C. Courroux, S. Bonacorsi, A. Birgy</i>
Genomic surveillance for infection prevention and outbreak investigation			E0902	09:48	A decade of invasive Group B <i>Streptococcus</i> infection in South African neonates and infants: findings from a retrospective laboratory-based study <i>M. Said*</i> (Pretoria, South Africa), <i>I. Majira, R. Peters, S. Vally Omar, K. Govender</i>
Chair	<i>Richard V. Goering</i> (Omaha, Nebraska, United States)		E0903	09:54	Asplenia and functional hyposplenia in community-acquired bacterial meningitis in adults <i>E. Schepers*</i> (Amsterdam, The Netherlands), <i>V. Boon, E. Drost, M. Brouwer, D. Van De Beek</i>
E0890	09:30	From potential to practice: an internationally transferable roadmap for implementing whole genome sequencing in infection prevention and control <i>J. Price*</i> (Brighton, United Kingdom), <i>J. Otter, E. Jauneikaite</i>	E0904	10:00	Neurological manifestations attributable to <i>Mycoplasma pneumoniae</i> in adults during the 2023-2024 epidemic: clinical features, management, and outcomes <i>M. Holub*</i> (Paris, France), <i>R. Palich, A. Gavaud, C. Louapre, A. Bleibtreu, C. Cazanave, V. Pourcher, M. Le Marechal, G. Martin Blondel</i>
E0891	09:36	Full-chain genomic surveillance reveals ecological and genetic determinants of <i>Staphylococcus aureus</i> transmission <i>S. Liu*</i> (Beijing, China), <i>K. Wang, M. Wang, C. Yao, Q. Wang, H. Wang</i>	E0905	10:06	Increasing importance of <i>Streptococcus anginosus</i> group as a cause of invasive streptococcal infection in the UK: a retrospective longitudinal observational study <i>E. Gil*</i> (London, United Kingdom), <i>J. Hatcher, S. De Saram, T. Patel, T. Lamagni, R. Guy, M. Marks, J. Brown</i>
E0892	09:42	Exploring filth files as sentinels of hospital environments in 16 countries and regions: high prevalence of clinically relevant antimicrobial-resistant bacteria observed in resource-limited settings <i>K. Sands*</i> (Oxford, United Kingdom), <i>E.A. Portal, T. Iannetelli, S. Premchand-Branker, T. Beard, M. Li, K. Cook, A.K. Lankapalli, V. Dougnon, A. Gaye, A. Opazo-Capurro, A.M. Soliman, M.H. Legese, J. Acolatse, E. Carretto, E.G. Kibaru, O. Sy, K. Iregbu, A. Zukowska, M.C. Seck, A.R. Mansaray, H. Kuo, C. Graham, P. Nel, C. Achi, T.R. Walsh</i>	E0906	10:12	In experimental neurosteriosis, the matrix metalloproteinases inhibitor clemastat protects the brain from apoptotic neuronal injury <i>D. Grandgirard*</i> (Bern, Switzerland), <i>E. Stahovic, M. Erhardt, S.L. Leib</i>
E0893	09:48	Genomic insights into carbapenem-resistant <i>Klebsiella pneumoniae</i> from bloodstream infections in Crete, Greece <i>K. Tryfinopoulou*</i> (Heraklion, Greece), <i>G.C. Karfaki, D. Marinopoulou, T. Iatridi, M. Malliarou, E. Skliva, D. Stafylaki, E. Chatzidospyridaki, S. Karakonstantis, P. Ioannou, D. Kofteridis, A. Psaroulaki, D. Chochlakis</i>	E0907	10:18	Rhbd12 modulates inflammation, coagulation and vascular responses in experimental pneumococcal meningitis <i>D. Bakker*</i> (Amsterdam, The Netherlands), <i>R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Beek</i>
E0894	09:54	ST11 on the move: recurrent capsule switching and the rise of KL62 <i>Y. Feng*</i> (Chengdu, China), <i>Z. Zong</i>	OS131	11:00 - 12:00	Hall A1-1
E0895	10:00	Outbreak of carbapenemase-carrying plasmids in Urology: implications of bladder irrigation pipe systems <i>A. Freijo Cancio*</i> (Seville, Spain), <i>A. Freijo, M. Delgado-Valverde, J. Rodriguez-Baño, R. López-Marquez, A. Pascual, L. López-Cerero</i>			

TRN

1-hour Oral Session

**Bacterial adaptation: from colonization to pathogenesis**

<i>Chairs</i>		<i>Michael Bachman (Ann Arbor, Michigan, United States)</i> <i>Elisabeth Grohmann (Berlin, Germany)</i>		
00908	11:00	<b>Listeria monocytogenes</b> clonality within the brain revealed by sequence tag-based analysis of microbial populations (STAMP) <i>K. Toms* (Paris, France), P. Gastineau, J. Gaillard, P. Thouvenot, S. Levallois, M. Lecuit</i>	00920	11:24
00909	11:12	Integrated multi-omics reveals coordinated <b>Staphylococcus aureus</b> metabolic, iron transport, and stress responses to human serum <i>A. Hachani* (Melbourne, Australia), W. Mujcharyyakul, C. Walsh, S. Giulieri, C. Cramond, K.A. Lecaio, T. Stinear, B. Howden, R. Guerillot</i>	00921	11:36
00910	11:24	IgaA mutation enhances extracellular polysaccharides production and virulence via Rcs phosphorelay in <b>Enterobacter cloacae complex</b> <i>Y. Li* (Beijing, China), M. Zhou, Y. Xu</i>	00922	11:48
00911	11:36	Transcriptional reprogramming driving enterococcal persistence unveiled by RNA-sequencing <i>J. Guerreiro* (Lisboa, Portugal), C. Geraldes, C. Silva, F. Vale, E. Cunha, L. Tavares, J. Fernandes Guerreiro, M. Oliveira</i>		
00912	11:48	Polymicrobial biofilm communities potentiate host damage in a 3D human bladder microtissue model <i>R. Garcia Maset* (Oxford, United Kingdom), A. Crowther, V. Chu, I. White, L. Pasquina-Lemonche, M. Hadjifrangiskou, E. Stride, D. Carugo, J. Rohn</i>		

OS132 11:00 - 12:00 Hall A1-3

1-hour Oral Session

IPC

**Modernising surgical site infection surveillance: AI, automation and patient-centred monitoring**

<i>Chair</i>		<i>Gabriel Birgand (Nantes, France)</i> <i>TBA</i>		
00913	11:00	Impact of a computerised decision support system on the adequacy of surgical antibiotic prophylaxis (SAP) and surgical site infections (SSI) <i>A. Agostinho* (Geneva, Switzerland), L. Hermant, E. Chalot, J. Sobel, W. Rey, D. Teixeira, J. Goncerut, A. Freitas, J. Achcar, F. Bellissimo-Rodrigues, S. Harbarth</i>		
00914	11:12	Transforming free text into usable data: large language models to support automated surgical site infection surveillance <i>E. Chalot* (Geneva, Switzerland), A. Agostinho, J. Sobel, D. Teixeira, S. Harbarth, M. Abbas</i>		
00915	11:24	Explainable artificial intelligence models for predicting surgical site infections: a scoping review of predictive features and model transparency <i>S. Lu* (Hong Kong, China), R. Sun, Y. Liu, E. Tartari Bonnici, L. Yang, L. Zhou</i>		
00916	11:36	National surveillance of surgical site infections in Belgium: results and evolution of the Sciensano NSIH-SSI program <i>T. Tamminga* (Brussels, Belgium), K. Mertens, L. Van Imshoot</i>		
00917	11:48	Patient-reported, prospective, and digital surveillance of post-caesarean surgical site infections in the outpatient setting: the SECURE Sectio study <i>K. Last* (Bonn, Germany), M.N. Kröncke, M. Jaskolski, E. Frücht, F. Droop, N. Scholten, N.T. Mutters, B. Strizek</i>		

OS133 11:00 - 12:00 Hall A1-5

1-hour Oral Session

ANT CLN PHEI

**Community-acquired pneumonia: know your enemies, treat them well**

<i>Chairs</i>		<i>Niessen Annabel (Utrecht, The Netherlands)</i> <i>Aurélien Dinh (Garches, France)</i>		
00918	11:00	Pneumococcal pneumonia in adults, re-emergence of vaccine serotypes: a prospective multi-centre cohort study in Germany, 2020-2023 <i>C. Bahrs* (Vienna, Austria), N. Rose, G. Barten-Neiner, C. Fleischmann-Struzek, M.P.G. Van Der Linden, G.</i>		

*Rohde, J. Rupp, M. Witznath, J. Rademacher, M.W. Pletz*

00919	11:12	Incidence and burden of medically and non-medically-attended <b>Mycoplasma pneumoniae</b> , 2024-2025 <i>J. King* (Marshfield, United States), J. Petrie, B. Kieke, O. Alonge, W. Meng, Z. Zheng, I. Leony Lasso, Y. Park, E.C. Newbern, C. Canan, J. Meece, E. Viscidi, E.J. Anderson, H. Nguyen</i>		
00920	11:24	Genomic surveillance reveals global spread of macrolide-resistant <b>Bordetella pertussis</b> linked to vaccine changes <i>J. Feng* (Shanghai, China), C. Min</i>		
00921	11:36	Real-world applicability of a three-day antibiotic regimen for community-acquired pneumonia: a ten-year retrospective study across four Swiss university centres <i>T. Brahier* (Lausanne, Switzerland), J. Regina, G. Carra, M. Méan, N. Boillat Blanco</i>		
00922	11:48	Cardiovascular risk of clarithromycin use in patients hospitalised with community-acquired pneumonia <i>S. Bastrup Israelsen* (Hvidovre, Denmark), M. Fally, P. Ravn, L. Kolte, M. Schmidt, T. Benfield, A. Matthews</i>		

OS134 11:00 - 12:00 Hall A2-2

CLN DX

1-hour Oral Session

**Changing landscape of opportunistic infections in the immunocompromised host**

<i>Chairs</i>		<i>Malgorzata Mikulska (Genoa, Italy)</i> <i>Lior Neshet (Beersheba, Israel)</i>		
00923	11:00	MUCOPS interventional trial: blood Mucorales PCR screening in high-risk haematology patients <i>Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, E. Boon, T. Mercier, A. Schouwvlieghe, K. Beuselincx, K. Lagrou, J. Maertens</i>		
00924	11:12	Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA) <i>T. Morris* (Saint-Etienne, France), L. Fouillet, J. Cornillon, A. Fayard, V. Dupont, E. Daguene, C. Thieblemont, E. Bachy, G. Manson, C. Herbaux, I. Yakoub-Agha, T. Gastinne, D. Blaise, L. Roulin, F.X. Gros, P. Bories, R. Houot, S. Le Gouill, E. Botelho-Nevers</i>		
00925	11:24	Strategies for management of human cytomegalovirus (HCMV) reactivation in haematopoietic stem cell transplant recipients (HSCTRs) in the era of letermovir <i>I. Cassaniti* (Pavia, Italy), D. Mele, M. Michele, F. Zavaglio, G. Grassia, N. Polverelli, D. Russo, A. Algarotti, T. Lazzarotto, F. Bonifazi, P. Chiusolo, F. Baldanti, D. Lilleri</i>		
00926	11:36	Transplantation and geographic medicine: analysis of data from the Spanish National Transplant Organisation (ONT), 2015-2024 <i>F. Norman* (Madrid, Spain), B. Mahillo, M.D. Corbacho-Loarte, M. Gonzalez-Sanz, S. Chamorro-Tojeiro, F. Gioia, D. Gayoso-Cantero, B. Dominguez-Gil, J. Fortun, P. Martin-Davila</i>		
00927	11:48	Risk factors for invasive mold infections in heart transplant recipients: a nationwide matched case-control study <i>B. Hoellinger* (Strasbourg, France), E. Epailly, F. Vuotto, V. Letscher-Bru, S. Loidant, C. Goeminne, R. Coelho, G. Laurent, S. Guendouz, G. Melica, F. Botterel, D. Maubon, A. Boignard, S. Pattier, F. Morio, C. Chabanne, J.P. Gangneux, K. Blanchart, J. Bonhomme, S. Grosjean, F. Dalle, C. Nafeh-Bizet, L. Favennec, B. Pilmis, J. Guilhaire, A. Gigandon, G. Pasquier, V. Dupasquier, C. Vignals, M. Lefranc, P. Tirard-Collet, L. Sebbag, L. Van Den Bogaart, F. Lantermier, M. Saito, F. Danion</i>		

OS135 11:00 - 12:00 Hall A3-2

1-hour Oral Session

AMR PHEI

**Harnessing wastewater for surveillance of AMR**

<i>Chairs</i>		<i>Henry-Michel Cauchie (Belvaux, Luxembourg)</i> <i>Amy Mathers (Charlottesville, United States)</i>		
00928	11:00	Longitudinal wastewater metagenomics allows genomic and clinical surveillance of human-		

		<b>associated viruses</b> <i>M. Karatas*</i> (Leuven, Belgium), <i>M. Bloemen, J. Swinnen, L. Close, M. Van Ranst, E. Wollants, J. Matthijssens</i>
00929	11:12	<b>From influent to effluent: antibiotic resistance gene dynamics in WWTPs</b> <i>C. Stoffers*</i> (Groningen, The Netherlands), <i>M. Lokate, L. Gard, A. Voss, J.W.A. Rossen</i>
00930	11:24	<b>Associations between antimicrobials and antimicrobial resistance genes in urban wastewater</b> <i>M. Penney*</i> (Calgary, Canada), <i>D. Kuzma, K. Aleshia, M. Kayla, O. Christine, D. Kristine, A. Emily, A. Nicole, W. Barbara, L. Jangwoo, W. Benson, C. Rhonda, M. Janine, V. Laura, P. Chloe, R.M. Elissa, D. Bruce, N. Diego, B. Herman, C. John, K.H. Susana, H. Casey, P. Michael</i>
00931	11:36	<b>Hospital use of ciprofloxacin and sulfamethoxazole correlates with their concentrations in hospital wastewater in Norway, 2019-2025</b> <i>H.J. Espvik*</i> (Oslo, Norway), <i>M. Grung, C. Vogelsang, K.M. Gravningen</i>
00932	11:48	<b>Cross-compartment genomic epidemiology of cephalosporin- and carbapenem-resistant Enterobacterales: an international multi-centre study in patients, hospital aquatic environments and wastewater</b> <i>N. Macesic*</i> (Melbourne, Australia), <i>M. De Kraker, A. Peleg, N. Hassoun-Kheir, M. Andre, D. Andrey, M. Beiers, X. Bertrand, B. Burri, D. Haber, S. Harbarth, J. Hawkey, M. Karram, L. Opatowski, M. Paul, R. Patwa, R. Sierra, K. Van Hoorde</i>

OS129	11:00 - 12:00	Hall ICM 13a
	1-hour Oral Session	

<b>Making phages GMP-ready: the manufacturing challenge</b>		
<i>Chairs</i>	<i>Ran Nir-Paz (Jerusalem, Israel)</i> <i>Jean-Paul Pirnay (Brussels, Belgium)</i>	

00933	11:00	<b>Consensus-based guideline on personalised bacteriophage therapy</b> <i>S. Würstle*</i> (Frankfurt, Germany), <i>S. Lieberknecht-Jouy, M. Vehreschild, A. Classen</i>
00935	11:24	<b>Virulent phage infection triggers prophage induction and lysogenic conversion in <i>Staphylococcus aureus</i>: implications for therapeutic phage production safety and virulence dynamic</b> <i>P.A. Pastouriaux*</i> (Lyon, France), <i>M. Bonhomme, P. Martins-Simoes, L. Blazere, E. Helluin, K. Royet, M. Medina, C. Kolenda, F. Laurent, F. Laumay</i>
00936	11:36	<b>Tailoring the next generation bacteriophage therapy with a cell-free system</b> <i>S.C. Nang*</i> (Melbourne, Australia), <i>H.H.Y. Yu, H. Wickremasinghe, X. Li, J. Zhao, J. Li</i>
00937	11:48	<b>Implementation of the first French public platform for the production of GMP-grade therapeutic phages at reasonable cost</b> <i>F. Laurent*</i> (Lyon, France), <i>L. Frédéric, M. Medina, B. Lapras, C. Kolenda, C. Marchand, F. Laumay, C. Merienne, M. Bonhomme, F. Pirot</i>

OS130	11:00 - 12:00	Hall ICM 13b
	1-hour Oral Session	

<b>Navigating clinical realities in travelers and migrant populations</b>		
<i>Chairs</i>	<i>Andreas Neumayr (Basel, Switzerland)</i> <i>Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)</i>	

00938	11:00	<b>Safety of the dengue vaccine TAK-003 and risk factors for developing adverse events in travellers from non-endemic areas: a real-world prospective multi-centre pharmacovigilance study in Spain</b> <i>D. Camprubi-Ferrer*</i> (Barcelona, Spain), <i>D. Camprubi Ferrer, M. Saloni, L. Valerio, J. Villar, V. Lopez-Lopez, C. Bertran-Cobo, D. Garcia, E. Jurado, M.L. Machado, C. Masuet, S. Cuevas Marin, I. Gonzalez Nieto, D. Herena Garcia, R. Morales, A. Gomila-Grange, I. Vera, F. Vila, N. Martin, T. De Alba, N. Morales Llorente, E. Gorriz Hidalgo, J. Muñoz</i>
00939	11:12	<b>Cluster of rash dominant dengue fever in newly arrived Chinese expatriates at Bangalore (India): a sentinel event in travel health</b> <i>A. Mb*</i> (Bangalore Rural, India), <i>S. Banti, D. Shobha, R. Surendran</i>
00940	11:24	<b>AdMIRE study: development and validation of a WHO-aligned tool to assess healthcare access and antibiotic use among migrant populations in Europe: a</b>

		<b>multicountry Delphi and psychometric study on behalf of ESGITM group</b> <i>G. Guido*</i> (Bari, Italy), <i>A. Abbara, M. Asaduzzaman, F.B. Farkas, K. Diabate, A. Duvignaud, V. Holmberg, S. Ibrahim, S. Jordao, R. Papagni, L. Jung, B. Lakatos, M. Orcutt, A. Saracino, A. Requena-Méndez, E. Romancenco, M. Schiavone, C. Shortall, C. Napoli, D. Mosca, P. Luga, J. Llenas Garcia, E. Nicastrí, A. Corpolongo, P. Bodenman, E. Florence, F. Eick, L. Závorszky, S. Severoni, C.M. Wejse, F. Di Gennaro</i>
00941	11:36	<b>Imported leishmaniasis in Europe (2000-2024): a systematic review of travel-related case reports</b> <i>J. Acosta España*</i> (Quito, Ecuador), <i>S.M. Alcocer-Veintimilla, V.A. Pillajo-Gangotena, J.D. Acosta-España, A. Abbara, M. González-Sanz, A. Rodríguez-Morales</i>
00942	11:48	<b>Seroprevalence of <i>Burkholderia pseudomallei</i> among international travelers: a preliminary result</b> <i>G.M. Ali*</i> (Bangkok, Thailand), <i>G. Zschebek, C.M.S. Cagape, N. Saiprom, S. Tandhavanant, R. Phunpang, M.N. Burtnick, P.J. Brett, T. Siripoon, H.A. Imad, C. Chewapreecha, W. Cheirakul, N. Chantratita, W. Matsee</i>

SY158	11:00 - 12:00	Hall A1-4
	1-hour Symposium	
<b>Detecting parasites using metagenomics and proteomics</b>		
<i>Chairs</i>	<i>Hanne Brekke (Oslo, Norway)</i> <i>Dora Buonfrate (Negrar, Italy)</i>	

S0439	11:00	<b>Unmasking hidden worlds: the power of metagenomics in parasitology</b> <i>Francesco Asnicar</i> (Trento, Italy)
S0440	11:30	<b>From proteomics to the bench</b> <i>Momar Ndao</i> (Montreal, Quebec, Canada)
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)		

SY159	11:00 - 12:00	Hall A2-1
	1-hour Symposium	
<b>To AI or not to AI: latest trends in digital innovation for respiratory virus detection and management</b>		
<i>Chairs</i>	<i>Benjamin Cowling (Pokfulam, Hong Kong)</i> <i>Esmeralda Valiente (Berlin, Germany)</i>	

S0441	11:00	<b>Using AI-enabled diagnostics to strengthen biosecurity and address gaps in servicing remote populations</b> <i>Holly Seale</i> (Sydney, Australia)
S0442	11:30	<b>Latest trends in AI-supported respiratory virus surveillance and monitoring</b> <i>Jude Kong</i> (Toronto, Canada)
Co-organised with: Australasian Society for Infectious Diseases (ASID), ESCMID Study Group for Respiratory Viruses (ESGREV), International Pediatric Association (IPA)		

SY160	11:00 - 12:00	Hall A3-1
	1-hour Symposium	
<b>Emerging resistance to new antibiotics: are we already losing the newest tools?</b>		
<i>Chairs</i>	<i>Ana Gales (São Paulo, Brazil)</i> <i>Balaji Veeraraghavan (Vellore, India)</i>	

S0443	11:00	<b>Current prevalence and clinical impact of resistance to new drugs</b> <i>Timothy R. Walsh</i> (Oxford, United Kingdom)
S0444	11:30	<b>How to minimise resistance to new drugs</b> <i>Elena Carrara</i> (Verona, Italy)

SY157	11:00 - 12:00	Hall B0-1
	1-hour Symposium	
<b>Personalised antimicrobial stewardship for resistant pathogens: beyond clinical trials</b>		
<i>Chairs</i>	<i>Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)</i> <i>Tomislav Kostyanev (Esbjerg, Denmark)</i>	

S0437	11:00	<b>blaNDM-producing Enterobacterales: optimal selection of adjuvant <math>\beta</math>-lactamase inhibitors</b> <i>Jacob Strahilevitz (Jerusalem, Israel)</i>	
S0438	11:30	<b><i>Mycobacterium tuberculosis</i> mutations associated with drug resistance: the way forward</b> <i>Iñaki Comas (Valencia, Spain)</i>	
<hr/>			
SY155	11:00 – 12:00		Hall ICM 1
		1-hour Symposium	
<b>Year in paediatric ID</b>			
<i>Chairs</i>		<i>Julia Anna Bielicki (London, United Kingdom)</i> <i>Hervé Haas (Nice, France)</i>	
S0433	11:00	<b>Epidemiology, diagnosis, treatment</b> <i>Ulrich Von Both (Munich, Germany)</i>	
S0434	11:30	<b>Infection prevention and vaccines</b> <i>Dana Danino (Beer Sheva, Israel)</i>	
<hr/>			
SY156	11:00 – 12:00		Hall ICM 5
		1-hour Symposium	
<b>Decoding resistance: the new ESCMID guidelines to halt transmission of multidrug-resistant Gram-negatives</b>			
<i>Chairs</i>		<i>Ana Budimir (Zagreb, Croatia)</i> <i>Andreas Voss (Groningen, The Netherlands)</i>	
S0435	11:00	<b>The ESCMID blueprint for prevention: a deep dive into the new guidelines</b> <i>Evelina Tacconelli (Verona, Italy)</i>	
S0436	11:30	<b>Making the guidelines stick: Innovative implementation strategies for effective uptake</b> <i>Bianca Albers (Zurich, Switzerland)</i>	
<b>Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee</b>			
<hr/>			
EF136	11:00 – 12:00		Arena 2
		ePoster Flash Session	
<b>Novel aspects in antimicrobial susceptibility testing and resistance detection</b>			
<i>Chair</i>		<i>Alberto Antonelli (Florence, Italy)</i>	
E0943	11:00	<b>Rapid MALDI-TOF MS synergy testing to guide combination therapy in critical infections</b> <i>M. Bexkens* (Rotterdam, The Netherlands), S. Van Den Berg, C. De Vogel, W. De Jong, A. Muller</i>	
E0944	11:06	<b>NANOMUR: innovative nanomotion technology for antibiotic susceptibility testing: a game-changer for urinary tract infections?</b> <i>A. Delfino* (Lausanne, Switzerland), D.C. Cijn, O.Y. Chén, A. Sturm, D. Cichocka, G. Greub</i>	
E0945	11:12	<b>Not all MIC plates are equal: method-driven shifts in cefiderocol susceptibility for NDM-producing Enterobacterales</b> <i>M. Bouillon* (Caen, France), C. Isnard, S. Le Hello, F. Gravey</i>	
E0946	11:18	<b>A multi-centre evaluation of routine susceptibility testing methods for linezolid using a clinical <i>Enterococcus</i> strain collection</b> <i>S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koevinge, J. Boelens, N. Botteldoorn, P.J. Ceyssens, M. Chemais, C. Deckers, S. Desmet, S. Gils, T.D. Huang, B. Lissolr, K. Magerman, C. Meex, K. Floré, A.M. Van Den Abeele, E. Van Honacker, K. Vernelen, I. Verstreken, V. Matheussens, S. Vandamme</i>	
E0947	11:24	<b>Challenges of phenotypic antimicrobial susceptibility testing of <i>Enterococcus faecium</i> for vancomycin using semi-automated systems and their causes</b> <i>T. Ruegamer* (Cologne, Germany), C. Arz, A. Hiergeist, R. Arazo Del Pino, U. Reischl, P.G. Higgins, A. Gessner, A. Dudakova, M. Simon, J. Jantsch</i>	
E0948	11:30	<b>Waiting for the answer: validation of newly implemented VITEK 2 automated susceptibility testing cards can cause treatment delays in an intensive care unit population</b> <i>S. Boettcher* (Detroit, United States), A. Abed, N. Everson, R. Kenney, R.</i>	
E0949	11:36	<b>Utility of tetracycline susceptibility as a predictor of doxycycline activity in non-diphtheriae <i>Corynebacterium</i>: a retrospective analysis</b> <i>K. Barrett* (Rochester, United States), O. Abu Saleh, M. Fida</i>	
E0950	11:42	<b><i>In vitro</i> evaluation of cefiderocol against <i>Achromobacter xylosoxidans</i> isolates from people with cystic fibrosis</b> <i>F. Tolio* (Verona, Italy), G. Toccaceli, A. Bertocelli, A. Mazzariol</i>	
E0951	11:48	<b>Rethinking ESBL Detection in Enterobacterales: Comparison of EUCAST and CLSI Guidelines and Development of a Clavulanate-Free Algorithm</b> <i>L.K. Muhsal* (Osnabrueck, Germany), A. Hamprecht</i>	
<hr/>			
EF137	11:00 – 12:00		Arena 3
		ePoster Flash Session	
<b>Bacterial vaccine pipeline: focus on <i>Staphylococcus</i> and <i>Klebsiella</i></b>			
<i>Chair</i>		<i>Guido Werner (Wernigerode, Germany)</i>	
E0952	11:00	<b>AntiPan: a genome-informed in silico pipeline for advancing subunit vaccine discovery against <i>Staphylococcus aureus</i></b> <i>M. Elhadidy* (Giza, Egypt), M.S. Ibrahim, J.A. Fahmy, M.A. Helal, F.T. Hakim, L.R. Sidarous, N.E. Attallah, S. Abouelhadid, E. Badr</i>	
E0953	11:06	<b>Rational selection of vaccine candidates based on proteomic analysis of thermal stress-induced <i>S. aureus</i> dispersion</b> <i>B. Vieira* (Bragança Paulista, Brazil), G.C. Mantini Cangussu, T. Rojas Converso, A. Hakansson</i>	
E0954	11:12	<b>Kp-OMV4: a broadly active OMV vaccine against <i>Klebsiella pneumoniae</i></b> <i>B. Cano Castañón* (Madrid, Spain), A. Pérez, M.J. McConnell, B. Cano-Castañón, S. Prieto Martín-Gil, A. Tajuelo Moreno-Palancas, E. Gato, P. Miguela-Villoldo, D. Fousteris, A. Peláez García, F. Docando, D. Megias, A.J. Martín-Galiano</i>	
E0955	11:18	<b>Wide strain coverage and protection predicted for K-Vax, a vaccine for prevention of disease by <i>K. pneumoniae</i> presenting OmpA and OmpK36 assembled into chimeric LPS-null whole-cells of <i>A. baumannii</i></b> <i>J. Infante Viñolo* (Dos Hermanas, Spain), A.I. Rodriguez-Rosado, A. Alonso-Del Valle, J. Sa Pessoa, R. Calderon-Gonzalez, M. Garcia-Lopez, L. Del Pozo-Acebo, M. Cordero-Alba, M.J. McConnell, J.A. Bengoechea, J.J. Infante</i>	
E0956	11:24	<b>Broad computational and experimental screening of antigenic loops in the <i>Klebsiella pneumoniae</i> porinome</b> <i>A. Pérez Gómez* (Madrid, Spain), S. Prieto Martín-Gil, A. Tajuelo, B. Cano, D. Fousteris, L. Vaughan, P. Miguela-Villoldo, E. Gato, A. Pérez, A.J. Martín Galiano, M.J. McConnell</i>	
E0957	11:30	<b>Assessment of KpID as a promising antigen for vaccine development against <i>Klebsiella pneumoniae</i></b> <i>A. Tajuelo Moreno-Palancas* (Madrid, Spain), A. Tajuelo, S. Prieto Martín-Gil, L. Vaughan, B. Cano-Castañón, P. Miguela-Villoldo, D. Fousteris, V. Mas, A.J. Martín-Galiano, M.J. McConnell, A. Pérez, E. Gato</i>	
E0958	11:36	<b>Developing an outer membrane vesicle-based vaccine against <i>Klebsiella pneumoniae</i></b> <i>K. Winter* (Vancouver, Canada), K. Chu, N. Wilks, S. Cai, A. Tejani, W.L. Kuan, I. Hadad, L. Presley, T. Harn, M. Lo, M. Sadarangani</i>	
E0959	11:42	<b>Cost-effectiveness analysis of PCV21, an adult specific 21-valent pneumococcal conjugate vaccine, vs PCV20 in adults in Germany</b> <i>P. Mueller* (Boston, United States), M. Simuzingili, L. Lang, M. De Lepper, K. Owusu-Edusei</i>	
E0960	11:48	<b>Development of a non-invasion intranasal vaccine for <i>Klebsiella pneumoniae</i> urinary tract infection</b> <i>L.K. Siu* (Zhunan, Taiwan), M.H. Huang</i>	
<hr/>			
EF138	11:00 – 12:00		Arena 4
		ePoster Flash Session	
<b>Pneumococcal vaccines: impact and serotype dynamics</b>			
<i>Chair</i>		<i>Ron Dagan (Beer-Sheva, Israel)</i>	
E0961	11:00	<b>The first comprehensive whole genome sequencing of <i>Streptococcus pneumoniae</i> from the Arabian Gulf</b>	

**region: Implications for vaccine strategies** *A. Senok\**  
(Dubai, United Arab Emirates), *S. Verma, L. Mohamed, E. Kaambo, S. Boucherabine, M. Senghore, A. Nabi, M. Habou, F. Jabeen, A. Alatoom, N. Abdulrazzaq, W. Jamal, R. Nassar, E. Mokaddas, D. Everett*

E0962	11:06	<b>Dominance of PCV13-nonPCV10 serotypes in paediatric invasive pneumococcal infections in Serbia after sequential PCV programs</b> <i>N. Vuckovic Opavski*</i> (Belgrade, Serbia), <i>M. Jovicevic, J. Kabic, D. Kekic, Z. Vasiljevic, O. Hadzic Simovic, S. Laban Nestorovic, T. Djordjevic, D. Medic, L. Ranin, I. Gajic</i>
E0963	11:12	<b>Serotype evolution and sequence types of <i>Streptococcus pneumoniae</i> meningitis isolates before and after PCV13 introduction in Algeria</b> <i>S. Bouheraoua*</i> (Algiers, Algeria), <i>A.E. Deghmane, K. Hebbachi, R. Lalam, F. Djedjig, C. Bentchouala, R. Abi Ayad, S. Mahrane, M.K. Taha, H. Tali Maamar</i>
E0964	11:18	<b>Assessing the impact of different pneumococcal conjugate vaccine (PCV) programs on invasive pneumococcal disease (IPD) using population based surveillance in Ontario</b> <i>A. Mcgeer*</i> (Toronto, Canada), <i>A. Shigayeva, Z. Zhong, C. Amirov, A. Belhaj, S. Chakrabarti, D. Chen, W. Gold, A. Golden, L. Goneau, C. Kandel, S. Krajden, R. Lovinsky, I. Martin, L. Matukas, T. Mazzulli, M. Muller, J. Nadarajah, K. Ostrowska, N. Rau, D. Ricciuto, D. Richardson, D. Rose, M. Saffie, V. Sales, A. Simor, C. Vermeiren</i>
E0965	11:24	<b>Would implementing a risk-based or an age-based PCV20 vaccination program in adults 60+ years in Brazil be cost effective and budget saving?</b> <i>L. Huang*</i> (Collegeville Pa, United States), <i>R.F. Alexandre, A. Claro, R. Ferreira, D. Pachito</i>
E0966	11:30	<b>Estimated impact of pneumococcal conjugate vaccine implementation on disease burden and mortality: strategies to guide PCV program introduction in low-resource settings</b> <i>T. Ngamprasertchai*</i> (Bangkok, Thailand), <i>V. Mahd-Adam, W. Pan-Ngum</i>
E0967	11:36	<b>Long-term persistence of pneumococcal antibodies five years after sequential PCV13 and PPSV23 vaccination in kidney transplant recipients: indications for revaccination</b> <i>L. Van De Sand*</i> (Essen, Germany), <i>B. Wilde, K. Völk, O. Witzke, M. Lindemann, N. Mülling</i>
E0968	11:42	<b>Effect of introducing pneumococcal conjugate vaccines into national immunisation programmes on antimicrobial-resistant <i>Streptococcus pneumoniae</i> disease burden across 188 countries: a synthetic-control study</b> <i>Z. Chen*</i> (Shanghai, China), <i>C. Zhihui, L. Zhonghua, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong</i>
E0969	11:48	<b>Immunogenicity and safety of a 21-valent pneumococcal conjugate vaccine (V116) compared with the 23-valent polysaccharide vaccine (PPSV23) in older adults: a systematic review and meta-analysis of randomised controlled trials</b> <i>H. Mewafy*</i> (Giza, Egypt), <i>M. Abdrabou</i>

KN154	11:00 - 12:00	Hall ICM 14
	Keynote lecture	

**Genetics underlying susceptibility and immunity to infection**  
*Chairs* *Jan A.J.W. Kluytmans* (Utrecht, The Netherlands)  
*Gülşen Özkaya Şahin* (Lund, Sweden)

K0432	11:00	<i>Filomeen Haerynck</i> (Ghent, Belgium)
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)		

ME161	11:00 - 12:00	Hall A1-2
	Meet-the-Expert	

**Clinical challenges and management strategies for slowly progressing cutaneous infections**

M0445	11:00	<i>Maria Luisa Aznar</i> (Barcelona, Spain)
M0446	11:12	<i>Richard Odame Phillips</i> (Kumasi, Ghana)
Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)		

FO162	11:00 - 12:00	Arena 1
	Open Forum	

**Integrating Sustainable Development Goals (SDGs) 3 and 5 in policy and practice**  
*Chair* *Sabine Bélard* (Tübingen, Germany)

FO447	11:00	<b>From policy to practice: gender equality in the SDG framework</b> <i>Irit Nachtigall</i> (Berlin, Germany)
FO448	11:10	<b>Gender and access to infectious disease diagnostics and treatment</b> <i>Daniela Fusco</i> (Hamburg, Germany)
FO449	11:20	<b>Integrating gender and community realities into AMR for SDGs 3 &amp; 5 in Sub-Saharan Africa</b> <i>Judith Asin</i> (Nairobi, Kenya)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

OS140	13:30 - 14:30	Hall A1-1
	1-hour Oral Session	

**Transforming diagnostic microbiology with AI**  
*Chairs* *Benjamin Peter Howden* (Melbourne, Australia)  
*Mariska Leeflang* (Amsterdam, The Netherlands)

O0970	13:30	<b>Democratising MALDI-TOF AMR prediction: from Transformers to simple Neural Networks without accuracy loss, reducing energy costs via knowledge distillation</b> <i>A. Guerrero-López*</i> (Zurich, Switzerland), <i>L. De Ancos Villa</i>
O0971	13:42	<b>A novel auditable diagnostic support system using constrained retrieval-augmented generation improves accuracy and efficiency in parasitology morphology identification</b> <i>C.C. Hung*</i> (New Taipei, Taiwan)
O0972	13:54	<b>ParaScout: microscopic helminth detection using AI</b> <i>R. Zonneveld*</i> (Amsterdam, The Netherlands), <i>S. Slavenburg, C. Tieken, R. Koelewijn, L. Van Lieshout, I. Feoktistov, J. Van Hellemond</i>
O0973	14:06	<b>Transformer AI in clinical microbiology: ProkBERT improves detection of plasmids and mobile genetic elements</b> <i>G. Lorenzin*</i> (Trento, Italy), <i>M. Carlin, D. Krizsán, B. Ligeti</i>
O0974	14:18	<b>Accuracy of Gram stain interpretation by smartphone-based computer-aided diagnosis app in blood culture samples</b> <i>K. Ebisawa Furui*</i> (Kobe, Japan), <i>G. Ohji, K. Yamamoto, I. Miyatsuka, A. Moriya, K. Akamatsu, H. Nomoto, M. Kurokawa, K. Ohnuma, M. Kusuki, Y. Uemura, N. Ohmagari</i>

SY166	13:30 - 14:30	Hall A1-4
	1-hour Symposium	

**One Health beyond AMR: the challenge of *Clostridioides difficile* infection control outside the hospital**  
*Chairs* *Marcela Krutova* (Prague, Czechia)  
*Ana Vale* (Dublin, Ireland)

S0406	13:30	<b><i>Clostridioides difficile</i> in extra-human sources</b> <i>Mónica Oleastro</i> (Lisbon, Portugal)
S0407	14:00	<b>Dynamics of transmission of <i>Clostridioides difficile</i> within and outside the hospital</b> <i>Semeh Bejaoui</i> (Bologna, Italy)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD), ESCMID Study Group for Veterinary Microbiology (ESGVM)

SY165	13:30 - 14:30	Hall BO-1
	1-hour Symposium	

**Beneath the capsule of *Klebsiella pneumoniae*: hypervirulence, fitness and adaptive evolution**  
*Chairs* *Christian Stephan Lentz* (Tromsø, Norway)  
*Shiri Navon-Venezia* (Ariel, Israel)

S0404 13:30 What constitutes hypervirulence during *Klebsiella pneumoniae* infection? Yunn-Hwen Gan (Singapore, Singapore)

S0405 14:00 Adaptive evolution and in-host dissemination of *Klebsiella pneumoniae* Michael Bachman (Ann Arbor, Michigan, United States)

EW169 13:30 - 15:30 Hall A2-1  
2-hour Educational Session

CLN

**UTIs off the beaten path: complex patients, complex choices**

Chairs Suzanne Geerlings (Amsterdam, The Netherlands)  
Angela Huttner (Geneva, Switzerland)

W0416 13:30 UTI in kidney-transplant patients: what's new and what's safe? Dionysios Neofytos (Geneva, Switzerland)

W0417 13:50 UTI and bacteriuria in pregnancy: two and the same? Barbara Trautner (St. Louis, United States)

W0418 14:10 UTI in patients with stones and stents: rocks and hard places Lorenz Leitner (Zurich, Switzerland)

W0419 14:30 UTI in neurogenic bladder/spinal cord injury patients Ruxandra Calin (Paris, France)

Co-organised with: ESCMID Study Group for Urinary Tract Infections (ESGUTI)

EW170 13:30 - 15:30 Hall A2-2  
2-hour Educational Session

CLN DX

**Take the right path: tips on HIV resistance management in the era of antiretrovirals**

Chairs Claudia Cortes (Santiago, Chile)  
Botond Lakatos (Budapest, Hungary)

W0420 13:30 State-of-the art approach to HIV resistance analysis Ivailo Alexiev (Sofia, Bulgaria)

W0421 13:50 Epidemiology of HIV resistance in Europe and beyond Dimitrios Paraskevis (Athens, Greece)

W0422 14:10 HIV resistance management in the era of long-acting antivirals Dan Otelea (Bucharest, Romania)

W0423 14:30 Drug resistance testing for optimising HIV management Anna Maria Geretti (London, United Kingdom)

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Dat'AIDS Working Group

EW171 13:30 - 15:30 Hall A3-1  
2-hour Educational Session

ANT CLN

**Managing bloodstream infections and endocarditis in the context of drug injection or homelessness**

Chairs Brigitte Lamy (Bobigny, France)  
Aneta Nyčová (Praha, Czechia)

W0424 13:30 Epidemiology and features of bloodstream infections among PWID Asko Jarvinen (Helsinki, Finland)

W0425 13:50 Alternative antibiotic regimens and delivery strategies for infective endocarditis in PWID Burcu Isler (Gold Coast, Australia)

W0426 14:10 Is combination treatment necessary for *Staphylococcus aureus* infections? Sara Grillo (Barcelona, Spain)

W0427 14:30 Oral antibiotics for bacteraemia in people who use drugs Pierre Tattévin (Rennes, France)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

EW172 13:30 - 15:30 Hall A3-2  
2-hour Educational Session

CLN DX

**Transplant infectious diseases: real-world challenges through the eyes of the next generation**

Chairs Roy Chemaly (Houston, United States)  
Nathan Peiffer-Smadja (Paris, France)

W0428 13:30 Understanding and applying cell-mediated immunity in transplant infectious diseases Carla Walti (Basel, Switzerland)

W0429 13:50 CNS complications in patients treated with CAR-T cells Marjorie Batista (São Paulo, Brazil)

W0430 14:10 How much is enough? Rational empiric therapy in febrile immunocompromised patients Yuri Vanbiervliet (Leuven, Belgium)

W0431 14:30 Challenges for diagnostic stewardship in transplant recipients Ankit Mittal (Hyderabad, India)

Co-organised with: ESGAP, ESGICH, ESGIB, ESCMID Scientific Affairs Subcommittee, ESGREV, International Immunocompromised Host Society (IHS)

EW167 13:30 - 15:30 Hall ICM 13a  
2-hour Educational Session

PRO

**Inside the black box: leading and developing clinical guidelines**

Chairs Blin Nagavci (Gjakova, Kosovo)  
Luigia Scudeller (Pavia, Italy)

W0408 13:30 How to chair a guideline panel and survive Mark G. J. De Boer (Leiden, The Netherlands)

W0409 13:50 Deconstructing guidelines: how to ensure and assess their trustworthiness Mical Paul (Haifa, Israel)

W0410 14:10 Pitfalls in developing guidelines: conflicts of interest, panel composition, and updating José Ramón Paño-Pardo (Zaragoza, Spain)

W0411 14:30 More than a logo: the strategic role of societies in guideline development Marcus Zervos (Detroit, United States)

Co-organised with: ESCMID Guidelines Subcommittee, CMI Board of Editors

EW168 13:30 - 15:30 Hall ICM 13b  
2-hour Educational Session

CLN DX

**A diagnostic odyssey: how to enhance diagnostic stewardship**

Chairs Polona Maver Vodisar (Ljubljana, Slovenia)  
Neven Papic (Zagreb, Croatia)

W0412 13:30 Should I order an IGRA test? Could this be a mycobacterial infection? Christoph Lange (Borstel, Germany)

W0413 13:50 Do I have antibodies or just anxiety? Gen Z gets real about serology Jean-Luc Murk (Blaricum, The Netherlands)

W0414 14:10 PCR tests: the superheroes of infection detection... or just really good sidekicks? Snjezana Zidovec Lepej (Zagreb, Croatia)

W0415 14:30 Serum, culture, PCR: but wait, fungi still have a few tricks up their sleeve! Katrien Lagrou (Leuven, Belgium)

OS139 13:30 - 15:30 Hall ICM 5  
2-hour Oral Session

CLN DX TRN

**Clinical metagenomics: from sample processing to actionable results**

Chairs Hege Vangstein Aamot (Lørenskog, Norway)  
Gilbert Greub (Lausanne, Switzerland)

O0975 13:30 From sample to treatment in four hours: bringing metagenomics precision to complicated UTI diagnostics and management R. Ahmad\* (Hamar, Norway), A.B. Bellankimath, S. Branders, K. Isabell, A. Jawad, A. Fatemeh, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner

O0976 13:42 Multi-centre evaluation of the EasySeq Full-Length 16S Sequencing kit for bacterial identification in clinical samples T.T. Severs\* (Zwolle, The Netherlands), S.D. Pas, S.A. Boers, L. Gard, J.W.A. Rossen, L.B. Van Alphen, R.M. Koeck, P.W. Smit, R.Y. Yahiaoui, S.P.F. Matamoros, B. Van Den Bosch, P.

00977	13:54	<b>Rapid species identification in community-acquired bacteraemia using a short pre-culturing step followed by 16S nanopore sequencing</b> <i>D. Nestor*</i> (Orebro, Sweden), <i>M. Ekström, S. Cajander, P. Mölling, M. Sundqvist</i>
00978	14:06	<b>Insights from over 11,000 clinical samples in over five years of routine metagenomics in Germany</b> <i>S. Grumaz*</i> (Duisburg, Germany), <i>J. Becher, C. Disqué, K. Rensing, J. Bottlang, D. Borda-Molina, P. Stevens</i>
00979	14:18	<b>MetaGENomic Sequencing to detect Infections in SOTR (Solid Organ Transplant Recipients): Interim analysis of the mGENESIS registry</b> <i>S. Khalil*</i> (Houston, United States), <i>A. Chandorkar, D.W. Charles, L. Fontana, T. Taylor, I. Kaur, D.R. Kaul, Z. Raglow, J. Schaenman, K. Obeid, S. Nair, C.E. Harris, R.O. Adekunle, A. Mills, S. Yang, J.R. Shah, L. Ogawa, H. Hassouna, J. Polega, J. Morillas, P. Vijayvargiya, S. Imam, N. Vissichelli, M. Morales, R. Shrestha, J. Hand, Z. Esquer, J. Goldman, E. Eichenberger, M.R. Sohail</i>
00980	14:30	<b>Implementation of respiratory metagenomics during the 2024/25 autumn/winter season in a large UK specialist referral hospital</b> <i>M. Ibrahim*</i> (Southampton, United Kingdom), <i>S. Green, N. Norton, E. Pelosi, J. Swabe, C. Mckenzie, A. Alcolea-Medina, L.B. Snell, D. Ward, A. Dushianthan, M. Grocott, J. Edgeworth, K. Saeed</i>
00981	14:42	<b>Rapid hybridisation capture workflow for targeted metagenomics of respiratory infections</b> <i>O.E. Torres Montaguth*</i> (London, United Kingdom), <i>A. Busam, L.M. Martin Bernal, T. Brooks, I. Ringue, G. Kuczmar, A. Kopeck, S. Buddle, L. Ahmed, R. Williams, J. Brown, S. Morfopoulou, J. Breuer</i>
00982	14:54	<b>Ultra-rapid µCaler hybrid-capture tNGS with a fully automated workstation for comprehensive detection of respiratory pathogens</b> <i>W. Feili*</i> (Beijing, China), <i>Y. Liping, G. Shan, X. Bangxiang, Z. Jiaying, Z. Lili, Z. Yulin</i>
00983	15:06	<b>The world's first direct from raw sample to report NGS platform: delivering rapid BSI pathogen ID and AMR from whole blood clinical samples</b> <i>S. Reed*</i> (London, United Kingdom), <i>E. Brown, R. Samuel, D. Seth, D. Dylan, E. Oscar, S. Yazmine, P. Hannah, P. Maria, S. Laura, E. Liz, M.B. Joanna, M. Raegan, L. William, P. Marie, G. Flavia, S. Shagun, D. Jennifer, S. Peter, G. Hailey, C. Giselle, K. Daniel, W. Jason, C. Brandon, N. Cristian, R. Jonathan, M. Christian, P. Shane, V. Steven, D. Miroslav, J. Isaac, M.C. Fraser, M. Daniel, W. David, W. Graham, W. Michele</i>
00984	15:18	<b>An open-source, on-site nanopore sequencing workflow for rapid microbial cell-free DNA (mcfDNA) detection in bloodstream infections</b> <i>M. Banz*</i> (Jena, Germany), <i>S. Hagel, M. Pletz, C. Brandt</i>

**SY164 13:30 – 15:30 Hall A1-2**

2-hour Symposium



**From childhood to adulthood: overcoming barriers in vaccine prevention**

*Chairs* *Hervé Haas (Nice, France)*  
*Tina Tan (Chicago, United States)*

S0400	13:30	<b>Meningococcal disease: how and why do vaccination schedules differ across Europe?</b> <i>Adam Finn (Bristol, United Kingdom)</i>
S0401	14:00	<b>Measles: lessons learned from a recent epidemic in the era of vaccine hesitancy</b> <i>Adriana Pistol (Bucharest, Romania)</i>
S0403	14:30	<b>Pneumococcal disease prevention: a lifespan approach</b> <i>Emmanuelle Varon (Creteil, France)</i>

Co-organised with: Société de Pathologie Infectieuse de Langue Française, French Pediatric Infectious Diseases Group (GPIP), Infectious Diseases Society of America (IDSA)

**SY163 13:30 – 15:30 Hall ICM 1**

2-hour Symposium



**Global landscape of AMR surveillance in Gram-negative bacteria**

*Chairs* *Patrick Mcgann (Silver Spring, Maryland, United States)*  
*Paul A. Tambyah (Singapore, Singapore)*

S0396	13:30	<b>Insights from the genomic surveillance of CRE in Europe: ongoing challenges</b> <i>Lemonia Skoura (Thessaloniki, Greece)</i>
S0397	14:00	<b>Current epidemiology of CRAB in Europe: diagnostic advances</b> <i>Paul G. Higgins (Cologne, Germany)</i>
S0398	14:30	<b>Revolutionising informal AMR data sources vs traditional interfaces</b> <i>Tin Tin Myaing (Bangkok, Thailand)</i>
S0399	15:00	<b>Genomic insights into AMR surveillance: lessons from South and South-East Asia</b> <i>Balaji Veeraraghavan (Vellore, India)</i>

Co-organised with: AMR Action Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Public Health Microbiology (ESGPHM), ECDC, ISID

**EF141 13:30 – 14:30 Arena 2**

ePoster Flash Session



**New threats to occupational health**

*Chair* *Biljana Carevic (Oslo, Norway)*

E0985	13:30	<b>SIREN RespOME study: <i>Staphylococcus aureus</i> nasal and throat colonisation in a UK healthcare worker cohort</b> <i>V. Hall*</i> (London, United Kingdom), <i>S. Foulkes, K. Bellis, A. Atti, E.M. Harrison, J. Islam</i>
E0986	13:36	<b>Healthcare worker KAP tools regarding flu and COVID-19 vaccination: reliability and structural stability pre- and post-campaign</b> <i>M. Latorre-Millán*</i> (Saragossa, Spain), <i>A. Milagro, I. Ezpeleta, J.M. Alvarez-Zarate, L. Clusa</i>
E0987	13:42	<b>Healthcare workers' infection prevention strategies in primary healthcare facilities of rohingya refugee camps in Bangladesh</b> <i>S.M.M. Hasan*</i> (Dhaka, Bangladesh), <i>S.A. Prema</i>
E0988	13:48	<b>Occupational blood exposure among Sri Lankan healthcare workers: a six-year review</b> <i>T. Pattiyakumbura*</i> (Kandy, Sri Lanka), <i>R. Muthugala, L. Rajamanthrie, S. Paththamperuma</i>
E0989	13:54	<b>Late diagnosis of infectious diseases and disease transmission among health care workers in a tertiary care hospital</b> <i>R. Tafveez*</i> (Karachi, Pakistan), <i>A. Ali, S. Farhan, N. Virani, R. Roshan, S.F. Mahmood</i>
E0990	14:00	<b>Prioritising healthcare workers for Lassa fever vaccination in Nigeria</b> <i>D. Smith*</i> (Paris, France), <i>K.B. Pouwels, S. Okogbenin, T.D. Hollingsworth, K. Holohan, O.O. Ayodeji</i>
E0991	14:06	<b>Do we spread bacteria when 'shooting' disposable gloves after use?</b> <i>F. Schaumburg*</i> (Münster, Germany), <i>J. Skorning, T. Grebe, P. Neuhaus</i>
E0992	14:12	<b>Bridging the know-do gap: evaluation of a multimodal intervention to increase infection prevention competency of healthcare workers in Bangladeshi hospitals</b> <i>S.A. Sumon*</i> (Dhaka, Bangladesh), <i>M.G.D. Harun</i>
E0993	14:18	<b>Evaluating mask performance through total inward leakage: a human volunteer study</b> <i>K. Lassing*</i> (Nijmegen, The Netherlands), <i>H. Wertheim, P. Scheepers</i>

**EF142 13:30 – 14:30 Arena 3**

ePoster Flash Session



**Next-generation diagnostics for reproductive health**

E0994	13:30	<b>Vaginal microbiome dysbiosis and post-treatment shifts in Indian women with bacterial vaginosis: insights from shotgun metagenomic and resistome profiling</b> <i>G. Gurmeet*</i> (Chandigarh, India), <i>R. Yadav, R. Bagga, A. Arora, S. Sethi</i>
E0995	13:36	<b>Hologic Panther system in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and <i>Trichomonas vaginalis</i> vaginitis</b> <i>N. Aparisi*</i> (Valencia, Spain), <i>N. Aparisi Valero, M. Palomeque Matos, A. Orts Fullana, L. Andrés Eslava, J.L. Ramos Martí, V. Marqués Nova, L. Suarez Lopez, M.G. Ferrando Cerda, M.J. Lahiguera Abalos, N. Talón Costa, L. Sempere Mira, C. Gimeno Cardona, D. Ocete Mochón</i>
E0996	13:42	<b>Comparative evaluation of diagnostic strategies for</b>

		<b>bacterial vaginosis: Nugent score, Hay-Ison Score, culture with chromogenic plate, and two molecular tests</b> <i>O. Dauvalder*</i> (Lyon, France), <i>M. Andrea, H. Salord, T. Roussel-Gaillard</i>	
E0997	13:48	<b>High-throughput multiplex PCR for detection of infertility-associated STIs in gynecologist-referred patients</b> <i>B. Cullhaj*</i> (Tirana, Albania), <i>I. Marku, D. Sino</i>	
E0998	13:54	<b>Diagnostic accuracy of Xpert CT/NG assay at the point-of-care for the detection of neonatal <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> infection: cohort study in Papua New Guinea</b> <i>L. Braunack-Mayer*</i> (Bern, Switzerland), <i>M.A. Riddell, A. Mengi, L.M. Valley, P.H. Cunningham, M. Starr, H. Wand, B.D. Spycher, R. Guy, M. Laman, W.S. Pomat, A.J. Valley, N. Low</i>	
E0999	14:00	<b>Detection of <i>Treponema pallidum</i> in saliva and its application to molecular epidemiology</b> <i>K. Imai*</i> (Saitama, Japan), <i>Y. Ohama, A. Sato, M. Tanaka, R. Omachi, S.I. Nakayama, M. Tokano, N. Tarumoto, T. Maeda, Y. Akeda</i>	
E1000	14:06	<b>Expanding diagnostic options for STIs: qPCR screening using routine liquid cytology samples</b> <i>H. Alonso*</i> (San Mateo De Gallego, Spain), <i>E. Teresa, E. Villarreal, M. Lopez, S. Aznar, S. Lucea, M. Barco</i>	
E1001	14:12	<b>A pragmatic approach to scaling STI screening in low-resource settings: pooled '3-in-1' Xpert® CT/NG testing achieves high predictive performance at reduced costs among Indonesian MSM</b> <i>S. Suwanti*</i> (Jakarta, Indonesia), <i>R.L. Hamers, Y.W. Anggraini, N. Kawi, H. Luis, J. Jeny, D.P. Rahmawati, E.P. Sihotang, M. Oktaviani, P.P. Januraga, E. Sukmaningrum, E. Yuniastuti, E.J. Sanders, S. Wignall, K. Gedela</i>	
E1002	14:18	<b>Large-scale molecular surveillance of bacterial STIs in Brazil: a four-year multi-state analysis of over 335,000 RT-PCR tests for <i>Chlamydia trachomatis</i>, <i>Neisseria gonorrhoeae</i>, and <i>Mycoplasma genitalium</i></b> <i>V. Passarelli*</i> (São Paulo, Brazil), <i>P. Cappellano, C. Dos Santos Lazar, F. Goldemberg, M. Chiarastelli Salomão, A. Martins Fontes, F. Marques Rodrigues, J. De Sá, F.H. Da Silva, C. Granato, G. Hughes, S. Figueiredo Costa</i>	

SY173	14:30 – 15:30	Hall A1-5
	1-hour Symposium	

<b>Future-proofing IPC: smarter strategies for tomorrow's challenges</b>		
Chairs	<i>Elisabeth Presterl</i> (Vienna, Austria) <i>Andreas F. Widmer</i> (Füllinsdorf, Switzerland)	

S0451	14:30	<b>Advancing prevention of catheter-associated infections: from care bundles to integrated multimodal IPC strategies</b> <i>Camelia Bogaert</i> (Gent, Belgium)
S0452	15:00	<b>From firefighting to foresight: shifting IPC from reactive to proactive</b> <i>Nico Tom Mutters</i> (Bonn, Germany)

EF143	14:30 – 15:30	Arena 1
	ePoster Flash Session	
<b>Shaping policy for antimicrobial use and AMR</b>		
Chair	<i>Babette Rump</i> (Middelburg, The Netherlands)	

E1004	14:30	<b>An intersectionality-based policy analysis of antimicrobial resistance in national action plans in WHO European region</b> <i>E. Magrini*</i> (Rome, Italy), <i>C. Shortall, C. Naim, E. Short, A. Abbara</i>
E1005	14:36	<b>Carbon impact of blood-culture utilisation changes during a global supply constraint</b> <i>E. Chan*</i> (Melbourne, Australia), <i>P. Kinsella, C. O'shea, K. Cronin, K. Bond, S. Mcalister, F. Mcgain</i>
E1006	14:42	<b>The environmental impact of antibiotic treatment: a life-cycle analysis of intravenous-inpatient, -outpatient and oral treatment options</b> <i>P. Elders*</i> (Amsterdam, The Netherlands), <i>J. Hovius, K. Sigaloff, B. Joosten, T. De Vries, L. Kouwenberg, E. Cohen, E. Van Bree, F. De Haes, S. Geerlings</i>
E1007	14:48	<b>Towards a global health equity framework for antimicrobial resistance: mapping indicators across disciplines, domains, and levels of aggregation</b> <i>T.</i>

		<i>Makamu*</i> (Cape Town, South Africa), <i>C. Bonaconsa, S. Mkhumbuzi, A. Kona, M. Mendelson, E. Charani</i>
E1008	14:54	<b>Strengthening public health policies for antimicrobial resistance: insights from the EU-JAMRAI 2 sustainability guidance tool</b> <i>B. Davido*</i> (Paris, France), <i>D. Merillon, M. Fuentes-Braesch</i>
E1009	15:00	<b>Valuing sustainable access to antibiotics: stakeholder reasoning on trade-offs, preparedness, and ethical priorities in Sweden, Italy, and Bulgaria</b> <i>M. Torre*</i> (Rome, Italy), <i>M. Ancillotti, D. Mascalconi, R. Biasiotto, A. Diukendjieva, G. Kyosovska, C. Munthe, E. Baraldi, S. Wagrell</i>
E1010	15:06	<b>How visual representations of AMR and One Health limit possible futures of One Health</b> <i>M.L. Wöhrle*</i> (Edinburgh, United Kingdom)
E1011	15:12	<b>Impact of World Health Organization's AWaRe antibiotics on the gut microbiome: a systematic review and meta-analysis</b> <i>A. Di Gallo*</i> (Milan, Italy), <i>E. Crivellaro, A. Banfi, L. Barcellini, S. Panelli, C. Giaroni, E. Fusco, G. Zuccotti, M. Sharland, L. Folgori</i>

EF144	14:30 – 15:30	Arena 4
	ePoster Flash Session	

<b>Clinical and epidemiological perspectives on neglected parasitic and fungal diseases</b>		
Chair	<i>Jaya Tapadar Née Chakravarty</i> (Varanasi, India)	

E1012	14:30	<b>Effectiveness of PAIR and aspiration for hepatic hydatid cysts: ten years of experience from a UK referral centre</b> <i>L. Blundell*</i> (London, United Kingdom), <i>M. Bojorquez-Segura, M. James, D. Lawrence, T. Pissanou, G. Godbole, Z. Amin, L. Nabarro</i>
E1013	14:36	<b>Structured treatment interruption in alveolar echinococcosis: patient selection and predictors of successful outcome</b> <i>A.L. Allgaeuer*</i> (Ulm, Germany), <i>L. Heinzmann, L. Peters, W. Jiang, B. Gruener</i>
E1014	14:42	<b>Epidemiological and molecular study of relapse cases of infection with the microsporidia <i>Enterocytozoon bieneusi</i></b> <i>C. Nourrisson*</i> (Clermont-Ferrand, France), <i>M. Moniot, P. Combes, F. Dalle, D. Costa, P. Poirier</i>
E1015	14:48	<b>Intestinal microsporidiosis in immunocompetent individuals: data from the French NRC CMAP (2018–2024)</b> <i>P. Poirier*</i> (Clermont-Ferrand, France), <i>C. Nourrisson, P. Combes, M. Moniot, L. Favenne, F. Dalle, D. Costa</i>
E1016	14:54	<b>The skin to heart connection: linking scabies and skin infections to rheumatic heart disease in a New Zealand national cohort study</b> <i>S. Gupta*</i> (Auckland, New Zealand), <i>S. Thornley</i>
E1017	15:00	<b>Scabies prevalence in children under five years old in Ecuadorean remote indigenous communities after the cessation of ivermectin administration</b> <i>A. Garcia Mingo*</i> (London, United Kingdom), <i>A. Garcia-Mingo, M. González Sanz, M. Castro Aliaga, M. Caicedo Orobio, E. Salazar, R. Basu Roy, V. Velasco Tirado, M. Cáceres Alonso</i>
E1018	15:06	<b>Epidemiological shifts in visceral leishmaniasis incidence, relapse, and mortality in Brazil: analysis using National Notifiable Diseases Information System</b> <i>D.G. Assefa*</i> (Dilla, Ethiopia), <i>G. Cota, J.P. Wilson, J.A. Mendes, C. Naylor, R. Peplow, S. Singh-Phulgenda, M.S. Saito, P.J. Guerin, P. Dahal</i>
E1019	15:12	<b>Epidemiological and clinical features of leishmaniasis in a tertiary hospital in Brazil</b> <i>O.H. Pradi Guenther*</i> (Curitiba, Brazil), <i>E. Dyminski Parente Ribeiro, F. Tomiotto-Pellissier</i>
E1020	15:18	<b>A ten-year follow-up of <i>Leishmania donovani</i> transmission dynamics during the visceral leishmaniasis elimination campaign in India</b> <i>A.K. Singh*</i> (Varanasi, India), <i>S. Sundar, E. Hasker</i>

ME174	14:30 – 15:30	Hall A1-3
	Meet-the-Expert	
<b>How to use serological tests for Lyme borreliosis</b>		

**M0453**    **14:30**    *Mariska Leeflang (Amsterdam, The Netherlands)*

**M0454**    **14:42**    *Ram B. Dessau (Slagelse, Denmark)*

**Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)**